

별첨

배제문헌

1. 국외 DB

1. Abbas A, Schell BP, Georgel PT. Role of human leukocyte antigen G (HLA-G) in breast cancer pathogenesis. *Biochemistry and Cell Biology*. 2013;91 (6):395-6.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2. Abdallah R, Youness RA, El Meckawy N, El Sebaei AF, Abdelmotaal A, Assal RA. Down-regulated miR-486-5p acts as a tumor suppressor in breast cancer patients by targeting the metastatic mediator ICAM-1. *Annals of Oncology*. 2017;28 (Supplement 11):xi22.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
3. Abdallah R, Youness RA, El Meckawy N, El Sebaei AF, Abdelmotaal A, Assal RA. Paradoxical effects of miR-486-5p on the oncogenic and immunogenic profiles in triple negative breast cancer (TNBC). *European Journal of Cancer*. 2018;92 (Supplement 3):S123.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
4. Abdel-Latif M, Afifi A, Soliman R, Elkhouly A, Abdelmotaal A, Youness RA. A new quercetin glycoside enhances TNBC immunological profile through TP53/miR-155/MICA/ULBP2. *Annals of Oncology*. 2019;30 (Supplement 7):vii7-vii8.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
5. Abdul Hafid SR, Radhakrishnan AK, Nesaretnam K. Tocotrienols are good adjuvants for developing cancer vaccines. *BMC Cancer*. 2010;10 (5).
배제사유 : 동물실험 및 전임상시험연구
6. Abe R, Sawano A, Ueki H, Akimoto M, Kimura M. [Experimental studies on the enhanced effects of chemoendocrine therapy in breast cancer]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1987;14(3 Pt 2):785-92.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
7. Abken H, Hombach A, Reinhard G, Marten A, Schlimper C, Glasmacher A, et al. Cellular immunotherapy after autologous hematopoietic stem cell transplantation: Experimental strategies and clinical experiences. *Leukemia and Lymphoma*. 2003;44(4):583-92.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
8. Abolarinwa BA, Ibrahim RB, Huang YH. Conceptual development of immunotherapeutic approaches to gastrointestinal cancer. *International Journal of Molecular Sciences*. 2019;20

(18) (4624).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

9. Abouelghar A, Hasnah R, Taouk G, Saad M, Karam M. Prognostic values of the mRNA expression of natural killer receptor ligands and their association with clinicopathological features in breast cancer patients. *Oncotarget*. 2018;9(43):27171-96.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

10. Abrahao CA, Bomfim E, Lopes-Junior LC, Pereira-da-Silva G. Complementary Therapies as a Strategy to Reduce Stress and Stimulate the Immunity of Women With Breast Cancer. *Journal of Evidence-based Integrative Medicine*. 2019;24:2515690X19838897.

배제사유 : 철회된 문헌

11. Abrahao CA, Bomfim E, Lopes-Junior LC, Pereira-da-Silva G. Retraction: Complementary Therapies as a Strategy to Reduce Stress and Stimulate the Immunity of Women With Breast Cancer (*Journal of evidence-based integrative medicine (2020) 25*). *Journal of evidence-based integrative medicine*. 2019;24:2515690X19838897.

배제사유 : 철회된 문헌

12. Absi AA, Wurzer H, Guerin C, Hoffmann C, Moreau F, Mao X, et al. Actin cytoskeleton remodeling drives breast cancer cell escape from natural killer-mediated cytotoxicity. *Cancer Research*. 2018;78(19):5631-43.

배제사유 : 동물실험 및 전임상시험연구

13. Abu N, Mohamed NE, Yeap SK, Lim KL, Akhtar MN, Zulfadli AJ, et al. In vivo antitumor and antimetastatic effects of flavokawain B in 4T1 breast cancer cell-challenged mice. *Drug design, development & therapy*. 2015;9:1401-17.

배제사유 : 동물실험 및 전임상시험연구

14. Abu N, Mohamed NE, Yeap SK, Lim KL, Akhtar MN, Zulfadli AJ, et al. In Vivo Anti-Tumor Effects of Flavokawain A in 4T1 Breast Cancer Cell-Challenged Mice. *Current Medicinal Chemistry - Anti-Cancer Agents*. 2015;15(7):905-15.

배제사유 : 동물실험 및 전임상시험연구

15. Aceituno-Madera P, Salazar-Nievas M, Moreno-Suarez F. Blastic plasmacytoid dendritic cell neoplasm: A case report. *Journal of the American Academy of Dermatology*. 2018;79 (3 Supplement 1):AB58.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

16. Acheampong DO, Adokoh CK, Ampomah P, Agyirifo DS, Dadzie I, Ackah FA, et al. Bispecific antibodies (bsAbs): Promising immunotherapeutic agents for cancer therapy. *Protein and Peptide Letters*. 2017;24(5):456-65.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

17. Actrn. Effect of resistance training on natural killer cell activity in women recovering from breast cancer treatment: a randomised controlled trial. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12612000346875>. 2012.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

18. Adams S, Diamond JR, Hamilton EP, Pohlmann PR, Tolaney SM, Molinero L, et al. Phase

Ib trial of atezolizumab in combination with nabpaclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). Journal of Clinical Oncology. Conference. 2016;34(Supplement 15).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

19. Adcock DM, Fink LM, Marlar RA, Cavallo F, Zangari M. The hemostatic system and malignancy. Clinical Lymphoma and Myeloma. 2008;8(4):230-6.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

20. Afferri C, Buccione C, Andreone S, Galdiero MR, Varricchi G, Marone G, et al. The pleiotropic immunomodulatory functions of IL-33 and its implications in tumor immunity. Frontiers in Immunology. 2018;9(NOV).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

21. Agaague S, Hargreaves A, De Sousa P, De Waele P, Gilham D. The high expression of NKG2D ligands on tumor and the lack of surface expression on healthy tissues provides a strong rationale to support NKG2D-based therapeutic approaches for cancer. Annals of Oncology. 2018;29 (Supplement 8):viii420.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

22. Ageitos AG, Ino K, Ozerol I, Tarantolo S, Heimann DG, Talmadge JE. Restoration of T and NK cell function in GM-CSF mobilized stem cell products from breast cancer patients by monocyte depletion. Bone Marrow Transplantation. 1997;20(2):117-23.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

23. Ageitos AG, Singh RK, Ino K, Ozerol I, Tarantolo S, Reed EK, et al. IL-2 expansion of T and NK cells from growth factor-mobilized peripheral blood stem cell products: monocyte inhibition. Journal of Immunotherapy. 1998;21(6):409-17.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

24. Aguilera NSI, Tavassoli FA, Chu WS, Abbondanzo SL. T-cell lymphoma presenting in the breast: A histologic, immunophenotypic and molecular genetic study of four cases. Modern Pathology. 2000;13(6):599-605.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

25. Ahmad MF. Ganoderma lucidum: A rational pharmacological approach to surmount cancer. Journal of Ethnopharmacology. 2020;260 (113047).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

26. Ahmed I, Ahmad U, Yong Yoke K, Fauziah O. Non-specific immunostimulatory capacity of newcastle disease virus (NDV) and suppression of breast cancer cells. International Journal of Pharmaceutical and Clinical Research. 2014;6(3):196-200.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

27. Ahmed M, Cheung NV. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Letters. 2014;588(2):288-97.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

28. Ahonen M, Parviainen S, Diaconu I, Cerullo V, Hemminki A. CD40-ligand armed vaccinia virus for induction of anti-tumor immune response. *Molecular Therapy*. 2012;1):S75.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
29. Aigner K, Drothler S, Schlaf R, Aigner KR. Immune activation after Regional Chemotherapy - NK-cell, CD4+ and CD8+ T-cell response. *European Journal of Surgical Oncology*. 2020;46 (2):e153-e4.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
30. Akbari M, Sheikhi A, Darchin M, Baharifar N, Zahirizadeh M, Yousefi S, et al. Effects of coping skills training program on immune system and pain in breast cancer patients. [Persian]. *Koomesh*. 2018;20(1):53-62.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
31. Akiki M, Haddad FG, Kourie HR, Khaddage A, Smayra VT. PD-L1: An unavoidable biomarker in advanced triple-negative breast cancer. *Biomarkers in Medicine*. 2019;13(18):1539-41.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
32. Akimoto M, Ishii H, Nakajima Y, Iwasaki H, Tan M, Abe R, et al. Assessment of host immune response in breast cancer patients. *Cancer Detection & Prevention*. 1986;9(3-4):311-7.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
33. Akimoto M, Nishihira T, Hirakawa H, Abe M, Ohuchi N, Mori S, et al. [Improved therapeutic effect of sequential immunotherapy with cyclophosphamide, large doses of OK-432 and recombinant interleukin-2 in breast cancer patients with disseminated metastatic liver tumors]. *Nippon Geka Gakkai Zasshi. Journal of Japan Surgical Society*. 1991;92(1):64-74.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
34. Akinfieva O, Nabiev I, Sukhanova A. New directions in quantum dot-based cytometry detection of cancer serum markers and tumor cells. *Critical Reviews in Oncology/Hematology*. 2013;86(1):1-14.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
35. Akiyama S, Yamauchi A, Yamashita T, Nimura H, Abe H. Retrospective analysis of the clinical efficacy of a dendritic cell-based cancer vaccine in patients with advanced or recurrent breast cancer. *Personalized Medicine Universe*. 2012;1(1):25-32.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
36. Akiyoshi T, Arinaga S, Nanbara S, Karimine N, Inoue H, Takamuku K, et al. The effect of recombinant interleukin 2 in combination with mitomycin C on advanced cancer. *Japanese Journal of Surgery*. 1990;20(3):365-8.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
37. Al Absi A, Wurzer H, Guerin C, Hoffmann C, Moreau F, Mao X, et al. Actin Cytoskeleton Remodeling Drives Breast Cancer Cell Escape from Natural Killer-Mediated Cytotoxicity.

Cancer Research. 2018;78(19):5631-43.

배제사유 : 동물실험 및 전임상시험연구

38. Al Faqih S. Diurnal cortisol rhythm as a predictor of breast cancer survival. European Journal of Cancer, Supplement. 2010;8 (3):210.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

39. Aladily TN, Nathwani BN, Miranda RN, Kansal R, Yin CC, Protzel R, et al. Extranodal NK/T-cell lymphoma, nasal type, arising in association with saline breast implant: expanding the spectrum of breast implant-associated lymphomas. American Journal of Surgical Pathology. 2012;36(11):1729-34.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

40. Alajeely AAA, Mahmood AS, Zangor JR, Ali SHM. Assessment of breast cancer tissue microenvironment for human cytomegalovirus infection and CD4- and CD8- positive tumor infiltrating lymphocytes. Biochemical and Cellular Archives. 2019;19(Supplement1):2499-505.

배제사유 : 동물실험 및 전임상시험연구

41. Albanesi M, Mancardi DA, Jonsson F, Iannascoli B, Fiette L, Di Santo JP, et al. Neutrophils mediate antibody-induced antitumor effects in mice. Blood. 2013;122(18):3160-4.

배제사유 : 동물실험 및 전임상시험연구

42. Albershardt TC, Campbell DJ, Parsons AJ, Ter Meulen JH, Berglund P. Preclinical characterization of LV305, a lentiviral vector targeting tumors expressing NY-ESO-1. Cancer Research. Conference: 106th Annual Meeting of the American Association for Cancer Research, AACR. 2015;75(15 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

43. Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nature Medicine. 1998;4(11):1321-4.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

44. Albertini MR, Gibson DF, Robinson SP, Howard SP, Tans KJ, Lindstrom MJ, et al. Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine-activated killer cells. Journal of Immunotherapy. 1992;11(1):30-9.

배제사유 : 동물실험 및 전임상시험연구

45. Albertini MR, Howard SP, Fisch P, Lindstrom MJ, Hank JA, Gould MN, et al. Modulation of target-cell culture conditions alters susceptibility to lymphocyte-mediated lysis. Journal of Immunotherapy with Emphasis on Tumor Immunology. 1993;13(4):243-51.

배제사유 : 동물실험 및 전임상시험연구

46. Albuquerque K, Tell D, Lobo P, Millbrandt L, Mathews HL, Janusek LW. Impact of partial versus whole breast radiation therapy on fatigue, perceived stress, quality of life and natural killer cell activity in women with breast cancer. BMC Cancer. 2012;12:251.

배제사유 : 동물실험 및 전임상시험연구

47. Aldrich JF, Lowe DB, Shearer MH, Winn RE, Jumper CA, Kennedy RC. Vaccines and

immunotherapeutics for the treatment of malignant disease. Clinical and Developmental Immunology. 2010;2010 (697158).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

48. Alexia C, Cren M, Louis-Plence P, Vo DN, El Ahmadi Y, Dufourcq-Lopez E, et al. Polyoxidonium◆ Activates Cytotoxic Lymphocyte Responses Through Dendritic Cell Maturation: Clinical Effects in Breast Cancer. Frontiers in Immunology. 2019;10:2693.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

49. Algarra I, Gaforio JJ, Cabrera T, Collado A, Garrido F. The biological consequences of altered MHC class I expression in tumours. Journal of Biological Regulators and Homeostatic Agents. 1999;13(2):90-6.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

50. AlHossiny M, Luo L, Frazier WR, Steiner N, Gusev Y, Kallakury B, et al. Ly6E/K Signaling to TGFbeta Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance. Cancer Research. 2016;76(11):3376-86.

배제사유 : 동물실험 및 전임상시험연구

51. Alistar A, Chou JW, Nagalla S, Black MA, D'Agostino R, Jr., Miller LD. Dual roles for immune metagenes in breast cancer prognosis and therapy prediction. Genome Medicine. 2014;6(10):80.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

52. Alistar AT, Chifman J, D'Agostino R, Miller LD. Gene expression signatures of effector immune cell abundance are significantly associated with recurrence risk in colon cancer. Cancer Immunology Research. Conference: CRI CIMT EATI AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival. United States. 2016;4(1 Supplement).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

53. Alizadeh D, Katsanis E, Larmonier N. Role of reactive oxygen species in doxorubicin-induced apoptosis of myeloid-derived suppressor cells. Cancer Research. Conference: 105th Annual Meeting of the American Association for Cancer Research, AACR. 2014;74(19 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

54. Alizadeh D, Trad M, Hanke NT, Larmonier CB, Janikashvili N, Bonnotte B, et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Research. 2014;74(1):104-18.

배제사유 : 동물실험 및 전임상시험연구

55. Alkins R, Burgess A, Ganguly M, Francia G, Kerbel R, Wels WS, et al. Focused ultrasound delivers targeted immune cells to metastatic brain tumors. Cancer Research. 2013;73(6):1892-9.

배제사유 : 동물실험 및 전임상시험연구

56. Alkins R, Burgess A, Ganguly M, Wels W, Hynynen K. Blood-brain barrier disruption with focused ultrasound allows brain tumor therapy with targeted immune cells. Neuro-Oncology. 2012;6:vi36.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

57. Alkins R, Burgess A, Kerbel R, Wels WS, Hynnen K. Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival. *Neuro-Oncology*. 2016;18(7):974-81.

배제사유 : 동물실험 및 전임상시험연구

58. Allans R, Burgess A, Francia G, Kerbel R, Wels W, Hynnen K. Early treatment of HER2-Amplified brain tumours with targeted NK-92 cells and focused ultrasound improves survival. *Neuro-Oncology*. 2014;5):v159.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

59. Allavena P, Damia G, Colombo T, Maggioni D, D'Incalci M, Mantovani A. Lymphokine-activated killer (LAK) and monocyte-mediated cytotoxicity on tumor cell lines resistant to antitumor agents. *Cellular Immunology*. 1989;120(1):250-8.

배제사유 : 동물실험 및 전임상시험연구

60. Almeida-Porada G, Soland M, Boura J, Porada CD. Regenerative medicine: Prospects for the treatment of inflammatory bowel disease. *Regenerative Medicine*. 2013;8(5):631-44.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

61. Almendro V, Gascon P. Angiogenesis and the tumour microenvironment. *Advances in Gastrointestinal Cancers*. 2008;6(2):3-6.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

62. Alomar SY, Alkhuriji A, Trayhurn P, Alhethel A, Al-Jurayyan A, Mansour L. Association of the genetic diversity of killer cell immunoglobulin-like receptor genes and HLA-C ligand in Saudi women with breast cancer. *Immunogenetics*. 2017;69(2):69-76.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

63. Alonso EN, Obiol DJ, Balogh GA. A nutrigenomic agent induces breast cancer prevention in BALBc mice. *Cancer Prevention Research*. Conference: 11th Annual AACR International Conference on Frontiers in Cancer Prevention Research. Anaheim, CA United States. Conference Publication: 2012;5(11 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

64. Alonso EN, Orozco M, Eloy Nieto A, Balogh GA. Genes related to suppression of malignant phenotype induced by Maitake D-Fraction in breast cancer cells. *Journal of Medicinal Food*. 2013;16(7):602-17.

배제사유 : 동물실험 및 전임상시험연구

65. Aloysius MM, Robins RA, Eremin JM, Eremin O. Vaccination therapy in malignant disease. *Surgeon*. 2006;4(5):309-20.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

66. Alshaker HA, Matalka KZ. IFN-gamma, IL-17 and TGF-beta involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors. *Cancer Cell International*. 2011;11 (33).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

67. Altankova I, Mincheff M, Tchakarov S, Zoubak S, Botev C, Krusteva E, et al. Immune cell phenotypes and T-1/T-2 cytokine profile of peripheral blood mononuclear cells as parameters of immune dysfunction in advanced cancer patients. *Clinical Application of Immunology*. 2002;1(1):34-41.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
68. Alter BP, Giri N, Calvo KR, Maric I, Arthur DC, Hickstein DD, et al. Clinically silent carriers in families with myelodysplastic syndrome due to GATA2 mutations. *Blood Conference: 54th Annual Meeting of the American Society of Hematology, ASH*. 2012;120(21).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
69. Altevogt P, Bretz NP, Ridinger J, Utikal J, Umansky V. Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation. *Seminars in Cancer Biology*. 2014;28:51-7.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
70. Altinoz MA, Ozpinar A, Elmaci I. Reproductive epidemiology of glial tumors may reveal novel treatments: high-dose progestins or progesterone antagonists as endocrino-immune modifiers against glioma. *Neurosurgical Review*. 2019;42(2):351-69.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
71. Altundag K, Mohamed AS, Altundag O, Silay YS, Gunduz E, Demircan K. SRL172 (killed *Mycobacterium vaccae*) may augment the efficacy of trastuzumab in metastatic breast cancer patients. *Medical Hypotheses*. 2005;64(2):248-51.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
72. Alyan M, Mahmoud A, Khalil O, Yassien M, Hosni HMS, Nemrr E, et al. Stem cells: A novel target for ovarian cancer therapy. *Tumori*. 2019;105 (1 Supplement):24-5.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
73. Ambatipudi S, Horvath S, Perrier F, Cuenin C, Hernandez-Vargas H, Le Calvez-Kelm F, et al. DNA methylome analysis identifies accelerated epigenetic ageing associated with postmenopausal breast cancer susceptibility. *European Journal of Cancer*. 2017;75:299-307.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
74. Ames E, Canter RJ, Grossenbacher SK, Mac S, Chen M, Smith RC, et al. NK cells preferentially target tumor cells with a cancer stem cell phenotype. *Journal of Immunology*. 2015;195(8):4010-9.
배제사유 : 동물실험 및 전임상시험연구
75. Ames E, Hallett WH, Murphy WJ. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition. *Clinical & Experimental Immunology*. 2009;155(3):504-13.
배제사유 : 동물실험 및 전임상시험연구
76. Ames IH, Garcia AM, John PA. Decreased natural cytotoxicity in mice with high incidence of mammary adenocarcinoma. *Clinical Immunology and Immunopathology*.

1986;38(2):265-73.

배제사유 : 동물실험 및 전임상시험연구

77. Ammori J, Hamzeh K, Graor H, Kim J. Requirement of innate immunity in tumor-bearing mice cured by adoptive immunotherapy using tumor-draining lymph nodes. *Journal of Immunology Research*. 2015;2015 (170852).
- 배제사유 : 동물실험 및 전임상시험연구
78. Amo L, Tamayo-Orbegozo E, Maruri N, Buque A, Solaun M, Rinon M, et al. Podocalyxin-like protein 1 functions as an immunomodulatory molecule in breast cancer cells. *Cancer Letters*. 2015;368(1):26-35.
- 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
79. An T, Sood U, Pietruk T, Cummings G, Hashimoto K, Crissman JD. In situ quantitation of inflammatory mononuclear cells in ductal infiltrating breast carcinoma. Relation to prognostic parameters. *American Journal of Pathology*. 1987;128(1):52-60.
- 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
80. Anari F, Ramamurthy C, Zibelman M. Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer. *Future Oncology*. 2018;14(14):1409-21.
- 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
81. Anaya-Ruiz M, Bandala C, Martinez-Morales P, Landeta G, Martinez-Contreras RD, Martinez-Montiel N, et al. Emerging drugs for the treatment of breast cancer brain metastasis: A review of patent literature. *Recent Patents on Anti-Cancer Drug Discovery*. 2018;13(3):348-59.
- 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
82. Andersen BL, Farrar WB, Golden-Kreutz D, Kutz LA, MacCallum R, Courtney ME, et al. Stress and immune responses after surgical treatment for regional breast cancer. *Journal of the National Cancer Institute*. 1998;90(1):30-6.
- 배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
83. Andersen BL, Goyal NG, Westbrook TD, Bishop B, Carson WE, 3rd. Trajectories of Stress, Depressive Symptoms, and Immunity in Cancer Survivors: Diagnosis to 5 Years. *Clinical Cancer Research*. 2017;23(1):52-61.
- 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
84. Andersen BL, Thornton LM, Shapiro CL, Farrar WB, Mundy BL, Yang HC, et al. Biobehavioral, immune, and health benefits following recurrence for psychological intervention participants. *Clinical Cancer Research*. 2010;16(12):3270-8.
- 배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
85. Anderson KS. Tumor vaccines for breast cancer. *Cancer Investigation*. 2009;27(4):361-8.
- 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
86. Andorsky DJ, Timmerman JM. Interleukin-21: Biology and application to cancer therapy. *Expert Opinion on Biological Therapy*. 2008;8(9):1295-307.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

87. Andrianov IG, Dobkin AN, Kiselev OI, Okukov VB, Semiglazov VF. In vitro immunomodulating effect of vasopressin and interleukin-2 on natural killer activity in breast cancer patients. [Russian]. Voprosy Onkologii. 1989;35(10):1186-91.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

88. Andrianov IG, Katashkova TN. [The effect of autoplasma of patients with breast cancer on the functional activity of natural killer cells and adhering mononuclear cells in peripheral blood in vitro]. Eksperimentalnaia Onkologiia. 1989;11(5):64-6.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

89. Andrianov IG, Voronov SM, Dobkin AN, Okulov VB, Orlov AB. [Functional activity of the natural killers and macrophages in patients with breast tumors]. Voprosy Onkologii. 1988;34(12):1455-60.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

90. Anel A, Pardo J, Villalba M. Editorial: The Natural Killer Cell Interactome in the Tumor Microenvironment: Basic Concepts and Clinical Application. *Frontiers in Immunology*. 2020;11 (872).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

91. Anfossi S, Giordano A, Huo L, Alvarez RH, Valero V, Hortobagyi GN, et al. High miR-19a serum levels correlate with favorable prognosis in patients with metastatic HER2+ inflammatory breast cancer and may result from an effective antibody-dependent cell-mediated cytotoxicity induced by trastuzumab. *Cancer Research Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium*. San Antonio, TX United States. Conference Publication: 2015;75(9 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

92. Anfossi S, Huo L, Woodward WA, Ueno NT, Valero V, Calin GA, et al. High serum miR-19a levels correlated with favorable prognosis in patients with metastatic HER2+ breast cancer and might result from effective antibody-dependent cell-mediated cytotoxicity (ADCC) induced by trastuzumab and Th1-mediated antitumor immune response. *Cancer Research Conference: 38th Annual CTRC AACR San Antonio Breast Cancer Symposium*. San Antonio, TX United States. Conference Publication: 2016;76(4 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

93. Angel Nivya M, Raja K, Kumaravel M, Sasidharan S, Seethapathy GS. Role of nutraceuticals in cancer. *International Journal of Pharmacy and Pharmaceutical Sciences*. 2012;4(SUPPL. 4):415-20.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

94. Angell H, Ros VR, Standifer N, Lai Z, Gresty C, Delord JP, et al. Phase II basket study of olaparib and durvalumab: Biomarker analysis in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC) and relapsed small-cell lung cancer (SCLC) patients. *Journal for ImmunoTherapy of Cancer. Conference: 32nd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC*.

2017;5(Supplement 2).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

95. Angka L, De Souza C, Baxter K, Khan S, Market M, Martel AB, et al. Perioperative arginine immunonutrition prevents metastases by accelerating natural killer cell recovery after surgery. *Annals of Surgical Oncology*. 2020;27 (Supplement 1):S17-S8.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
96. Angka L, Khan ST, Kilgour MK, Xu R, Kennedy MA, Auer RC. Dysfunctional natural killer cells in the aftermath of cancer surgery. *International Journal of Molecular Sciences*. 2017;18 (8) (1787).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
97. Anonymous. 15th International Biennial Congress of the Metastasis Research Society. Clinical and Experimental Metastasis. Conference: 15th International Biennial Congress of the Metastasis Research Society. Heidelberg Germany. Conference Publication:. 2015;32(3).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
98. Anonymous. AACR Special Conference: The Function of Tumor Microenvironment in Cancer Progression. *Cancer Research*. Conference: AACR Special Conference on The Function of Tumor Microenvironment in Cancer Progression. 2016;76(15 Supplement).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
99. Anonymous. Abstract Book of ESMO Asia Congress 2016. *Annals of Oncology*. Conference: ESMO Asia Congress. 2016;27(Supplement 9).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
100. Anonymous. Abstracts of the 5th International Academy of Pathology Malaysian Division, Annual Scientific Meeting 2018: Mediastinal and Breast Pathology. *Malaysian Journal of Pathology*. Conference: 5th Annual Scientific Meeting of the International Academy of Pathology Malaysian Division, IAPMD. 2018;40(3).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
101. Anonymous. American Society of Breast Surgeons 2018. *Annals of Surgical Oncology*. Conference: 19th Annual Meeting of the American Society of Breast Surgeons. United States. 2018;25(2 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
102. Anonymous. An innate immune pathway regulates breast cancer metastasis. *Cancer Discovery*. 2012;2(9).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
103. Anonymous. Bromelain monograph. *Alternative Medicine Review*. 2010;15(4):361-8.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
104. Anonymous. Comment. *CME Bulletin Haematology*. 2000;3(1):19.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
105. Anonymous. CpG 7909: PF 3512676, PF-3512676. *Drugs in R & D*. 2006;7(5):312-6.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

106. Anonymous. Discussion. *Surgery* (United States). 2019;166(4):507-8.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
107. Anonymous. EUROANAESTHESIA 2014: The European Anaesthesiology Congress. *European Journal of Anaesthesiology*. Conference: European Anaesthesiology Congress, EUROANAESTHESIA. 2014;31(SUPPL. 52).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
108. Anonymous. How tumour cells lie in wait. *Nature*. 2016;531(7596):552.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
109. Anonymous. Proffered Abstracts from the 17th Biennial Congress of the Metastasis Research Society. Clinical and Experimental Metastasis. Conference: 17th Biennial Congress of the Metastasis Research Society. United States. 2019;36(2).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
110. Anonymous. Research Highlights. *Molecular Therapy*. 2020;28(4):991-4.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
111. Antoni M. Changes in benefit finding during psychosocial intervention in women treated for breast cancer: Biobehavioral correlates. *Psycho-Oncology*. 2010;1):S19.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
112. Antoni MH. Effects of psychosocial interventions in patients treated for breast cancer: Psycho-neuro-immunologic processes. *Psycho-Oncology*. 2009;2):S27-S8.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
113. Antoni MH. Psychoneuroendocrinology and psychoneuroimmunology of cancer: Plausible mechanisms worth pursuing? *Brain, Behavior, and Immunity*. 2003;17(1 SUPPL.):S84-S91.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
114. Antonioli L, Blandizzi C, Pacher P, Hasko G. Immunity, inflammation and cancer: A leading role for adenosine. *Nature Reviews Cancer*. 2013;13(12):842-57.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
115. Apte RN, Voronov E. Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy? *Immunological Reviews*. 2008;222(1):222-41.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
116. Aptsiauri N, Cabrera T, Pawelec G, Gouttefangeas C, Derhovanessian E, Garrido F, et al. International conference: Progress in vaccination against cancer-2006 (PIVAC 6), Granada, Spain. *Cancer Immunology, Immunotherapy*. 2007;56(8):1311-22.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
117. Arafar A. Cytokine induced killer cell immunotherapy in cancer treatment: from bench to bedside. *Biomedical Research and Therapy*. 2014;1 (2) (12).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
118. Aranda F, Vacchelli E, Eggemont A, Galon J, Fridman WH, Zitvogel L, et al. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. *OncoImmunology*.

2014;3 (2) (e27297).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

119. Araujo JM, Gomez AC, Aguilar A, Salgado R, Balko JM, Bravo L, et al. Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer. *Scientific Reports.* 2018;8(1):4899.

배제사유 : 동물실험 및 전임상시험연구

120. Ardizzoja M, Masera RG, Tacconis P, Sartori ML, Arisio R, Massobrio M, et al. Natural killer (NK) cell activity of women with gross cystic disease is inhibited in vitro by breast cyst fluid. *Anticancer Research.* 1994;14(2A):555-9.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

121. Arinaga S, Karimine N, Takamuku K, Nanbara S, Inoue H, Abe R, et al. Laboratory correlates of chemoimmunotherapy with low-dose recombinant interleukin-2 and mitomycin C in patients with advanced carcinoma. *Cancer Investigation.* 1994;12(6):588-96.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

122. Arnaout A, Robertson S, Addison C, Chang N, Pond G, Clemons M. A randomized, double-blind, placebo-controlled window of opportunity trial evaluating clinical effects of high dose vitamin D in patients with breast cancer. *Cancer research. Conference: 39th annual CTRC-AACR san antonio breast cancer symposium. United states.* 2017;77(4 Supplement 1) .

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

123. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? *British Journal of Cancer.* 2006;94(2):259-67.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

124. Aronov DA, Zhukov VV, Semushina SG, Moiseeva EV. Imbalances in cellular immunological parameters in blood predetermine tumor onset in a natural mouse model of breast cancer. *Cancer Immunology, Immunotherapy.* 2019;68(5):721-9.

배제사유 : 동물실험 및 전임상시험연구

125. Arteaga CL, Dugger TC, Winnier AR, Forbes JT. Evidence for a positive role of transforming growth factor-beta in human breast cancer cell tumorigenesis. *Journal of Cellular Biochemistry - Supplement.* 1993;17G:187-93.

배제사유 : 동물실험 및 전임상시험연구

126. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. *Journal of Clinical Investigation.* 1993;92(6):2569-76.

배제사유 : 동물실험 및 전임상시험연구

127. Arteaga CL, Koli KM, Dugger TC, Clarke R. Reversal of tamoxifen resistance of human breast carcinomas *in vivo* by neutralizing antibodies to transforming growth factor-beta.

Journal of the National Cancer Institute. 1999;91(1):46-53.

배제사유 : 동물실험 및 전임상시험연구

128. Asadujjaman M, Cho KH, Jang DJ, Kim JE, Jee JP. Nanotechnology in the arena of cancer immunotherapy. Archives of Pharmacal Research. 2020;43(1):58-79.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
129. Ascierto ML, Idowu MO, Zhao Y, Bedognetti D, Tomei S, Ascierto PA, et al. NK cell molecular signatures are predictive of relapse free survival of favorable prognosis of breast cancer patients. Journal of Immunotherapy. 2012;35 (9):754-5.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
130. Ascierto ML, Idowu MO, Zhao Y, Khalak H, Payne KK, Wang XY, et al. Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. Journal of Translational Medicine. 2013;11:145.
배제사유 : 동물실험 및 전임상시험연구
131. Ascierto ML, Kmiecik M, Idowu MO, Bedognetti D, De Maria A, Bear HD, et al. Immunologic markers associated with favorable prognosis in breast cancer patients: Role of innate immune system. Journal of Clinical Oncology. Conference. 2011;29(27 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
132. Ascierto ML, M OI, Zhao Y, Bedognetti D, Ascierto PA, Bear HD, et al. Involvement of NK cell molecular signatures in favorable prognosis of breast cancer patients. Journal of Clinical Oncology. Conference. 2012;30(15 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
133. Ascierto ML, Payne KK, Kmiecik M, Idowu MO, Dumur C, Bedognetti D, et al. Role of NK and NKT cells in breast cancer patients: Association with favorable prognosis. Journal of Immunotherapy. 2011;34 (9):696.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
134. Ascierto ML, Shrestha Y, Zhang Q, Wang J, Si H, Greenlees L, et al. Durvalumab induces an NK cell response associated with clinical benefit of patients with advanced NSCLC. Cancer Research. Conference: American Association for Cancer Research Annual Meeting. 2019;79(13 Supplement).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
135. Asgari A, Sharifzadeh S, Ghaderi A, Hosseini A, Ramezani A. In vitro cytotoxic effect of Trastuzumab in combination with Pertuzumab in breast cancer cells is improved by interleukin-2 activated NK cells. Molecular Biology Reports. 2019;46(6):6205-13.
배제사유 : 동물실험 및 전임상시험연구
136. Ash SA, Buggy DJ. Does regional anaesthesia and analgesia or opioid analgesia influence recurrence after primary cancer surgery? An update of available evidence. Best Practice and Research: Clinical Anaesthesiology. 2013;27(4):441-56.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
137. Ashkar A. Humanized mice: Experimental model for the study of human diseases. Cell

Journal. 2011;1):9.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

138. Ashouri E, Ghaderi A, Rajalingam R. KIR3DS1-2DS1-2DS5, receptors implicated in NK cell activation provide a risk of developing advanced stage breast cancer. *Human Immunology*. 2010;1):S17.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

139. Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz LB, Roger P, Guiu S, et al. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. *Journal for Immunotherapy of Cancer*. 2019;7(1):29.

배제사유 : 동물실험 및 전임상시험연구

140. Atanackovic D, Pollok K, Faltz C, Boeters I, Jung R, Nierhaus A, et al. Patients with solid tumors treated with high-temperature whole body hyperthermia show a redistribution of naive/memory T-cell subtypes. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*. 2006;290(3):R585-R94.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

141. Au Q, Nguyen K, Padmanabhan R, Kuller A, Moler E, Hoe N. MultiOmyx multiplexed tumor infiltrating lymphocyte panel provides comprehensive immunophenotyping from a single FFPE slide. *Cancer Research Conference: 107th Annual Meeting of the American Association for Cancer Research, AACR*. 2016;76(14 Supplement).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

142. Augustine TN, Dix-Peek T, Duarte R, Candy GP. Establishment of a heterotypic 3D culture system to evaluate the interaction of TREG lymphocytes and NK cells with breast cancer. *Journal of Immunological Methods*. 2015;426:1-13.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

143. Augusto DG. The impact of KIR polymorphism on the risk of developing cancer: Not as strong as imagined? *Frontiers in Genetics*. 2016;7 (JUN) (121).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

144. Aureli A, Canossi A, Del Beato T, Novelli G, Buonomo O, Papola F, et al. Influence of HLA-KIR and FCGR3A genes on breast cancer development and progression. *Hla*. 2019;93 (5):326-7.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

145. Aurisicchio L, Peruzzi D, Conforti A, Dharmapuri S, Biondo A, Giampaoli S, et al. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of toll-like receptor 9. *Clinical Cancer Research*. 2009;15(5):1575-84.

배제사유 : 동물실험 및 전임상시험연구

146. Avdeev S, Stakheeva M, Odyshev V, Faltin V, Slonimskay E. Effect of xenon anaesthesia on relapse-free survival in treatment of breast cancer: Relation with immune status. *European Journal of Anaesthesiology*. 2014;52):11.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

147. Avigan D, Wu Z, Joyce R, Elias A, Richardson P, McDermott D, et al. Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer. *Bone Marrow Transplantation*. 2000;26(2):169-76.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
148. Awad AR, Youness RA, Ibrahim M, Abdelmotaal AA, Assal RA, Gad MZ. A novel acetylated derivative of vitexin improves the immunogenic profile of breast cancer through tuning miR-20a/MICA Axis. *Annals of Oncology*. 2018;29 (Supplement 6):vi18.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
149. Awad AR, Youness RA, Ibrahim M, Motaal AA, El-Askary HI, Assal RA, et al. An acetylated derivative of vitexin halts MDA-MB-231 cellular progression and improves its immunogenic profile through tuning miR- 20a-MICA/B axis. *Natural Product Research*. 2019;1-5.
배제사유 : 동물실험 및 전임상시험연구
150. Ayuso JM, Truttschel R, Gong MM, Humayun M, Virumbrales-Munoz M, Vitek R, et al. Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model. *Oncoimmunology*. 2019;8(3):1553477.
배제사유 : 동물실험 및 전임상시험연구
151. Ayuso JM, Virumbrales-Munoz M, McMinn PH, Rehman S, Fitzgerald CM, Beebe DJ, et al. Microfluidics and oncoimmunology: New in vitro models to study solid tumor immunotherapy. *Cancer Immunology Research*. Conference: AACR Special Conference on Tumor Immunology and Immunotherapy. United States. 2020;8(3 SUPPL).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
152. Azambuja JH, Ludwig N, Braganhol E, Whiteside TL. Inhibition of the adenosinergic pathway in cancer rejuvenates innate and adaptive immunity. *International Journal of Molecular Sciences*. 2019;20 (22) (5698).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
153. Bach LE, Mazulis A, Lakha A. A rare case of gastric outlet obstruction in stage IV breast cancer. *American Journal of Gastroenterology*. 2016;111 (Supplement 1):S1098.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
154. Bachanova V, Miller JS. NK cells in therapy of cancer. *Critical Reviews in Oncogenesis*. 2014;19(1-2):133-41.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
155. Badr NM, Berditchevski F, Shaaban AM. The Immune Microenvironment in Breast Carcinoma: Predictive and Prognostic Role in the Neoadjuvant Setting. *Pathobiology*. 2020;87(2):61-74.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
156. Badrinath N, Yoo SY. Recent advances in cancer stem cell-targeted immunotherapy. *Cancers*. 2019;11 (3) (310).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

157. Bae J, Hideshima T, Tai YT, Munshi NC, Anderson KC. Enhanced CD138 peptide-specific cytotoxic T lymphocyte activities against breast, colon and pancreatic cancers in combination with pembrolizumab (anti-PD1). *Journal of Clinical Oncology Conference*. 2019;37(Supplement 15).
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
158. Baek S, Kim CS, Kim SB, Kim YM, Kwon SW, Kim Y, et al. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial. *Journal of Translational Medicine*. 2011;9:178.
- 배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
159. Baginska J, Viry E, Berchem G, Poli A, Noman MZ, Van Moer K, et al. Autophagic degradation of granzyme B impairs NK-mediated killing of hypoxic tumor cells. *Cancer Research Conference: 105th Annual Meeting of the American Association for Cancer Research, AACR*. 2014;74(19 SUPPL 1).
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
160. Baginska J, Viry E, Berchem G, Poli A, Noman MZ, van Moer K, et al. Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. *Proceedings of the National Academy of Sciences of the United States of America*. 2013;110(43):17450-5.
- 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
161. Bahattab E, Khatlani T, Abomaray FM, Messaoudi SA, Abumaree MH. Cancer Conditioned Medium Modulates Functional and Phenotypic Properties of Human Decidua Parietalis Mesenchymal Stem/Stromal Cells. *Tissue Engineering and Regenerative Medicine*. 2019;16(6):615-30.
- 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
162. Bahrami B, Hosseini A, Talei AR, Ghaderi A, Razmkhah M. Adipose Derived Stem Cells Exert Immunomodulatory Effects on Natural Killer Cells in Breast Cancer. *Cell Journal*. 2017;19(1):137-45.
- 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
163. Bai J, He A, Zhang W, Yang Y, Zhang P, Gu L, et al. MLAA-34: A new leukemia-associated antigen for immunotherapy against acute monocytic leukemia. *Blood Conference: 56th Annual Meeting of the American Society of Hematology, ASH*. 2014;124(21).
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
164. Bai X, Yi M, Jiao Y, Chu Q, Wu K. Blocking TGF-beta signaling to enhance the efficacy of immune checkpoint inhibitor. *OncoTargets and Therapy*. 2019;12:9527-38.
- 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
165. Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, De Cesaris MG, et al. Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. *Breast Cancer Research & Treatment*. 2002;73(1):61-73.
- 배제사유 : 동물실험 및 전임상시험연구

166. Baj G, Arnulfo A, Deaglio S, Tibaldi E, Surico N, Malavasi F. All-trans retinoic acid inhibits the growth of breast cancer cells by up-regulating ICAM-1 expression. *Journal of Biological Regulators & Homeostatic Agents*. 1999;13(2):115-22.
배제사유 : 동물실험 및 전임상시험연구
167. Bakacs T, Garam T, Ringwald G. Comparison of the natural cell mediated and antibody dependent cell mediated cytotoxicity measured as a function of target cell number in patients with mammary tumors and healthy female blood donors. *Archiv fur Geschwulstforschung*. 1981;51(4):327-37.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
168. Bakema JE, Ganzevles SH, Fluitsma DM, Schilham MW, Beelen RHJ, Valerius T, et al. Targeting FcalphaRI on polymorphonuclear cells induces tumor cell killing through autophagy. *Journal of Immunology*. 2011;187(2):726-32.
배제사유 : 동물실험 및 전임상시험연구
169. Bakema JE, Van Egmond M. Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer. *Fc Receptors*. 2014;Current Topics in Microbiology and Immunology. 382:373-92.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
170. Baker BS, Harrington JE, Choi BS, Kropf P, Muller I, Hoffman CJ. A randomised controlled pilot feasibility study of the physical and psychological effects of an integrated support programme in breast cancer. *Complementary Therapies in Clinical Practice*. 2012;18(3):182-9.
배제사유 : 동물실험 및 전임상시험연구
171. Baker BS, Harrington JE, Hoffman CJ. The effects of integrating the Haven programme with standard medical treatment in women with breast cancer: A randomised feasibility pilot study. *European Journal of Integrative Medicine*. 2011;3 (2):e110-e1.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
172. Bakke AC, Purtzer MZ, Newton P. The effect of hypnotic-guided imagery on psychological well-being and immune function in patients with prior breast cancer. *Journal of Psychosomatic Research*. 2002;53(6):1131-7.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
173. Bakr MAEM, Amr SAER, Mohamed SA, Hamed HB, A.M.A EL-R, Mostafa MAM, et al. Comparison between the effects of intravenous morphine, tramadol, and ketorolac on stress and immune responses in patients undergoing modified radical mastectomy. *Clinical Journal of Pain*. 2016;32(10):889-97.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
174. Balamurugan K, Sterneck E. Hypoxia augments macrophage-induced T-cell suppression. *Personalized Medicine*. 2011;8(2):129-30.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

175. Balch CM, Riley LB, Bae YJ, Salmeron MA, Platsoucas CD, von Eschenbach A, et al. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. *Archives of Surgery*. 1990;125(2):200-5.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
176. Balch CM, Tilden AB, Dougherty PA, Cloud GA. Depressed levels of granular lymphocytes with natural killer (NK) cell function in 247 cancer patients. *Annals of Surgery*. 1983;198(2):192-9.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
177. Balko JM, Nixon M, Gonzalez-Ericsson PI, Pilkinton MA, McDonnell WJ, Sanchez V, et al. Immunologic correlates of long-term outcome in the residual disease of triple-negative breast cancer after neoadjuvant chemotherapy. *Cancer Research Conference: San Antonio Breast Cancer Symposium, SABCS*. 2019;80(4 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
178. Balkwill FR, Goldstein L, Stebbing N. Differential action of six human interferons against two human carcinomas growing in nude mice. *International Journal of Cancer*. 1985;35(5):613-7.
배제사유 : 동물실험 및 전임상시험연구
179. Balkwill FR, Moodie EM, Freedman V, Fantes KH. Human interferon inhibits the growth of established human breast tumours in the nude mouse. *International Journal of Cancer*. 1982;30(2):231-5.
배제사유 : 동물실험 및 전임상시험연구
180. Balkwill FR, Moodie EM, Freedman V. An animal model system for investigating the antitumor effects of human interferon. *Journal of Interferon Research*. 1983;3(3):319-26.
배제사유 : 동물실험 및 전임상시험연구
181. Balogh KN, Cross JV. The macrophage migration inhibitory factor promotes breast cancer metastasis through interaction with the host immune response. *Cancer Immunology Research. Conference: CRI CIMT EATI AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival. United States*. 2016;4(1 Supplement).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
182. Baltrusch HJ, Stangel W, Titze I. Stress, cancer and immunity. New developments in biopsychosocial and psychoneuroimmunologic research. *Acta Neurologica*. 1991;13(4):315-27.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
183. Banik D, Moufarrij S, Villagra A. Immunoepigenetics combination therapies: An overview of the role of HDACs in cancer immunotherapy. *International Journal of Molecular Sciences*. 2019;20 (9) (2241).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
184. Baniyash M. TCR zeta-chain downregulation: Curtailing an excessive inflammatory

immune response. *Nature Reviews Immunology*. 2004;4(9):675-87.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

185. Banks RE, Forbes MA, Patel PM, Storr M, Hallam S, Clarke D, et al. Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effects. *Cytokine*. 2000;12(4):388-96.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

186. Banna GL, Aversa SML, Crivellari G, Ghiootto C, Chiarion-Sileni V, Monfardini S. Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer [5]. *British Journal of Cancer*. 2006;94(10):1550-2.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

187. Bano JD, Flores-Flores R, Josselin E, Goubard A, Ganier L, Castellano R, et al. A bispecific antibody-based approach for targeting mesothelin in triple negative breast cancer. *Frontiers in Immunology*. 2019;10 (JULY) (1593).

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

188. Bano K, Konda M, Atwal D, Parikh R, Ananthula A, Jillella A, et al. Retrospective review of patients with large granular lymphocyte (LGL) leukemia in a single institution over a period of 11 years. *Blood*. Conference: 61st Annual Meeting of the American Society of Hematology, ASH. 2019;134(Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

189. Banyai E, Jozsa E, Jakubovits E, Vargay A, Zsigmond O, Horvath Z. Evidence based research on the role of hypnosis as a psychological intervention in the care of breast cancer patients: A randomised prospective controlled study. *Psycho-Oncology*. 2017;26 (Supplement 3):61.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

190. Baragano Raneros A, Martin-Palanco V, Fernandez AF, Rodriguez RM, Fraga MF, Lopez-Larrea C, et al. Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia. *Genes & Immunity*. 2015;16(1):71-82.

배제사유 : 동물실험 및 전임상시험연구

191. Barak V. Immunological markers for breast cancer - Review. *Anticancer Research*. 2011;31 (5):1962.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

192. Baraya YS, Wong KK, Yaacob NS. The immunomodulatory potential of selected bioactive plant-based compounds in breast cancer: A review. *Anti Cancer Agents in Medicinal Chemistry*. 2016;16.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

193. Baraya YS, Wong KK, Yaacob NS. The Immunomodulatory Potential of Selected Bioactive Plant-Based Compounds in Breast Cancer: A Review. *Current Medicinal Chemistry - Anti-Cancer Agents*. 2017;17(6):770-83.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

194. Barbarin A, Cayssials E, Jacomet F, Nunez NG, Basbous S, Lefevre L, et al. Phenotype of NK-like CD8(+) T cells with innate features in humans and their relevance in cancer diseases. *Frontiers in Immunology*. 2017;8 (MAR) (316).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
195. Barcelo H, Brady NJ, Schwertfeger KL, Gross M, Thyagarajan B. Neutrophil specific mitochondrial DNA copy number as a biomarker for breast cancer. *Cancer Research Conference: 106th Annual Meeting of the American Association for Cancer Research, AACR*. 2015;75(15 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
196. Bargostavan MH, Eslami G, Esfandiari N, Shams Shahemabadi A. MMP9 promoter polymorphism (-1562 C/T) does not affect the serum levels of soluble MICB and MICA in breast cancer. *International Journal of Reproductive BioMedicine*. 2017;15 (4 Supplement 1):37.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
197. Bargostavan MH, Eslami G, Esfandiari N, Shams Shahemabadi A. MMP9 Promoter Polymorphism (-1562 C/T) Does not Affect the Serum Levels of Soluble MICB and MICA in Breast Cancer. *Iranian Journal Of Immunology: IJI*. 2016;13(1):45-53.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
198. Barnes S. The biochemistry, chemistry and physiology of the isoflavones in soybeans and their food products. *Lymphatic Research & Biology*. 2010;8(1):89-98.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
199. Barni S, Lissoni P, Paolorossi F, Rescaldani R, Crispino S, Archili C, et al. Mitoxantrone as a single agent in pretreated metastatic breast cancer: effects on T lymphocyte subsets and their relation to clinical response. *Tumori*. 1991;77(3):227-31.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
200. Barnie PA, Zhang P, Lv H, Wang D, Su X, Su Z, et al. Myeloid-derived suppressor cells and myeloid regulatory cells in cancer and autoimmune disorders (Review). *Experimental and Therapeutic Medicine*. 2017;13(2):378-88.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
201. Barra NG, Fan IY, Gillen JB, Chew M, Marcinko K, Steinberg GR, et al. High Intensity Interval Training Increases Natural Killer Cell Number and Function in Obese Breast Cancer-challenged Mice and Obese Women. *Journal of Cancer Prevention*. 2017;22(4):260-6.
배제사유 : 동물실험 및 전임상시험연구
202. Barsoum IB, Hamilton TK, Li X, Cotechini T, Miles EA, Siemens DR, et al. Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: Role of nitric oxide. *Cancer Research*. 2011;71(24):7433-41.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
203. Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, et al. Rapid breast cancer disease progression following Cyclin Dependent Kinase 4 and 6 inhibitor

discontinuation. *Journal of cancer*. 2017;8(11):2004?9.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

204. Bastid J, Regairaz A, Bonnefoy N, Dejou C, Giustiniani J, Laheurte C, et al. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. *Cancer Immunology Research*. 2015;3(3):254-65.
배제사유 : 동물실험 및 전임상시험연구
205. Basu A, Ramamoorthi G, Jia Y, Faughn J, Wiener D, Awshah S, et al. Immunotherapy in breast cancer: Current status and future directions. *Advances in Cancer Research*. 2019;143:295-349.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
206. Basudhar D, Bharadwaj G, Somasundaram V, Cheng RYS, Ridnour LA, Fujita M, et al. Understanding the tumour micro-environment communication network from an NOS2/COX2 perspective. *British Journal of Pharmacology*. 2019;176(2):155-76.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
207. Bauernhofer T, Kuss I, Henderson B, Baum AS, Whiteside TL. Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. *European Journal of Immunology*. 2003;33(1):119-24.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
208. Baxevanis CN, Reclos GJ, Gritzapis AD, Dedousis GV, Missitzis I, Papamichail M. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. *Cancer*. 1993;72(2):491-501.
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
209. Bazhenov SM, Dorosevich AE, Naperstnikov VV. [Lymphocytes of the blood, regional lymph nodes and tumor tissue in breast cancer]. *Voprosy Onkologii*. 1988;34(9):1040-8.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
210. Beano A, Signorino E, Evangelista A, Brusa D, Mistrangelo M, Polimeni MA, et al. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. *Journal of Translational Medicine*. 2008;6:25.
배제사유 : 동물실험 및 전임상시험연구
211. Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. *Cancer and Metastasis Reviews*. 2013;32(3-4):643-71.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
212. Beck B, Blanpain C. Unravelling cancer stem cell potential. *Nature Reviews Cancer*. 2013;13(10):727-38.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
213. Beers SA, Glennie MJ. Neutrophils: "Neu players" in antibody therapy? *Blood*. 2013;122(18):3093-4.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

214. Beika T, Tanaka N, Yamada J, Hizuta A, Onishi K, Akura Y, et al. [Effect of human recombinant beta-interferon on natural killer activity of peripheral lymphocytes in cancer patients]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]. 1985;12(2):362-5.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

215. Beitsch P, Lotzova E, Hortobagyi G, Pollock R. Natural immunity in breast cancer patients during neoadjuvant chemotherapy and after surgery. Surgical Oncology. 1994;3(4):211-9.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

216. Bekaii-Saab TS, Roda JM, Guenterberg KD, Ramaswamy B, Young DC, Ferketich AK, et al. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Molecular Cancer Therapeutics. 2009;8(11):2983-91.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

217. Bell LK, Ainsworth NL, Lee SH, Griffiths JR. MRI & MRS assessment of the role of the tumour microenvironment in response to therapy. NMR in Biomedicine. 2011;24(6):612-35.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

218. Beloeil H. Local anesthetics and inflammation. Regional Anesthesia and Pain Medicine. 2012;1):E172-E4.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

219. Belyaev NN, Abramova VA. Transmission of "split anergy" from tumor infiltrating to peripheral NK cells in a manner similar to "infectious tolerance". Medical Hypotheses. 2014;82(2):129-33.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

220. Benatar T, Cao MY, Lee Y, Li H, Feng N, Gu X, et al. Virulizin induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors. Cancer Immunology, Immunotherapy. 2008;57(12):1757-69.

배제사유 : 동물실험 및 전임상시험연구

221. Benbenishty A, Lubart A, Lavon H, Glasner A, Blinder P, Ben-Eliyahu S. Brain metastasis: The impact of surgical stress, immune stimulation and nk cells. Cancer Microenvironment. 2015;1):S59-S60.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

222. Benci JL, Johnson LR, Choa R, Xu Y, Qiu J, Zhou Z, et al. Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. Cell. 2019;178(4):933-48.e14.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

223. Ben-Efraim S. One hundred years of cancer immunotherapy: A critical appraisal. Tumor

Biology. 1999;20(1):1-24.

배제사유 : 동물실험 및 전임상시험연구

224. Ben-Eliyahu S, Shaashua L, Haldar R, Zmora O. Perioperative blockade of stressinflammatory responses improves biomarkers of metastasis in excised tumours and blood samples: Phase II clinical trials in colorectal and breast cancer patients. ESMO Open. 2018;3 (Supplement 2):A236-A7.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
225. Ben-Ezra J, Sheibani K. Antigenic phenotype of the lymphocytic component of medullary carcinoma of the breast. Cancer. 1987;59(12):2037-41.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
226. Benish M, Ben-Eliyahu S. Surgery as a double-edged sword: A clinically feasible approach to overcome the metastasis-promoting effects of surgery by blunting stress and prostaglandin responses. Cancers. 2010;2(4):1929-51.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
227. Benner B, Scarberry L, Suarez-Kelly LP, Duggan MC, Campbell AR, Smith E, et al. Generation of monocyte-derived tumor-associated macrophages using tumor-conditioned media provides a novel method to study tumor-associated macrophages in vitro. Journal for Immunotherapy of Cancer. 2019;7(1):140.
배제사유 : 동물실험 및 전임상시험연구
228. Ben-Shmuel A, Biber G, Barda-Saad M. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy? Frontiers in Immunology. 2020;11 (275).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
229. Berczi I, Katafuchi T. Introduction: Advances in neuroimmune biology: A comprehensive way to look at biology. Advances in Neuroimmune Biology. 2011;1(1):1-9.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
230. Berezhnaya NM, Belova OB, Vinnichuk YD, Tarutinov VI. Expression of E-cadherin in drug resistant human breast cancer cells and their sensitivity to lymphokine-activated lymphocytes action. Experimental Oncology. 2009;31(4):242-5.
배제사유 : 동물실험 및 전임상시험연구
231. Bereznaya NM, Kirnasovskaya EA, Vinnichuk YD, Belova OB, Lukyanova NY. Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors. Experimental Oncology. 2008;30(4):295-9.
배제사유 : 동물실험 및 전임상시험연구
232. Berger CL, Edelson R. Cancer immunotherapy: From promise to practice. Drugs of the Future. 2008;33(5):411-23.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
233. Berkahn L. Immunologic methods of purging in autologous stem cell transplantation. Journal of Hematotherapy and Stem Cell Research. 2000;9(2):147-59.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

234. Berken A. Case for adoptive immunotherapy in cancer. *Lancet*. 1982;2(8309):1190-2.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

235. Berkley AM, Toy E, Cook R, Ye Z, Grogan J, Schartner J, et al. Immunosuppressive effects of sMIC abrogate immunotherapy efficacy in a mouse model of breast cancer. *Journal of Immunology. Conference: 105th Annual Meeting of the American Association of Immunologists, IMMUNOLOGY*. 2018;200(1 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

236. Bernardini G, Santoni A. The pathophysiological role of Chemokines in the regulation of NK cell tissue homing. *Critical Reviews in Oncogenesis*. 2014;19(1-2):77-90.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

237. Berry J, Green BJ, Matheson DS. Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer. *European Journal of Cancer & Clinical Oncology*. 1987;23(5):517-20.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

238. Berry J, Green BJ, Matheson DS. Modulation of natural killer cell activity in stage I postmenopausal breast cancer patients on low-dose aminoglutethimide. *Cancer Immunology, Immunotherapy*. 1987;24(1):72-5.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

239. Beswick EJ. NK cells set sights on cancer stem cells. *Science Translational Medicine*. 2015;7(306).

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

240. Betzler M, Flad HD, Huget R, Schreml W, Schlag P, Herfarth C. [Quantitative and functional response of a lymphatic subpopulation during adjuvant intermittent chemo-immunotherapy in breast cancer]. *Chirurgisches Forum fur Experimentelle und Klinische Forschung*. 1978(1978):227-30.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

241. Beuth J, Ko HL, Gabius HJ, Burrichter H, Oette K, Pulverer G. Behavior of lymphocyte subsets and expression of activation markers in response to immunotherapy with galactoside-specific lectin from mistletoe in breast cancer patients. *Clinical Investigator*. 1992;70(8):658-61.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

242. Beuth J, Ko HL, Tunggal L, Gabius HJ, Steuer M, Uhlenbruck G, et al. Mistletoe lectin in attendant therapy of mammary carcinoma - First clinical experiences. [German]. *Medizinische Welt*. 1993;44(3):217-20.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

243. Beuth J, Ko HL, Tunggal L, Geisel J, Pulverer G. [Comparative studies on the immunoactive action of galactoside-specific mistletoe lectin. Pure substance compared

to the standardized extract]. Arzneimittel-Forschung. 1993;43(2):166-9.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

244. Beuth J, Moss RW. Immunotherapy with mistletoe lectin-1: A scientific approach in complementary oncology. Zeitschrift fur Onkologie. 1998;30(1):1-5.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
245. Beuth J, Stoffel B, Ko HL, Buss G, Tunggal L, Pulverer G. [Immunoactive effects of various mistletoe lectin-1 dosages in mammary carcinoma patients]. Arzneimittel-Forschung. 1995;45(4):505-7.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
246. Beuth J. Proteolytic enzymes in oncology, update 2003. [German]. Deutsche Zeitschrift fur Onkologie. 2003;35(1):30-6.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
247. Bhan AK, DesMarais CL. Immunohistologic characterization of major histocompatibility antigens and inflammatory cellular infiltrate in human breast cancer. Journal of the National Cancer Institute. 1983;71(3):507-16.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
248. Bharati S, Chowdhury T, Bergese S, Ghosh S. Anesthetics impact on cancer recurrence: What do we know? Journal of Cancer Research and Therapeutics. 2016;12(2):464-8.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
249. Bhardwaj N. Harnessing the immune system to treat cancer. Journal of Clinical Investigation. 2007;117(5):1130-6.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
250. Bhargav H, Metri K, Raghuram N, Ramarao NH, Koka PS. Enhancement of cancer stem cell susceptibility to conventional treatments through complementary yoga therapy: possible cellular and molecular mechanisms. Journal of Stem Cells. 2012;7(4):261-7.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
251. Bhatia A, Kumar Y. Cancer stem cells and tumor immunoediting: putting two and two together. Expert Review of Clinical Immunology. 2016;12(6):605-7.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
252. Bhave NS, Parihar R, Lewis A, Karpa V, Carson WE. The role of monocytes in promoting natural killer cell activation in response to antibody-coated tumor cells and IL-12. Cancer Research. Conference: 102nd Annual Meeting of the American Association for Cancer Research, AACR. 2011;71(8 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
253. Bhave NS, Parihar R, Lewis A, Karpa V, Skinner C, Carson WE. Monocytes enhance natural killer cell cytokine production in response to antibody coated tumor cells in the presence of IL-12. Journal of Immunotherapy. 2010;33 (8):885.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
254. Bhome R, Al Saihati HA, Goh RW, Bullock MD, Primrose JN, Thomas GJ, et al.

Translational aspects in targeting the stromal tumour microenvironment: From bench to bedside. *New Horizons in Translational Medicine*. 2016;3(1):9-21.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

255. Bhutani D, Vaishampayan UN. Monoclonal antibodies in oncology therapeutics: Present and future indications. *Expert Opinion on Biological Therapy*. 2013;13(2):269-82.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

256. Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. *The Lancet Oncology*. 2014;15(2):e58-68.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

257. Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. *Nature Medicine*. 2012;18(8):1224-31.

배제사유 : 동물실험 및 전임상시험연구

258. Biederick KD, Schmidt-Wolf IGH. Efficacy of cytokine-induced killer cells targeting CD40 and GITR. *Oncology Letters*. 2019;17(2):2425-30.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

259. Bierie B, Moses HL. Transforming growth factor beta (TGF-beta) and inflammation in cancer. *Cytokine and Growth Factor Reviews*. 2010;21(1):49-59.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

260. Bifari F, Lisi V, Mimiola E, Pasini A, Krampera M. Immune modulation by mesenchymal stem cells. *Transfusion Medicine and Hemotherapy*. 2008;35(3):194-204.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

261. Bilgi O, Karagoz B, Turken O, Kandemir EG, Ozturk A, Gumus M, et al. Peripheral blood gamma-delta T cells in advanced-stage cancer patients. *Advances in Therapy*. 2008;25(3):218-24.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

262. Billhult A, Lindholm C, Gunnarsson R, Stener-Victorin E. The effect of massage on cellular immunity, endocrine and psychological factors in women with breast cancer -- a randomized controlled clinical trial. *Autonomic Neuroscience-Basic & Clinical*. 2008;140(1-2):88-95.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

263. Billhult A, Lindholm C, Gunnarsson R, Stener-Victorin E. The effect of massage on immune function and stress in women with breast cancer--a randomized controlled trial. *Autonomic Neuroscience-Basic & Clinical*. 2009;150(1-2):111-5.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

264. Bird L. Tumour immunology: Innate surveillance. *Nature Reviews Immunology*. 2016;16(3):132-3.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

265. Biroccio A, Cherfils-Vicini J, Augereau A, Pinte S, Bauwens S, Ye J, et al. TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells. *Nature Cell Biology*. 2013;15(7):818-28.
배제사유 : 동물실험 및 전임상시험연구
266. Biswas BK, Guru SA, Sumi MP, Jamatia E, Gupta RK, Lali P, et al. Natural Killer Cells Expanded and Preactivated Exhibit Enhanced Antitumor Activity against Different Tumor Cells in Vitro. *Asian Pacific journal of cancer prevention : APJCP*. 2020;21(6):1595-605.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
267. Biswas T, Fritzemeier R, Mark A, Meifcner T, Young BM, Pegram MD. Antibody-dependent cell-mediated cytotoxicity (ADCC) tolerance to monoclonal antibody therapeutics in human breast and colon cancer cell lines. *Cancer Research. Conference: 107th Annual Meeting of the American Association for Cancer Research, AACR*. 2016;76(14 Supplement).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
268. Biswas T, Fritzemeier R, Mark A, Meissner T, Young B, Jones BL, et al. Molecular and phenotypic characterization of breast and colorectal cancer cells selected for resistance to antibody-dependent cell-mediated cytotoxicity (ADCC). *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2017;77(13 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
269. Blagodatski A, Yatsunskaya M, Mikhailova V, Tiasto V, Kagansky A, Katanaev VL. Medicinal mushrooms as an attractive new source of natural compounds for future cancer therapy. *Oncotarget*. 2018;9(49):29259-74.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
270. Blair BG, Bardelli A, Park BH. Somatic alterations as the basis for resistance to targeted therapies. *Journal of Pathology*. 2014;232(2):244-54.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
271. Blanc E, Eberhardt A, Herbulot J, Le Beux C, Colombe A, Morel AP, et al. The alarmin IL-33 is expressed in breast cancer: An emerging role in breast cancer immunity via the activation of NK cells? *Cancer Immunology Research. Conference: AACR Special Conference on Tumor Immunology and Immunotherapy*. 2016;5(3 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
272. Blanchard DK, Kavanagh JJ, Sinkovics JG, Cavanagh D, Hewitt SM, Djeu JY. Infiltration of interleukin-2-inducible killer cells in ascitic fluid and pleural effusions of advanced cancer patients. *Cancer Research*. 1988;48(22):6321-7.
배제사유 : 동물실험 및 전임상시험연구
273. Block KI, Boyd DB, Gonzalez N, Vojdani A. The immune system in cancer. *Integrative Cancer Therapies*. 2002;1(3):294-316.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
274. Block KI. In This Issue. *Integrative Cancer Therapies*. 2015;14(5):407-8.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

275. Blomgren H, Baral E, Edsmyr F, Strenger LE, Petrini B, Wasserman J. Natural killer activity in peripheral lymphocyte population following local radiation therapy. *Acta Radiologica - Oncology*. 1980;19(2):139-43.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
276. Blomgren H, Rotstein S, Petrini B, Wasserman J. Blood lymphocyte population 4 to 6 years after adjuvant cyclic chemotherapy for operable breast carcinoma. *Acta Radiologica - Oncology*. 1985;24(2):123-7.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
277. Blomgren H, Strenger LE, Petrini B, Wasserman J. Changes of the spontaneous cytotoxicity of the blood lymphocyte population following local radiation therapy for breast cancer. *European Journal of Cancer and Clinical Oncology*. 1982;18(7):637-43.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
278. Blumenthal RD. Technology evaluation: Onyx-105, Onyx. *Current Opinion in Molecular Therapeutics*. 2003;5(6):668-72.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
279. Bobek V, Boubelik M, Kovarik J, Taltynov O. Inhibition of adhesion breast cancer cells by anticoagulant drugs and cimetidine. *Neoplasma*. 2003;50(2):148-51.
배제사유 : 동물실험 및 전임상시험연구
280. Bobrie A, Thery C. Unraveling the physiological functions of exosome secretion by tumors. *OncoImmunology*. 2013;2 (1) (e22565).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
281. Boddy AM, Fortunato A, Wilson Sayres M, Aktipis A. Fetal microchimerism and maternal health: A review and evolutionary analysis of cooperation and conflict beyond the womb. *BioEssays*. 2015;37(10):1106-18.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
282. Bodey B, Bodey B, Jr., Siegel SE, Kaiser HE. Fas (APO-1, CD95) receptor expression and new options for immunotherapy in childhood medulloblastomas. *Anticancer Research*. 1999;19(4B):3293-314.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
283. Bodey B, Bodey Jr B, Siegel SE, Kaiser HE. Fas (APO-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells? *In Vivo*. 1999;13(4):357-73.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
284. Boghossian S, Robinson S, Von Delwig A, Manas D, White S. Immunotherapy for treating metastatic colorectal cancer. *Surgical Oncology*. 2012;21(2):67-77.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
285. Boh B, Berovic M. Grifola frondosa (Dicks.: Fr.) S.F. Gray (maitake mushroom):

Medicinal properties, active compounds, and biotechnological cultivation. International Journal of Medicinal Mushrooms. 2007;9(2):89-108.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

286. Boivin MJ, Aaron GP, Felt NG, Shamoun L. Preliminary study on the effects of treatment for breast cancer: Immunological markers as they relate to quality of life and neuropsychological performance. BMC Women's Health. 2020;20 (1) (109).

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

287. Boligan KF, Mesa C, Fernandez LE, Von Gunten S. Cancer intelligence acquired (CIA): Tumor glycosylation and sialylation codes dismantling antitumor defense. Cellular and Molecular Life Sciences. 2015;72(7):1231-48.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

288. Bolton EJ, King J, Prektes AP, Clingan PR, Phadke K, Morris DL. A randomised controlled trial of an oral muramyl dipeptide (GMDP) for the reduction of leukopenia and thrombocytopenia in patients receiving cytotoxic chemotherapy. Surgical Research Communications. 1998;19(2-4):117-28.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

289. Bonavita E, Galdiero MR, Jaillon S, Mantovani A. Phagocytes as Corrupted Policemen in Cancer-Related Inflammation. Advances in Cancer Research. 2015;128:141-71.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

290. Bondarenko G, Ugolkov A, Rohan S, Kulesza P, Dubrovskyi O, Gursel D, et al. Patient-derived tumor xenografts are susceptible to formation of human lymphocytic tumors. Neoplasia. 2015;17(9):735-41.

배제사유 : 동물실험 및 전임상시험연구

291. Boniface JD, Poschke I, Mao Y, Kiessling R. Tumor-dependent down-regulation of the zeta-chain in T-cells is detectable in early breast cancer and correlates with immune cell function. International Journal of Cancer. 2012;131(1):129-39.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

292. Bonilla F, Alvarez-Mon M, Merino F, de la Hera A, Ales JE, Espana P, et al. Interleukin-2 induces cytotoxic activity in lymphocytes from regional axillary nodes of breast cancer patients. Cancer. 1988;61(4):629-34.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

293. Bonilla F, Alvarez-Mon M, Merino F, Giron JA, Menendez JL, Espana P, et al. Natural killer activity in patients with breast cancer. European Journal of Gynaecological Oncology. 1990;11(2):103-9.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

294. Boomsma MF, Garssen B, Slot E, Berbee M, Berkhof J, Meezenbroek EDJ, et al. Breast cancer surgery-induced immunomodulation. Journal of Surgical Oncology. 2010;102(6):640-8.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

295. Borden EC, Holland JF, Dao TL, Guterman JU, Wiener L, Chang YC, et al. Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial. *Annals of Internal Medicine*. 1982;97(1):1-6.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
296. Bordon Y. Tumour immunology: NK cells bring in the troops. *Nature Reviews Immunology*. 2018;18(3):151.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
297. Borgeat A. Evidence of impact of RA immunomodulation. *Regional Anesthesia and Pain Medicine*. 2014;1):e27-e8.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
298. Borghaei H, Alpaugh RK, Bernardo P, Palazzo IE, Dutcher JP, Venkatraj U, et al. Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group. *Journal of Immunotherapy*. 2007;30(4):455-67.
배제사유 : 동물실험 및 전임상시험연구
299. Borghaei H, Smith MR, Campbell KS. Immunotherapy of cancer. *European Journal of Pharmacology*. 2009;625(1-3):41-54.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
300. Borisov VA, Guseva OA. Immunocorrecting action of the Selective Chronophototherapy of the breast cancer and the cancer of the brain. *Photodiagnosis and Photodynamic Therapy*. 2012;1):S10.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
301. Borysenko JZ. Behavioral--physiological factors in the development and management of cancer. *General Hospital Psychiatry*. 1982;4(1):69-74.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
302. Bos PD, Plitas G, Rudra D, Lee SY, Rudensky AY. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. *Journal of Experimental Medicine*. 2013;210(11):2435-66.
배제사유 : 동물실험 및 전임상시험연구
303. Bose A, Chakraborty T, Chakraborty K, Pal S, Baral R. Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. *Cancer Immunity*. 2008;8 (10).
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
304. Bossennec M, Di Roio A, Caux C, Menetrier-Caux C. MDR1 in immunity: friend or foe? *OncoImmunology*. 2018;7 (12) (e1499388).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
305. Bottcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerozo M, Sammicheli S, et al. NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment

Promoting Cancer Immune Control. Cell. 2018;172(5):1022-37.e14.

배제사유 : 동물실험 및 전임상시험연구

306. Bottero V, Withoff S, Verma IM. NF-kappaB and the regulation of hematopoiesis. *Cell Death and Differentiation*. 2006;13(5):785-97.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
307. Bottos A, Gotthardt D, Gill JW, Gattelli A, Frei A, Tzankov A, et al. Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models. *Nature communications*. 2016;7:12258.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
308. Bouchlaka MN, Redelman D, Murphy WJ. Immunotherapy following hematopoietic stem cell transplantation: Potential for synergistic effects. *Immunotherapy*. 2010;2(3):399-418.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
309. Bou-Dargham MJ, Liu Y, Sang QXA, Zhang J. The different immune evasion mechanisms in human prostate cancer. *Cancer Research Conference*. 2018;78(13 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
310. Boudreau JE, Bonehill A, Thielemans K, Wan Y. Engineering dendritic cells to enhance cancer immunotherapy. *Molecular Therapy*. 2011;19(5):841-53.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
311. Bouet-Toussaint F, Genetel N, Rioux-Leclercq N, Bansard JY, Leveque J, Guille F, et al. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer. *European Cytokine Network*. 2000;11(2):217-24.
배제사유 : 동물실험 및 전임상시험연구
312. Bourzac K. Medical imaging: Removing the blindfold. *Nature*. 2013;504(7480):S10-S2.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
313. Bovill JG. Editorial: Surgery for cancer: Does anesthesia matter? *Anesthesia and Analgesia*. 2010;110(6):1524-6.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
314. Bower JE, Ganz PA, Aziz N, Fahey JL, Cole SW. T-cell homeostasis in breast cancer survivors with persistent fatigue. *Journal of the National Cancer Institute*. 2003;95(15):1165-8.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
315. Bower JE, Ganz PA, Aziz N, Olmstead R, Irwin MR, Cole SW. Inflammatory responses to psychological stress in fatigued breast cancer survivors: Relationship to glucocorticoids. *Brain, Behavior, and Immunity*. 2007;21(3):251-8.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
316. Bower JE, Kemeny ME, Taylor SE, Fahey JL. Finding positive meaning and its association with natural killer cell cytotoxicity among participants in a bereavement-related

disclosure intervention. *Annals of Behavioral Medicine*. 2003;25(2):146-55.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

317. Bowles JA, Weiner GJ. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. *Journal of Immunological Methods*. 2005;304(1-2):88-99.
배제사유 : 동물실험 및 전임상시험연구
318. Boxhammer R, Weirather J, Steidl S, Endell J. MOR202, a human anti-CD38 monoclonal antibody, mediates potent tumoricidal activity in vivo and shows synergistic efficacy in combination with different antineoplastic compounds. *Blood*. 2015;126 (23):3015.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
319. Boyiadzis M, Foon KA. Natural killer cells: From bench to cancer therapy. *Expert Opinion on Biological Therapy*. 2006;6(10):967-70.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
320. Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: Implications for the design of novel and rationale-based combined treatments against cancer. *Cell Death and Differentiation*. 2014;21(1):15-25.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
321. Brack ME, Boterberg T, Depypere HT, Stove C, Leclercq G, Mareel MM. The citrus methoxyflavone tangeretin affects human cell-cell interactions. *Advances in Experimental Medicine & Biology*. 2002;505:135-9.
배제사유 : 동물실험 및 전임상시험연구
322. Bracke ME, Depypere HT, Boterberg T, Van Marck VL, Vennekens KM, Vanluchene E, et al. Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer. *Journal of the National Cancer Institute*. 1999;91(4):354-9.
배제사유 : 동물실험 및 전임상시험연구
323. Brackett CM, Kojouharov B, Veith J, Greene KF, Burdelya LG, Gollnick SO, et al. Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. *Proceedings of the National Academy of Sciences of the United States of America*. 2016;113(7):E874-E83.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
324. Braun SE, Chen K, Foster RG, Kim CH, Hromas R, Kaplan MH, et al. The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. *Journal of Immunology*. 2000;164(8):4025-31.
배제사유 : 동물실험 및 전임상시험연구
325. Bregni M, Ueno NT, Childs R. The second international meeting on allogeneic transplantation in solid tumors. *Bone Marrow Transplantation*. 2006;38(8):527-37.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
326. Breitmeyer JB. Immunotherapy of breast cancer. *Cancer Treatment & Research*. 1992;60:331-56.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

327. Bremers AJA, Parmiani G. Immunology and immunotherapy of human cancer: Present concepts and clinical developments. *Critical Reviews in Oncology/Hematology*. 2000;34(1):1-25.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
328. Brenner BG, Benarrosh S, Margolese RG. Peripheral blood natural killer cell activity in human breast cancer patients and its modulation by T-cell growth factor and autologous plasma. *Cancer*. 1986;58(4):895-902.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
329. Brenner BG, Friedman G, Margolese RG. The relationship of clinical status and therapeutic modality to natural killer cell activity in human breast cancer. *Cancer*. 1985;56(7):1543-8.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
330. Brenner BG, Gryllis C, Gornitsky M, Cupples W, Wainberg M. Differential effects of chemotherapy-induced and HIV-1-induced immunocompromise on NK and LAK activities using breast cancer and HIV-1 seropositive patient populations. *Anticancer Research*. 1991;11(2):969-74.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
331. Brenner BG, Margolese RG. The relationship of chemotherapeutic and endocrine intervention on natural killer cell activity in human breast cancer. *Cancer*. 1991;68(3):482-8.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
332. Brenner BG, McCrea EL, Margolese RG. Cytolysis of mammary tumor targets by resting, interleukin-2 stimulated and in vitro cultured peripheral blood lymphocytes from breast cancer patients. *Anticancer Research*. 1988;8(4):653-8.
배제사유 : 동물실험 및 전임상시험연구
333. Brenner BG, Vo C, Wainberg MA. Different effects of breast cancer, HIV-1 infection and chemotherapy on inducible natural immunity. *Leukemia*. 1994;8 Suppl 1:S183-5.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
334. Breunig C, Kublbeck M, Miller M, Antonelli D, Wirth C, Erdem N, et al. Proffered Paper: miRNA induces escape from NK cell-mediated cytotoxicity and resistance towards apoptosis in breast cancer. *European Journal of Cancer*. 2014;5):S11.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
335. Breunig C, Pahl J, Kublbeck M, Miller M, Antonelli D, Erdem N, et al. MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells. *Cell Death & Disease*. 2017;8(8):e2973.
배제사유 : 동물실험 및 전임상시험연구

336. Brignone C, Gutierrez M, Mefti F, Brain E, Jarcau R, Cvitkovic F, et al. First-line chemoimmunotherapy in metastatic breast carcinoma: Combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. *Journal of Translational Medicine*. 2010;8 (71).
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
337. Brittenden J, Heys SD, Ross J, Park KG, Eremin O. Natural cytotoxicity in breast cancer patients receiving neoadjuvant chemotherapy: effects of L-arginine supplementation. *European Journal of Surgical Oncology*. 1994;20(4):467-72.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
338. Brittenden J, Park KG, Heys SD, Ross C, Ashby J, Ah-See A, et al. L-arginine stimulates host defenses in patients with breast cancer. *Surgery*. 1994;115(2):205-12.
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
339. Brodt P. Role of the microenvironment in liver metastasis: From pre- to prometastatic niches. *Clinical Cancer Research*. 2016;22(24):5971-82.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
340. Bronchud MH, Tresserra F, Zantop BS. Epigenetic changes found in uterine decidual and placental tissues can also be found in the breast cancer microenvironment of the same unique patient: Description and potential interpretations. *Oncotarget*. 2018;9(5):6028-41.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
341. Bronger H, Kraeft S, Schwarz-Boeger U, Cerny C, Stockel A, Avril S, et al. Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer. *Breast Cancer Research*. 2012;14(1):R30.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
342. Bronger H, Kraeft S, Stockel A, Welk A, Kiechle M, Schmitt M, et al. Effect of cyclooxygenase inhibition on CXCR3 ligand secretion in breast cancer. *Journal of Clinical Oncology. Conference*. 2011;29(27 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
343. Bronger H, Schwarz-Boeger U, Kraeft S, Stoeckel A, Welk A, Kiechle M, et al. Modulation of CXCL9 release by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer. *Archives of Gynecology and Obstetrics*. 2010;1:S107.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
344. Bronger H, Schwarz-Boeger URM, Kraeft S, Stockel A, Welk A, Kiechle M, et al. The effects of cyclooxygenase inhibition on CXCR3 ligand secretion in breast cancer. *Journal of Clinical Oncology. Conference: ASCO Annual Meeting*. 2011;29(15 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
345. Brotherton H, Hallmark C, Rogers H. The impact of stress management on immune response in breast cancer patients: A systematic review and meta-analysis of lymphocyte outcomes shortly after intervention. *Psycho-Oncology*. 2014;3):124.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

346. Brower V. Mechanistic research illuminating connection among depression, stress, and survival. *Journal of the National Cancer Institute*. 2014;106(3):dju069.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

347. Brower V. Researchers attempting to define role of cytokines in cancer risk. *Journal of the National Cancer Institute*. 2005;97(16):1175-7.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

348. Brown RE, Bernath AM, Lewis GO. HER-2/neu protein-receptor-positive breast carcinoma: an immunologic perspective. *Annals of Clinical & Laboratory Science*. 2000;30(3):249-58.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

349. Brozovic G, Stefancic L, Goranovic T, Vrdoljak DV. Regional anaesthesia in cancer surgery: An update. *Periodicum Biologorum*. 2015;117(2):219-23.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

350. Bruckheimer EM, Fazenbaker CA, Gallagher S, Mulgrew K, Fuhrmann S, Coffman KT, et al. Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. *Neoplasia*. 2009;11(6):509-17.

배제사유 : 동물실험 및 전임상시험연구

351. Brugmann A, Sorensen BS. Identifying responders to trastuzumab therapy in breast cancer. *Future Oncology*. 2011;7(6):767-73.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

352. Bruhn C. Immunotherapy against cancer. [German]. *Deutsche Apotheker Zeitung*. 2005;145(6):67-8.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

353. Bruno A, Dovizio M, Tacconelli S, Contursi A, Ballerini P, Patrignani P. Antithrombotic agents and cancer. *Cancers*. 2018;10 (8) (253).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

354. Bryant G, Wang L, Mulholland DJ. Overcoming oncogenic mediated tumor immunity in prostate cancer. *International Journal of Molecular Sciences*. 2017;18 (7) (1542).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

355. Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, coactivation, and costimulation of resting human natural killer cells. *Immunological Reviews*. 2006;214(1):73-91.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

356. Buck RH, Thomas DL, Winship TR, Cordle CT, Kuchan MJ, Baggs GE, et al. Effect of dietary ribonucleotides on infant immune status. Part 2: immune cell development. *Pediatric research*. 2004;56(6):891?900.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

357. Buckley A, Mc Quaid S, Johnson P, Buggy D. Serum from women undergoing breast cancer surgery, randomized to propofol-paravertebral anaesthetic technique, maintain natural killer cell anti-tumour activity compared with sevoflurane-opioid technique. *European Journal of Anaesthesiology*. 2014;52):2.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
358. Buckley A, McQuaid S, Johnson P, Buggy D. Effect of anaesthetic technique on ER positive breast cancer cell apoptosis in the presence of CD56+ NK cells. *Irish Journal of Medical Science*. 2013;2):S60.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
359. Buckley A, McQuaid S, Johnson P, Buggy DJ. Effect of anaesthetic technique on the natural killer cell anti-tumour activity of serum from women undergoing breast cancer surgery: a pilot study. *British Journal of Anaesthesia*. 2014;113 Suppl 1:i56-62.
배제사유 : 동물실험 및 전임상시험연구
360. Budczies J, Bockmayr M, Klauschen F, Stenzinger A, Denkert C. Deciphering the impact of tumor genetics on immune cell infiltration in major solid cancer types. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2017;77(13 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
361. Budczies J, Sinn BV, Pfitzner BM, Villegas-Angel S, Ingold-Heppner B, Wienert S, et al. Deciphering the connection of tumor genetics, tumor immune cell infiltration and prognosis in breast cancer. *Annals of Oncology*. 2017;28 (Supplement 1):iii15.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
362. Budinsky AC, Brodowicz T, Wiltschke C, Czerwenka K, Michl I, Krainer M, et al. Decreased expression of ICAM-1 and its induction by tumor necrosis factor on breast-cancer cells in vitro. *International Journal of Cancer*. 1997;71(6):1086-90.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
363. Buggy DJ, Hemmings HC. Special issue on anaesthesia and cancer. *British Journal of Anaesthesia*. 2014;113(SUPPL. 1):i1-i3.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
364. Bui T, Shinn KM, O'Koren EG, Derrick A, Godfrey B, Belle I, et al. Enhanced proliferation and effector functions of human immune cells in response to immune checkpoint therapy of MDA-MB-231 tumor bearing huNOG mice engrafted with human CD34+ cells. *Cancer Research. Conference*. 2018;78(13 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
365. Buijs C, Rodenhuis S, Seynaeve CM, van Hoesel QG, van der Wall E, Smit WJ, et al. Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life. *Journal of clinical oncology*. 2007;25(34):5403?9.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
366. Buijs JT, Juarez P, Guise TA. Therapeutic strategies to target TGF-beta in the treatment

of bone metastases. Current Pharmaceutical Biotechnology. 2011;12(12):2121-37.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

367. Buisseret L, Garaud S, Allard B, Cousineau I, Chouinard G, Sotiriou C, et al. CD73 expression on tumor-infiltrating breast cancer leukocytes. Cancer Research. Conference: 106th Annual Meeting of the American Association for Cancer Research, AACR. 2015;75(15 SUPPL. 1).
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
368. Buisseret L, Pommey S, Allard B, Garaud S, Ameye L, Di Leo A, et al. Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial. Annals of Oncology. 2017;28 (Supplement 1):iii11.
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
369. Buisseret L, Pommey S, Allard B, Garaud S, Bergeron MA, Cousineau I, et al. Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial. Cancer Research. Conference: San Antonio Breast Cancer Symposium, SABCS. 2017;78(4 Supplement 1).
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
370. Buller CW, Mathew PA, Mathew SO. Roles of NK Cell Receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in Cancer. Cancers. 2020;12(7):01.
- 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
371. Bullis C, Han S, Davare M. Multiplexed immunohistochemistry and the immune microenvironment of primary central nervous system tumors. Neuro-Oncology. 2019;21 (Supplement 6):vi147-vi8.
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
372. Bunk S, Trbic A, Winkler AM, Weber A, Schwarz HP, Reipert BM, et al. Intravenous immunoglobulins suppress antibody-dependent effector functions of human peripheral blood cells. Journal of Clinical Immunology. 2012;1):S33.
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
373. Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Translating tumor antigens into cancer vaccines. Clinical and Vaccine Immunology. 2011;18(1):23-34.
- 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
374. Buonomo OC, Petrella G, Esser A, Buonomo C, Scaggiante J, Vanni G. Impact of awake breast surgery on post-operative lymphocyte responses. European Journal of Cancer. 2014;2):S156.
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
375. Burd R, Dziedzic TS, Xu Y, Caligiuri MA, Subjeck JR, Repasky EA. Tumor cell apoptosis, lymphocyte recruitment and tumor vascular changes are induced by low temperature, long duration (fever-like) whole body hyperthermia. Journal of Cellular Physiology. 1998;177(1):137-47.
- 배제사유 : 동물실험 및 전임상시험연구
376. Burdelya LG, Brackett CM, Kojouharov B, Gitlin, II, Leonova KI, Gleiberman AS, et al.

Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(20):E1857-66.

배제사유 : 동물실험 및 전임상시험연구

377. Burks J, Reed RE, Desai SD. Free ISG15 triggers an antitumor immune response against breast cancer: a new perspective. *Oncotarget*. 2015;6(9):7221-31.

배제사유 : 동물실험 및 전임상시험연구

378. Burns LJ, Weisdorf DJ, DeFor TE, Repka TL, Ogle KM, Hummer C, et al. Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer. *Experimental Hematology*. 2000;28(1):96-103.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

379. Burns LJ, Weisdorf DJ, DeFor TE, Vesole DH, Repka TL, Blazar BR, et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: A phase I/II trial. *Bone Marrow Transplantation*. 2003;32(2):177-86.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

380. Burns LJ, Weisdorf DJ, DeFor TE, Vesole DH, Repka TL, Blazar BR, et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. *Bone Marrow Transplantation*. 2003;32(2):177-86.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

381. Burrows GD. Editorial. *Stress and Health*. 2007;23(3):139-40.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

382. Bussing A, Troger W, Stumpf C, Schietzel M. Local reactions to treatments with viscum album L. extracts and their association with T-lymphocyte subsets and quality of life. *Anticancer Research*. 2008;28(3 B):1893-7.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

383. Byrne K, Levins KJ, Buggy DJ. Can anesthetic-analgesic technique during primary cancer surgery affect recurrence or metastasis? *Canadian Journal of Anesthesia*. 2016;63(2):184-92.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

384. Byrne SN, Halliday GM. Dendritic cells: Making progress with tumour regression? *Immunology and Cell Biology*. 2002;80(6):520-30.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

385. Cabioglu N, Muslumanoglu M, Tutuncu Y, Adin-Cinar S, Gurel N, Kiran B, et al. Immune changes in patients with locally advanced breast cancer receiving neoadjuvant chemotherapy. *Turkish Journal of Immunology*. 2008;13(1):15-20.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

386. Caccamo N, Meraviglia S, Scarpa F, La Mendola C, Santini D, Bonanno CT, et al. Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer: Doubts no more. *Expert Opinion on Biological Therapy*. 2008;8(7):875-83.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
387. Cacho-Diaz B, Garcia-Botello DR, Wegman-Ostrosky T, Reyes-Soto G, Ortiz-Sanchez E, Herrera-Montalvo LA. Tumor microenvironment differences between primary tumor and brain metastases. *Journal of Translational Medicine*. 2020;18(1):1.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
388. Cai X, Dai Z, Reeves RS, Caballero-Benitez A, Duran KL, Delrow JJ, et al. Autonomous stimulation of cancer cell plasticity by the human NKG2D lymphocyte receptor coexpressed with its ligands on cancer cells. *PLoS ONE*. 2014;9 (10) (v).
배제사유 : 동물실험 및 전임상시험연구
389. Caldeira JC, Perrine M, Pericle F, Cavallo F. Virus-like particles as an immunogenic platform for cancer vaccines. *Viruses*. 2020;12 (5) (488).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
390. Callejas BE, Martinez-Saucedo D, Terrazas LI. Parasites as negative regulators of cancer. *Bioscience Reports*. 2018;38 (5) (BSR20180935).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
391. Camacho JA. Biotech innovation in a first-to-file world. *Nature Biotechnology*. 2012;30(5):401-3.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
392. Campbell A, Brautbar N, Vojdani A. Suppressed natural killer cell activity in patients with silicone breast implants: Reversal upon explantation. *Toxicology and Industrial Health*. 1994;10(3):149-54.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
393. Campbell AR, Duggan MC, Suarez-Kelly LP, Bhave N, Opheim KS, McMichael EL, et al. MICA-Expressing Monocytes Enhance Natural Killer Cell Fc Receptor-Mediated Antitumor Functions. *Cancer Immunology Research*. 2017;5(9):778-89.
배제사유 : 동물실험 및 전임상시험연구
394. Campesato LF, Silva APM, Cordeiro L, Correa BR, Navarro FCP, Zanin RF, et al. High IL-1R8 expression in breast tumors promotes tumor growth and contributes to impaired antitumor immunity. *Oncotarget*. 2017;8(30):49470-83.
배제사유 : 동물실험 및 전임상시험연구
395. Campoli M, Chang CC, Oldford SA, Edgecombe AD, Drover S, Ferrone S. HLA antigen changes in malignant tumors of mammary epithelial origin: Molecular mechanisms and clinical implications. *Breast Disease*. 2004;20:105-25.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
396. Camussi G, Deregibus MC, Tetta C. Tumor-derived microvesicles and the cancer

microenvironment. Current Molecular Medicine. 2013;13(1):58-67.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

397. Cannon MJ, O'Brien TJ. Cellular immunotherapy for ovarian cancer. Expert Opinion on Biological Therapy. 2009;9(6):677-88.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

398. Canossi A, Aureli A, Del Beato T, Novelli G, Buonomo O, Sconocchia G. Evaluation of NK cell cytotoxicity biomarkers of tumor progression in breast cancer. Hla. 2018;91(5):447.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

399. Cantaluppi V, Medica D, Quercia AD, Dellepiane S, Boaglio E, Clari R, et al. Circulating plasma extracellular vesicles trigger inflammation and hamper innate and adaptive immune response in patients with end stage chronic kidney disease. Nephrology Dialysis Transplantation. 2015;3):iii39.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

400. Cappuzzello E, Sommaggio R, Kellner C, Peipp M, Rosato A. Enhancing Cytokine-Induced Killer (CIK) cell activity with Her2-specific Fc-engineered antibodies and antibody derivatives. European Journal of Cancer. 2018;92 (Supplement 1):S23-S4.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

401. Cappuzzello E, Sommaggio R, Zanovello P, Rosato A. Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells. Cytokine and Growth Factor Reviews. 2017;36:99-105.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

402. Caragine TA, Imai M, Frey AB, Tomlinson S. Expression of rat complement control protein Crry on tumor cells inhibits rat natural killer cell-mediated cytotoxicity. Blood. 2002;100(9):3304-10.

배제사유 : 동물실험 및 전임상시험연구

403. Caragine TA, Okada N, Frey AB, Tomlinson S. A tumor-expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer. Cancer Research. 2002;62(4):1110-5.

배제사유 : 동물실험 및 전임상시험연구

404. Caras I, Grigorescu A, Stavaru C, Radu DL, Mogos I, Szegli G, et al. Evidence for immune defects in breast and lung cancer patients. Cancer Immunology, Immunotherapy. 2004;53(12):1146-52.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

405. Caratelli S, Arriga R, Sconocchia T, Ottaviani A, Lanzilli G, Pastore D, et al. In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab. International Journal of Cancer. 2020;146(1):236-47.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

406. Cardillo M, Yankelevich B, Mazumder A, Lupu R. Heregulin induces increase in

sensitivity of an erbB-2-overexpressing breast cancer cell type to lysis by lymphokine-activated killer cells. *Cancer Immunology, Immunotherapy*. 1996;43(1):19-25.
배제사유 : 동물실험 및 전임상시험연구

407. Carlson E, Kistler M, Soon-Shiong P, Lee J, Nangia C, Sender L, et al. NANT Cancer Vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater TNBC and head and neck SCC. *Journal for ImmunoTherapy of Cancer. Conference: 33rd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2018;6(Supplement 1)*.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
408. Carlson LE, Speca M, Patel KD, Goodey E. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress, and immune parameters in breast and prostate cancer outpatients. *Psychosomatic Medicine*. 2003;65(4):571-81.
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
409. Carmichael AR, Daley AJ, Rea DW, Bowden SJ. Physical activity and breast cancer outcome: a brief review of evidence, current practice and future direction. *European Journal of Surgical Oncology*. 2010;36(12):1139-48.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
410. Carosella ED, Horuzsko A. HLA-G and cancer. *Seminars in Cancer Biology*. 2007;17(6):411-2.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
411. Carpenter PM, Gatanaga T, Nguyen HP, Hiserodt JC. Lymphocyte and monocyte-induced motility of MCF-7 cells by tumor necrosis factor-alpha. *International Journal of Cancer*. 1997;71(1):64-70.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
412. Carson WE, 3rd, Shapiro CL, Crespin TR, Thornton LM, Andersen BL. Cellular immunity in breast cancer patients completing taxane treatment. *Clinical Cancer Research*. 2004;10(10):3401-9.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
413. Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, et al. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. *European Journal of Immunology*. 2001;31(10):3016-25.
배제사유 : 동물실험 및 전임상시험연구
414. Carter CR, Hogan BV, Cole JY, Shenoy HG, Horgan KM, Hughes TA. The expression of activating natural killer cell receptors in patients with primary breast cancer. *Cancer Research. Conference: 31st Annual San Antonio Breast Cancer Symposium. San Antonio, TX United States. Sponsor: UT Health Science Center San Antonio School of Medicine, American Association for Cancer Research, Baylor College of Medicine . Conference Publication: 2009;69(2 Suppl. S)*.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

415. Cartron G. FCGR3A polymorphism story: A new piece of the puzzle. Leukemia and Lymphoma. 2009;50(9):1401-2.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

416. Castiello L, Arico E, D'Agostino G, Santodonato L, Belardelli F. In situ vaccination by direct dendritic cell inoculation: The coming of age of an old idea? Frontiers in Immunology. 2019;10 (SEP) (2303).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

417. Cattaruzza F, Yeung P, Wang M, Brunner A, Le Scolan E, Cain J, et al. Pharmacodynamic biomarkers for anti-TIGIT treatment and prevalence of TIGIT expression in multiple solid tumor types. Cancer Research. Conference: American Association for Cancer Research Annual Meeting. 2017;77(13 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

418. Cavallo F, Offringa R, van der Burg SH, Forni G, Melief CJM. Vaccination for Treatment and Prevention of Cancer in Animal Models. Advances in Immunology. 2006;90:175-213.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

419. Cebon J, Gedye C, John T, David ID. Immunotherapy of advanced or metastatic melanoma. Clinical Advances in Hematology and Oncology. 2007;5(12):994-1006.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

420. Cecchetti S, Ricci A, Iorio E, Paris L, Pisanu ME, Portella L, et al. Phosphatidylcholine-specific phospholipase C as a target to manipulate CXCR4-CXCL12 signaling pathway in human lymphoblastoid cells. European Journal of Cancer. 2012;5:S89.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

421. Cemazar M, Jarm T, Sersa G. Cancer electrogene therapy with interleukin-12. Current Gene Therapy. 2010;10(4):300-11.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

422. Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Research. 2010;70(11):4297-309.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

423. Chabannon C, Mfarrej B, Guia S, Ugolini S, Devillier R, Blaise D, et al. Manufacturing natural killer cells as medicinal products. Frontiers in Immunology. 2016;7 (NOV) (504).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

424. Chae WJ, Bothwell ALM. Canonical and Non-Canonical Wnt Signaling in Immune Cells. Trends in Immunology. 2018;39(10):830-47.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

425. Chaganty BK, Lu Y, Qiu S, Somanchi SS, Lee DA, Fan Z. Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of

natural killer cells and stimulation of IFNgamma secretion. *Oncoimmunology*. 2016;5(4):e1100790.

배제사유 : 동물실험 및 전임상시험연구

426. Chaiyasisit K, Wiwanitkit V. Effect of tropical mushroom, *Coriolus versicolor*, on natural killer cell. *Annals of Tropical Medicine and Public Health*. 2016;9(5):360-1.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

427. Chakraborty NG. Genetically predisposed, life style and occurrence of metastatic cancer. *Indian Journal of Human Genetics*. 2007;13(2):48-9.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

428. Challita-Eid PM, Abboud CN, Morrison SL, Penichet ML, Rosell KE, Poles T, et al. A RANTES-antibody fusion protein retains antigen specificity and chemokine function. *Journal of Immunology*. 1998;161(7):3729-36.

배제사유 : 동물실험 및 전임상시험연구

429. Chamaraux-Tran TN, Piegeler T. The Amide Local Anesthetic Lidocaine in Cancer Surgery-Potential Antimetastatic Effects and Preservation of Immune Cell Function? A Narrative Review. *Frontiers in Medicine*. 2017;4:235.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

430. Chames P, Baty D. Bispecific antibodies for cancer therapy. *Current Opinion in Drug Discovery and Development*. 2009;12(2):276-83.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

431. Chan HT, Chin YM, Low SK. The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics. *Oncology and Therapy*. 2019;7(1).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

432. Chan IS, Knutsdottir H, Ramakrishnan G, Padmanaban V, Warrier M, Ramirez JC, et al. Cancer cells educate natural killer cells to a metastasis-promoting cell state. *Journal of Cell Biology*. 2020;219(9):07.

배제사유 : 동물실험 및 전임상시험연구

433. Chandra D, Jahangir A, Quispe-Tintaya W, Einstein MH, Gravekamp C. Myeloid-derived suppressor cells have a central role in attenuated *Listeria monocytogenes*-based immunotherapy against metastatic breast cancer in young and old mice. *British Journal of Cancer*. 2013;02.

배제사유 : 동물실험 및 전임상시험연구

434. Chandwani KD, Ryan JL, Peppone LJ, Janelsins MM, Sprod LK, Devine K, et al. Cancer-related stress and complementary and alternative medicine: A review. *Evidence-based Complementary and Alternative Medicine*. 2012;2012 (979213).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

435. Chang CH, Liu D, Goldenberg DM. Directing NK cells to Trop-2-expressing breast and other cancers, with chimeric antigen receptors. *Cancer Research. Conference: 39th Annual CTRC AACR San Antonio Breast Cancer Symposium*. United States. 2017;77(4 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

436. Chang WA, Tsai MJ, Kuo PL, Hung JY. Role of galectins in lung cancer (Review). Oncology Letters. 2017;14(5):5077-84.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

437. Chapman L, Abdi J, Galvez-Peisl S, Keating A. Immunophenotypic and functional characterisation of Mesodermal Killer (MK) cells: a novel cell type and potential cellular therapy for cancer. Cytotherapy. 2020;22 (5 Supplement):S121.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

438. Chartrain M, Chu L. Development and production of commercial therapeutic monoclonal antibodies in mammalian cell expression systems: An overview of the current upstream technologies. Current Pharmaceutical Biotechnology. 2008;9(6):447-67.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

439. Charych DH, Rubas W, Dixit V, Cetz J, Pena R, Langowski JL, et al. Immune memory in nonclinical models after treatment with NKTR-214, an engineered cytokine biased towards expansion of CD8+ T cells in tumor. Journal of Clinical Oncology. Conference. 2016;34(Supplement 15).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

440. Chatterjee S, Chatterjee A, Jana S, Roy H, Nargis N, Bhattacharyya A. Breast tumor-associated exosomes mediate loss of antitumor immune response by arresting cytotoxic T cell functions in the tumor microenvironment. Annals of Oncology. Conference: European Society for Medical Oncology Asia Congress, ESMO. 2018;29(Supplement 9).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

441. Chavez-Blanco A, De La Cruz-Hernandez E, Dominguez GI, Rodriguez-Cortez O, Alatorre B, Perez-Cardenas E, et al. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. International Journal of Oncology. 2011;39(6):1491-9.

배제사유 : 동물실험 및 전임상시험연구

442. Chawla A, Alatrash G, Wu Y, Mittendorf EA. Immune aspects of the breast tumor microenvironment. Breast Cancer Management. 2013;2(3):231-44.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

443. Check JH, Dougherty MP, DiAntonio G, Vaniver J, Duroseau M, Srivastava MD. Comparison of serum progesterone levels of the immunomodulatory protein, the progesterone induced blocking factor, in people with BRCA-2 mutations associated with and not associated with a high risk of cancer. Cancer Research. Conference: 106th Annual Meeting of the American Association for Cancer Research, AACR. 2015;75(15 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

444. Check JH, Rosenberg A, Check DL, DiAntonio A, Rui H, Cohen R, et al. Serum levels of the immunomodulatory protein, the progesterone induced blocking factor (PIBF) which is found in high levels during pregnancy is not higher in women with progesterone (P)

receptor (R) positive vs. Negative breast cancer. Clinical and Experimental Obstetrics and Gynecology. 2017;44(2):187-9.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

445. Check JH, Rosenberg A, Di Antonio A, Rui H, Cohen R, Di Antonio G. Serum levels of the immunomodulatory protein, the progesterone induced blocking factor (PIBF) are not higher in women with progesterone (P) receptor (R) positive vs. negative breast cancer. Cancer Research. Conference: 106th Annual Meeting of the American Association for Cancer Research, AACR. 2015;75(15 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

446. Check JH, Sansoucie L, Chern J, Amadi N, Srivastava M, Larece K. Evidence that progesterone receptor antagonists may help in the treatment of a variety of cancers by locally suppressing natural killer cell activity. Clinical and Experimental Obstetrics and Gynecology. 2007;34(4):207-11.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

447. Check JH. The importance of the immunomodulatory protein, progesterone-induced blocking factor, in allowing cancer cells to escape immune surveillance and therapeutic considerations. Anticancer Research. 2014;34 (10):5860-2.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

448. Chen E, Qin X, Peng K, Xu X, Li W, Cheng X, et al. Identification of Potential Therapeutic Targets among CXC Chemokines in Breast Tumor Microenvironment Using Integrative Bioinformatics Analysis. Cellular Physiology and Biochemistry. 2018;45(5):1731-46.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

449. Chen EP, Smyth EM. COX-2 and PGE2-dependent immunomodulation in breast cancer. Prostaglandins and Other Lipid Mediators. 2011;96(1-4):14-20.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

450. Chen JY, Lai YS, Chu PY, Chan SH, Wang LH, Hung WC. Cancer-derived VEGF-C increases chemokine production in lymphatic endothelial cells to promote CXCR2-dependent cancer invasion and MDSC recruitment. Cancers. 2019;11 (8) (1120).

배제사유 : 동물실험 및 전임상시험연구

451. Chen KC, Su TC, Chen DR, Liou JH. A case report: Blastic plasmacytoid dendritic cell neoplasm is misdiagnosed as breast infiltrating ductal carcinoma. International Journal of Surgical Pathology. 2015;23(1):84-8.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

452. Chen LZ, Xie Z, Feng ZH, Huang G, Yin ZM, Yu ZH. Effect of cognitive behavioral intervention therapy on immunological function of patients with breast cancer. [Chinesel]. Chinese Journal of Clinical Rehabilitation. 2004;8(29):6310-1.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

453. Chen S, Wainwright DA, Wu JD, Wan Y, Matei DE, Zhang Y, et al. CD73: An emerging checkpoint for cancer immunotherapy. Immunotherapy. 2019;11(11):983-97.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

454. Chen S, Zhou Z, Lin W, Li J, Liu F, Ye Y. Associations of MICA gene polymorphism with susceptibility of breast cancer cells to NK cell-mediated cytotoxicity. [Chinese]. Chinese Journal of Cancer Biotherapy. 2018;25(1):73-8.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
455. Chen VM, McIlroy K, Loui JP, Fay K, Ward C. Extramedullary presentation of acute leukaemia: a case of myeloid/natural killer cell precursor leukaemia. Pathology. 2003;35(4):325-9.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
456. Chen W, Chan AS, Dawson AJ, Liang X, Blazar BR, Miller JS. FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function. Biology of Blood & Marrow Transplantation. 2005;11(1):23-34.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
457. Chen WY, Wu F, You ZY, Zhang ZM, Guo YL, Zhong LX. Analyzing the differentially expressed genes and pathway cross-talk in aggressive breast cancer. Journal of Obstetrics and Gynaecology Research. 2015;41(1):132-40.
배제사유 : 동물실험 및 전임상시험연구
458. Chen X, Du Y, Lin X, Qian Y, Zhou T, Huang Z. CD4 + CD25 + regulatory T cells in tumor immunity. International Immunopharmacology. 2016;34:244-9.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
459. Chen X, Han J, Chu J, Zhang L, Zhang J, Chen C, et al. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget. 2016;7(19):27764-77.
배제사유 : 동물실험 및 전임상시험연구
460. Chen X, Lu P, Chen L, Yang SJ, Shen HY, Yu DD, et al. Perioperative propofol-paravertebral anesthesia decreases the metastasis and progression of breast cancer. Tumor Biology. 2015;36(11):8259-66.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
461. Chen Y, Mo J, Jia X, He Y. The B7 Family Member B7-H6: a New Bane of Tumor. Pathology and Oncology Research. 2018;24(4):717-21.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
462. Chen YH, Wang S, He MF, Zhao H, Zhu HY, Yu XM, et al. Prevalence of Heterotypic Tumor/Immune Cell-In-Cell Structure In Vitro and In Vivo Leading to Formation of Aneuploidy. PLoS ONE. 2013;8 (3) (e59418).
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
463. Chen YM, Yang WK, Whang-Peng J, Kuo BIT, Perng RP. Elevation of interleukin-10 levels in malignant pleural effusion. Chest. 1996;110(2):433-6.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
464. Chen Z, Liu L, Liang R, Luo Z, He H, Wu Z, et al. Bioinspired Hybrid Protein Oxygen

Nanocarrier Amplified Photodynamic Therapy for Eliciting Anti-tumor Immunity and Abscopal Effect. *Acs Nano.* 2018;12(8):8633-45.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

465. Chen Z, Wang L, Xu T, Wang Q, Kang L, Zhao Q. Generation of bispecific antibodies by Fc heterodimerization and their application. *Current Pharmaceutical Biotechnology.* 2016;17(15):1324-32.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

466. Chen Z, Zhang P, Xu Y, Yan J, Liu Z, Lau WB, et al. Surgical stress and cancer progression: The twisted tango. *Molecular Cancer.* 2019;18 (1) (132).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

467. Chenchik A, Makhanov M, Komarov A, Sastry S, Frangou C. CancerNet: Molecular profiling of tumor microenvironment for biomarker discovery. *Journal of Immunology. Conference: 103rd Annual Meeting of the American Association of Immunologists, IMMUNOLOGY.* 2016;196(SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

468. Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. *Cellular and Molecular Immunology.* 2013;10(3):230-52.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

469. Cherfils-Vicini J, Iltis C, Cervera L, Pisano S, Croce O, Sadouni N, et al. Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein TRF2. *EMBO Journal.* 2019;38 (11) (e100012).

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

470. Chesney JA, Mitchell RA. 25 Years on: A retrospective on migration inhibitory factor in tumor angiogenesis. *Molecular Medicine.* 2015;21(Supplement 1):S19-S24.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

471. Chew V, Abastado JP. Immunomodulation of the tumor microenvironment by Toll-like receptor-3 (TLR3) ligands. *Oncogenomics.* 2013;2 (4) (e23493).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

472. Chi CI. Postoperative analgesia and short- or long-term prognosis of malignancy. [http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-INR-17011092.](http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-INR-17011092) 2017.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

473. Chi CO. A controlled trial of Autologous and umbilical cord blood cytokine-induced killer cells (U-CIKs) infusion on influence of the immune function in Advanced Cancer after Radiotherapy.

[http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-ONRC-13002992.](http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-ONRC-13002992) 2013.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

474. Chi CO. Multi-center clincal study of umbilical cord blood cytokine-induced killer cells (U-CIKs) infusion on influence of the immune function in Advanced Cancer after Chemotherapy.

[http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-ONRC-13002983.](http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-ONRC-13002983) 2013.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

475. Chi CT. A randomized, controlled trial of the efficacy of TCM exercise on body-mind health of Chinese women with breast cancer. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-TRC-14004290>. 2014.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

476. Chia S, Wright J, Raza M, Morley N. Hyperferritinemia and EBV viraemia are poor predictors of HLH post allogeneic stem cell transplantation. British Journal of Haematology. 2019;185 (Supplement 1):67.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

477. ChiCtr. To study the effect of fat dissolving for mastoscopic axillary lymph node dissection on the regulation of the immunity of breast cancer patients. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR1800015950>. 2018.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

478. Chidambaram R, Balamurugan M, Senthilkumar R, Srinivasan T, Rajmohan M, Karthick R, et al. Combining AIET with chemotherapy - Lessons learnt from our experience Microscopy. Journal of Stem Cells and Regenerative Medicine. 2013;9(2):P42-P3.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

479. Chidambaram R, Terunuma H, Balamurugan M, Dedeepiya VD, Sumana P, Senthilkumar R, et al. Cell-based immunotherapy in stage IIIA inflammatory breast cancer with declining innate immunity following successive chemotherapies: A case report. Molecular & Clinical Oncology. 2017;7(3):493-7.

배제사유 : 동물실험 및 전임상시험연구

480. Chihara G. [Evaluation and consideration of BRM-BRM and HDP (host defense potentiators)]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]. 1988;15(4 Pt 2-3):1588-96.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

481. Chin Y, Janseens J, Vandepitte J, Vandenbrande J, Opdebeek L, Raus J. Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Research. 1992;12(5):1463-6.

배제사유 : 동물실험 및 전임상시험연구

482. Ching C, Wong C, Cruz MV. Natural killer cell function in cancer patients treated with natural leukocyte interferon-alpha. Hawaii Medical Journal. 1986;45(11):394+7-8+408.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

483. Chiplunkar S, Dhar S, Wesch D, Kabelitz D. gammadelta T cells in cancer immunotherapy: Current status and future prospects. Immunotherapy. 2009;1(4):663-78.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

484. Chiron D, Pellat-Deceunynck C, Maillasson M, Bataille R, Jego G. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis. Journal of Immunology. 2009;183(7):4371-7.

배제사유 : 동물실험 및 전임상시험연구

485. Chirumbolo S. Alpha-bisabolol, not a matter for cancer therapy. Commentary: "Research on the immunosuppressive activity of ingredients contained in sunscreens". *Frontiers in Pharmacology*. 2015;6 (MAY) (96).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
486. Chitadze G, Lettau M, Bhat J, Wesch D, Steinle A, Furst D, et al. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17. *International Journal of Cancer*. 2013;133(7):1557-66.
배제사유 : 동물실험 및 전임상시험연구
487. Cho EA, Oh HE. [Effects of laughter therapy on depression, quality of life, resilience and immune responses in breast cancer survivors]. *Journal of Korean Academy of Nursing*. 2011;41(3):285-93.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
488. Cho HM, Rosenblatt JD, Tolba K, Shin SJ, Shin DS, Calfa C, et al. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response. *Cancer Research*. 2010;70(24):10121-30.
배제사유 : 동물실험 및 전임상시험연구
489. Cho JS, Lee MH, Kim SI, Park S, Park HS, Oh E, et al. The Effects of Perioperative Anesthesia and Analgesia on Immune Function in Patients Undergoing Breast Cancer Resection: A Prospective Randomized Study. *International Journal of Medical Sciences*. 2017;14(10):970-6.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
490. Cho JS, Park MH, Lee JS, Yoon JH. Reduced MUC4 expression is a late event in breast carcinogenesis and is correlated with increased infiltration of immune cells as well as promoter hypermethylation in invasive breast carcinoma. *Applied Immunohistochemistry & Molecular Morphology*. 2015;23(1):44-53.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
491. Cho OH. [Effects of a comprehensive rehabilitation program for mastectomy patients]. Daehan Ganho Haghoeji. 2004;34(5):809-19.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
492. Chockley P, Keshamouni V. Metastasis-specific, NK cell-mediated, immune surveillance of lung cancer. *Journal of Immunology*. Conference: 105th Annual Meeting of the American Association of Immunologists, IMMUNOLOGY. 2018;200(1 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
493. Choi AH, O'Leary MP, Chaurasia S, Lu J, Kim SI, Fong Y, et al. Novel chimeric parapoxvirus CF189 as an oncolytic immunotherapy in triple-negative breast cancer. *Surgery*. 2018;163(2):336-42.
배제사유 : 동물실험 및 전임상시험연구
494. Chollat-Namy M, Ben Safta-Saadoun T, Haferssas D, Meurice G, Chouaib S, Thiery J.

The pharmacological reactivation of p53 function improves breast tumor cell lysis by granzyme B and NK cells through induction of autophagy. *Cell Death & Disease*. 2019;10(10):695.

배제사유 : 동물실험 및 전임상시험연구

495. Chong AS, Scuderi P, Grimes WJ, Hersh EM. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor. *Journal of Immunology*. 1989;142(6):2133-9.

배제사유 : 동물실험 및 전임상시험연구

496. Chong G, Morse MA. Combining cancer vaccines with chemotherapy. *Expert Opinion on Pharmacotherapy*. 2005;6(16):2813-20.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

497. Chorvath B, Sedlak J. Hematopoietic cell differentiation antigens (CD system 1997). Cancer research relevance. *Neoplasma*. 1998;45(5):273-6.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

498. Christine C, Holbl A, Muller M, Kolbe T, Decker T, Sexl V. STAT1-deficient mice develop a myeloproliferative syndrome resembling human CML. *Haematologica*. 2012;1:475-6.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

499. Chu DT, Bac ND, Nguyen KH, Tien NLB, Thanh VV, Nga VT, et al. An update on anti-CD137 antibodies in immunotherapies for cancer. *International Journal of Molecular Sciences*. 2019;20 (8) (1822).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

500. Chu PG, Arber DA, Weiss LM. Expression of T/NK-cell and plasma cell antigens in nonhematopoietic epithelioid neoplasms: An immunohistochemical study of 447 cases. *American Journal of Clinical Pathology*. 2003;120(1):64-70.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

501. Chuang LT, Lotzova E, Cook KR, Cristoforoni P, Morris M, Wharton JT. Effect of new investigational drug taxol on oncolytic activity and stimulation of human lymphocytes. *Gynecologic Oncology*. 1993;49(3):291-8.

배제사유 : 동물실험 및 전임상시험연구

502. Chumsri S, Tait N, Shetty J, Lewis J, Medeiros M, Bao T, et al. A phase II study of letrozole and lapatinib followed by an addition of everolimus in postmenopausal women with advanced endocrine resistant breast cancer (BC). *Cancer Research. Conference: 36th Annual CTRC AACR San Antonio Breast Cancer Symposium. San Antonio, TX United States. Conference Publication*: 2013;73(24 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

503. Chun BM, Page DB, McArthur HL. Combination Immunotherapy Strategies in Breast Cancer. *Current Breast Cancer Reports*. 2019;11(4):228-40.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

504. Chung JF, Lee SJ, Sood AK. Immunological and pleiotropic effects of individual

beta-blockers and their relevance in cancer therapies. Expert Opinion on Investigational Drugs. 2016;25(5):501-5.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

505. Ciechanowicz SJ, Ma D. Anaesthesia for oncological surgery - Can it really influence cancer recurrence? Anaesthesia. 2016;71(2):127-31.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

506. Cirello V, Fugazzola L. Positive Effect of Fetal Cell Microchimerism on Tumor Presentation and Outcome in Papillary Thyroid Cancer. Chimerism. 2014;5(3):106-8.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

507. Claerhout H, Lierman E, Michaux L, Verhoef G, Boeckx N. A monocentric retrospective study of 138 therapy-related myeloid neoplasms. Annals of Hematology. 2018;97(12):2319-24.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

508. Clark CA, Gupta HB, Padron A, Zhang D, Hurez V, Turk MJ, et al. Tumor-intrinsic PD-L1 alters tumor chemokines, NK cell trafficking and function, and renders distant PD-L1 null tumors responsive to alphapD-L1. Cancer Research. Conference: American Association for Cancer Research Annual Meeting. 2017;77(13 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

509. Clark DA, Dhesy-Thind S, Arredondo JL, Ellis PM, Ramsay JA. The Receptor for the CD200 Tolerance-Signaling Molecule Associated with Successful Pregnancy is Expressed by Early-Stage Breast Cancer Cells in 80% of Patients and by Term Placental Trophoblasts. American Journal of Reproductive Immunology. 2015;74(5):387-91.

배제사유 : 동물실험 및 전임상시험연구

510. Clark NM, Martinez LM, Eff CC, Bos PD. Role of macrophages in the therapeutic effect of regulatory t cell ablation in breast cancer. Journal of Immunology. Conference: 104th Annual Meeting of the American Association of Immunologists, AAI. 2017;198(1 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

511. Clarke R. Human breast cancer cell line xenografts as models of breast cancer - The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. Breast Cancer Research and Treatment. 1996;39(1):69-86.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

512. Clausen J, Enk M, Vergeiner B, Eisendle K, Petzer AL, Gastl G, et al. Suppression of natural killer cells in the presence of CD34+ blood progenitor cells and peripheral blood lymphocytes. Biology of Blood & Marrow Transplantation. 2004;10(10):691-7.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

513. Clausen J, Vergeiner B, Enk M, Petzer AL, Gastl G, Gunsilius E. Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells. Immunobiology. 2003;207(2):85-93.

배제사유 : 동물실험 및 전임상시험연구

514. Clayton A, Tabi Z. Exosomes and the MICA-NKG2D system in cancer. *Blood Cells Molecules & Diseases*. 2005;34(3):206-13.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
515. Clayton MF, Dingley C, Donaldson G. The integration of emotional, physiologic, and communication responses to medical oncology surveillance appointments during breast cancer survivorship. *Cancer Nursing*. 2017;40(2):124-34.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
516. Clayton MF, Donaldson GW, DeSchweinitz P. Cancer recurrence concerns predict increased interleukin activity surrounding a medical follow-up visit. *Brain, Behavior, and Immunity*. 2010;1:S18-S9.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
517. Clemenceau B, Gallot G, Vivien R, Gaschet J, Campone M, Vie H. Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy. *Journal of Immunotherapy*. 2006;29(1):53-60.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
518. Clemenceau B, Guillaume T, Robillard N, Vivien R, Peterlin P, Garnier A, et al. In vitro comparison of ADCC and CAR sensitivity of adult HER-2+ B-ALL using the NK-92 human cell line transduced with a human CD16 (ADCC) or an anti-HER2 chimeric antigen receptor (CAR). *Blood*. Conference: 58th Annual Meeting of the American Society of Hematology, ASH. 2016;128(22).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
519. Clive KS, Tyler JA, Clifton GT, Holmes JP, Mittendorf EA, Ponniah S, et al. Use of GM-CSF as an adjuvant with cancer vaccines: Beneficial or detrimental? *Expert Review of Vaccines*. 2010;9(5):519-25.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
520. Clouthier DL, Yang C, Lien S, Gray D, Colombo I, Lheureux S, et al. A technical feasibility report on correlative studies from the investigator-initiated phase II study of pembrolizumab (Pembro) immunological response evaluation (INSPIRE). *Journal of clinical oncology*. Conference: 2017 annual meeting of the american society of clinical oncology, ASCO. United states. 2017;35(15 Supplement 1) .
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
521. Clynes R, Knutson KL, Ballman KV, Erskine CL, Norton N, Sumrall SV, et al. Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies N0337 and N98-32-52. *Journal of Clinical Oncology*. Conference. 2013;31(15 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
522. Cohen I. Bioinformatic correlates of immune exclusion and metabolism in breast cancer

and melanoma. Molecular Imaging and Biology. 2017;19 (1 Supplement 1):S725.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

523. Cohen M, Klein E, Kuten A, Fried G, Zinder O, Pollack S. Increased emotional distress in daughters of breast cancer patients is associated with decreased natural cytotoxic activity, elevated levels of stress hormones and decreased secretion of Th1 cytokines. International Journal of Cancer. 2002;100(3):347-54.

배제사유 : 동물실험 및 전임상시험연구

524. Cohen M, Pollack S. Mothers with breast cancer and their adult daughters: the relationship between mothers' reaction to breast cancer and their daughters' emotional and neuroimmune status. Psychosomatic Medicine. 2005;67(1):64-71.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

525. Collins D, O'Donovan N, Mahgoub T, Gately K, Hughes C, Davies A, et al. Trastuzumab (T) and pertuzumab (P)-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) in tyrosine kinase inhibitor (TKI)-treated breast cancer (BC) cell lines. Journal of Clinical Oncology. Conference. 2014;32(15 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

526. Collins DM, Gaynor N, Conlon NT, O'Donovan N, Crown JP. HER2-targeted antibody dependent cell-mediated cytotoxicity (ADCC) mediated by NK cells against tyrosine kinase inhibitor (TKI)-treated breast cancer (BC) cell lines. Annals of Oncology. 2019;30 Suppl 3:iii18.

배제사유 : 동물실험 및 전임상시험연구

527. Collins DM, Madden SF, Eustace AJ, Toomey S, Kay EW, Fay J, et al. Tumor CXCL16/CXCR6 expression and soluble CXCL16 in HER2+ breast cancer (BC). Cancer Research. Conference: San Antonio Breast Cancer Symposium, SABCS. 2017;78(4 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

528. Collins DM, O'Donovan N, Dean J, Hogan AE, Ballot J, McDonnell D, et al. Effect of trastuzumab on antibody-dependent cellular cytotoxicity (ADCC) in HER2 nonamplified (non-amp) breast cancer (BC) cells. Journal of Clinical Oncology. Conference. 2010;28(15 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

529. Collins DM, O'Donovan N, McGowan P, O'Sullivan F, Duffy MJ, Crown J. Trastuzumab binds to HER2 non-amplified breast cancer cells and induces ADCC. European Journal of Cancer. 2011;1):S122.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

530. Collins DM, O'Donovan N, McGowan PM, O'Sullivan F, Duffy MJ, Crown J. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Annals of Oncology. 2012;23(7):1788-95.

배제사유 : 동물실험 및 전임상시험연구

531. Collova E, Rovati B, Grasso D, Bencardino K, Manzoni M, Danova M. Effect of peg-filgrastim-supported dose-dense adjuvant chemotherapy on the peripheral blood

leukocyte phenotype in breast cancer patients. Molecular Medicine Reports. 2009;2(1):85-8.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

532. Colombo M, Corsi F, Foschi D, Mazzantini E, Mazzucchelli S, Morasso C, et al. HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches. Pharmacological Research. 2010;62(2):150-65.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

533. Colotta F, Peri G, Villa A, Mantovani A. Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage. Journal of Immunology. 1984;132(2):936-44.

배제사유 : 동물실험 및 전임상시험연구

534. Comes A, Di Carlo E, Musiani P, Rosso O, Meazza R, Chiodoni C, et al. IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice. European Journal of Immunology. 2002;32(7):1914-23.

배제사유 : 동물실험 및 전임상시험연구

535. Compagno D, Tiraboschi C, Garcia JD, Rondon Y, Corapi E, Velazquez C, et al. Galectins as checkpoints of the immune system in cancers, their clinical relevance, and implication in clinical trials. Biomolecules. 2020;10 (5) (750).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

536. Concetti A, Amici A, Petrelli C, Tibaldi A, Provinciali M, Venanzi FM. Autoantibody to p185erbB2/neu oncoprotein by vaccination with xenogenic DNA. Cancer Immunology, Immunotherapy. 1996;43(5):307-15.

배제사유 : 동물실험 및 전임상시험연구

537. Conrick-Martin I, Buggy DJ. The effects of anesthetic and analgesic techniques on immune function. Journal of Clinical Anesthesia. 2013;25(4):253-4.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

538. Conroy MJ, Dunne MR, Donohoe CL, Reynolds JV. Obesity-associated cancer: An immunological perspective. Proceedings of the Nutrition Society. 2016;75(2):125-38.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

539. Conti L, Arista MC, Callopoli A, Di Filippo F, De Franceschi L, Macale E, et al. Flow cytometric evaluation of lymphocyte subsets in non-treated neoplastic patients. Journal of Experimental and Clinical Cancer Research. 1996;15(3):257-64.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

540. Contreras Ortiz O, Stolar A. Immunological changes in human breast cancer. European Journal of Gynaecological Oncology. 1988;9(6):502-14.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

541. Cook JL, Miura TA, Ikle DN, Lewis AM, Jr., Routes JM. E1A oncogene-induced sensitization of human tumor cells to innate immune defenses and chemotherapy-induced apoptosis in vitro and in vivo. *Cancer Research*. 2003;63(12):3435-43.
배제사유 : 동물실험 및 전임상시험연구
542. Cooley S, Burns LJ, Repka T, Miller JS. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. *Experimental Hematology*. 1999;27(10):1533-41.
배제사유 : 동물실험 및 전임상시험연구
543. Cordle CT, Winship TR, Schaller JP, Thomas DJ, Buck RH, Ostrom KM, et al. Immune status of infants fed soy-based formulas with or without added nucleotides for 1 year: part 2: immune cell populations. *Journal of pediatric gastroenterology and nutrition*. 2002;34(2):145-53.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
544. Correale P, Tagliaferri P, Celio L, Genua G, Montagnani S, Bianco AR. Verapamil upregulates sensitivity of human colon and breast cancer cells to LAK-cytotoxicity in vitro. *European Journal of Cancer*. 1991;27(11):1393-5.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
545. Corso CD, Ali AN, Diaz R. Radiation-induced tumor neoantigens: Imaging and therapeutic implications. *American Journal of Cancer Research*. 2011;1(3):390-412.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
546. Costarelli L, Malavolta M, Giacconi R, Cipriano C, Gasparini N, Tesei S, et al. In vivo effect of alpha-bisabolol, a nontoxic sesquiterpene alcohol, on the induction of spontaneous mammary tumors in HER-2/neu transgenic mice. *Oncology Research*. 2010;18(9):409-18.
배제사유 : 동물실험 및 전임상시험연구
547. Coudert B. Circadian concepts in normal and neoplastic breast. *Chronobiology International*. 2002;19(1):221-35.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
548. Coupland LA, Chong BH, Parish CR. Beware of NK cells in pre-clinical metastasis models. *Clinical and Experimental Metastasis*. 2013;30(7):945-7.
배제사유 : 동물실험 및 전임상시험연구
549. Coyne JC, Palmer SC. More claims about depression, immune function, and survival that exceed the evidence [5]. *Journal of Clinical Oncology*. 2007;25(33):5328-9.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
550. Crane E, List A. Immunomodulatory drugs. *Cancer Investigation*. 2005;23(7):625-34.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
551. Crespo J, Vatan L, Maj T, Liu R, Kryczek I, Zou W. Phenotype and tissue distribution of

CD28H+ immune cell subsets. *OncoImmunology*. 2017;6 (12) (e1362529).

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

552. Cristiani CM, Palella E, Sottile R, Tallerico R, Garofalo C, Carbone E. Human NK cell subsets in pregnancy and disease: Toward a new biological complexity. *Frontiers in Immunology*. 2016;7 (DEC) (656).

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

553. Critchley-Thorne RJ, Simons DL, Yan N, Miyahira AK, Dirbas FM, Johnson DL, et al. Impaired interferon signaling is a common immune defect in human cancer. *Proceedings of the National Academy of Sciences of the United States of America*. 2009;106(22):9010-5.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

554. Cronin-Fenton DP, Norgaard M, Heide-Jorgensen U, Ahern TP, Lash TL, Christiansen P, et al. Opioids and breast cancer recurrence: A danish population-based cohort study. *Pharmacoepidemiology and Drug Safety*. 2014;1):45.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

555. Crough T, Purdie DM, Okai M, Maksoud A, Nieda M, Nicol AJ. Modulation of human Valpha24(+)Vbeta11(+) NKT cells by age, malignancy and conventional anticancer therapies. *British Journal of Cancer*. 2004;91(11):1880-6.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

556. Cruz FM, Munhoz BA, Alves BCA, Gehrke FS, Fonseca FLA, Kuniyoshi RK, et al. Biomarkers of fatigue related to adjuvant chemotherapy for breast cancer: Evaluation of plasma and lymphocyte expression. *Clinical and Translational Medicine*. 2015;4(1):1-9.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

557. Ctri. Effect of Yoga on body immunity in cancer cells. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2018/10/016002>. 2018.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

558. Cui J, Liu Y, Wang X. The roles of glycodelin in cancer development and progression. *Frontiers in Immunology*. 2017;8 (NOV) (1685).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

559. Cui X, Zhu C, Chen P, Qu M, Zhang B, Li H. Effect of pectoral nerve block type II under general anesthesia on the immune function of patients with breast cancer. *American Journal of Surgery*. 2020;08:08.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

560. Cully M. Double boost for cancer cell therapy. *Nature Reviews. Drug Discovery*. 2020;19(3):165.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

561. Cunningham TD, Jiang X, Shapiro DJ. Expression of high levels of human proteinase inhibitor 9 blocks both perforin/granzyme and Fas/Fas ligand-mediated cytotoxicity. *Cellular Immunology*. 2007;245(1):32-41.

배제사유 : 동물실험 및 전임상시험연구

562. Cunningham-Rundles S, Filippa DA, Braun Jr DW. Natural cytotoxicity of peripheral blood lymphocytes and regional lymph node cells in breast cancer in women. *Journal of the National Cancer Institute.* 1981;67(3):585-90.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

563. Curiel TJ, Gupta HB, Padron A, Pandeswara S, Sareddy G, Yuan B, et al. Cell-intrinsic and spatially divergent tumor programmed death ligand 1 (PD-L1) signals modify local and systemic anti-tumor immunity through novel chemokine effects. *Journal of Immunology. Conference: 105th Annual Meeting of the American Association of Immunologists, IMMUNOLOGY.* 2018;200(1 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

564. Curigliano G, Locatelli M, Fumagalli L, Goldhirsch A. Immunity and autoimmunity: Revising the concepts of response to cancer. *Breast.* 2011;1):S7.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

565. Curigliano G, Spitaleri G, Dettori M, Locatelli M, Scarano E, Goldhirsch A. Vaccine immunotherapy in breast cancer treatment: promising, but still early. *Expert Review of Anticancer Therapy.* 2007;7(9):1225-41.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

566. Curigliano G. Immunity and autoimmunity in breast cancer. *Breast Cancer Research.* 2011;2):S2.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

567. Curigliano G. Immunity and autoimmunity: revising the concepts of response to breast cancer. *Breast.* 2011;20 Suppl 3:S71-4.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

568. Cussen H, Fould GA, Hopkinson K, Multhoff G, Pockley AG. Influence of breast cancer-derived factors on the responsiveness of human natural killer (NK) cells to IL-2 stimulation and their cytotoxic potential. *Immunology.* 2010;1):67.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

569. Czuczman MS, Gregory SA, van Der Jagt R. B-cell non-hodgkin lymphoma: A case-based discussion of recent advances in patient management. *Clinical Advances in Hematology and Oncology.* 2010;8(7):1-15.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

570. Da Silva MC, Cerwenka A, Muckenthaler MU. The role of iron in cancer and in the polarization of tumor-associated macrophages. *American Journal of Hematology.* 2013;88 (5):E183-E4.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

571. Dai Z, Wan X, Kang H, Ji Z, Liu L, Liu X, et al. Clinical effects of shenqi fuzheng injection in the neoadjuvant chemotherapy for local advanced breast cancer and the effects on T-lymphocyte subsets. *Journal of Traditional Chinese Medicine.* 2008;28(1):34-8.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

572. Daikeler T, Maas K, Weiss B, Hartmann J, Knobloch A, Arning M, et al. The influence of gemcitabine on the CD4/CD8 ratio in patients with solid tumours. *Oncology Reports*. 1997;4(3):561-4.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

573. Dakshinamurthy P, Mukunda P, Prasad Kodaganti B, Shenoy BR, Natarajan B, Maliwalave A, et al. Charge variant analysis of proposed biosimilar to Trastuzumab. *Biologicals*. 2017;46:46-56.

배제사유 : 동물실험 및 전임상시험연구

574. Daldrup-Link HE, Meier R, Rudelius M, Piontek G, Piert M, Metz S, et al. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. *European Radiology*. 2005;15(1):4-13.

배제사유 : 동물실험 및 전임상시험연구

575. Dagleish AG. Practical aspects in the use of biomarkers for the development of cancer vaccines. *Current Cancer Therapy Reviews*. 2008;4(2):161-5.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

576. Damele L, Ottonello S, Mingari MC, Pietra G, Vitale C. Targeted therapies: Friends or foes for patient's NK cell-mediated tumor immune-surveillance? *Cancers*. 2020;12 (4) (774).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

577. Damiens E, El Yazidi I, Mazurier J, Elass-Rochard E, Duthille I, Spik G, et al. Role of heparan sulphate proteoglycans in the regulation of human lactoferrin binding and activity in the MDA-MB-231 breast cancer cell line. *European Journal of Cell Biology*. 1998;77(4):344-51.

배제사유 : 동물실험 및 전임상시험연구

578. Damiens E, Mazurier J, el Yazidi I, Masson M, Duthille I, Spik G, et al. Effects of human lactoferrin on NK cell cytotoxicity against haematopoietic and epithelial tumour cells. *Biochimica et Biophysica Acta*. 1998;1402(3):277-87.

배제사유 : 동물실험 및 전임상시험연구

579. Daniele V, Simeone P, Frank J, Trerotola M, Anna G, Loredana C, et al. Translating epithelial mesenchymal transition markers into the clinic: Novel insights from proteomics. *EuPA Open Proteomics*. 2016;10:31-41.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

580. Danilova AB, Danilov AO, Fakhrumdinova OL, Badueva IA, Moiseenko VM. [Immunochemical assay of MIC A production by tumor cells in vitro and in vivo as a component of antitumor vaccine development]. *Voprosy Onkologii*. 2010;56(5):576-82.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

581. Danner M, Luger TA. Human keratinocytes and epidermoid carcinoma cell lines produce a cytokine with interleukin 3-like activity. *Journal of Investigative Dermatology*. 1987;88(4):353-61.
배제사유 : 동물실험 및 전임상시험연구
582. Danova M, Comolli G, Olgiati A, Cavalli C, Zanirato S. Immunological effects of Eribulin mesylate administration in advanced breast cancer patients. *Italian Journal of Medicine*. 2019;13 (Supplement 2):4.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
583. Dar TB, Henson RM, Shiao SL. Targeting innate immunity to enhance the efficacy of radiation therapy. *Frontiers in Immunology*. 2019;10 (JAN) (3077).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
584. Das J, Kumar S, Khanna S, Mehta Y. Are we causing the recurrence-impact of perioperative period on long-term cancer prognosis: Review of current evidence and practice. *Journal of Anaesthesiology Clinical Pharmacology*. 2014;30(2):153-9.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
585. D'Atri S, Fuggetta MP, Giganti G, Tentori L, Roselli M, Nunziata C, et al. Comparative studies between in vitro and in vivo effects of human beta-interferon on natural killer activity and its relevance to immunochemotherapy. *Cancer Immunology, Immunotherapy*. 1988;27(2):163-70.
배제사유 : 동물실험 및 전임상시험연구
586. Datta R, Riley CL, Dodi IA, Rees RC. NK cell, monocyte and non T cell biomarkers as prognostic indicators in cancer immunotherapy. *Current Cancer Therapy Reviews*. 2008;4(2):120-4.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
587. Davies B, Hiby S, Gardner L, Loke YW, King A. HLA-G expression by tumors. *American Journal of Reproductive Immunology*. 2001;45(2):103-7.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
588. Davies DM, Maher J. Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T Cells. *Archivum Immunologiae et Therapiae Experimentalis*. 2010;58(3):165-78.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
589. Davis-Marcisak EF, Sherman TD, Orugunta P, Stein-O'Brien GL, Puram SV, Roussos Torres ET, et al. Differential variation analysis enables detection of tumor heterogeneity using single-cell RNA-sequencing data. *Cancer Research*. 2019;79(19):5102-12.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
590. De Brabander B, Gerits P. Chronic and acute stress as predictors of relapse in primary breast cancer patients. *Patient Education & Counseling*. 1999;37(3):265-72.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
591. De Kruijf E, Engels C, Van De Water W, Bastiaannet E, Smit V, Van De Velde C, et al.

Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients. *Journal of Immunotherapy*. 2012;35 (9):756.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

592. De Kruijf EM, Engels CC, Van De Water W, Bastiaannet E, Smit V, Van De Velde CJH, et al. Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients. *European Journal of Cancer*. 2013;2):S473.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

593. de Kruijf EM, Engels CC, van de Water W, Bastiaannet E, Smit VT, van de Velde CJ, et al. Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients. *Breast Cancer Research & Treatment*. 2013;142(2):355-64.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

594. De Kruijf EM, Sajet A, Van Nes JG, Natanov R, Putter H, Smit VT, et al. HLA-E and HLA-G tumor expression is of prognostic value for clinical outcome of early breast cancer patients, but exclusively in classical HLA class I tumor-negative patients. *Cancer Research*. Conference: 101st Annual Meeting of the American Association for Cancer Research, AACR. 2010;70(8 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

595. de Kruijf EM, Sajet A, van Nes JG, Putter H, Smit VT, Eagle RA, et al. NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. *BMC Cancer*. 2012;12:24.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

596. De Kruijf EM, Sajet A, Van Nes JGH, Natanov R, Putter H, Smit VTHBM, et al. HLA-E and HLA-G tumour expression is of prognostic value for clinical outcome of early breast cancer patients, but exclusively in classical HLA class I tumor-negative patients. *European Journal of Cancer*, Supplement. 2010;8 (3):173.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

597. De Martino M, Mercogliano MF, Tkach M, Venturutti L, Elizalde PV, Schillaci R. Immunotherapy against breast cancer based on Stat3 blockade. *Cancer Research*. Conference: 106th Annual Meeting of the American Association for Cancer Research, AACR. 2015;75(15 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

598. De Martino M, Tkach M, Bruni S, Rocha D, Mercogliano MF, Cenciarini ME, et al. Blockade of Stat3 oncogene addiction induces cellular senescence and reveals a cell-nonautonomous activity suitable for cancer immunotherapy. *Oncoimmunology*. 2020;9(1):1715767.

배제사유 : 동물실험 및 전임상시험연구

599. De Negri P. Potential influence of the postoperative analgesia regimens on cancer-related outcome. *Regional Anesthesia and Pain Medicine*. 2011;2):E37-E8.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

600. De Ruysscher D, Waer M, Vandepitte M, Aerts R, Vantongelen K, van der Schueren E. Changes of lymphocyte subsets after local irradiation for early stage breast cancer and

seminoma testis: long-term increase of activated (HLA-DR+) T cells and decrease of "naive" (CD4-CD45R) T lymphocytes. European Journal of Cancer. 1992;28A(10):1729-34.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

601. De Santis F, Del Vecchio M, Castagnoli L, De Braud F, Di Cosimo S, Franceschini D, et al. Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting. Cytokine & Growth Factor Reviews. 2018;44:1-10.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
602. Dedeepiya V, Ramanan G, Munirathnam D, Sumana P, Terunuma H, Senthilkumar R, et al. Hurdles overcome in technology transfer for AIET and positive outcome in Indian patients. Journal of Stem Cells and Regenerative Medicine. 2012;8(3):207-9.
배제사유 : 동물실험 및 전임상시험연구
603. Dedeepiya V, Terunuma H, Manjunath S, Senthilkumar R, Thamaraiakannan P, Srinivasan T, et al. Autologous Immune Enhancement Therapy for cancer using NK cells and CTLs without feeder layers; our six year experience in India. Journal of Stem Cells & Regenerative Medicine. 2011;7(2):95.
배제사유 : 동물실험 및 전임상시험연구
604. Dedeepiya VD, Terunuma H, Deng X, Baskar S, Manjunath SR, Senthilkumar R, et al. A comparative analysis of in vitro expansion of natural killer cells of a patient with autoimmune haemolytic anaemia and ovarian cancer with patients with other solid tumours. Oncology Letters. 2012;3(2):435-40.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
605. Dedoussis G, Menounos P, Papadopoulos N, Gounaris A, Karameris A. Reduction of susceptibility to NK lysis in cisplatin-resistant K562 cell lines. Anticancer Research. 1998;18(4C):3081-5.
배제사유 : 동물실험 및 전임상시험연구
606. Deepalakshmi K, Mirunalini S. Therapeutic properties and current medical usage of medicinal mushroom: Ganoderma lucidum. International Journal of Pharmaceutical Sciences and Research. 2011;2(8):1922-9.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
607. Deguchi A, Maru Y. Dickkopf-1 helps metastasis by immune evasion. Translational Cancer Research. 2017;6(Supplement9):S1422-S4.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
608. Del Bano J, Flores-Flores R, Josselin E, Goubard A, Ganier L, Castellano R, et al. A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer. Frontiers in Immunology. 2019;10:1593.
배제사유 : 동물실험 및 전임상시험연구
609. Delconte RB, Kolesnik TB, Dagley LF, Rautela J, Shi W, Putz EM, et al. CIS is a potent checkpoint in NK cell-mediated tumor immunity. Nature Immunology. 2016;17(7):816-24.
배제사유 : 동물실험 및 전임상시험연구
610. Delconte RB, Kolesnik TB, Rautela J, Smyth MJ, Nicholson SE, Huntington ND. Targeting

regulators of natural killer cell homeostasis in cancer immunotherapy. European Journal of Immunology. 2016;46 (Supplement 1):65.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

611. D'Elios MM, Del Prete G, Amedei A. New frontiers in cell-based immunotherapy of cancer. Expert Opinion on Therapeutic Patents. 2009;19(5):623-41.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

612. Delort L, Rossary A, Farges MC, Vasson MP, Caldefie-Chezet F. Leptin, adipocytes and breast cancer: Focus on inflammation and anti-tumor immunity. Life Sciences. 2015;140:37-48.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

613. deMagalhaes-Silverman M, Donnenberg A, Lemmersky B, Elder E, Lister J, Rybka W, et al. Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. Journal of Immunotherapy. 2000;23(1):154-60.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

614. Demaria S, Pilones KA, Formenti SC, Dustin ML. Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment. OncoImmunology. 2013;2 (3) (e23127).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

615. Demark-Wahnefried W, Rogers LQ, Gibson JT, Harada S, Fruge AD, Oster RA, et al. Randomized trial of weight loss in primary breast cancer: Impact on body composition, circulating biomarkers and tumor characteristics. International Journal of Cancer. 2020;146(10):2784-96.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

616. Demirtzoglou FJ, Papadopoulos S, Zografos G. Cytolytic and cytotoxic activity of a human natural killer cell line genetically modified to specifically recognize HER-2/neu overexpressing tumor cells. Immunopharmacology and Immunotoxicology. 2006;28(4):571-90.

배제사유 : 동물실험 및 전임상시험연구

617. Demoulin S, Herfs M, Delvenne P, Hubert P. Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: Insight into the molecular mechanisms. Journal of Leukocyte Biology. 2013;93(3):343-52.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

618. Deng W, Liu J, Pan H, Li L, Zhou C, Wang X, et al. A Bispecific Antibody Based on Pertuzumab Fab Has Potent Antitumor Activity. Journal of Immunotherapy. 2018;41(1):1-8.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

619. Deng Z, Zhang W, Han Y, Zhang S. [Radiofrequency ablation inhibits lung metastasis ofbreast cancer in mice]. Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]. 2015;37(7):497-500.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

620. Depypere HT, Bracke ME, Boterberg T, Mareel MM, Nuytinck M, Vennekens K, et al. Inhibition of tamoxifen's therapeutic benefit by tangeretin in mammary cancer. European Journal of Cancer. 2000;36(SUPPL. 4):73.
배제사유 : 동물실험 및 전임상시험연구
621. Derakhshandeh R, Webb TJ. Quantitative real-time PCR based diagnostic to assess NKT cell function in breast cancer patients. Journal for ImmunoTherapy of Cancer. Conference: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer, SITC. 2016;4(Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
622. Derevnina NA, Polevaia EB, Veskova TK, Trubcheninova LP, Bogatyrev VN. [Disorders of the immune system in benign lesions and cancer of the breast]. Voprosy Onkologii. 1989;35(7):810-6.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
623. Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy. Journal of Cellular Physiology. 2019;234(2):1313-25.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
624. Desbois M, Beal C, Charrier M, Besse B, Meurice G, Cagnard N, et al. IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: Implications for antimetastatic treatment. Journal for ImmunoTherapy of Cancer. 2020;8 (1) (jitec-2020-000632).
배제사유 : 동물실험 및 전임상시험연구
625. Desmond F, McCormack J, Mulligan N, Stokes M, Buggy DJ. Effect of anaesthetic technique on immune cell infiltration in breast cancer: a follow-up pilot analysis of a prospective, randomised, investigator-masked study. Anticancer Research. 2015;35(3):1311-9.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
626. DeVita Jr VT, Hellman S, Rosenberg SA. From the editors. Cancer Journal. 2003;9(4):231.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
627. Dewan Md Z, Terunuma H, Takada M, Tanaka Y, Abe H, Sata T, et al. Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo. Breast Cancer Research and Treatment. 2007;104(3):267-75.
배제사유 : 동물실험 및 전임상시험연구
628. Dewan MZ, Takada M, Terunuma H, Deng X, Ahmed S, Yamamoto N, et al. Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients. Biomedicine & Pharmacotherapy. 2009;63(9):703-6.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
629. Dewan MZ, Terunuma H, Ahmed S, Ohba K, Takada M, Tanaka Y, et al. Natural killer

cells in breast cancer cell growth and metastasis in SCID mice. *Biomedicine & Pharmacotherapy*. 2005;59 Suppl 2:S375-9.

배제사유 : 동물실험 및 전임상시험연구

630. Dewan MZ, Terunuma H, Takada M, Tanaka Y, Abe H, Sata T, et al. Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells *in vivo*. *Breast Cancer Research & Treatment*. 2007;104(3):267-75.

배제사유 : 동물실험 및 전임상시험연구

631. Dhar S, Chiplunkar SV. Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vgamma9Vdelta2 T cells. *Cancer Immunity*. 2010;10.

배제사유 : 동물실험 및 전임상시험연구

632. Dhimolea E, Reichert JM. World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA. *mAbs*. 2012;4(1):4-13.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

633. Dhodapkar MV. Personalized immune-interception of cancer and the battle of two adaptive systems - When is the time right? *Cancer Prevention Research*. 2013;6(3):173-6.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

634. Di Carlo E, Cappello P, Sorrentino C, D'Antuono T, Pellicciotta A, Giovarelli M, et al. Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: Sharing a common Th1 anti-tumour immune pathway. *Journal of Pathology*. 2005;205(1):82-91.

배제사유 : 동물실험 및 전임상시험연구

635. Di Carlo E, Comes A, Orengo AM, Rosso O, Meazza R, Musiani P, et al. IL-21 Induces Tumor Rejection by Specific CTL and IFN-gamma-Dependent CXC Chemokines in Syngeneic Mice. *Journal of Immunology*. 2004;172(3):1540-7.

배제사유 : 동물실험 및 전임상시험연구

636. Di Carlo E, De Totero D, Piazza T, Fabbri M, Ferrini S. Role of IL-21 in immune-regulation and tumor immunotherapy. *Cancer Immunology, Immunotherapy*. 2007;56(9):1323-34.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

637. Di Mitri D, Toso A, Alimonti A. Molecular pathways: Targeting Tumor-infiltrating myeloid-derived suppressor cells for cancer therapy. *Clinical Cancer Research*. 2015;21(14):3108-12.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

638. Di Modica M, Sfondrini L, Regondi V, Varchetta S, Oliviero B, Mariani G, et al. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. *Oncotarget*. 2016;7(1):255-65.

배제사유 : 동물실험 및 전임상시험연구

639. Diab A, Hurwitz ME, Tannir N, Bernatchez C, Haymaker C, Bentebibel SE, et al. PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic

solid tumor malignancies. Annals of Oncology. 2017;28 (Supplement 5):v427.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

640. Diab A, Marcondes M, Tagliaferri MA, Hoch U, Zhang J, Rubas W, et al. REVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies. Annals of Oncology. 2018;29 (Supplement 8):viii146-viii7.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
641. Diab A, Tannir NM, Bernatchez C, Haymaker CL, Bentebibel SE, Curti BD, et al. A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors. Add to Collection. Journal of Clinical Oncology. Conference. 2017;35(15 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
642. Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. The Lancet Oncology. 2014;15(11):e493-e503.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
643. Dias AS, Almeida CR, Helguero LA, Duarte IF. Metabolic crosstalk in the breast cancer microenvironment. European Journal of Cancer. 2019;121:154-71.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
644. Dieci MV, Griguolo G, Miglietta F, Guarneri V. The immune system and hormone-receptor positive breast cancer: Is it really a dead end? Cancer Treatment Reviews. 2016;46:9-19.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
645. Dieing A, Schulz CO, Schmid P, Luftner D, Jehn C, Fenner M, et al. Influence of long-term bisphosphonate therapy on peripheral gamma-delta-T-cells in patients with metastatic breast cancer. Onkologie. 2003;26:218-9.
배제사유 : 동물실험 및 전임상시험연구
646. Diermeier-Daucher S, Ortmann O, Buchholz S, Brockhoff G. Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. mAbs. 2012;4(5):614-22.
배제사유 : 동물실험 및 전임상시험연구
647. Diessner J, Bruttel V, Becker K, Pawlik M, Stein R, Hausler S, et al. Targeting breast cancer stem cells with HER2-specific antibodies and natural killer cells. American Journal of Cancer Research. 2013;3(2):211-20.
배제사유 : 동물실험 및 전임상시험연구
648. Diessner J, Bruttel V, Stein RG, Horn E, Hausler SF, Dietl J, et al. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). Cell Death & Disease. 2014;5:e1149.
배제사유 : 동물실험 및 전임상시험연구
649. Dietrich EM. Warfarin inhibits tumor metastasis through an immune-modulatory,

coagulation-independent manner that involves NK cells: Possible anti-tumor effects in patients with OSCC? *Research Journal of Medical Sciences*. 2015;9(3):64-6.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

650. Dillman RO. Cancer immunotherapy. *Cancer Biotherapy and Radiopharmaceuticals*. 2011;26(1):1-64.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

651. Dimberu PM, Leonhardt RM. Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear. *Yale Journal of Biology and Medicine*. 2011;84(4):371-80.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

652. Ding H, Wei Y. Chimeric protein MICA-G129R bridges breast cancer cells and natural killer cells. *Journal for ImmunoTherapy of Cancer*. Conference: 34th Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2019;7(Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

653. Ding H, Yang X, Wei Y. Fusion proteins of NKG2D/NKG2DL in cancer immunotherapy. *International Journal of Molecular Sciences*. 2018;19 (1) (177).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

654. do Nascimento JCF, de Oliveira Vasconcelos A, Seabra M, Beltrao EIC, Rocha CRC. The challenge of determining the impact of FUT3 tumor-associated polymorphism rs2306969 (-6951 C> T) in invasive breast cancer cells. *Molecular Biology Reports*. 2019;46(3):3531-6.

배제사유 : 동물실험 및 전임상시험연구

655. Doi M, Yokoyama A, Kondo K, Ohnishi H, Ishikawa N, Hattori N, et al. Anti-tumor effect of the anti-KL-6/MUC1 monoclonal antibody through exposure of surface molecules by MUC1 capping. *Cancer Science*. 2006;97(5):420-9.

배제사유 : 동물실험 및 전임상시험연구

656. Dolcetti R, Crivellari D, Muraro E, Martorelli D, Miolo G, Lombardi D, et al. Immunologic profiling and clinical outcome in HER2+ breast cancer patients treated in a neoadjuvant phase II study: A step forward to understand trastuzumab activity. *Journal of Clinical Oncology*. Conference: ASCO Annual Meeting. 2011;29(15 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

657. Dolcetti R, Crivellari D, Muraro E, Martorelli D, Miolo G, Lombardi D, et al. Neoadjuvant trastuzumab and paclitaxel combination induces a high rate of pathological complete responses in locally advanced breast cancer by exploiting host antitumor immunity. *Cancer Research*. Conference: 34th Annual CTRC AACR San Antonio Breast Cancer Symposium. San Antonio, TX United States. Conference Publication: 2011;71(24 SUPPL. 3).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

658. Dominguez F, Goldstein AL, Tsolas O. Role in disease diagnosis/prognosis/therapy. *International Journal of Thymology*. 1999;7(12-13):642-4.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

659. Dong C. Helper T Cells and Cancer-Associated Inflammation: A New Direction for Immunotherapy? *Journal of Interferon and Cytokine Research*. 2017;37(9):383-5.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
660. Dong JR, Wan H, Zhou AG. Effect of "Ru'aishuhou herbs"on the clinical symptom immunity function in patients with breast cancer postoperation. International forum on chinese and western oncology papers album [guo ji zhong xi yi zhong liu yan jiu lun tan lun wen zhuan ji]. 2008;12(1):281?8.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
661. Dong Z, Dong C. From the guest editors: Cancer-associated inflammation and tumor microenvironment. *Cancer Journal (United States)*. 2013;19(6):459-60.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
662. Donmez C, Groves MJ. Activity of a mycobacterial antineoplastic glycan against human breast cancer. *Anticancer Research*. 1997;17(1A):445-50.
배제사유 : 동물실험 및 전임상시험연구
663. Dorfman C, Andersen B. Social support, health, and recurrent breast cancer: Understanding psychological and biological mechanisms. *Psycho-Oncology*. 2015;2):7.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
664. Dorosevich AE. [Circulating and tumor tissue-bound immune complexes in patients with breast cancer]. *Arkhiv Patologii*. 1983;45(7):30-6.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
665. Dorosevich AE. [Morphological signs of the blocking effect of immunoglobulins and immune complexes in breast cancer before and after radiotherapy]. *Arkhiv Patologii*. 1988;50(4):11-6.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
666. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. *Immunological Reviews*. 2014;257(1):107-26.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
667. Dou J, Gu N. Emerging strategies for the identification and targeting of cancer stem cells. *Tumor Biology*. 2010;31(4):243-53.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
668. Dranoff G. Coordinated tumor immunity. *Journal of Clinical Investigation*. 2003;111(8):1116-8.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
669. Dryzhak VI, Yaremenko AV, Khramtsova NS. Changes in blood - Natural killer cell level in patients with breast and colorectal cancer. [Russian]. *Voprosy Onkologii*. 1989;35(5):585-9.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구

670. Du J, He Y, Zeng H, Dong Z. Myeloid-specific inactivation of PDK1-MTOR1 signaling promotes NK cell-mediated antitumor immunity and inflammation by reprogramming macrophage polarization. *European Journal of Immunology*. 2019;49 (Supplement 3):1524.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
671. Du YJ, Lin ZM, Zhao YH, Feng XP, Wang CQ, Wang G, et al. Stability of the recombinant anti-erbB2 scFv-Fc-interleukin-2 fusion protein and its inhibition of HER2-overexpressing tumor cells. *International Journal of Oncology*. 2013;42(2):507-16.
배제사유 : 동물실험 및 전임상시험연구
672. Ducret JP, Caille P, Sancho Garnier H, Amiel JL, Michelson M, Hovanessian AG, et al. A phase I clinical tolerance study of polyadenylic-polyuridylic acid in cancer patients. *Journal of Biological Response Modifiers*. 1985;4(2):129-33.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
673. Duda DG, Ziehr DR, Guo H, Ng M, Barry WT, Higgins MJ, et al. Effect of cabozantinib treatment on circulating immune cell populations in patients with metastatic triple-negative breast cancer (TNBC). *Journal of Clinical Oncology. Conference*. 2016;34(Supplement 15).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
674. Dudek AZ, Yunis C, Harrison LI, Kumar S, Hawkinson R, Cooley S, et al. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. *Clinical Cancer Research*. 2007;13(23):7119-25.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
675. Duechler M, Peczek L, Zuk K, Zalesna I, Jeziorski A, Czyz M. The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes. *Immunobiology*. 2014;219(2):158-65.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
676. Duong MN, Cleret A, Matera EL, Chettab K, Mathe D, Valsesia-Wittmann S, et al. Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity. *Breast Cancer Research*. 2015;17:57.
배제사유 : 동물실험 및 전임상시험연구
677. Duong MN, Cleret A, Matera EL, Chettab K, Poloni D, Valsesia-Wittmann S, et al. Adipocytes inhibit trastuzumab-mediated ADCC via induction of GDF15. *Cancer Research. Conference: 105th Annual Meeting of the American Association for Cancer Research, AACR*. 2014;74(19 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
678. Duong MN, Matera EL, Mathe D, Evesque A, Valsesia-Wittmann S, Clemenceau B, et al. Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies. *mAbs*. 2015;7(1):192-8.
배제사유 : 동물실험 및 전임상시험연구

679. duPre SA, Redelman D, Hunter Jr KW. Microenvironment of the murine mammary carcinoma 4T1: Endogenous IFN-gamma affects tumor phenotype, growth, and metastasis. *Experimental and Molecular Pathology*. 2008;85(3):174-88.
배제사유 : 동물실험 및 전임상시험연구
680. Dutt S, Rajasekaran N, Marabelle A, Houot R, Sadaram M, Hebb J, et al. Sequential tumor and immune targeted immunotherapy: Anti-tumor activity of antibody drug conjugate Trastuzumab Emtansine (T-DM1) with CD137 stimulation in HER-2+ breast cancer therapy. *Cancer Research Conference: 106th Annual Meeting of the American Association for Cancer Research, AACR*. 2015;75(15 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
681. Eagle RA, Flack G, Warford A, Martinez-Borra J, Jafferji I, Traherne JA, et al. Cellular expression, trafficking, and function of two isoforms of human ULBP5/RAET1G. *PLoS ONE*. 2009;4 (2) (e4503).
배제사유 : 동물실험 및 전임상시험연구
682. Eckert F, Schilbach K, Klumpp L, Bardoscia L, Sezgin EC, Schwab M, et al. Potential role of CXCR4 targeting in the context of radiotherapy and immunotherapy of cancer. *Frontiers in Immunology*. 2018;9 (3018).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
683. Eckert K, Mayer G, Stange R, Kalden M, Krasagakis K, Maurer HR. Effects of thymic peptides, in vitro, on the impaired immunocytotoxicity of peripheral blood mononuclear cells from tumor patients. *International Journal of Oncology*. 1997;10(3):481-6.
배제사유 : 동물실험 및 전임상시험연구
684. Eckert K, Stange R, Kalden M, Krasagakis K, Maurer HR. Low molecular thymic peptides improve the deficient immunocytotoxicity of mononuclear cells from tumor patients in vitro. *Oncology Reports*. 1997;4(6):1343-7.
배제사유 : 동물실험 및 전임상시험연구
685. Eddy JL, Krukowski KN, Konley TL, Loster K, Witek-Janusek L, Mathews HL. Differential epigenetic effects of short and long term glucocorticoid treatment on natural killer cell effector genes. *Brain, Behavior, and Immunity*. 2009;2):S34.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
686. Edwards SC, Kilbey A, Wiesheu R, Morris ER, Hayman L, Rami D, et al. Regulation of IL-17-producing gammadelta T cells in breast cancer metastasis. *British Journal of Cancer*. 2018;119 (1):20.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
687. Eissa IR, Naoe Y, Bustos-Villalobos I, Ichinose T, Tanaka M, Zhiwen W, et al. Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials. *Frontiers in Oncology*. 2017;7:149.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
688. Eissler N, Rolny C. The role of immune semaphorins in cancer progression. *Experimental Cell Research*. 2013;319(11):1635-43.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

689. Eitler J, Wotschel N, Klingemann H, Wels WS, Tonn T. Live cell imaging of lytic granule motility in anti-ErbB2 CAR NK cells and FcR NK cells plus Herceptin towards ErbB2+ breast cancer cells. *Cytotherapy*. 2020;22 (5 Supplement):S199.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

690. Elam JL, Carpenter JS, Shu XO, Boyapati S, Friedmann-Gilchrist J. Methodological issues in the investigation of ginseng as an intervention for fatigue. *Clinical Nurse Specialist*. 2006;20(4):183-9.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

691. Elaskalani O, Berndt MC, Falasca M, Metharom P. Targeting platelets for the treatment of cancer. *Cancers*. 2017;9 (7) (94).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

692. El-Baiomy EM, Salem ML, El-Amir A, Sabry NA, Wallston KA, El-Mashad N. Correlations between MHL scores and Indicators of Immune Response in Egyptian Women with Breast Cancer. *The gulf journal of oncology*. 2020;1(32):7-11.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

693. El-Deeb NM, El-Adawi HI, El-Wahab AEA, Haddad AM, El Enshasy HA, He YW, et al. Modulation of NKG2D, KIR2DL and Cytokine Production by Pleurotus ostreatus Glucan Enhances Natural Killer Cell Cytotoxicity Toward Cancer Cells. *Frontiers in Cell & Developmental Biology*. 2019;7:165.

배제사유 : 동물실험 및 전임상시험연구

694. Elezov DS, Kudryavtsev IV. PD-1 receptor on immune cells, its expression and potential role in cancer therapy. *Cellular Therapy and Transplantation*. 2019;8(2):8-16.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

695. El-Gazzar A, Cai X, Reeves RS, Dai Z, Caballero-Benitez A, McDonald DL, et al. Effects on tumor development and metastatic dissemination by the NKG2D lymphocyte receptor expressed on cancer cells. *Oncogene*. 2014;33(41):4932-40.

배제사유 : 동물실험 및 전임상시험연구

696. ElGhonaimy EA, El-Shinawi M, Abd-El-Tawab R, El Mamlouk T, Sloane BF, Mohamed MM. Biological characterization of tumor-associated leukocytes in positive and negative lymph node breast cancer patients. *Cancer Research Conference: 35th Annual CTRC AACR San Antonio Breast Cancer Symposium*. San Antonio, TX United States. Conference Publication: 2012;72(24 SUPPL. 3).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

697. Elkak A, Al Sarakbi W, Mokbel K. SYK expression in human breast cancer. *Journal of Carcinogenesis*. 2005;4(1):7.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

698. Elkhouly A, Youness RA, Gad M. miR-486-5p Counteracts the Shedding of MICA/B and CD155 Immune-Ligands in TNBC Patients. *Annals of Oncology*. 2019;30 (Supplement 11):xi60-xi1.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

699. Ellinidi VN, Anikeeva NV, Goncharova OA, Krasnozhon DA. [Natural killer cells (CD56, CD16) as a factor of local antitumor immunity in breast cancer]. Voprosy Onkologii. 2005;51(4):447-9.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

700. Elliott RL, Jiang X, Head JF. Reversal of immune suppression in cancer by manipulation of tumor iron metabolism. Journal of Immunotherapy. 2010;33 (8):869.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

701. Elliott RL, Jiang XP. Tumor microenvironment immunosuppression: Role of neglected molecules iron and HLA-G. Cancer Immunology Research. Conference. 2017;6(9 Supplement).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

702. El-Shinawi M, Abdelwahab SF, Sobhy M, Nouh MA, Sloane BF, Mohamed MM. Capturing and characterizing immune cells from breast tumor microenvironment: an innovative surgical approach. Annals of Surgical Oncology. 2010;17(10):2677-84.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

703. Elster D, Tollot M, Schlegelmilch K, Ori A, Rosenwald A, Sahai E, et al. TRPS1 shapes YAP/TEAD-dependent transcription in breast cancer cells. Nature Communications. 2018;9 (1) (3115).

배제사유 : 동물실험 및 전임상시험연구

704. Elvington M, Scheiber M, Yang X, Lyons K, Jacqmin D, Wadsworth C, et al. Complement-dependent modulation of antitumor immunity following radiation therapy. Cell Reports. 2014;8(3):818-30.

배제사유 : 동물실험 및 전임상시험연구

705. Emens LA, Adams S, Loi S, Schneeweiss A, Rugo HS, Winer EP, et al. IMpassion130: A Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC). Journal of Clinical Oncology. Conference. 2016;34(Supplement 15).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

706. Emtage PC, Wan Y, Hitt M, Graham FL, Muller WJ, Zlotnik A, et al. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Human Gene Therapy. 1999;10(5):697-709.

배제사유 : 동물실험 및 전임상시험연구

707. Engel AL, Sun GC, Gad E, Rastetter L, Wenner C, Lu H. Innate immune activation and vaccine adjuvant potential of TLR-2 agonist, poly saccharide krestin (PSK). Journal of Immunotherapy. 2011;34 (9):690.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

708. Engel J, Honig A, Meyer S, Dietl J, Kwok B, Ortmann O, et al. Specific inhibitor of ERK 1/2 AEZS-131: Anticancer activity in models of human cancers with and without

- overactivation of ERK1/2. *Oncology Research and Treatment*. 2014;1):131.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
709. Engel JB, Honig A, Kapp M, Hahne JC, Meyer SR, Dietl J, et al. Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1. *Archives of Gynecology & Obstetrics*. 2014;289(1):141-7.
배제사유 : 동물실험 및 전임상시험연구
710. Engels CC, Fontein DB, Kuppen PJ, de Kruijf EM, Smit VT, Nortier JW, et al. Immunological subtypes in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma. *British Journal of Cancer*. 2014;111(3):532-8.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
711. Erdogan ZM, Katzenellenbogen BS. Systems biology of gene regulation by estrogen receptors and kinases in breast cancer. *Endocrine Reviews*. Conference: 97th Annual Meeting and Expo of the Endocrine Society, ENDO. 2015;36(Supplement 2).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
712. Eremin O, Ashby J, Stephens JP. Human natural cytotoxicity in the blood and lymphoid organs of healthy donors and patients with malignant disease. *International Journal of Cancer*. 1978;21(1):35-41.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
713. Eremin O, Coombs RR, Ashby J. Lymphocytes infiltrating human breast cancers lack K-cell activity and show low levels of NK-cell activity. *British Journal of Cancer*. 1981;44(2):166-76.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
714. Eremin O, Walker MB, Simpson E, Heys SD, Ah-See AK, Hutcheon AW, et al. Immuno-modulatory effects of relaxation training and guided imagery in women with locally advanced breast cancer undergoing multimodality therapy: a randomised controlled trial. *Breast*. 2009;18(1):17-25.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
715. Erra Diaz F, Dantas E, Geffner J. Unravelling the interplay between extracellular acidosis and immune cells. *Mediators of Inflammation*. 2018;2018 (1218297).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
716. Escobar G, Moi D, Ranghetti A, Ozkal-Baydin P, Squadrito ML, Kajaste-Rudnitski A, et al. Genetic engineering of hematopoiesis for targeted IFN-alpha delivery inhibits breast cancer progression. *Science Translational Medicine*. 2014;6 (217) (217ra3).
배제사유 : 동물실험 및 전임상시험연구
717. Espinoza-Delgado I, Childs RW. Nonmyeloablative transplantation for solid tumors: A new frontier for allogeneic immunotherapy. *Expert Review of Anticancer Therapy*. 2004;4(5):865-75.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
718. Esteve N, Ferrer A, Mora C, Gomez G, Ribera H, Garrido P. Does the anesthesia have

any influence on surgical outcome? [Spanish]. Revista de la Sociedad Espanola del Dolor. 2014;21(3):162-74.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

719. Eucr DK. Tocotrienol in combination with preoperative chemotherapy for women with breast cancer.

<http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2016-000080-16-DK>. 2016.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

720. Euhus DM, Kimura L, Arnold B. Expansion of CD3+CD56+ lymphocytes correlates with induction of cytotoxicity by interleukin-2 gene transfer in human breast tumor cultures. Annals of Surgical Oncology. 1997;4(5):432-9.

배제사유 : 동물실험 및 전임상시험연구

721. EUROANAESTHESIA 2014: the European Anaesthesiology Congress. European journal of anaesthesiology. 2014;31.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

722. Evans ES, Hackney AC, McMurray RG, Randell SH, Muss HB, Deal AM, et al. Impact of Acute Intermittent Exercise on Natural Killer Cells in Breast Cancer Survivors. Integrative Cancer Therapies. 2015;14(5):436-45.

배제사유 : 동물실험 및 전임상시험연구

723. Evans KN, Bulmer JN, Kilby MD, Hewison M. Vitamin D and placental-decidua function. Journal of the Society for Gynecologic Investigation. 2004;11(5):263-71.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

724. Evans MK, Sauer SJ, Nath S, Robinson TJ, Morse MA, Devi GR. X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity. Cell Death & Disease. 2016;7:e2073.

배제사유 : 동물실험 및 전임상시험연구

725. Evans RA. Breast cancer: the dilemma of local recurrence. Medical Hypotheses. 1989;29(3):151-3.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

726. Evans RA. Natural killer cells and the Guy's Hospital trials. Archives of Surgery. 1988;123(7):913-4.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

727. Evans RA. Preservation surgery for malignant disease: why it works. Southern Medical Journal. 1989;82(12):1534-7.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

728. Evans W. NK cell recruitment and exercise: Potential immunotherapeutic role of shear stress and endothelial health. Medical Hypotheses. 2017;109:170-3.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

729. Everts M. Targeted therapies directed to tumor-associated antigens. Drugs of the Future. 2005;30(10):1067-76.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

730. Ezaki K. [Clinical and immunological studies of human fibroblast interferon and human lymphoblastoid interferon in malignant diseases]. Gan No Rinsho - Japanese Journal of Cancer Clinics. 1983;29(6):598-602.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

731. Fabian CJ, Khan SA, Garber JE, Dooley WC, Yee LD, Klemp JR, et al. Randomized Phase IIB Trial of the Lignan Secoisolariciresinol Diglucoside in Pre-menopausal Women at Increased Risk for Development of Breast Cancer. Cancer prevention research (Philadelphia, Pa.). 2020.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

732. Fabian KP, Padgett MR, Donahue RN, Solocinski K, Robbins Y, Allen CT, et al. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. Journal for ImmunoTherapy of Cancer. 2020;8 (1) (e000450).

배제사유 : 동물실험 및 전임상시험연구

733. Faget J, Bendriss-Vermare N, Bachelot T, Sisirak V, Gobert M, Durand I, et al. Functionally altered plasmacytoid DC in breast tumor environment play a central role in Treg and Tr1-like expansion through ICOS engagement. Cancer Research. Conference: 103rd Annual Meeting of the American Association for Cancer Research, AACR. 2012;72(8 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

734. Faget J, Biota C, Bachelot T, Gobert M, Dezutter-Dambuyant C, Treilleux I, et al. Early detection of tumor cells by innate immune cells leads to Treg recruitment through CCL22 production by tumor cells. Cancer Research. Conference: 101st Annual Meeting of the American Association for Cancer Research, AACR. 2010;70(8 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

735. Faget J, Biota C, Bachelot T, Gobert M, Treilleux I, Goutagny N, et al. Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells. Cancer Research. 2011;71(19):6143-52.

배제사유 : 동물실험 및 전임상시험연구

736. Fairey AS, Courneya KS, Field CJ, Bell GJ, Jones LW, Mackey JR. Randomized controlled trial of exercise and blood immune function in postmenopausal breast cancer survivors. Journal of Applied Physiology. 2005;98(4):1534-40.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

737. Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. Journal of Hematology and Oncology. 2015;8 (1) (130).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

738. Fang JM, Bi AH. Observation of activity of IL-2 produced by mononuclear cells in tumor draining lymph-node. Journal of Tongji Medical University. 1989;9(2):91-4.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

739. Fang Y, Deshan L, Shuli W, Lan X. Effects of electro-acupuncture on T cell subpopulations, NK activity, humoral immunity and leukocyte count in patients undergoing chemotherapy. *Journal of Traditional Chinese Medicine*. 2007;27(1):19-21.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
740. Farag SS, Caligiuri MA. Human natural killer cell development and biology. *Blood Reviews*. 2006;20(3):123-37.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
741. Faraut B, Bayon V, Leger D. Neuroendocrine, immune and oxidative stress in shift workers. *Sleep Medicine Reviews*. 2013;17(6):433-44.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
742. Farhood B, Goradel NH, Mortezaee K, Khanlarkhani N, Salehi E, Nashtaei MS, et al. Melatonin as an adjuvant in radiotherapy for radioprotection and radiosensitization. *Clinical and Translational Oncology*. 2019;21(3):268-79.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
743. Farhood B, khadamoradi E, Hoseini-Ghahfarokhi M, Motevaseli E, Mirtavoos-Mahyari H, Eleojo Musa A, et al. TGF-beta in radiotherapy: Mechanisms of tumor resistance and normal tissues injury. *Pharmacological Research*. 2020;155 (104745).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
744. Farooqi AA, Khalid S, Ahmad A. Regulation of cell signaling pathways and miRNAs by resveratrol in different cancers. *International Journal of Molecular Sciences*. 2018;19 (3) (652).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
745. Farragher B. Psychiatric morbidity in breast cancer. *Irish Journal of Medical Science*. 1998;167(3):164-5.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
746. Farsaci B, Donahue RN, Grenga I, Lepone LM, Kim PS, Dempsey B, et al. Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. *Cancer Immunology Research*. 2016;4(9):755-65.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
747. Fattorossi A, Battaglia A, Pierelli L, Malinconico P, Andreocci L, Perillo A, et al. Effects of granulocyte-colony-stimulating factor and granulocyte/macrophage-colony-stimulating factor administration on T cell proliferation and phagocyte cell-surface molecules during hematopoietic reconstitution after autologous peripheral blood progenitor cell transplantation. *Cancer Immunology, Immunotherapy*. 2001;49(12):641-8.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
748. Febbraio MA. Exercise metabolism in 2016: Health benefits of exercise - more than meets the eye! *Nature Reviews Endocrinology*. 2017;13(2):72-4.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

749. Felder M, Kapur A, Rakhmili A, Connor J, Patankar MS. MUC16 protects ovarian cancer cells from the cytolytic responses of human and murine natural killer cells and macrophages. *Cancer Research*. Conference: AACR Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances. 2012;73(1 SUPPL. 1).
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
750. Fenerty KE, Padgett M, Wolfson B, Gameiro SR, Su Z, Lee JH, et al. Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition. *Journal for Immunotherapy of Cancer*. 2018;6(1):133.
- 배제사유 : 동물실험 및 전임상시험연구
751. Feng H, Dong Y, Wu J, Qiao Y, Zhu G, Jin H, et al. Epirubicin pretreatment enhances NK cell-mediated cytotoxicity against breast cancer cells in vitro. *American Journal Of Translational Research*. 2016;8(2):473-84.
- 배제사유 : 동물실험 및 전임상시험연구
752. Feng W, Cai B, Wang L, Chen J. [Research on clinical significance of CD3+CD56+NKT cells and CD3-CD56+NK cells in patients with malignant tumors]. *Chinese Journal of Lung Cancer*. 2007;10(5):429-32.
- 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
753. Fer MF, Beman J, Stevenson HC, Maluish A, Moratz C, Delawter T, et al. A trial of autologous plasma perfusion over protein A in patients with breast cancer. *Journal of Biological Response Modifiers*. 1984;3(3):352-8.
- 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
754. Fernandes A, Pesci-Feltri A, Garcia-Fleury I, Lopez M, Guida V, De Macedo M, et al. Lymphocyte subsets predictive value and possible involvement of human papilloma virus infection on breast cancer molecular subtypes. *World Journal of Clinical Oncology*. 2018;9(7):123-32.
- 배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
755. Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: Mechanisms of action and new perspectives of clinical use. *Biochimie*. 2007;89(6-7):884-93.
- 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
756. Ferreira LMR, Gammadelta T Cells: Innately adaptive immune cells. *International Reviews of Immunology*. 2013;32(3):223-48.
- 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
757. Ferris RL, Lotze MT, Leong SPL, Hoon DSB, Morton DL. Lymphatics, lymph nodes and the immune system: Barriers and gateways for cancer spread. *Clinical and Experimental Metastasis*. 2012;29(7):729-36.
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
758. Feuerer M, Rocha M, Bai L, Umansky V, Solomayer EF, Bastert G, et al. Enrichment of

memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. International Journal of Cancer. 2001;92(1):96-105.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

759. Feyerabend T, Wiedemann GJ, Richter E, Hegewisch-Becker S. Hyperthermia as an adjunct to the standard treatment of neoplastic diseases: Few cures but some advances. Onkologie. 1999;22(2):122-7.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

760. Fhorghlu MN, Barrett S. A Review of Radiation-Induced Lymphocyte Apoptosis as a Predictor of Late Toxicity After Breast Radiotherapy. Journal of Medical Imaging and Radiation Sciences. 2019;50(2):337-44.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

761. Fiebig HH, Siegling A, Volk HD, Friebel A, Knolle P, Limmer A, et al. Inactivated orf virus (*Parapoxvirus ovis*) induces antitumoral activity in transplantable tumor models. Anticancer Research. 2011;31(12):4185-90.

배제사유 : 동물실험 및 전임상시험연구

762. Fillion L, Lemire L, Mandeville R, Piche R. Cognitive appraisal, stress state, and cellular immunity responses before and after diagnosis of breast tumor. International Journal of Rehabilitation and Health. 1996;2(3):169-87.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

763. Finak G, Bertos N, Pepin F. Stromal gene expression predicts clinical outcome in breast cancer. Advances in Breast Cancer. 2008;5(2):43.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

764. Finn OJ. A Believer's Overview of Cancer Immunosurveillance and Immunotherapy. Journal of Immunology. 2018;200(2):385-91.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

765. Finn OJ. Immuno-oncology: Understanding the function and dysfunction of the immune system in cancer. Annals of Oncology. 2012;23(SUPPL.8):viii6-viii9.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

766. Fischer A, Ben-Eliyahu S. Perioperative Stress, Inflammation, and Cancer Progression: Opportunities for Intervention in Breast and Colorectal Cancer Surgery Utilizing Beta-Adrenergic Blockade and COX-2 Inhibition. Current Anesthesiology Reports. 2018;8(4):386-92.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

767. Fischer C, Jorgenson E, Ilagan Y, Taylor H. BPA exposure in utero leads to localized immune system dysregulation within mouse mammary gland: A potential mechanism programming breast cancer risk. Reproductive Sciences. 2014;1):206A.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

768. Fisher M, Yang LX. Anticancer effects and mechanisms of polysaccharide-K (PSK): Implications of cancer immunotherapy. Anticancer Research. 2002;22(3):1737-54.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

769. Fisk B, Ioannides CG, Aggarwal S, Wharton JT, O'Brian CA, Restifo N, et al. Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon-gamma in a multidrug-resistant small cell lung cancer line. *Lymphokine & Cytokine Research.* 1994;13(2):125-31.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

770. Fitton JH, Stringer DN, Karpiniec SS. Therapies from fucoidan: An update. *Marine Drugs.* 2015;13(9):5920-46.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

771. Fleming GF, Meropol NJ, Rosner GL, Hollis DR, Carson WE, 3rd, Caligiuri M, et al. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. *Clinical Cancer Research.* 2002;8(12):3718-27.

배제사유 : 동물실험 및 전임상시험연구

772. Flemming A. Cancer: Unleashing NK cell anti-metastatic activity. *Nature Reviews Drug Discovery.* 2014;13(4):257.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

773. Flueh C, Hufnagel R, Synowitz M, Held-Feindt J. Nkg2dl expression and dormancy in cerebral metastases: Impact of chemotherapeutic treatment. *Neuro-Oncology.* 2019;21(Supplement 3):iii41.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

774. Flueh C, Mafael V, Adamski V, Hattermann K, Synowitz M, Held-Feindt J. NKG2D ligand expression and tumor dormancy in brain metastases. *Neuro-Oncology.* 2018;20(Supplement 3):iii271-iii2.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

775. Fluh C, Mafael V, Adamski V, Synowitz M, Held-Feindt J. Dormancy and NKG2D system in brain metastases: Analysis of immunogenicity. *International Journal of Molecular Medicine.* 2020;45(2):298-314.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

776. Folkerts H, Hilgendorf S, Vellenga E, Bremer E, Wiersma VR. The multifaceted role of autophagy in cancer and the microenvironment. *Medicinal Research Reviews.* 2019;39(2):517-60.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

777. Fontein DBY, Engels CC, Bastiaannet E, De Kruijf EM, Liefers GJ, Nortier JWR, et al. Immunological subtypes in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma. *European Journal of Cancer.* 2013;2):S150.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

778. Forbes JF. Timing of breast cancer surgery in the menstrual cycle and outcome. *Annals of Oncology.* 1991;2(4):243.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

779. Forde PF, Hall LJ, De Kruijf M, Bourke MG, Doddy T, Sadadcharam M, et al. Non-viral immune electrogene therapy induces potent antitumour responses and has a curative effect in murine colon adenocarcinoma and melanoma cancer models. *Gene Therapy*. 2015;22(1):29-39.
배제사유 : 동물실험 및 전임상시험연구
780. Forget P, Coulie PG, Retsky M, Demicheli R, Machiels JP, De Kock M. Is there a rationale for an anesthesiologist's role against cancer recurrence? *Acta Anaesthesiologica Belgica*. 2013;64(1):15-24.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
781. Formenti SC. Combining radiation therapy with immunotherapy: Clinical translation. *Journal of Translational Medicine*. Conference: Melanoma Bridge. 2014;13(SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
782. Forti RL, Mitchell WM, Hubbard WC, Workman RJ, Forbes JT. Pleiotropic activities of human interferons are mediated by multiple response pathways. *Proceedings of the National Academy of Sciences of the United States of America*. 1984;81(1):170-4.
배제사유 : 동물실험 및 전임상시험연구
783. Forti RL, Mitchell WM, Workman RJ, Forbes JT, Hubbard WC. A functional cyclooxygenase enzyme is not required for mediation of the pleiotropic effects of human alpha or beta interferon. *Prostaglandins*. 1983;26(3):409-20.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
784. Foulds GA, Alamoudi AA, Hopkinson K, Multhoff G, Pockley AG. Induction on membrane Hsp70 expression on human T and NK cell populations: A novel immunoregulatory mechanism? *Immunology*. 2010;1):59-60.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
785. Foulds GA, Cussen HE, Multhoff G, Pockley AG. Influence of breast cancer cell-derived factors on the phenotype and cytotoxicity of human CD56lowCD16+ and CD56highCD16 NK cell subsets. *Immunology*. 2011;1):85.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
786. Foulds GA, Vadakekolathu J, Abdel-Fatah TMA, Nagarajan D, Reeder S, Johnson C, et al. Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer. *Frontiers in Immunology*. 2018;9:2028.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
787. Fowler DH. Shared biology of GVHD and GVT effects: Potential methods of separation. *Critical Reviews in Oncology/Hematology*. 2006;57(3):225-44.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
788. Fraker LD, Halter SA, Forbes JT. Growth inhibition by retinol of a human breast carcinoma cell line in vitro and in athymic mice. *Cancer Research*. 1984;44(12 Pt 1):5757-63.
배제사유 : 동물실험 및 전임상시험연구

789. Franciszkiewicz K, Boissonnas A, Boutet M, Combadiere C, Mami-Chouaib F. Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. *Cancer Research*. 2012;72(24):6325-32.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
790. Franco A. Glycoconjugates as vaccines for cancer immunotherapy: Clinical trials and future directions. *Anti-Cancer Agents in Medicinal Chemistry*. 2008;8(1):86-91.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
791. Franks HA, Wang Q, Patel PM. New anticancer immunotherapies. *Anticancer Research*. 2012;32(7):2439-54.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
792. Frasci G. Treatment of breast cancer with chemotherapy in combination with filgrastim: Approaches to improving therapeutic outcome. *Drugs*. 2002;62(SUPPL. 1):17-31.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
793. Frazao A, Messaoudene M, Nunez N, Dulphy N, Roussin F, Sedlik C, et al. CD16+NKG2Ahigh Natural Killer Cells Infiltrate Breast Cancer-Draining Lymph Nodes. *Cancer Immunology Research*. 2019;7(2):208-18.
배제사유 : 동물실험 및 전임상시험연구
794. Frazao A, Rethacker L, Messaoudene M, Avril MF, Toubert A, Dulphy N, et al. NKG2D/NKG2-Ligand pathway offers new opportunities in cancer treatment. *Frontiers in Immunology*. 2019;10 (00661).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
795. Fredrikson M, Furst CJ, Lekander M, Rotstein S, Blomgren H. Trait anxiety and anticipatory immune reactions in women receiving adjuvant chemotherapy for breast cancer. *Brain, Behavior, & Immunity*. 1993;7(1):79-90.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
796. Freling E, Granel-Brocard F, Serrier C, Ortonne N, Barbaud A, Schmutz JL. [Extranodal NK/T-cell lymphoma, nasal-type, revealed by cutaneous breast involvement]. *Annales de Dermatologie et de Venereologie*. 2015;142(2):104-11.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
797. Fremd C, Schuetz F, Sohn C, Beckhove P, Domschke C. B cell-regulated immune responses in tumor models and cancer patients. *OncoImmunology*. 2013;2 (7) (e25443).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
798. Friedl A, Jordan VC. Oestradiol stimulates growth of oestrogen receptor-negative MDA-MB-231 breast cancer cells in immunodeficient mice by reducing cell loss. *European Journal of Cancer*. 1994;30A(10):1559-64.
배제사유 : 동물실험 및 전임상시험연구
799. Friedmann-Morvinski D, Eshhar Z. Adoptive immunotherapy of cancer using effector lymphocytes redirected with antibody specificity. Update on Cancer Therapeutics.

2006;1(1):25-32.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

800. Frostad S, Kalland T, Aakvaag A, Laerum OD. Hemoregulatory peptide (HP5b) dimer effects on normal and malignant cells in culture. *Stem Cells*. 1993;11(4):303-11.

배제사유 : 동물실험 및 전임상시험연구

801. Fu D, Geschwind JF, Karthikeyan S, Miller E, Kunjithapatham R, Wang Z, et al. Metabolic perturbation sensitizes human breast cancer to NK cell-mediated cytotoxicity by increasing the expression of MHC class I chain-related A/B. *Oncoimmunology*. 2015;4(3):e991228.

배제사유 : 동물실험 및 전임상시험연구

802. Fu Q, Cash SE, Andersen JJ, Kennedy CR, Madadi AR, Raghavendra M, et al. Intracellular patterns of sialophorin expression define a new molecular classification of breast cancer and represent new targets for therapy. *British Journal of Cancer*. 2014;110(1):146-55.

배제사유 : 동물실험 및 전임상시험연구

803. Fu T, Li SJ, Song D, Fan ZM. Application of Aiyishu injection in adjuvant treatment of breast cancer after operation and curative effect evaluation. [Chinese]. *Journal of Jilin University Medicine Edition*. 2007;33(4):744-6.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

804. Fu Y, Guo F, Chen H, Lin Y, Fu X, Zhang H, et al. Core needle biopsy promotes lung metastasis of breast cancer: An experimental study. *Molecular & Clinical Oncology*. 2019;10(2):253-60.

배제사유 : 동물실험 및 전임상시험연구

805. Fuchs U. Viscum album lectin in oncology. [German]. *Zeitschrift fur Phytotherapie*. 1994;15(4):230-1.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

806. Fuenmayor J, Montano RF. Novel antibody-based proteins for cancer immunotherapy. *Cancers*. 2011;3(3):3370-93.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

807. Fuentes-Raspall MJ, Caragol I, Alonso C, Ramon y Cajal T, Fisas D, Seoane A, et al. Apoptosis for prediction of radiotherapy late toxicity: lymphocyte subset sensitivity and potential effect of TP53 Arg72Pro polymorphism. *Apoptosis*. 2015;20(3):371-82.

배제사유 : 동물실험 및 전임상시험연구

808. Fugazzola L, Cirello V, Beck-Peccoz P. Fetal microchimerism as an explanation of disease. *Nature Reviews Endocrinology*. 2011;7(2):89-97.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

809. Fugazzola L, Cirello V, Beck-Peccoz P. Microchimerism and endocrine disorders. *Journal of Clinical Endocrinology and Metabolism*. 2012;97(5):1452-61.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

810. Fuggetta MP, D'Onofrio C, Bonmassar E. Role of biological response modifiers in immunochemotherapy of solid tumors and retroviral-induced leukemia. *Annali Dell'Istituto Superiore di Sanita*. 1990;26(3-4):385-95.
배제사유 : 동물실험 및 전임상시험연구
811. Fujihara S, Mori H, Kobara H, Rafiq K, Niki T, Hirashima M, et al. Galectin-9 in cancer therapy. *Recent Patents on Endocrine, Metabolic and Immune Drug Discovery*. 2013;7(2):130-7.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
812. Fujii R, Wong HC, Schlom J, Hodge JW. An IL-15 superagonist enhances antibody-dependent cell-mediated cytotoxicity against breast cancer cells regardless of FCGR3A (CD16) genotype and rescues NK cell from TGF-beta1-induced immunosuppression. *Cancer Research*. Conference: San Antonio Breast Cancer Symposium, SABCS. 2017;78(4 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
813. Fujisawa T, Yamaguchi Y. [Immunity in cancer patients and their household contacts]. *Gan No Rinsho - Japanese Journal of Cancer Clinics*. 1987;33(5 Suppl):535-8.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
814. Fukumoto H, Nishio K, Ohta S, Hanai N, Fukuoka K, Ohe Y, et al. Effect of a chimeric anti-ganglioside GM2 antibody on ganglioside GM2-expressing human solid tumors in vivo. *International Journal of Cancer*. 1999;82(5):759-64.
배제사유 : 동물실험 및 전임상시험연구
815. Fulton A, Heppner G, Roi L, Howard L, Russo J, Brennan M. Relationship of natural killer cytotoxicity to clinical and biochemical parameters of primary human breast cancer. *Breast Cancer Research & Treatment*. 1984;4(2):109-16.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
816. Fulton A, Kundu N, Kochel T, Ma X, Reader J. Prostaglandin E receptor EP4 is a therapeutic target in breast cancer stem cells. *Cancer Research*. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium. San Antonio, TX United States. Conference Publication: 2015;75(9 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
817. Fulton A, Miller F, Weise A, Wei WZ. Prospects of controlling breast cancer metastasis by immune intervention. *Breast Disease*. 2006;26:115-27.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
818. Fulton AM, Kundu N, Ma X, Kochel T, Reader J. The prostaglandin E receptor EP4 is upregulated on breast cancer stem-like cells and regulates sensitivity to Natural Killer cells. *Cancer Research*. Conference: 106th Annual Meeting of the American Association for Cancer Research, AACR. 2015;75(15 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
819. Fulton AM, Ma X, Kundu N, Ioffe O, Goloubeva O, Konger R, et al. Opposing roles of

the COX-2 pathway receptors EP1 and EP4 in metastasis and contribution to disparities. Cancer Research. Conference: 101st Annual Meeting of the American Association for Cancer Research, AACR. 2010;70(8 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

820. Funaki J, Kokura S, Tsuchiya R, Matsuyama T, Okajima M, Sakai H, et al. Promising efficacy of immunotherapy combined with cetuximab-mediated ADCC. [Japanese]. Biotherapy. 2011;25(5):803-10.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

821. Funke AM. [Potential of selenium in gynecologic oncology]. Medizinische Klinik. 1999;94 Suppl 3:42-4.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

822. Fusella F, Secli L, Brancaccio M. Escaping NK cells and recruiting neutrophils: How Morgana/NF-kappaB signaling promotes metastasis. Molecular & Cellular Oncology. 2018;5(3):e1432258.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

823. Fusella F, Secli L, Busso E, Krepeleva A, Moiso E, Rocca S, et al. The IKK/NF-kappaB signaling pathway requires Morgana to drive breast cancer metastasis. Nature communications. 2017;8(1):1636.

배제사유 : 동물실험 및 전임상시험연구

824. Gabrilovich D, Pisarev V. Tumor escape from immune response: Mechanisms and targets of activity. Current Drug Targets. 2003;4(7):525-36.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

825. Gach K, Wyrebska A, Fichna J, Janecka A. The role of morphine in regulation of cancer cell growth. Naunyn-Schmiedeberg's Archives of Pharmacology. 2011;384(3):221-30.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

826. Gaffey MJ, Frierson HF, Jr., Mills SE, Boyd JC, Zarbo RJ, Simpson JF, et al. Medullary carcinoma of the breast. Identification of lymphocyte subpopulations and their significance. Modern Pathology. 1993;6(6):721-8.

배제사유 : 동물실험 및 전임상시험연구

827. Gajovic N, Jurisevic M, Pantic J, Radosavljevic G, Arsenijevic N, Lukic ML, et al. Attenuation of NK cells facilitates mammary tumor growth in streptozotocin-induced diabetes in mice. Endocrine-Related Cancer. 2018;25(4):493-507.

배제사유 : 동물실험 및 전임상시험연구

828. Galluzzi L, Chan TA, Kroemer G, Wolchok JD, Lopez-Soto A. The hallmarks of successful anticancer immunotherapy. Science Translational Medicine. 2018;10 (459) (eaat7807).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

829. Galluzzi L, Kepp O, Kroemer G. Reverse Warburg: Straight to cancer. Cell Cycle. 2012;11(6):1059.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

830. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: Immunostimulation by anticancer drugs. *Nature Reviews Drug Discovery*. 2012;11(3):215-33.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
831. Galy A, Rudraraju S, Baynes R, Klein J. Recovery of lymphocyte and dendritic cell subsets after autologous CD34+ cell transplantation. *Bone Marrow Transplantation*. 2000;25(12):1249-55.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
832. Ganapathy-Kanniappan S. Editorial: Cancer metabolism: Molecular targeting and implications for therapy. *Frontiers in Oncology*. 2017;7 (SEP) (232).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
833. Ganesan S, Bhanot G, Mehnert JM, Silk AW, Ross JS, Pavlick D, et al. Mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers. *Journal of Clinical Oncology*. 2017;35 (7 Supplement 1):35.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
834. Gao D, Fish EN. Chemokines in breast cancer: Regulating metabolism. *Cytokine*. 2018;109:57-64.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
835. Gao X, Wang X, Yang Q, Zhao X, Wen W, Li G, et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. *Journal of Immunology*. 2015;194(1):438-45.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
836. Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of Ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. *Immunological Investigations*. 2003;32(3):201-15.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
837. Garam T, Bakacs T, Totpal K, Svastits E, Ringwald G, Petranyi G. [NK (natural killer) and K (killer) cell activity in breast cancer. Relation of the stage of the disease to cytotoxic activity]. *Orvosi Hetilap*. 1983;124(1):15-8.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
838. Garcia-Chagollan M, Carranza-Torres IE, Carranza-Rosales P, Guzman-Delgado NE, Ramirez-Montoya H, Martinez-Silva MG, et al. Expression of NK Cell Surface Receptors in Breast Cancer Tissue as Predictors of Resistance to Antineoplastic Treatment. *Technology in Cancer Research & Treatment*. 2018;17:1533033818764499.
배제사유 : 동물실험 및 전임상시험연구
839. Gardiner CM, Finlay DK. What fuels natural killers? Metabolism and NK cell responses. *Frontiers in Immunology*. 2017;8 (APR) (367).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
840. Gareau AJ, Brien C, Gebremeskel S, Liwski RS, Johnston B, Bezuhly M. Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast

cancer. Clinical & Experimental Metastasis. 2018;35(1-2):25-35.

배제사유 : 동물실험 및 전임상시험연구

841. Garland M, Doherty D, Golden-Mason L, Fitzpatrick P, Walsh N, O'Farrelly C. Stress-related hormonal suppression of natural killer activity does not show menstrual cycle variations: implications for timing of surgery for breast cancer. Anticancer Research. 2003;23(3B):2531-5.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
842. Garland MR, Lavelle E, Doherty D, Golden-Mason L, Fitzpatrick P, Hill A, et al. Cortisol does not mediate the suppressive effects of psychiatric morbidity on natural killer cell activity: a cross-sectional study of patients with early breast cancer. Psychological Medicine. 2004;34(3):481-90.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
843. Garner C, Seery TE, Nangia CS, Lee JH, Huang L, Sender LS, et al. Correlation between circulating cell-free RNA biomarkers and response during combination immunotherapy in previously refractory metastatic TNBC patients. Journal of Clinical Oncology. Conference. 2019;37(Supplement 15).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
844. Garner WL, Minton JP, James AG, Hoffmann CC. Human breast cancer and impaired NK cell function. Journal of Surgical Oncology. 1983;24(1):64-6.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
845. Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Advances in Cancer Research. 2001;83:117-58.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
846. Garrido F. MHC/HLA class I loss in cancer cells. Advances in Experimental Medicine and Biology. 2019;1151:15-78.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
847. Garritson BK, Nikaein A, Peters GN, Gorman MA, King CC, Liepa GU. Effect of major dietary modifications on immune system in patients with breast cancer: a pilot study. Cancer Practice. 1995;3(4):239-46.
배제사유 : 동물실험 및 전임상시험연구
848. Garssen B, Boomsma MF, Beelen RHJ. Psychological factors in immunomodulation induced by cancer surgery: A review. Biological Psychology. 2010;85(1):1-13.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
849. Gatti-Mays ME, Balko JM, Gameiro SR, Bear HD, Prabhakaran S, Fukui J, et al. If we build it they will come: targeting the immune response to breast cancer. NPJ Breast Cancer. 2019;5:37.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
850. Gavriliuc O, Zogorean R, Bojin F, Paunescu V. CAR-based immunotherapy of

EGFR-positive solid tumours using cytokine-activated peripheral blood killer cells. Human Gene Therapy. 2019;30 (12):A7.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

851. Gaynor N, Noone J, Monedero J, Murphy EE, O'Gorman DJ, Crown J, et al. The effect of relieving adenosine-mediated immunosuppression on trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity (T-ADCC) against HER2+ breast cancer cell lines. Cancer Research. Conference. 2018;79(4 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
852. Gebremeskel S, Clattenburg DR, Slauenwhite D, Lobert L, Johnston B. Natural killer T cell activation overcomes immunosuppression to enhance clearance of postsurgical breast cancer metastasis in mice. Oncoimmunology. 2015;4(3):e995562.
배제사유 : 동물실험 및 전임상시험연구
853. Gehrman M, Radons J, Molls M, Multhoff G. The therapeutic implications of clinically applied modifiers of heat shock protein 70 (Hsp70) expression by tumor cells. Cell Stress and Chaperones. 2008;13(1):1-10.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
854. Geller M, Cooley S, Judson P, Ghebre R, Downs L, Carson L, et al. A phase II study of allogeneic natural killer cells in patients with recurrent ovarian and breast cancer. Gynecologic Oncology. 2010;1:S9.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
855. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13(1):98-107.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 갑마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
856. Geller MA, Cooley S, Weigel B, Argenta PA, Carson LF, Downs LS, et al. First human experience of an immunomodulator toll-like receptor-7 (TLR-7) agonist administered in a prolonged dosing schedule to patients with heavily pretreated recurrent breast, ovarian and cervix cancers. Gynecologic Oncology. 2009;1:S58-S9.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
857. Gennari JL, Veronesi R, De Souza Gennari M. Edible mushroom Agaricus sylvaticus used as therapeutics complement in a patient with breast cancer and lung metastasis. [Portuguese]. Revista Brasileira de Medicina. 2002;59(7):537-8.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
858. Georgiannos SN, Renaut A, Goode AW, Sheaff M. The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators. Surgery. 2003;134(5):827-34.
배제사유 : 동물실험 및 전임상시험연구
859. Geranpayehvaghei M, Shi Q, Zhao B, Li S, Xu J, Taleb M, et al. Targeting Delivery of Platelets Inhibitor to Prevent Tumor Metastasis. Bioconjugate Chemistry.

2019;30(9):2349-57.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

860. Gercel-Taylor C, Huffman JP, Taylor DD, Owens KJ, Eisenberg BL. Interleukin-2 activation of cytotoxic cells in postmastectomy seroma. *Journal of Surgical Research*. 1996;61(1):89-96.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

861. Gerdes CA, Nicolini VG, Herter S, Van Puijenbroek E, Lang S, Roemmele M, et al. GA201 (RG7160): A novel, humanized, glycoengineered anti - EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. *Clinical Cancer Research*. 2013;19(5):1126-38.

배제사유 : 동물실험 및 전임상시험연구

862. Gerits P, De Brabander B. Psychosocial predictors of psychological, neurochemical and immunological symptoms of acute stress among breast cancer patients. *Psychiatry Research*. 1999;85(1):95-103.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

863. Gertler A, Elinav E. Novel superactive leptin antagonists and their potential therapeutic applications. *Current Pharmaceutical Design*. 2014;20(4):659-65.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

864. Ghannam S, Bouffi C, Djouad F, Jorgensen C, Noel D. Immunosuppression by mesenchymal stem cells: Mechanisms and clinical applications. *Stem Cell Research and Therapy*. 2010;1 (1) (2).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

865. Gharib M, Mainguene C, Tamboise E, Tamboise A, Beaupain R. Lymphokine-activated killer cells induce differentiation in MCF-7 breast carcinoma nodules but not in mastosis nodules maintained in three-dimensional culture. *Tumour Biology*. 1994;15(2):90-100.

배제사유 : 동물실험 및 전임상시험연구

866. Gharib M, Mainguene C, Tamboise E, Tamboise A, Lievre N, Amouroux J, et al. [Effects of LAK cells activated by IL-2 on MCF-7 human breast cancer cell line maintained in organotypic culture]. *Bulletin du Cancer*. 1993;80(8):659-65.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

867. Ghiringhelli F, Rebe C, Hichami A, Delmas D. Immunomodulation and anti-inflammatory roles of polyphenols as anticancer agents. *Anti-Cancer Agents in Medicinal Chemistry*. 2012;12(8):852-73.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

868. Ghochikyan A, Pichugin A, Bagaev A, Davtyan A, Hovakimyan A, Tukhvatulin A, et al. Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax, as a therapeutic strategy for metastatic breast cancer. *Journal of Translational Medicine*. 2014;12 (1) (322).

배제사유 : 동물실험 및 전임상시험연구

869. Ghoneum M, Gollapudi S. Modified arabinoxylan rice bran (MGN-3/biobran) enhances yeast-induced apoptosis in human breast cancer cells in vitro. *Anticancer Research*. 2005;25(2 A):859-70.
배제사유 : 동물실험 및 전임상시험연구
870. Ghoneum M, Wimbley M, Salem F, McKlain A, Attallah N, Gill G. Immunomodulatory and anticancer effects of active hemicellulose compound (AHCC). *International Journal of Immunotherapy*. 1995;11(1):23-8.
배제사유 : 동물실험 및 전임상시험연구
871. Giacomini P, Giorda E, Fraioli R, Nicotra MR, Vitale N, Setini A, et al. Low prevalence of selective human leukocyte antigen (HLA)-A and HLA-B epitope losses in early-passage tumor cell lines. *Cancer Research*. 1999;59(11):2657-67.
배제사유 : 동물실험 및 전임상시험연구
872. Gibbons JA, Kanwar RK, Kanwar JR. Lactoferrin and cancer in different cancer models. *Frontiers in Bioscience - Scholar*. 2011;3 S(3):1080-8.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
873. Gibson JT, Nagareddy P, Norian LA. Obesity-induced changes in baseline immune responses to pre-clinical breast cancer. *Journal of Immunology. Conference: 104th Annual Meeting of the American Association of Immunologists, AAI*. 2017;198(1 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
874. Gil-Bernabe AM, Lucotti S, Muschel RJ. Coagulation And Metastasis: What Does The Experimental Literature Tell Us? *British Journal of Haematology*. 2013;162(4):433-41.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
875. Gilham DE, Maher J. 'Atypical' CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors. *Immunotherapy*. 2017;9(9):723-33.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
876. Gillgrass AE, Chew MV, Krneta T, Ashkar AA. Overexpression of IL-15 promotes tumor destruction via NK1.1+ cells in a spontaneous breast cancer model. *BMC Cancer*. 2015;15 (1) (293).
배제사유 : 동물실험 및 전임상시험연구
877. Gilliam AC. Update on graft versus host disease. *Journal of Investigative Dermatology*. 2004;123(2):251-7.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
878. Giraudo L, Gammaitoni L, Cangemi M, Rotolo R, Aglietta M, Sangiolo D. Cytokine-induced killer cells as immunotherapy for solid tumors: Current evidence and perspectives. *Immunotherapy*. 2015;7(9):999-1010.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
879. Gisterek I, Frydecka I, Swiatonowski G, Fidler S, Kornafel J. Tumour-infiltrating CD4 and CD8 T lymphocytes in breast cancer. *Reports of Practical Oncology and*

Radiotherapy. 2008;13(4):206-9.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

880. Gitto SB, Beardsley JM, Nakkina SP, Oyer JL, Cline KA, Litherland SA, et al. Identification of a novel IL-5 signaling pathway in chronic pancreatitis and crosstalk with pancreatic tumor cells. *Cell Communication and Signaling*. 2020;18 (1) (95).
배제사유 : 동물실험 및 전임상시험연구

881. Giuliani N, Airoldi I. Novel insights into the role of interleukin-27 and interleukin-23 in human malignant and normal plasma cells. *Clinical Cancer Research*. 2011;17(22):6963-70.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

882. Giuliano S, Ohanna M, Ballotti R, Bertolotto C. Advances in melanoma senescence and potential clinical application. *Pigment Cell and Melanoma Research*. 2011;24(2):295-308.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

883. Glajcar A, Szpor J, Tyrak KE, Streb J, Hodorowicz-Zaniewska D, Okon K. Lymphoid environment in molecular subtypes of breast cancer. *Polish Journal of Pathology*. 2018;69(2):169-81.

배제사유 : 동물실험 및 전임상시험연구

884. Glassy MC, McKnight ME. Requirements for human antibody cocktails for oncology. *Expert Opinion on Biological Therapy*. 2005;5(10):1333-8.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

885. Glumac PM, LeBeau AM. The role of CD133 in cancer: a concise review. *Clinical and Translational Medicine*. 2018;7 (1) (18).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

886. Go F, Knight DA, Smyth MJ, Stewart TJ. Potential for immunotherapeutic control of CSC-like cells through their expression of fas and DR5 death receptors. *Journal of Immunotherapy*. 2011;34 (9):689.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

887. Goddard ET, Bozic I, Riddell SR, Ghajar CM. Dormant tumour cells, their niches and the influence of immunity. *Nature Cell Biology*. 2018;20(11):1240-9.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

888. Godinho I. Monoclonal proliferation of CD56-/+DIM NK cells: A case report. *Cytometry Part B - Clinical Cytometry*. 2012;82B (6):408-9.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

889. Godoy-Calderon MJ, Gonzalez-Marcano E, Carballo J, Convit AF. Evaluation of a ConvitVax/anti-PD-1 combined immunotherapy for breast cancer treatment. *Oncotarget*. 2019;10(61):6546-60.

배제사유 : 동물실험 및 전임상시험연구

890. Goff SL, Zacharakis N, Assadipour Y, Prickett TD, Gartner JJ, Somerville R, et al. Recognition of autologous neoantigens by tumor infiltrating lymphocytes derived from

human breast cancer metastases. *Journal for ImmunoTherapy of Cancer*. Conference: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer, SITC. 2016;4(Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

891. Gogoi D, Chiplunkar SV. Targeting gamma delta T cells for cancer immunotherapy:Bench to bedside. *Indian Journal of Medical Research*, Supplement. 2013;138(NOV):755-61.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

892. Goh J, Kirk EA, Lee SX, Ladiges WC. Exercise, physical activity and breast cancer: The role of tumor-associated macrophages. *Exercise Immunology Review*. 2012;18:157-75.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

893. Goldberg MV, Drake CG. LAG-3 in cancer immunotherapy. *Current Topics in Microbiology and Immunology*. 2010;344(1):269-78.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

894. Goldfarb Y, Ben-Eliyahu S. Surgery as a risk factor for breast cancer recurrence and metastasis: Mediating mechanisms and clinical prophylactic approaches. *Breast Disease*. 2007;26(1):99-114.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

895. Goldman A, Best D, Thiagarajan S, Jain M, Shanthappa B, Smalley M, et al. An ex-vivo human system elucidates a role for natural killer cells in the anticancer effect of drug combinations in triple negative breast cancer. *Journal for ImmunoTherapy of Cancer*. Conference: 34th Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer Part. 2019;7(Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

896. Goldstein D, Laszlo J. Interferon therapy in cancer: from imaginon to interferon. *Cancer Research*. 1986;46(9):4315-29.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

897. Goldstein MR, Mascitelli L. Surgery and cancer promotion: Are we trading beauty for cancer? *Qjm*. 2011;104(9):811-5.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

898. Golmoghaddam H, Pezeshki AM, Ghaderi A, Doroudchi M. CD1a and CD1d genes polymorphisms in breast, colorectal and lung cancers. *Pathology and Oncology Research*. 2011;17(3):669-75.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

899. Gomarasca M, Maroni P, Banfi G, Lombardi G. microRNAs in the Antitumor Immune Response and in Bone Metastasis of Breast Cancer: From Biological Mechanisms to Therapeutics. *International Journal of Molecular Sciences*. 2020;21(8):17.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

900. Gomes AQ, Martins DS, Silva-Santos B. Targeting gammadelta T lymphocytes for cancer immunotherapy: From novel mechanistic insight to clinical application. *Cancer Research*.

2010;70(24):10024-7.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

901. Gonzalez-Angulo AM, Lei X, Alvarez RH, Green MC, Murray JL, Valero V, et al. Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. *Cancer*. 2015;115(5):325-31.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

902. Gonzalez-Cabello R, Speisky H, Bannach R, Valenzuela A, Feher J, Gergely P. Effects of boldine on cellular immune functions in vitro. *Journal of Investigational Allergology & Clinical Immunology*. 1994;4(3):139-45.

배제사유 : 동물실험 및 전임상시험연구

903. Goodrich KH, Alvarez X, Holcombe RF. Effect of levamisole on major histocompatibility complex class I expression in colorectal and breast carcinoma cell lines. *Cancer*. 1993;72(1):225-30.

배제사유 : 동물실험 및 전임상시험연구

904. Gopalkrishnan L, Patil S, Chhaya S, Badwe R, Joshi N. HLA alleles in pre-menopausal breast cancer patients from western India. *Indian Journal of Medical Research*. 2006;124(3):305-12.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

905. Gopinath SK, Rao RM, Sanjeevarao VH, Diwakar RB, Basavalingaiah AS, Patil S. Effects of an Integrated Yoga Program on Mood States, Distress, Quality of Life, Diurnal Cortisol Rhythms and Natural Killer Cell Counts in Metastatic Breast Cancer Survivors 72. *Cancer research*. 2011;71(24 Supplement):Abstract no: P3?08?1.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 갑마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

906. Gorain B, Choudhury H, Yee GS, Bhattacharya SK. Adenosine Receptors as Novel Targets for the Treatment of Various Cancers. *Current Pharmaceutical Design*. 2019;25(26):2828-41.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

907. Goswami G, Upadhyay A, Gupta NK, Chaudhry R, Chawla D, Sreenivas V. Comparison of analgesic effect of direct breastfeeding, oral 25% dextrose solution and placebo during 1st DPT vaccination in healthy term infants: a randomized, placebo controlled trial. *Indian pediatrics*. 2013;50(7):649-53.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

908. Goto S, Sato M, Kaneko R, Itoh M, Sato S, Takeuchi S. Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients. *Cancer Immunology Immunotherapy*. 1999;48(8):435-42.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

909. Gottardis MM, Wagner RJ, Borden EC, Jordan VC. Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. *Cancer Research*.

1989;49(17):4765-9.

배제사유 : 동물실험 및 전임상시험연구

910. Goubran HA, Burnouf T, Radosevic M, El-Ekiaby M. The platelet-cancer loop. *European Journal of Internal Medicine*. 2013;24(5):393-400.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
911. Gough NR. Immune regulatory functions of mutant p53. *Science Signaling*. 2014;7 (357) (ec354).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
912. Goutagny N, Estornes Y, Hasan U, Lebecque S, Caux C. Targeting pattern recognition receptors in cancer immunotherapy. *Targeted Oncology*. 2012;7(1):29-54.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
913. Goutner A, Gouveia J, Ribaud P. In vivo and in vitro stimulation of NK cell activity by a preparation of lymphokines in man. *Journal of Clinical Hematology and Oncology*. 1981;11(4):No. 53.
배제사유 : 동물실험 및 전임상시험연구
914. Goyne HE, Cannon MJ. The case for HER2/neu as a therapeutic target for gynecologic malignancies. *Immunotherapy*. 2012;4(8):781-4.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
915. Graham CH, Hamilton T, Barsoum I, Hu N, Li X, Elliott J, et al. Nitric oxide-mediated inhibition of hypoxia-induced immune escape in cancer. *Nitric Oxide - Biology and Chemistry*. 2010;1):S18.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
916. Grangeon C, Cormary C, Douin-Echinard V, Favre G, Couderc B, Tilkin-Mariame AF. In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells. *Cancer Gene Therapy*. 2002;9(3):282-8.
배제사유 : 동물실험 및 전임상시험연구
917. Granot E, Jakobovich E, Rabinowitz R, Levy P, Schlesinger M. Effect of docosahexanoic acid (DHA) supplementation during pregnancy and lactation on infants' immune response. *Journal of pediatric gastroenterology and nutrition*. 2011;52:E143?E4.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
918. Grass GD, Welsh E, Berglund AE, Pettersson F, Mule JJ, Harrison LB, et al. Intrinsic immune landscapes between radiosensitive and radioresistant tumors. *International Journal of Radiation Oncology Biology Physics*. 2017;99 (2 Supplement 1):S23.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
919. Grebic D, Gulic T, Starcevic A, Alvirovic M, Blagojevic Zagorac G, Valkovic Zujic P, et al. The Role of Innate Immunity in the Pathogenesis of Breast Cancer. *Breast Care*. 2020.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
920. Green JS, Tsui BCH. Impact of anesthesia for cancer surgery: Continuing Professional

Development. Canadian Journal of Anesthesia. 2013;60(12):1248-69.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

921. Green TL, Cruse JM, Lewis RE, Craft BS. Circulating tumor cells (CTCs) from metastatic breast cancer patients linked to decreased immune function and response to treatment. Experimental & Molecular Pathology. 2013;95(2):174-9.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
922. Green V, Greenman J, Alexandropoulou A, Walker AA, Walker LG, Sharp DM. The endocrine and immunological effects of reflexology in women with early breast cancer: a randomised controlled trial. Psycho-oncology. 2009;18:S141?S2.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
923. Green VL, Alexandropoulou A, Walker MB, Walker AA, Sharp DM, Walker LG, et al. Alterations in the Th1/Th2 balance in breast cancer patients using reflexology and scalp massage. Experimental and therapeutic medicine. 2010;1(1):97?108.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
924. Greenberg SA, Kong SW, Thompson E, Gulla SV. Co-inhibitory T cell receptor KLRG1: human cancer expression and efficacy of neutralization in murine cancer models. Oncotarget. 2019;10(14):1399-406.
배제사유 : 동물실험 및 전임상시험연구
925. Greer S. Mind-body research in psychooncology. Advances in Mind-Body Medicine. 1999;15(4):236-44.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
926. Grekou AN, Toliou T, Stravoravdi P, Patakiouta F, Tsoukalas T, Pinakidis M, et al. Correlation of apoptosis with the distribution and composition of lymphocytic infiltrate in human breast carcinomas. Anticancer Research. 1996;16(6C):3991-5.
배제사유 : 동물실험 및 전임상시험연구
927. Grenga I, Donahue RN, Gulley JL, Heery C, Madan RA, Schlom J, et al. Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival. Journal for ImmunoTherapy of Cancer. Conference: 28th Annual Scientific Meeting of the Society for Immunotherapy of Cancer, SITC. 2013;1(SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
928. Grenga I, Lepone L, Gameiro S, Knudson KM, Fantini M, Tsang K, et al. Effect of the class I-HDAC inhibitor entinostat and the pan-HDAC inhibitor vorinostat on peripheral immune cell subsets. Journal for ImmunoTherapy of Cancer. Conference: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer, SITC. 2016;4(Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
929. Gri G, Chiodoni C, Gallo E, Stoppacciaro A, Liew FY, Colombo MP. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: A role for intrinsic tumor immunogenicity and IL-15. Cancer Research. 2002;62(15):4390-7.

배제사유 : 동물실험 및 전임상시험연구

930. Griffioen AW, Vyth-Dreese FA. Angiostasis as a way to improve immunotherapy. Thrombosis and Haemostasis. 2009;101(6):1025-31.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

931. Griffith CD, Kamath MB. Effect of halothane and nitrous oxide anaesthesia on natural killer lymphocytes from patients with benign and malignant breast disease. British Journal of Anaesthesia. 1986;58(5):540-3.

배제사유 : 동물실험 및 전임상시험연구

932. Gritzapis A, Dimitroulopoulos D, Paraskevas E, Baxevanis C, Papamichail M. Large-scale expansion of CD3+CD56+ lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants. Cancer Immunology, Immunotherapy. 2002;51(8):440-8.

배제사유 : 동물실험 및 전임상시험연구

933. Groh V, Smythe K, Dai Z, Spies T. Fas ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nature Immunology. 2006;7(7):755-62.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

934. Groner B, von Manstein V. Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition. Molecular and Cellular Endocrinology. 2017;451:1-14.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

935. Grossenbacher SK, Canter RJ, Murphy WJ. Natural killer cell immunotherapy to target stem-like tumor cells. Journal for ImmunoTherapy of Cancer. 2016;4 (1) (19).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

936. Grosso JF, Herbert LM, Owen JL, Lopez DM. MUC1/sec-expressing tumors are rejected in vivo by a T cell-dependent mechanism and secrete high levels of CCL2. Journal of Immunology. 2004;173(3):1721-30.

배제사유 : 동물실험 및 전임상시험연구

937. Gruber BL, Hersh SP, Hall NR, Waletzky LR, Kunz JF, Carpenter JK, et al. Immunological responses of breast cancer patients to behavioral interventions. Biofeedback & Self Regulation. 1993;18(1):1-22.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

938. Gruber IV, El Yousfi S, Durr-Storzer S, Wallwiener D, Solomayer EF, Fehm T. Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients. Anticancer Research. 2008;28(2A):779-84.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

939. Gruber IV, Hartkopf AD, Hahn M, Taran FA, Staebler A, Wallwiener D, et al. Relationship Between Hematogenous Tumor Cell Dissemination and Cellular Immunity in DCIS Patients. Anticancer Research. 2016;36(5):2345-51.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

940. Gudmundsdottir I, Gunnlaugur Jonasson J, Sigurdsson H, Olafsdottir K, Tryggvadottir L, Ogmundsdottir HM. Altered expression of HLA class I antigens in breast cancer: association with prognosis. International Journal of Cancer. 2000;89(6):500-5.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
941. Gudmundsdottir I, Ogmundsdottir HM. Variable natural killer function of tumour-infiltrating lymphocytes from breast carcinomas. APMIS. 1992;100(8):737-46.
배제사유 : 동물실험 및 전임상시험연구
942. Guillou PJ, Ramsden CW, Somers SS, Sedman PC. Suppression of the generation of lymphokine-activated killer (LAK) cells by serum-free supernatants of in vitro maintained tumour cell lines. British Journal of Cancer. 1989;59(4):515-21.
배제사유 : 동물실험 및 전임상시험연구
943. Guillou PJ, Sedman PC, Ramsden CW. Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro. Cancer Immunology, Immunotherapy. 1989;28(1):43-53.
배제사유 : 동물실험 및 전임상시험연구
944. Guinn BA. Immunotherapy at the American Association for Cancer Research 95th annual meeting: A personal impression. Cancer Immunology, Immunotherapy. 2005;54(3):290-5.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
945. Gujar S, Pol JG, Kroemer G. Heating it up: Oncolytic viruses make tumors 'hot' and suitable for checkpoint blockade immunotherapies. OncoImmunology. 2018;7 (8) (e1442169).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
946. Gunsilius E, Clausen J, Gastl G. Palliative immunotherapy of cancer. [German]. Therapeutische Umschau. 2001;58(7):419-24.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
947. Guo L, Chi Y, Xue J, Goswami S, Zhou B, Cao C, et al. Composition and distribution of tumorinfiltrating lymphocytes in breast cancer. Cancer Research. Conference: 107th Annual Meeting of the American Association for Cancer Research, AACR. 2016;76(14 Supplement).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
948. Gupta NK, Upadhyay A, Agarwal A, Goswami G, Kumar J, Sreenivas V. Randomized controlled trial of topical EMLA and breastfeeding for reducing pain during wDPT vaccination. European journal of pediatrics. 2013;172(11):1527?33.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
949. Gupta NK, Upadhyay A, Dwivedi AK, Agarwal A, Jaiswal V, Singh A. Randomized controlled trial of topical EMLA and vapocoolant spray for reducing pain during wDPT vaccination. World journal of pediatrics. 2017;1?6.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
950. Gupta P, Wright SE, Srivastava SK. PEITC treatment suppresses myeloid derived tumor

suppressor cells to inhibit breast tumor growth. *Oncoimmunology*. 2015;4(2):e981449.
배제사유 : 동물실험 및 전임상시험연구

951. Gutkin DW, Shurin MR. Clinical evaluation of systemic and local immune responses in cancer: Time for integration. *Cancer Immunology, Immunotherapy*. 2014;63(1):45-57.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
952. Guyton D, Caobi A, Singh SK, Peyser M, Dorak MT. HLA region and lung cancer susceptibility: Confirmation of BAT3/BAG6 association and functional replication. *Human Immunology*. 2012;1:12.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
953. Hadden JW. The immunology and immunotherapy of breast cancer: An update. *International Journal of Immunopharmacology*. 1999;21(2):79-101.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
954. Haen SP, Schmiedel BJ, Roth N, Faul C, Mohle R, Schmalzing M, et al. The role of Her2/Neu in ALL: Long term clinical follow-up of surface-positive patients and induction of NK cell ADCc by trastuzumab in vitro. *Blood*. Conference: 54th Annual Meeting of the American Society of Hematology, ASH. 2012;120(21).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
955. Hafeez U, Gan HK, Scott AM. Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. *Current Opinion in Pharmacology*. 2018;41:114-21.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
956. Hagemann T, Balkwill F, Lawrence T. Inflammation and Cancer: A Double-Edged Sword. *Cancer Cell*. 2007;12(4):300-1.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
957. Hagens CV, Giese T, Staudt A, Glenz A, Reinhard-Hennrich B, Loewe-Mesch A, et al. Does a treatment with Viscum album (Iscador P) in patients with breast cancer influence the expression of the T-cell receptor (TCR)-zeta chains of T- and NK-cells. *Phytomedicine*. 2011;18:S24.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
958. Hagstrom AD, Marshall PW, Lonsdale C, Papalia S, Cheema BS, Toben C, et al. The effect of resistance training on markers of immune function and inflammation in previously sedentary women recovering from breast cancer: a randomized controlled trial. *Breast Cancer Research & Treatment*. 2016;155(3):471-82.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
959. Hahm BJ, Jo B, Dhabhar FS, Palesh O, Aldridge-Gerry A, Bajestan SN, et al. Bedtime misalignment and progression of breast cancer. *Chronobiology International*. 2014;31(2):214-21.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
960. Haikala HM, Anttila JM, Marques E, Raatikainen T, Ilander M, Hakanen H, et al.

Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy. *Nature Communications*. 2019;10 (1) (620).

배제사유 : 동물실험 및 전임상시험연구

961. Hajati J, Ebrahimi M, Mohammad Hassan Z, Kazemi Ashtiani S, Gheflati Z. The effects of increased heat shock proteins expression in MDA-MB468 adeno-carcinoma cells on expansion and differentiation of hematopoietic stem cells from human umbilical cord blood. [Persian]. *Yakhteh*. 2007;9(2):91-102.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

962. Hajto T, Hostanska K, Gabius HJ. Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. *Cancer Research*. 1989;49(17):4803-8.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

963. Hajto T, Hostanska K. An investigation of the ability of Viscum album-activated granulocytes to regulate natural killer cells in vivo. *Clinical Trials Journal*. 1986;23(6):345-58.

배제사유 : 동물실험 및 전임상시험연구

964. Hajto T, Hostanska K. Effect of in vivo hyperthermia on human natural killer cells. *Clinical Trials Journal*. 1985;22(6):514-20.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

965. Hajto T, Lanzrein C. Frequency of large granular lymphocytes in peripheral blood of healthy persons and breast cancer patients. *Cancer Immunology, Immunotherapy*. 1983;16(1):65-6.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

966. Hajto T, Lanzrein C. Natural killer and antibody-dependent cell-mediated cytotoxicity activities and large granular lymphocyte frequencies in Viscum album-treated breast cancer patients. *Oncology*. 1986;43(2):93-7.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

967. Hajto T. Immunomodulatory effects of Iscador: A viscum album preparation. *Oncology*. 1986;43(SUPPL. 1):51-65.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

968. Hakim AA. A mechanism by which human breast carcinoma cells escape the host immune system. *Neoplasma*. 1988;35(6):691-705.

배제사유 : 동물실험 및 전임상시험연구

969. Hakim AA. Functional heterogeneity correlates with structural heterogeneity of breast carcinoma acid-soluble glycoproteins (42531). *Proceedings of the Society for Experimental Biology and Medicine*. 1987;185(2):158-76.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

970. Hakim AA. Peripheral blood lymphocytes from patients with cancer lack interleukin-2 (IL-2) receptor expression: isolation of mRNA encoding IL-2R. *Cancer Detection &*

Prevention. 1988;12(1-6):59-71.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

971. Hakim AA. Peripheral blood lymphocytes from patients with cancer lack interleukin-2 receptors. Cancer. 1988;61(4):689-701.

배제사유 : 동물실험 및 전임상시험연구

972. Haldar R, Lavon H, Elbaz E, Rozen E, Shabat-Simon M, Ben-Eliyahu S. Breast cancer patients undergoing surgery and subjected to perioperative inhibition of COX-2 and b-adrenoceptor blockade: Effects on number and cytotoxicity of circulating NK cells and their relations to cytokine levels. Brain, Behavior, and Immunity. 2016;57 (Supplement 1):e41.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

973. Haldar R, Shaashua L, Lavon H, Lyons YA, Zmora O, Sharon E, et al. Perioperative inhibition of beta-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome. Brain, Behavior, & Immunity. 2018;73:294-309.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

974. Hallett RM, Cockburn JG, Li B, Dvorkin-Gheva A, Hassell JA, Bane A. Identification and evaluation of network modules for the prognosis of basal-like breast cancer. Oncotarget. 2015;6(19):17713-24.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

975. Halpern GM, Mencia-Huerta JM, Puchois P, Braquet P. Analysis of the effect of various commercial nutraceutical preparations on the immune system. Progress in Nutrition. 2002;4(SUPPL. 1):24-54.

배제사유 : 동물실험 및 전임상시험연구

976. Halpern GM. Review, comments and discussion. Progress in Nutrition. 2002;4(SUPPL. 1):116-51.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

977. Hamidullah, Changkija B, Konwar R. Role of interleukin-10 in breast cancer. Breast Cancer Research and Treatment. 2012;133(1):11-21.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

978. Hamilton G, Reiner A, Teleky B, Roth E, Kolb R, Spona J, et al. Natural killer cell activities of patients with breast cancer against different target cells. Journal of Cancer Research & Clinical Oncology. 1988;114(2):191-6.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

979. Hamilton TK, Barsoum I, Li X, Miles EA, Elliott J, Siemens DR, et al. A mechanism of hypoxia-induced immune escape in cancer cells. Cancer Research. Conference: 102nd Annual Meeting of the American Association for Cancer Research, AACR. 2011;71(8 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

980. Hammond E, Haynes NM, Cullinane C, Brennan TV, Bampton D, Handley P, et al. Immunomodulatory activities of pixatimod: Emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors. *Journal for ImmunoTherapy of Cancer*. 2018;6 (1) (54).
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
981. Hamrin E, Ernerudh J, Rosen A. Immunological and Quality-of-Life Profiles in Women with Breast Cancer: Complementary versus Conventional Care. *Complementary Medical Research*. 2018;25(6):391-7.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
982. Hamzeh KW, Mauceri HJ, Darga TE, Weichselbaum RR, Posner MC, Meng Y. Interaction of radiation with CpG based peptide vaccination in a spontaneous murine tumor model. *Annals of Surgical Oncology*. 2012;19(1):S17.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
983. Han D, Wang K, Zhang T, Gao GC, Xu H. Natural killer cell-derived exosome-entrapped paclitaxel can enhance its anti-tumor effect. *European Review for Medical & Pharmacological Sciences*. 2020;24(10):5703-13.
배제사유 : 동물실험 및 전임상시험연구
984. Han KC, Park D, Ju S, Lee YE, Heo SH, Kim YA, et al. Streamlined selection of cancer antigens for vaccine development through integrative multi-omics and high-content cell imaging. *Scientific reports*. 2020;10(1):5885.
배제사유 : 동물실험 및 전임상시험연구
985. Han Y, Xie W, Song DG, Powell DJ, Jr. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells. *Journal of hematology & oncology*. 2018;11(1):92.
배제사유 : 동물실험 및 전임상시험연구
986. Han YT, Liu JH, Li YG, Cui L, Liu BW, Ma T, et al. The peripheral lymphocyte subsets correlates with clinicopathological characteristics of breast cancer patients. *International Journal of Clinical and Experimental Medicine*. 2017;10(1):1251-8.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
987. Hanssens V, De Jonge N, Hultberg A, Borg C, Michieli P, Dreier T, et al. The clinical potential of ARGX-111, an afucosylated anti-met antibody, in hematological malignancies and suppression of metastasis. *Annals of Oncology*. 2015;26(2):ii31.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
988. Hao YB, Yi SY, Ruan J, Zhao L, Nan KJ. New insights into metronomic chemotherapy-induced immunoregulation. *Cancer Letters*. 2014;354(2):220-6.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
989. Hara T, Tanegashima K. Pleiotropic functions of the CXC-type chemokine CXCL14 in mammals. *Journal of Biochemistry*. 2012;151(5):469-76.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

990. Harao M, Gao H, Chen JQ, Mittendorf EA, Babiera GV, DeSnyder SM, et al. Co-stimulation through 4-1BB/CD137 improves expansion and function of tumor-infiltrating T lymphocytes from primary and metastatic triple-negative breast cancer and inflammatory breast cancer. *Cancer Research*. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium. San Antonio, TX United States. Conference Publication: 2015;75(9 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
991. Hardy B, Raiter A, Rubin M, Sprecher E, Sella A, Flex D, et al. Cancer disease predictive diagnosis: BAT/CD3-positive lymphocytes in cancer patients. *International Journal of Oncology*. 2005;26(4):971-5.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
992. Hare NC, Arnott IDR, Satsangi J. Therapeutic options in acute severe ulcerative colitis. *Expert Review of Gastroenterology and Hepatology*. 2008;2(3):357-70.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
993. Haris M, Yadav SK, Rizwan A, Singh A, Wang E, Hariharan H, et al. Molecular magnetic resonance imaging in cancer. *Journal of Translational Medicine*. 2015;13 (1) (313).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
994. Harper A, Bhave N, Opheim K, Leudke E, Parihar R, Trikha P, et al. Monocyte expression of MICA enhances the Natural Killer Cell response to antibody-coated tumor targets. *Journal for ImmunoTherapy of Cancer*. Conference: 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer, SITC. 2014;2(SUPPL. 3).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
995. Harrer DC, Dorrie J, Schaft N. Chimeric Antigen Receptors in Different Cell Types: New Vehicles Join the Race. *Human Gene Therapy*. 2018;29(5):547-58.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
996. Harthun NL, Weaver AM, Brinckerhoff LH, Deacon DH, Gonias SL, Slingluff CL, Jr. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2. *Journal of Immunotherapy*. 1998;21(2):85-94.
배제사유 : 동물실험 및 전임상시험연구
997. Harvey JB, Phan LH, Villarreal OE, Bowser JL. CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. *Frontiers in Immunology*. 2020;11 (508).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
998. Hasegawa J, Sue M, Yamato M, Ichikawa J, Ishida S, Shibutani T, et al. Novel anti-EPHA2 antibody, DS-8895a for cancer treatment. *Cancer Biology & Therapy*. 2016;17(11):1158-67.
배제사유 : 동물실험 및 전임상시험연구
999. Hassan AB. Keys to the hidden treasures of the mannose 6-phosphate/insulin-like growth factor 2 receptor. *American Journal of Pathology*. 2003;162(1):3-6.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1000. Hatfield SM, Kjaergaard J, Lukashev D, Schreiber TH, Belikoff B, Abbott R, et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. *Science Translational Medicine*. 2015;7(277).

배제사유 : 동물실험 및 전임상시험연구

1001. Hatfield SM, Sitkovsky M. A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1alpha driven immunosuppression and improve immunotherapies of cancer. *Current Opinion in Pharmacology*. 2016;29:90-6.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1002. Haus E. News and views. *Chronobiology International*. 2007;24(6):1255-6.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1003. Haux J, Lam M, Marthinsen ABL, Strickert T, Lundgren S. Digitoxin, in non toxic concentrations, induces apoptotic cell death in Jurkat T cells in vitro. *Zeitschrift fur Onkologie*. 1999;31(1):14-20.

배제사유 : 동물실험 및 전임상시험연구

1004. Havrdova E, Horakova D, Kovarova I. Alemtuzumab in the treatment of multiple sclerosis: Key clinical trial results and considerations for use. *Therapeutic Advances in Neurological Disorders*. 2015;8(1):31-45.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1005. Hawkes JS, Gibson RA, Roberton D, Makrides M. Effect of dietary nucleotide supplementation on growth and immune function in term infants: a randomized controlled trial. *European journal of clinical nutrition*. 2006;60(2):254?64.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

1006. Hawkins MJ, Krown SE, Borden EC, Krim M, Real FX, Edwards BS, et al. American cancer society Phase I trial of naturally produced beta-interferon. *Cancer Research*. 1984;44(12 Pt 1):5934-8.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1007. Hayakawa Y, Rovero S, Forni G, Smyth MJ. alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. *Proceedings of the National Academy of Sciences of the United States of America*. 2003;100(16):9464-9.

배제사유 : 동물실험 및 전임상시험연구

1008. Hayakawa Y. Targeting NKG2D in tumor surveillance. *Expert Opinion on Therapeutic Targets*. 2012;16(6):587-99.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1009. Haynes NM, Smyth MJ. Immunotherapeutic strategies as adjuncts to local radiotherapy. *Immunotherapy*. 2012;4(2):129-31.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1010. He X, Jiang XH, Yie KY, Chen J, Zhang JB, Yie SM. An autoantibody against a 48-Kd fragment of human DNA-topoisomerase I in breast cancer: Implication for diagnosis and

prognosis, and antibody-dependent cellular cytotoxicity in vitro. *Cellular Immunology*. 2020;347:104007.

배제사유 : 동물실험 및 전임상시험연구

1011. He Y, Du J, Dong Z. Myeloid deletion of phosphoinositide-dependent kinase-1 enhances NK cell-mediated antitumor immunity by mediating macrophage polarization. *OncolImmunology*. 2020;9 (1) (1774281).

배제사유 : 동물실험 및 전임상시험연구

1012. Head JF, Jiang XP, Elliott RL. Iron upregulates HLA-G mRNA expression of the human MCF-7 breast cancer cell line. *Cancer Research*. Conference: 104th Annual Meeting of the American Association for Cancer Research, AACR. 2013;73(8 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1013. Heery CR, Ibrahim NK, Arlen PM, Mohebtash M, Murray JL, Koenig K, et al. Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: a Randomized Clinical Trial. *JAMA oncology*. 2015;1(8):1087?95.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1014. Heery CR, Ibrahim NK, Mohebtash M, Madan RA, Arlen PM, Bilusic M, et al. A phase 2 randomized trial of docetaxel (DOC) alone or in combination with therapeutic cancer vaccine, CEA-, MUC-1-TRICOM (PANVAC). *Cancer Research*. Conference: 35th Annual CTRC AACR San Antonio Breast Cancer Symposium. San Antonio, TX United States. Conference Publication: 2012;72(24 SUPPL. 3).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1015. Hefferon KL. Repurposing plant virus nanoparticles. *Vaccines*. 2018;6 (1) (11).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1016. Heffner KL, Loving TJ, Robles TF, Kiecolt-Glaser JK. Examining psychosocial factors related to cancer incidence and progression: In search of the silver lining. *Brain, Behavior, and Immunity*. 2003;17(1 SUPPL.):S109-S11.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1017. Heinly BM, Albrecht V, Beuth J. Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract. *Anticancer Research*. 1998;18(1B):583-6.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1018. Heinly BM, Albrecht V, Beuth J. Correlation of parameters of cellular immunity and beta-endorphin plasma levels after mistletoe lectin standardized therapy. [German]. *Zeitschrift fur Onkologie*. 1997;29(4):100-6.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1019. Heinly BM, Beuth J. The lectin of the mistletoe as immunomodulator: Effector effect on beta-endorphin and the release of cytokines in patients suffering from breast cancer. [German]. *Deutsche Zeitschrift fur Onkologie*. 1994;26(4):103-8.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1020. Heiss MM, Strohlein MA, Jager M, Kimmig R, Burges A, Schoberth A, et al. Immunotherapy of malignant ascites with trifunctional antibodies. International Journal of Cancer. 2005;117(3):435-43.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1021. Hekim C, Ilander M, Yan J, Michaud E, Smykla R, Vaha-Koskela M, et al. Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models. Cancer Immunology Research. 2017;5(2):157-69.
배제사유 : 동물실험 및 전임상시험연구
1022. Hellec C, Delos M, Carpentier M, Denys A, Allain F. The heparan sulfate 3-O-sulfotransferases (HS3ST) 2, 3B and 4 enhance proliferation and survival in breast cancer MDA-MB-231 cells. PLoS ONE [Electronic Resource]. 2018;13(3):e0194676.
배제사유 : 동물실험 및 전임상시험연구
1023. Hellerstein MK. Turnover of adipose components and mitochondrial DNA in humans: Kinetic biomarkers for human immunodeficiency virus - Associated lipodystrophy and mitochondrial toxicity? Clinical Infectious Diseases. 2003;37(SUPPL. 2):S52-S61.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1024. Helmy KY, Patel SA, Nahas GR, Rameshwar P. Cancer immunotherapy: Accomplishments to date and future promise. Therapeutic Delivery. 2013;4(10):1307-20.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1025. Hematti P. Role of mesenchymal stromal cells in solid organ transplantation. Transplantation Reviews. 2008;22(4):262-73.
배제사유 : 동물실험 및 전임상시험연구
1026. Hengst JC, Kempf RA, Kan-Mitchell J, Pham AT, Grunberg SM, Kortes VL, et al. Immunological effects of recombinant interferon-alpha 2 in cancer patients. Journal of Biological Response Modifiers. 1983;2(6):516-27.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1027. Hermanson DL, Kaufman DS. Utilizing chimeric antigen receptors to direct natural killer cell activity. Frontiers in Immunology. 2015;6 (APR) (195).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1028. Hernandez-Reif M, Field T, Ironson G, Beutler J, Vera Y, Hurley J, et al. Natural killer cells and lymphocytes increase in women with breast cancer following massage therapy. International Journal of Neuroscience. 2005;115(4):495-510.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1029. Hernandez-Reif M, Ironson G, Field T, Hurley J, Katz G, Diego M, et al. Breast cancer patients have improved immune and neuroendocrine functions following massage therapy. Journal of Psychosomatic Research. 2004;57(1):45-52.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

1030. Hersh EM, Quesada J, Murphy SG, Guttermann JU, Hutchins RD. Evaluation of therapy with methanol extraction residue of BCG (MER). *Cancer Immunology, Immunotherapy*. 1982;14(1):4-9.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1031. Hersh EM, Scuderi P, Grimes WJ, Chong A, Brailey JL, Gschwind CR, et al. Cytostatic and cytotoxic activity of lymphokine-activated killer cell supernatants. *Cancer Immunology, Immunotherapy*. 1989;30(1):65-70.
배제사유 : 동물실험 및 전임상시험연구
1032. Heuser C, Ganser M, Hombach A, Brand H, Denton G, Hanisch FG, et al. An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells. *British Journal of Cancer*. 2003;89(6):1130-9.
배제사유 : 동물실험 및 전임상시험연구
1033. Heys SD, Eremin O. The relevance of tumor draining lymph nodes in cancer. *Surgery, Gynecology & Obstetrics*. 1992;174(6):533-40.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1034. Hicks KC, Fantini M, Donahue RN, Schwab A, Knudson KM, Tritsch SR, et al. Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. *OncoImmunology*. 2018;7 (11) (e1466018).
배제사유 : 동물실험 및 전임상시험연구
1035. Hicks KC, Knudson KM, Malamas AS, Jones FR, Ordentlich P, Rabizadeh S, et al. Epigenetic reprogramming of the tumor microenvironment increases tumor sensitivity to multivalent immunotherapy combinations with an IL-15 superagonist plus vaccine or immune checkpoint blockade. *Journal for ImmunoTherapy of Cancer. Conference: 32nd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC*. 2017;5(Supplement 2).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1036. Hicks KC, Knudson KM, Ozawa Y, Schlom J, Gameiro SR. Evaluation of the anti-tumour efficacy and immune effects of N-809, a novel IL-15 superagonist/anti-PD-L1 bispecific agent. *Annals of Oncology*. 2019;30 (Supplement 5):v500.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1037. Hidderley M, Holt M. A pilot randomized trial assessing the effects of autogenic training in early stage cancer patients in relation to psychological status and immune system responses. *European Journal of Oncology Nursing*. 2004;8(1):61-5.
배제사유 : 동물실험 및 전임상시험연구
1038. Hiller J, Brodner G, Gottschalk A. Understanding clinical strategies that may impact tumour growth and metastatic spread at the time of cancer surgery. *Best Practice and Research: Clinical Anaesthesiology*. 2013;27(4):427-39.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구

1039. Hiller JG, Cole SW, Crone EM, Byrne DJ, Shackleford DM, Pang JB, et al. Preoperative beta-Blockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial. *Clinical Cancer Research*. 2020;26(8):1803-11.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1040. Hinterberger-Fischer M. [Prolactin as pro-inflammatory cytokine--considerations on consolidated immunotherapy after high dosage therapy]. *Acta Medica Austriaca - Supplement*. 2000;52:16-20.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1041. Hinze A, Gaudier-Diaz MM, Lustberg MB, DeVries AC. Breast cancer and social environment: Getting by with a little help from our friends. *Breast Cancer Research*. 2016;18 (1) (54).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1042. Hisamatsu K, Toge T, Yanagawa E, Hamada Y, Seto Y, Yamada H, et al. [Immune reactivities of lymphocytes from peripheral blood, regional lymph nodes and tumor-infiltrating lymphocytes in breast cancer]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1986;13(8):2555-61.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1043. Ho AD, Maruyama M, Maghazachi A, Mason JR, Gluck S, Corringham RE. Soluble CD4, soluble CD8, soluble CD25, lymphopoietic recovery, and endogenous cytokines after high-dose chemotherapy and blood stem cell transplantation. *Blood*. 1994;84(10):3550-7.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1044. Hoeres T, Smetak M, Pretscher D, Wilhelm M. Improving the efficiency of Vgamma9Vdelta2 T-cell immunotherapy in cancer. *Frontiers in Immunology*. 2018;9 (APR) (800).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1045. Hofmann MH, Mani R, Engelhardt H, Impagnatiello MA, Carotta S, Kerenyi M, et al. Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance. *Molecular Cancer Therapeutics*. 2020;19(4):1018-30.
배제사유 : 동물실험 및 전임상시험연구
1046. Hofmann S, Bruggemann S, Beyer T, Barth T, Deissler H, Lotfi R, et al. Tumor-infiltrating lymphocytes in breast cancer tissue comprise granzyme B-expressing B cells with cytotoxic potential. *Journal of Immunology. Conference: 99th Annual Meeting of the American Association of Immunologists, IMMUNOLOGY*. 2012;188(1 MeetingAbstracts).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1047. Hogan B, Peter M, Achuthan R, Carter C, Hughes T, Horgan K. Consequences of peri-operative immune suppression in breast cancer patients. *European Journal of Surgical Oncology*. 2009;35 (11):1201.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1048. Hogan BV, Peter MB, Orsi NM, Carter CR, Horgan KM, Hughes TA. Investigation of immuno-regulatory mechanisms relating to poor surgical wound healing and breast cancer recurrence. *Cancer Research*. Conference: 31st Annual San Antonio Breast Cancer Symposium. San Antonio, TX United States. Sponsor: UT Health Science Center San Antonio School of Medicine, American Association for Cancer Research, Baylor College of Medicine. Conference Publication: 2009;69(2 Suppl. S).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1049. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICA in malignant diseases. *International Journal of Cancer*. 2006;118(3):684-7.
배제사유 : 동물실험 및 전임상시험연구
1050. Holl EK, Frazier VN, Landa K, Beasley GM, Hwang ES, Nair SK. Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer. *Frontiers in Immunology*. 2019;10:1767.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1051. Holmes D. Buy buy bispecific antibodies. *Nature Reviews Drug Discovery*. 2011;10(11):798-800.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1052. Holt D, Ma X, Kundu N, Fulton A. Prostaglandin E2 (PGE2) suppresses natural killer cell function primarily through the PGE2 receptor EP4. *Cancer Immunology, Immunotherapy*. 2011;60(11):1577-86.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1053. Holt DM, Ma X, Kundu N, Collin PD, Fulton AM. Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4. *Journal of Immunotherapy*. 2012;35(2):179-88.
배제사유 : 동물실험 및 전임상시험연구
1054. Holtick U, Scheulen ME, Von Bergwelt-Baildon MS, Weihrauch MR. Toll-like receptor 9 agonists as cancer therapeutics. *Expert Opinion on Investigational Drugs*. 2011;20(3):361-72.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1055. Hone S, Kirschfink M, Mamidi S. Improved complement-dependent cellular cytotoxicity by PBLs and PMNs on HER2 positive tumors upon knockdown of membrane complement regulators. *Molecular Immunology*. 2014;61 (2):238-9.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1056. Hong CW, Zeng Q. Tapping the treasure of intracellular oncotargets with immunotherapy. *FEBS Letters*. 2014;588(2):350-5.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1057. Hong JT, Son DJ, Lee CK, Yoon DY, Lee DH, Park MH. Interleukin 32, inflammation and cancer. *Pharmacology & Therapeutics*. 2017;174:127-37.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1058. Hong XJ, Wang QQ. [A novel cancer-associated antigen RCAS1]. Zhejiang da Xue Xue Bao. Yi Xue Ban/Journal of Zhejiang University. Medical Sciences. 2005;34(6):578-81, 84.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1059. Honig A, Diessner J, Dietl J, Wischhusen J. T-DM1 and pertuzumab as new tools for HER2 specific antibody-therapy against breast cancer stem cells in HER2-positive mammary carcinoma. Cancer Research. Conference: 34th Annual CTRC AACR San Antonio Breast Cancer Symposium. San Antonio, TX United States. Conference Publication: 2011;71(24 SUPPL. 3).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1060. Honig A, Reim F, Becker K, Junker M, Dietl J, Wischhusen J. Selective escape of breast cancer stem cells immunoselected with Trastuzumab and natural killer cells. Archives of Gynecology and Obstetrics. 2010;1):S104-S5.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1061. Honkanen TJ, Moilanen T, Karihtala P, Tiainen S, Auvinen P, Vayrynen JP, et al. Prognostic and predictive role of spatially positioned tumour infiltrating lymphocytes in metastatic HER2 positive breast cancer treated with trastuzumab. Scientific Reports. 2017;7(1):18027.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1062. Hoober JK, Eggink LL, Cote R. Stories From the Dendritic Cell Guardhouse. Frontiers in Immunology. 2019;10 (2880).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1063. Hoover RG, Gullickson G, Kornbluth J. Natural killer lytic-associated molecule plays a role in controlling tumor dissemination and metastasis. Frontiers in Immunology. 2012;3:393.
배제사유 : 동물실험 및 전임상시험연구
1064. Horlock C, Stott B, Dyson PJ, Morishita M, Coombes RC, Savage P, et al. The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer. British Journal of Cancer. 2009;100(7):1061-7.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1065. Horny HP, Horst HA. Lymphoreticular infiltrates in invasive ductal breast cancer. A histological and immunohistological study. Virchows Archiv - A, Pathological Anatomy & Histopathology. 1986;409(2):275-86.
배제사유 : 동물실험 및 전임상시험연구
1066. Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nature Reviews Clinical Oncology. 2015;12(4):213-26.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1067. Horst HA, Horny HP. Characterization and frequency distribution of lymphoreticular infiltrates in axillary lymph node metastases of invasive ductal carcinoma of the breast.

- Cancer. 1987;60(12):3001-7.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1068. Horst HA, Horny HP. Frequency distribution of lymphoreticular infiltrates in invasive carcinoma of the female breast. *Cancer Detection & Prevention*. 1988;11(3-6):297-301.
배제사유 : 동물실험 및 전임상시험연구
1069. Hosaka T, Tokuda Y, Sugiyama Y, Hirai K, Okuyama T. Effects of a structured psychiatric intervention on immune function of cancer patients. *Tokai Journal of Experimental & Clinical Medicine*. 2000;25(4-6):183-8.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1070. Hoseini SS, Cheung NVK. Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies. *Cancer Letters*. 2017;399:44-52.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1071. Hoskins K, Weber BL. The biology of breast cancer. *Current Opinion in Oncology*. 1994;6(6):554-9.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1072. Hosokawa T. [Clinical study on the effect of intratumoral administration of OK-432 on breast cancer--anti-tumor immune response at the site of local injection]. *Nippon Geka Gakkai Zasshi. Journal of Japan Surgical Society*. 1991;92(5):577-86.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1073. Hossiny MA, Frazier WR, Steiner N, Kallakury B, Kumar R, Upadhyay G. Novel biomarkers Ly6E/K play important role in drug resistance and tumor immune escape. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2017;77(13 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1074. Houot R, Kohrt H, Levy R. Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody. *OncolImmunology*. 2012;1(6):957-8.
배제사유 : 동물실험 및 전임상시험연구
1075. Houot R, Kohrt H. CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies. *OncolImmunology*. 2014;3 (7) (e941740).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1076. Houot R, Kohrt HE, Marabelle A, Levy R. Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. *Trends in Immunology*. 2011;32(11):510-6.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1077. Hova B, Strohalm J, Kubackova K, Jelinkova M, Hovorka O, Kovar M, et al. Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs. *Journal of Controlled Release*. 2002;78(1-3):97-114.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1078. Hovaguimian F, Braun J, Z'Graggen B R, Schlapfer M, Dumrese C, Ewald C, et al.

Anesthesia and Circulating Tumor Cells in Primary Breast Cancer Patients: A Randomized Controlled Trial. *Anesthesiology*. 2020;17:17.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1079. Hovanessian AG, Youn JK, Buffet-Janvresse C, Riviere Y, Michelson M, Lacour J, et al. Enhancement of natural killer cell activity and 2'-5'A synthetase in operable breast cancer patients treated with polyadenylic/polyuridylic acid. *Cancer*. 1985;55(2):357-62.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1080. Hu J, Bernatchez C, Zhang L, Xia X, Kleinerman ES, Hung MC, et al. Induction of NKG2D ligands on solid tumors requires tumor-specific CD8+ T cells and histone acetyltransferases. *Cancer Immunology Research*. 2017;5(4):300-11.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

1081. Hu J, Sun C, Bernatchez C, Xia X, Hwu P, Dotti G, et al. T-cell homing therapy for reducing regulatory T cells and preserving effector T-cell function in large solid tumors. *Clinical Cancer Research*. 2018;24(12):2920-34.

배제사유 : 동물실험 및 전임상시험연구

1082. Hu J, Xu J, Li M, Zhang Y, Yi H, Chen J, et al. Targeting Lymph Node Sinus Macrophages to Inhibit Lymph Node Metastasis. *Molecular Therapy - Nucleic Acids*. 2019;16:650-62.

배제사유 : 동물실험 및 전임상시험연구

1083. Hu J, Zhao Q, Xia X, Gorlick R, Li S. Combination of chemotherapy and cytokine facilitates adoptive transferred effector T cells homing to the core of metastatic tumors. *Cancer Research Conference*. 2018;78(13 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1084. Hu Q, Shang L, Wang M, Tu K, Hu M, Yu Y, et al. Co-Delivery of Paclitaxel and Interleukin-12 Regulating Tumor Microenvironment for Cancer Immunochemotherapy. *Advanced Healthcare Materials*. 2020;9 (10) (1901858).

배제사유 : 동물실험 및 전임상시험연구

1085. Hu QP, Kuang JY, Yang QK, Bian XW, Yu SC. Beyond a tumor suppressor: Soluble E-cadherin promotes the progression of cancer. *International Journal of Cancer*. 2016;138(12):2804-12.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1086. Hu S, Wang X. The role of helper innate lymphoid cells in cancer. *Immunotherapy*. 2019;11(12):1067-81.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1087. Hu W, Liang J, Sun DS, Liu HR, Liu XL, Li Y. Anti-CD3 monoclonal antibody activated autologous killer cells in treatment of advanced malignant tumor: An observation of short-term effectiveness. [Chinese]. *Chinese Journal of Cancer Biotherapy*. 2008;15(2):155-8.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1088. Hu XB, Ouyang LZ, Tang LL. Interleukin-2 gene polymorphisms and prognosis of breast

- cancer. *Genetic Testing & Molecular Biomarkers*. 2013;17(6):453-7.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1089. Hu Y, Liu T, Mai F, Li J, Chen Y, Jing Y, et al. Selenium nanoparticles as new strategy to potentiate gammadelta T cell anti-tumor cytotoxicity through upregulation of tubulin-alpha acetylation. *Biomaterials*. 2019;222 (119397).
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1090. Hu Z. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer. *Scientific Reports*. 2020;10(1):2815.
배제사유 : 동물실험 및 전임상시험연구
1091. Huang J, Shibaguchi H, Tanaka T, Zhao J, Luo N, Hachimine K, et al. Possible applications of antibodies or their genes in cancer therapy. *Anticancer Research*. 2006;26(6 A):4019-25.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1092. Huang L, Qiao G, Morse MA, Wang X, Zhou X, Wu J, et al. Predictive significance of T cell subset changes during ex vivo generation of adoptive cellular therapy products for the treatment of advanced non-small cell lung cancer. *Oncology Letters*. 2019;18(6):5717-24.
배제사유 : 동물실험 및 전임상시험연구
1093. Huang SW, Lai YG, Liao NS. Adoptive natural killer cell therapy in murine cancer model. *European Journal of Immunology*. 2019;49 (Supplement 3):1805-6.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1094. Huang SW, Lai YG, Wu JQ, Liou YH, Liao NS. Natural killer cell cancer therapy in mouse model. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2019;79(13 Supplement).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1095. Huang W, Liu J, Zeng Y, Wu F, Li N, Chen K, et al. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer. *Cancer Chemotherapy & Pharmacology*. 2018;82(4):607-13.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1096. Huang W, Luo S, Burgess R, Yi YH, Huang GF, Huang RP. New insights into the tumor microenvironment utilizing protein array technology. *International Journal of Molecular Sciences*. 2018;19 (2) (559).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1097. Huang WQ, Wang JG, Chen L, Wei HJ, Chen H. SR140333 counteracts NK-1 mediated cell proliferation in human breast cancer cell line T47D. *Journal of Experimental & Clinical Cancer Research*. 2010;29:55.
배제사유 : 동물실험 및 전임상시험연구
1098. Huang Y, Wang Y, Li Y, Guo K, He Y. Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of

- ABCG2. Journal of Cancer Research and Clinical Oncology. 2011;137(5):829-37.
배제사유 : 동물실험 및 전임상시험연구
1099. Huang Y, Wang Y, Sun M, Zhou X, Deng L, Guo K. Effect of matrine on KG2D ligand expression in human multi-drug resistant nasopharyngeal carcinoma cells that highly express ABCG2. [Chinese]. Chinese Journal of Clinical Oncology. 2009;36(5):279-82+86.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1100. Huang YX, Guo KY, Wang Y, Chen JZ, Song CY. Sunitinib malate-induced high expression of NKG2D ligands in nasopharyngeal carcinoma cell ABCG2(high) CNE2/DDP. [Chinese]. Chinese Journal of Cancer Biotherapy. 2008;15(4):311-5.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1101. Huang YX, Wang Y, Li YH, Chen JZ, Qian M, Wu BY, et al. Dual immunological regulation effects of cetuximab on multidrug resistant nasopharyngeal carcinoma CNE2/DDP cells and NK cells. [Chinese]. Chinese Journal of Cancer Biotherapy. 2010;17(3):268-73.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1102. Huang YX, Wang Y, Li YH, Song CY, Chen JZ, He YJ, et al. Molecular targeted agents induce NKG2DLs expressions in multidrug resistant nasopharyngeal carcinoma CNE2/DDP cells. [Chinese]. Chinese Journal of Cancer Biotherapy. 2010;17(3):250-5.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1103. Huang YX, Wang Y, Li YH, Yang YL, Zhao TF, He QM, et al. Mechanism of sunitinib inducing NKG2DLs expressions in multidrug resistant nasopharyngeal carcinoma CNE2/DDP cells. [Chinese]. Chinese Journal of Cancer Biotherapy. 2010;17(3):256-61.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1104. Huber CH, Wolfel T. Immunotherapy of cancer: From vision to standard clinical practice. Journal of Cancer Research and Clinical Oncology. 2004;130(7):367-74.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1105. Huber V, Filipazzi P, Iero M, Fais S, Rivoltini L. More insights into the immunosuppressive potential of tumor exosomes. Journal of Translational Medicine. 2008;6 (63).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1106. Hudacek KD. A review of the effects of hypnosis on the immune system in breast cancer patients: a brief communication. International Journal of Clinical & Experimental Hypnosis. 2007;55(4):411-25.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1107. Hufnagel R, Synowitz M, Held-Feindt J, Flueh C. Chemoresistance in cerebral metastases: The role of tumor dormancy and nkg2d ligand expression. Glia. 2019;67 (Supplement 1):E715.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1108. Hultberg A, Morello V, Huyghe L, De Jonge N, Blanchetot C, Hanssens V, et al. Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage

over Inhibiting HGF/MET Signaling. *Cancer Research*. 2015;75(16):3373-83.
배제사유 : 동물실험 및 전임상시험연구

1109. Huntington N. CIS is a potent checkpoint in NK cell-mediated tumour immunity. *European Journal of Immunology*. 2016;46 (Supplement 1):792.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1110. Huo Q, Li Z, Cheng L, Yang F, Xie N. SIRT7 Is a Prognostic Biomarker Associated With Immune Infiltration in Luminal Breast Cancer. *Frontiers in Oncology*. 2020;10 (621).
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1111. Hurlimann J, Saraga P. Mononuclear cells infiltrating human mammary carcinomas: immunohistochemical analysis with monoclonal antibodies. *International Journal of Cancer*. 1985;35(6):753-62.
배제사유 : 동물실험 및 전임상시험연구
1112. Hussain M, Javeed A, Ashraf M, Al-Zaubai N, Stewart A, Mukhtar MM. Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy. *Pharmacological Research*. 2012;66(1):7-18.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1113. Hwang MH, Kim JE, Jeong SY, Lee SW, Lee J, Ahn BC. Monitoring of NK cells immunotherapy using in drug resistance of human breast adenocarcinoma MCF-7/ADR cells. *Molecular Imaging and Biology*. 2013;15(1):S443-S4.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1114. Hwang MH, Li XJ, Kim JE, Jeong SY, Lee SW, Lee J, et al. Potential Therapeutic Effect of Natural Killer Cells on Doxorubicin-Resistant Breast Cancer Cells In Vitro. *PLoS ONE [Electronic Resource]*. 2015;10(8):e0136209.
배제사유 : 동물실험 및 전임상시험연구
1115. Hynes NE, Bottos A, Gill J, Radimerski T, Tzankov A, Wodnar-Filipowicz A. The immunomodulatory effect of JAK inhibitors enhances metastasis by impairing antitumor immunity in preclinical models of breast cancer. *Cancer Research Conference: 106th Annual Meeting of the American Association for Cancer Research, AACR*. 2015;75(15 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1116. Iannello A, Ahmad A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. *Cancer and Metastasis Reviews*. 2005;24(4):487-99.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1117. Ibanez-Perez R, Guerrero-Ochoa P, Al-Wasaby S, Navarro R, Tapia-Galisteo A, De Miguel D, et al. Anti-tumoral potential of a human granulysin-based, CEA-targeted cytolytic immunotoxin. *Oncoimmunology*. 2019;8(11):1641392.
배제사유 : 동물실험 및 전임상시험연구
1118. Ibrahim NK, Yariz KO, Bondarenko I, Manikhas A, Semiglazov V, Alyasova A, et al.

Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clinical cancer research. 2011;17(21):6822?30.

배제사유 : 동물실험 및 전임상시험연구

1119. Iguchi-Manaka A, Okumura G, Ichioka E, Kiyomatsu H, Ikeda T, Bando H, et al. High expression of soluble CD155 in estrogen receptor-negative breast cancer. Breast Cancer. 2020;27(1):92-9.

배제사유 : 동물실험 및 전임상시험연구

1120. Iguchi-Manaka A, Okumura G, Kojima H, Cho Y, Hirochika R, Bando H, et al. Increased soluble CD155 in the serum of cancer patients. PLoS ONE. 2016;11 (4) (e0152982).

배제사유 : 동물실험 및 전임상시험연구

1121. Iliescu V, Fitzharris P, Knight RA. Absence of T cell-mediated cytotoxicity in breast cancer patients against a breast cancer-derived target cell. American Journal of Reproductive Immunology. 1981;1(6):295-8.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1122. Im SA, Bang YJ, Oh DY, Giaccone G, Bauer T, Nordstrom J, et al. Long-term responders to single-agent margetuximab, an Fc-modified anti-HER2 monoclonal antibody, in metastatic HER2+ breast cancer patients with prior anti-HER2 therapy. Cancer Research. Conference. 2018;79(4 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1123. Imamura M, Shook D, Kamiya T, Shimasaki N, Chai SMH, Coustan-Smith E, et al. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. Blood. 2014;124(7):1081-8.

배제사유 : 동물실험 및 전임상시험연구

1124. Inao T, Kotani H, Iida Y, Kartika ID, Okimoto T, Tanino R, et al. Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity. Cancer Science. 2019;110(9):2690-9.

배제사유 : 동물실험 및 전임상시험연구

1125. Inatsuka C, Yang Y, Gad E, Rastetter L, Disis ML, Lu H. Gamma delta T cells are activated by polysaccharide K (PSK) and contribute to the anti-tumor effect of PSK. Cancer Immunology, Immunotherapy. 2013;62(8):1335-45.

배제사유 : 동물실험 및 전임상시험연구

1126. Infante J, Ahlers CM, Hodi FS, Postel-Vinay S, Schellens JHM, Heymach JV, et al. A phase I, open-label study of GSK3174998 administered alone and in combination with pembrolizumab in patients (pts) with selected advanced solid tumors (ENGAGE-1). Cancer Research. Conference: 107th Annual Meeting of the American Association for Cancer Research, AACR. 2016;76(14 Supplement).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1127. Ino K, Ageitos AG, Singh RK, Talmadge JE. Activation-induced T cell apoptosis by monocytes from stem cell products. International Immunopharmacology.

2001;1(7):1307-19.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

1128. Ino K. Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer. *Current Opinion in Obstetrics and Gynecology*. 2011;23(1):13-8.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1129. Inoue T, Tashiro Y, Takeuchi M, Otani T, Tsuji-Takayama K, Okochi A, et al. Potent anti-tumor killing activity of the multifunctional Treg cell line HOZOT against human tumors with diverse origins. *International Journal of Oncology*. 2011;38(5):1299-306.
배제사유 : 동물실험 및 전임상시험연구
1130. Iqbal J, Yeong J, Lee B, Lim JCT, Thike AA, Tan PH. Molecular profiling of androgen receptor positive triple negative breast cancer. *Laboratory Investigation*. 2018;98 (Supplement 1):76.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1131. Iqbal J, Yeong J, Lee B, Lim JCT, Yo TTK, Thike AA, et al. Roles of PD-L1, PD-L2 and PD-1 in triple negative breast cancers: Perspective from an asian cohort. *Laboratory Investigation*. 2017;97 (Supplement 1):48A.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1132. Irie H, Schmidt PH, Port ER, Kinoshita Y, Soto A, Pisapati K, et al. Prospective serial sequencing of CTC/cfDNA and NK cell activity in patients undergoing multimodality treatment for triple negative breast cancer. *Journal of Clinical Oncology. Conference*. 2018;36(15 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1133. Irina D, Ryabchikov D, Beznos O, Vorotnikov I, Chkhikvadze N, Denchik D, et al. Prognostic value of disseminated tumor cells in patients with luminal breast cancer. *Clinical and Experimental Metastasis*. 2018;35 (3):180-1.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1134. Irshad S, Khiabany A, Flores-Borja F, Carcedo IG, Wong F, Beuron F, et al. Within the secretome: Immunomodulatory role of extracellular vesicles in breast cancers. *Journal for ImmunoTherapy of Cancer. Conference: 33rd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC*. 2018;6(Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1135. Isambert N, Fumoleau P, Paul C, Ferrand C, Zanetta S, Bauer J, et al. Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. *BMC Cancer*. 2013;13 (172).
배제사유 : 동물실험 및 전임상시험연구
1136. Iscaro A, Howard NF, Muthana M. Nanoparticles: Properties and applications in cancer immunotherapy. *Current Pharmaceutical Design*. 2019;25(17):1962-79.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1137. Isenalumhe L, Van Den Bergh M, Wang E, Schaible B, Ma Z, Zhang L, et al. High frequency of secondary malignancies in patients with large granular lymphocytic

- leukemia: A single institutional experience. *Haematologica*. 2017;102 (Supplement 2):748.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1138. Isenalumhe LL, Van Den Bergh M, Wang E, Schaible B, Ma Z, Zhang L, et al. Frequency of secondary malignancies (SM) in patients with large granular lymphocytic leukemia (LGLL): A single institutional experience. *Journal of Clinical Oncology Conference*. 2017;35(15 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1139. Isenberg JS, Vinod-Kumar S, White G, Ojeifo JO. Hematopoietic stem cells mobilization and immune response in tumor-bearing mice. *Annals of Plastic Surgery*. 2004;52(5):523-30; discussion 31.
배제사유 : 동물실험 및 전임상시험연구
1140. Ishigami S, Natsugoe S, Uenosono Y, Hata Y, Nakajo A, Miyazono F, et al. Infiltration of antitumor immunocytes into the sentinel node in gastric cancer. *Journal of Gastrointestinal Surgery*. 2003;7(6):735-9.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1141. Issa-Nummer Y, Loibl S, von Minckwitz G, Denkert C. Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy. *OncolImmunology*. 2014;3 (2) (e27926).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1142. Ito K, Hamamichi S, Abe T, Akagi T, Shirota H, Kawano S, et al. Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models. *Cancer Science*. 2017;108(11):2273-80.
배제사유 : 동물실험 및 전임상시험연구
1143. Itoh K, Tilden AB, Balch CM. Lysis of human solid tumor cells by lymphokine-activated natural killer cells. *Journal of Immunology*. 1986;136(10):3910-5.
배제사유 : 동물실험 및 전임상시험연구
1144. Itoi N, Umeda T, Ishida M, Murata S, Mori T, Kawai Y, et al. Infiltration of CD4, CD8, CD56, and Fox-P3-positive lymphocytes in breast carcinoma tissue after neoadjuvant chemotherapy with or without trastuzumab. *Breast Disease*. 2019;38(2):57-65.
배제사유 : 동물실험 및 전임상시험연구
1145. Iwamoto T, Pusztai L, Matsuoka J, Callari M, Kelly CM, Qi Y, et al. ER+/HER2+ and ER-/HER2+ breast cancers are molecularly distinct but immune gene signatures are prognostic and predictive in both groups. *Annals of Oncology*. 2012;9:ix74-ix5.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1146. Iwasaki T, Yamashita K, Tsujimura T, Kashiwamura S, Tsutsui H, Kaisho T, et al. Interleukin-18 inhibits osteolytic bone metastasis by human lung cancer cells possibly through suppression of osteoclastic bone-resorption in nude mice. *Journal of Immunotherapy*. 2002;25 Suppl 1:S52-60.
배제사유 : 동물실험 및 전임상시험연구

1147. Jabbar S, Chastain LG, Shrivastava P, Sarkar DK. Binge-like alcohol drinking prior to pregnancy induces immune incompetency and increases cancer susceptibility in offspring. *Alcoholism: Clinical and Experimental Research*. 2015;1):232A.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1148. Jabrane-Ferrat N, Calvo F, Faille A, Lagabrielle JF, Boisson N, Quillet A, et al. Recombinant gamma interferon provokes resistance of human breast cancer cells to spontaneous and IL-2 activated non-MHC restricted cytotoxicity. *British Journal of Cancer*. 1990;61(4):558-62.
배제사유 : 동물실험 및 전임상시험연구
1149. Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. *Nature Reviews Clinical Oncology*. 2016;13(6):370-83.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1150. Jacobs B, Ullrich E. The interaction of NK cells and dendritic cells in the tumor environment: How to enforce NK cell & DC action under immunosuppressive conditions? *Current Medicinal Chemistry*. 2012;19(12):1771-9.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1151. Jafari S, Froushani SMA, Tokmachi A. Combined Extract of Heated 4T1 and a Heat-Killed Preparation of Lactobacillus Casei in a Mouse Model of Breast Cancer. *Iranian Journal of Medical Sciences*. 2017;42(5):457-64.
배제사유 : 동물실험 및 전임상시험연구
1152. Jafarzadeh A, Fooladseresht H, Nemati M, Assadollahi Z, Sheikhi A, Ghaderi A. Higher circulating levels of chemokine CXCL10 in patients with breast cancer: Evaluation of the influences of tumor stage and chemokine gene polymorphism. *Cancer Biomarkers: Section A of Disease Markers*. 2016;16(4):545-54.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1153. Jahangir A, Chandra D, Quispe-Tintaya W, Singh M, Selvanesan BC, Gravekamp C. Immunotherapy with Listeria reduces metastatic breast cancer in young and old mice through different mechanisms. *OncoImmunology*. 2017;6 (9) (e1342025).
배제사유 : 동물실험 및 전임상시험연구
1154. Jaillon S, Galdiero MR, Del Prete D, Cassatella MA, Garlanda C, Mantovani A. Neutrophils in innate and adaptive immunity. *Seminars in Immunopathology*. 2013;35(4):377-94.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1155. Jain A. Curcumin suppresses PhIP induced inflammatory protein expression in breast epithelial cells. *Cancer Research Conference: American Association for Cancer Research Annual Meeting*. 2019;79(13 Supplement).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1156. Jain S. Biofield therapies for clinical populations: State of the science. *Psychosomatic Medicine*. 2015;77 (3):A117.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1157. Jakobisiak M, Golab J, Lasek W. Interleukin 15 as a promising candidate for tumor immunotherapy. *Cytokine and Growth Factor Reviews*. 2011;22(2):99-108.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1158. Jan CI, Huang SW, Canoll P, Lin YC, Lu HM, Chio SC, et al. Human leukocyte antigen G as a novel target for switch-based chimeric antigen receptor natural killer cell therapy of solid cancers. *Cancer Immunology Research*. Conference: AACR Special Conference on Tumor Immunology and Immunotherapy. United States. 2020;8(3 SUPPL).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1159. Janakiram M, Shah UA, Liu W, Zhao A, Schoenberg MP, Zang X. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. *Immunological Reviews*. 2017;276(1):26-39.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1160. Janji B, Baginska J, Medves S, Van Moer K, Chouaib S, Berchem G. Hypoxia-induced autophagy and TNF-alpha resistance in breast cancer cells leads to tumor evasion from NK-mediated immunosurveillance by downregulation of ICAM1. *Cancer Research*. Conference: 104th Annual Meeting of the American Association for Cancer Research, AACR. 2013;73(8 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1161. Janssen N, Fortis SP, Speigl L, Haritos C, Sotiriadou NN, Sofopoulos M, et al. Peripheral T cell responses to tumour antigens are associated with molecular, immunogenetic and cellular features of breast cancer patients. *Breast Cancer Research and Treatment*. 2017;161(1):51-62.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1162. Janssen N, Pawelec G, Speigl L, Fortis SP, Haritos C, Perez SA, et al. Immune profiling of breast cancer patients: Relationship between tumour antigen T cell responses with suppressor and effector leukocyte populations. *Journal for ImmunoTherapy of Cancer*. Conference: 30th Annual Scientific Meeting of the Society for Immunotherapy of Cancer, SITC. 2015;3(SUPPL. 2).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1163. Janusek L, Tell D, Mathews H. Epigenetic profile of women exhibiting a proinflammatory phenotype. *Psychosomatic Medicine*. 2015;77 (3):A50.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1164. Janusek LW, Tell D, Mathews HL. Mindfulness based stress reduction improves psychological well-being and restores immune function in women with breast cancer, from diagnosis through 6-months post-cancer treatment. *Brain, Behavior, and Immunity*. 2015;49 (Supplement 1):e37-e8.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1165. Javeed A, Ashraf M, Riaz A, Ghafoor A, Afzal S, Mukhtar MM. Paclitaxel and immune system. *European Journal of Pharmaceutical Sciences*. 2009;38(4):283-90.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1166. Jebakumar D, Walker K, Rao A. Gene expression analysis of modified tumor inflammation signature (TIS) in triple negative breast cancer among different ethnic groups. *Modern Pathology*. 2020;33 (3):186-8.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1167. Jenkins R. Welcome to the 14th volume of Future Oncology. *Future Oncology*. 2018;14(1):1-3.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1168. Jenny S, Vaclav V, Michael A. beta1,3-glucan anticancer efficacies and synergies: A review. *American Journal of Immunology*. 2014;10(3):131-43.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1169. Jerrells TR, Dean JH, Richardson G, Cannon GB, Herberman RB. Increased monocyte-mediated cytostasis of lymphoid cell lines in breast and lung cancer patients. *International Journal of Cancer*. 1979;23(6):768-76.
배제사유 : 동물실험 및 전임상시험연구
1170. Jasionek-Kupnicka D, Kulczycka D, Najder M, Olborski B, Kordek R. Phenotypic analysis of tumour infiltrating lymphocytes in breast cancer, colorectal cancer and gastric cancer tissue in comparison with normal control tissue and some clinico-pathological features. [Polish]. *Onkologia Polska*. 2002;5(3-4):129-34.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1171. Jewett A, Man YG, Tseng HC. Dual functions of natural killer cells in selection and differentiation of stem cells; role in regulation of inflammation and regeneration of Tissues. *Journal of Cancer*. 2013;4(1):12-24.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1172. Ji W, Zhou Y, Niu R. Effect of T-lymphocyte subpopulations in peripheral blood on disease-free survival of patients with different molecular subtypes of breast cancer. [Chinese]. *Chinese Journal of Clinical Oncology*. 2014;41(21):1363-7.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1173. Jia W, Martin TA, Zhang G, Jiang WG. Junctional adhesion molecules in cerebral endothelial tight junction and brain metastasis. *Anticancer Research*. 2013;33(6):2353-9.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1174. Jia Y, Xu L, Lin Q, Zhu M, Ding L, Wu K, et al. Levels of lymphocyte subsets in peripheral blood prior treatment are associated with aggressive breast cancer phenotypes or subtypes. *Medical Oncology*. 2014;31(6):981.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1175. Jiang H, Wang P, Li X, Wang Q, Deng ZB, Zhuang X, et al. Restoration of miR17/20a in solid tumor cells enhances the natural killer cell antitumor activity by targeting Mekk2. *Cancer Immunology Research*. 2014;2(8):789-99.
배제사유 : 동물실험 및 전임상시험연구

1176. Jiang X, Elliott R, Iron and HLA-G: Neglected immunosuppressive molecules in the human microenvironment. *Journal for ImmunoTherapy of Cancer*. Conference: 33rd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2018;6(Supplement 1).
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1177. Jiang X, Ellison SJ, Alarid ET, Shapiro DJ. Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells. *Oncogene*. 2007;26(28):4106-14.
- 배제사유 : 동물실험 및 전임상시험연구
1178. Jiang X, Patterson NM, Ling Y, Xie J, Helferich WG, Shapiro DJ. Low concentrations of the soy phytoestrogen genistein induce proteinase inhibitor 9 and block killing of breast cancer cells by immune cells. *Endocrinology*. 2008;149(11):5366-73.
- 배제사유 : 동물실험 및 전임상시험연구
1179. Jiang X, Shapiro DJ. The immune system and inflammation in breast cancer. *Molecular and Cellular Endocrinology*. 2014;382(1):673-82.
- 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1180. Jiang XP, Elliott RL. Decreased Iron in Cancer Cells and Their Microenvironment Improves Cytolysis of Breast Cancer Cells by Natural Killer Cells. *Anticancer Research*. 2017;37(5):2297-305.
- 배제사유 : 동물실험 및 전임상시험연구
1181. Jin F, Wu Z, Hu X, Zhang J, Gao Z, Han X, et al. The PI3K/Akt/GSK-3beta/ROS/eIF2B pathway promotes breast cancer growth and metastasis via suppression of NK cell cytotoxicity and tumor cell susceptibility. *Cancer Biology and Medicine*. 2019;16(1):38-54.
- 배제사유 : 동물실험 및 전임상시험연구
1182. Jin YT, Ying XX, Hu YH, Zou Q, Wang HY, Xu YH. aPKC inhibitors might be the sensitizer of chemotherapy and adoptive immunotherapy in the treatment of hASIPa-overexpressed breast cancer. *Oncology Research*. 2008;17(2):59-68.
- 배제사유 : 동물실험 및 전임상시험연구
1183. Jing H, Hettich M, Gaedicke S, Firat E, Bartholoma M, Niedermann G. Combination treatment with hypofractionated radiotherapy plus IL-2/anti-IL-2 complexes and its theranostic evaluation. *Journal for ImmunoTherapy of Cancer*. 2019;7 (1) (55).
- 배제사유 : 동물실험 및 전임상시험연구
1184. Jobim MR, Jobim M, Salim PH, Portela P, Jobim LF, Leistner-Segal S, et al. Analysis of KIR gene frequencies and HLA class I genotypes in breast cancer and control group. *Human Immunology*. 2013;74(9):1130-3.
- 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1185. Jogunoori W, Mishra L. Role of TGF-beta in alcohol-induced liver disease. *Advances in Experimental Medicine and Biology*. 2018;1032:93-104.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1186. John LB, Howland LJ, Flynn JK, West AC, Devaud C, Duong CP, et al. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. *Cancer Research*. 2012;72(7):1651-60.

배제사유 : 동물실험 및 전임상시험연구

1187. Johnson DB, Nixon MJ, Wang Y, Wang DY, Castellanos E, Estrada MV, et al. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. *Jci Insight*. 2018;3(24):20.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1188. Johrer K, Pleyer L, Olivier A, Maizner E, Zelle-Rieser C, Greil R. Tumour-immune cell interactions modulated by chemokines. *Expert Opinion on Biological Therapy*. 2008;8(3):269-90.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1189. Jordan VC, Gottardis MM, Robinson SP, Friedl A. Immune-deficient animals to study "hormone-dependent" breast and endometrial cancer. *Journal of Steroid Biochemistry*. 1989;34(1-6):169-76.

배제사유 : 동물실험 및 전임상시험연구

1190. Joshi HN, Langerod A, Troyanskaya OG, Borresen-Dale AL, Kristensen VN. Differential enrichment of pathways in association with TP53 mutation status of breast cancers. *European Journal of Cancer, Supplement*. 2010;8 (5):204.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1191. Joshi SS, Miller K, Jackson JD, Warkentin P, Kessinger A. Immunological properties of mononuclear cells from blood stem cell harvests following mobilization with erythropoietin + G-CSF in cancer patients. *Cytotherapy*. 2000;2(1):15-24.

배제사유 : 동물실험 및 전임상시험연구

1192. Joshi SS, Tarantolo SR, Kuszynski CA, Kessinger A. Antitumor therapeutic potential of activated human umbilical cord blood cells against leukemia and breast cancer. *Clinical Cancer Research*. 2000;6(11):4351-8.

배제사유 : 동물실험 및 전임상시험연구

1193. Jovanovic I, Gajovic N, Radosavljevic G, Pantic J, Pejnovic N, Arsenijevic N, et al. Innate lymphoid cells: Roles in tumour genesis and progression. *Serbian Journal of Experimental and Clinical Research*. 2015;16(2):85-91.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1194. Jovanovic I, Radosavljevic G, Mitrovic M, Juranic VL, McKenzie AN, Arsenijevic N, et al. ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. *European Journal of Immunology*. 2011;41(7):1902-12.

배제사유 : 동물실험 및 전임상시험연구

1195. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Arsenijevic NN, Lukic ML. IL-33/ST2 axis in innate and acquired immunity to tumors. *OncoImmunology*. 2012;1(2):229-31.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1196. Jprn U. Spiritual care of cancer patients by integrated medicine in a forest park. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000005004>. 2011.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1197. Julia EP, Amante A, Pampena MB, Mordoh J, Levy EM. Avelumab, an IgG1 anti-PD-L1 immune checkpoint inhibitor, triggers NK cell-mediated cytotoxicity and cytokine production against triple negative breast cancer cells. *Frontiers in Immunology*. 2018;9 (SEP) (2140).
배제사유 : 동물실험 및 전임상시험연구
1198. Julia EP, Mordoh J, Levy EM. Cetuximab and IL-15 Promote NK and Dendritic Cell Activation In Vitro in Triple Negative Breast Cancer. *Cells*. 2020;9(7):28.
배제사유 : 동물실험 및 전임상시험연구
1199. Julia EP, Pampena MB, Rocca YS, Mordoh J, Levy EM. Natural killer and dendritic cells collaborate in the immune response induced by Cetuximab and IL-15 against triple negative breast cancer. *Cancer Immunology Research*. Conference: AACR Special Conference on Tumor Immunology and Immunotherapy. 2016;5(3 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1200. Julian TB, Cobleigh MA, Siziopikou KP. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. *Breast Diseases*. 2011;22(3):282-3.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1201. Kabelitz D, Dechanet-Merville J. Editorial: "Recent advances in gamma/delta T cell biology: New ligands, new functions, and new translational perspectives". *Frontiers in Immunology*. 2015;6 (JUL) (371).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1202. Kabiljo J, Harpain F, Carotta S, Bergmann M. Radiotherapy as a backbone for novel concepts in cancer immunotherapy. *Cancers*. 2020;12 (1) (79).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1203. Kadagidze ZG, Chertkova AI, Zabotina TN, Korotkova OV, Borunova AA, Slavina EG. The main subpopulation regulatory lymphocytes in patients with malignant melanoma and breast cancer. [Russian]. *Immunologiya*. 2014;35(2):64-7.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1204. Kadambi S, Soto-Perez-de-Celis E, Garg T, Loh KP, Krok-Schoen JL, Battisti NML, et al. Social support for older adults with cancer: Young International Society of Geriatric Oncology review paper. *Journal of Geriatric Oncology*. 2020;11(2):217-24.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1205. Kaewkangsadan V, Verma C, Eremin JM, Cowley G, Ilyas M, Eremin O. Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): The crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC. *BMC Cancer*. 2018;18 (1) (123).

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

1206. Kaieda T, Imawari M, Yamasaki Z, Ohnishi S, Koike M, Idezuki Y, et al. Identification of a tumor-associated target antigen, ATM-1, for a human T-cell clone with activated killer activity and its existence in sera of cancer patients. *Cancer Research.* 1988;48(17):4848-54.

배제사유 : 동물실험 및 전임상시험연구

1207. Kajitani K, Ohdan H, Tanaka Y, Kataoka T. A novel concept of adoptive immunotherapy with tumor necrosis factor-related, apoptosis-inducing, ligand-expressing natural killer cells for eliciting an anti-breast-cancer response. *Journal of Clinical Oncology. Conference.* 2010;28(15 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1208. Kajitani K, Tanaka Y, Arihiro K, Kataoka T, Ohdan H. Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells. *Breast Cancer Research and Treatment.* 2012;134(1):139-55.

배제사유 : 동물실험 및 전임상시험연구

1209. Kajitani K, Tanaka Y, Ohdan H, Arihiro K, Kataoka T. [Mechanistic analysis of the antitumor efficacy of TRAIL-positive human natural killer cells]. *Nippon Rinsho - Japanese Journal of Clinical Medicine.* 2012;70 Suppl 7:208-13.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1210. Kalinski P, Muthuswamy R, Urban J. Dendritic cells in cancer immunotherapy: Vaccines and combination immunotherapies. *Expert Review of Vaccines.* 2013;12(3):285-95.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1211. Kalinski P, Urban J, Narang R, Berk E, Wieckowski E, Muthuswamy R. Dendritic cell-based therapeutic cancer vaccines: What we have and what we need. *Future Oncology.* 2009;5(3):379-90.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1212. Kalscheuer S, Khanna V, Kim H, Li S, Sachdev D, DeCarlo A, et al. Discovery of HSPG2 (Perlecan) as a Therapeutic Target in Triple Negative Breast Cancer. *Scientific Reports.* 2019;9(1):12492.

배제사유 : 동물실험 및 전임상시험연구

1213. Kaltenmeier CT, Vollmer LL, Vernetti LA, Caprio L, Davis K, Korotchenko VN, et al. A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity. *Journal of Pharmacology & Experimental Therapeutics.* 2017;361(1):39-50.

배제사유 : 동물실험 및 전임상시험연구

1214. Kaluderovic GN, Krajnovic T, Momcilovic M, Stosic-Grujicic S, Mijatovic S, Maksimovic-Ivanic D, et al. Ruthenium(II) p-cymene complex bearing 2,2'-dipyridylamine targets caspase 3 deficient MCF-7 breast cancer cells without disruption of antitumor immune response. *Journal of Inorganic Biochemistry.* 2015;153:315-21.

배제사유 : 동물실험 및 전임상시험연구

1215. Kamamura Y, Takahashi K, Komaki K, Monden Y. Effects of interferon-alpha and gamma on development of LAK activity from mononuclear cells in breast cancer patients. *Journal of Medical Investigation.* 1998;45(1-4):71-5.

배제사유 : 동물실험 및 전임상시험연구

1216. Kamigaki T, Ibe H, Okada S, Matsuda E, Tanaka M, Oguma E, et al. Improvement of impaired immunological status of patients with various types of advanced cancers by autologous immune cell therapy. *Anticancer Research.* 2015;35(8):4535-44.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

1217. Kan N, Imamura M. [Loco-regional immunotherapy with OK-432 and cultured autologous lymphocytes for patients with metastatic cancer]. *Human Cell.* 1993;6(2):100-5.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1218. Kan N, Okino T, Nakanishi M, Sato K, Mise K, Teramura Y, et al. [Experimental and clinical study of adoptive immunotherapy combined with preadministration of OK-432: a method to augment the therapeutic effect]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy].* 1989;16(4 Pt 2-2):1455-61.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1219. Kan N, Okino T, Nakanishi M, Satou K, Mise K, Ohgaki K, et al. [Clinical therapeutic effect of adoptive immunotherapy using IL-2-cultured autologous lymphocytes]. *Human Cell.* 1988;1(3):289-96.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1220. Kan N, Yamasaki S, Kodama H, Okino T, Ichinose Y, Moriguchi Y, et al. Bone metastasis as a prognostic factor in breast cancer patients with liver metastasis given OK-432-combined adoptive immunotherapy via the hepatic artery. *Biotherapy.* 1993;6(4):245-50.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1221. Kang DH, McArdle T, Park NJ, Weaver MT, Smith B, Carpenter J. Dose effects of relaxation practice on immune responses in women newly diagnosed with breast cancer: an exploratory study. *Oncology Nursing Forum.* 2011;38(3):E240-52.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

1222. Kang DH, Weaver MT, Park NJ, Smith B, McArdle T, Carpenter J. Significant impairment in immune recovery after cancer treatment. *Nursing Research.* 2009;58(2):105-14.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

1223. Kang HJ, Bae K, Kim JH, Cho CK, Yoo HS. Correlation Between Natural Killer Cell Activity and Systemic Inflammatory Markers for Heterogeneous Cancer Patients Treated With Whole Balance Cancer Therapy. *Integrative Cancer Therapies.* 2018;17(2):322-31.

배제사유 : 평가대상 검사의 영향을 보고한 의료결과가 보고되지 않은 경우

1224. Kang J, Demaria S, Cardenes HRR, Pilones KA, Jozsef G, Ng J, et al. Effect of Radiotherapy Variables on Circulating Effectors of Immune Response and Local Microbiome. International Journal of Radiation Oncology Biology Physics. 2019;105 (1 Supplement):E646.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1225. Kang TW, Kim HS, Lee BC, Shin TH, Choi SW, Kim YJ, et al. Mica Nanoparticle, STB-HO Eliminates the Human Breast Carcinoma Cells by Regulating the Interaction of Tumor with its Immune Microenvironment. Scientific Reports. 2015;5:17515.
배제사유 : 동물실험 및 전임상시험연구
1226. Karki R, Man SM, Kanneganti TD. Inflammasomes and cancer. Cancer Immunology Research. 2017;5(2):94-9.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1227. Karl E. Psychoneuroimmunology. [German]. Arztezeitschrift fur Naturheilverfahren. 2002;43(3):167-77.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1228. Karn T, Pusztai L, Rody A, Holtrich U, Becker S. The influence of host factors on the prognosis of breast cancer: Stroma and immune cell components as cancer biomarkers. Current Cancer Drug Targets. 2015;15(8):652-64.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1229. Katano M, Kubota E, Nagumo F, Matsuo T, Hisatsugu T, Tadano J. Inhibition of tumor cell growth by a human B-cell line. Biotherapy. 1994;8(1):1-6.
배제사유 : 동물실험 및 전임상시험연구
1230. Katano M, Morisaki T, Matsuo T, Nakamura M, Kubota E, Hisatsugu T. Interleukin-2 (IL-2) production by human B-cell line. Cellular Immunology. 1994;159(2):262-70.
배제사유 : 동물실험 및 전임상시험연구
1231. Katoh H, Watanabe M. Myeloid-derived suppressor cells and therapeutic strategies in cancer. Mediators of Inflammation. 2015;2015 (159269).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1232. Katoh M, Katoh M. Identification and characterization of human FMNL1, FMNL2 and FMNL3 genes in silico. International Journal of Oncology. 2003;22(5):1161-8.
배제사유 : 동물실험 및 전임상시험연구
1233. Kawabata A, Ohta N, Seiler G, Pyle MM, Ishiguro S, Zhang YQ, et al. Naive rat umbilical cord matrix stem cells significantly attenuate mammary tumor growth through modulation of endogenous immune responses. Cyotherapy. 2013;15(5):586-97.
배제사유 : 동물실험 및 전임상시험연구
1234. Kawaguchi K, Suzuki E, Yamaguchi A, Yamamoto M, Morita S, Toi M. Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. Breast Cancer. 2017;24(1):111-20.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1235. Kawaguchi K, Suzuki E, Yamamoto M, Yamaguchi A, Morita S, Toi M. Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. *European Journal of Cancer*. 2016;60 (Supplement 1):e18.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1236. Kawakami K, Kawakami M, Puri RK. Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease. *Molecular Cancer Therapeutics*. 2004;3(2):137-47.
배제사유 : 동물실험 및 전임상시험연구
1237. Kawalec P, Sladowska K, Malinowska-Lipien I, Brzostek T, Kozka M. European perspective on the management of rheumatoid arthritis: Clinical utility of tofacitinib. *Therapeutics and Clinical Risk Management*. 2018;14:15-29.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1238. Kawano Y, Roccaro AM, Ghobrial IM, Azzi J. Multiple Myeloma and the Immune Microenvironment. *Current Cancer Drug Targets*. 2017;17(9):806-18.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1239. Kawaoka T, Oka M, Takashima M, Ueno T, Yamamoto K, Yahara N, et al. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. *Oncology Reports*. 2008;20(1):155-63.
배제사유 : 동물실험 및 전임상시험연구
1240. Kawasaki BT, Farrar WL. Cancer stem cells, CD200 and immuno-evasion. *Trends in Immunology*. 2008;29(10):464-8.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1241. Kazi A, Hill R, Long TE, Kuhn DJ, Turos E, Dou QP. Novel N-thiolated beta-lactam antibiotics selectively induce apoptosis in human tumor and transformed, but not normal or nontransformed, cells. *Biochemical Pharmacology*. 2004;67(2):365-74.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1242. Kedar E, Ikejiri BL, Timonen T, Bonnard GD, Reid J, Navarro NJ, et al. Antitumor reactivity in vitro and in vivo of lymphocytes from normal donors and cancer patients propagated in culture with T cell growth factor (TCGF). *European Journal of Cancer & Clinical Oncology*. 1983;19(6):757-73.
배제사유 : 동물실험 및 전임상시험연구
1243. Keegan NM, Toomey S, Fay J, Madden SF, Moran B, Milewska M, et al. Effect of TCHL-based therapy on immune cell content in on-treatment, neoadjuvant-treated HER2-positive breast cancer patients. *Journal of Clinical Oncology. Conference*. 2017;35(15 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1244. Kees T, Egeblad M. Innate immune cells in breast cancer - From villains to heroes? *Journal of Mammary Gland Biology and Neoplasia*. 2011;16(3):189-203.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1245. Keller S, Sanderson MP, Stoeck A, Altevogt P. Exosomes: From biogenesis and secretion to biological function. *Immunology Letters*. 2006;107(2):102-8.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1246. Kelly P. The cancer critical care paradox. *Current Anaesthesia and Critical Care*. 2008;19(2):96-104.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1247. Kenne Sarenmalm E, Martensson LB, Andersson BA, Karlsson P, Bergh I. Mindfulness and its efficacy for psychological and biological responses in women with breast cancer. *Cancer Medicine*. 2017;6(5):1108-22.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1248. Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L, et al. Immunogenic cell death modalities and their impact on cancer treatment. *Apoptosis*. 2009;14(4):364-75.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1249. Kerekes D, Brahmbhatt RD, Hoskin TL, Pena A, Visscher DW, Stallings Mann ML, et al. MICA expression is decreased in benign breast lobules with fibrocystic changes. *Annals of Surgical Oncology*. 2015;1):S66-S7.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1250. Kerekes D, Visscher DW, Hoskin TL, Radisky DC, Brahmbhatt RD, Pena A, et al. CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes. *Breast Cancer Research & Treatment*. 2018;167(3):649-58.
배제사유 : 동물실험 및 전임상시험연구
1251. Keren L, Bosse M, West R, Bendall S, Angelo M. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. *Journal for ImmunoTherapy of Cancer*. Conference: 33rd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2018;6(Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1252. Kesebir S. Bipolar disorders and cancer. *Psycho-Oncology*. 2011;2):25.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1253. Kester JM, Bortz E. Interferon regulatory factor 3 and nf kappa B are required for expression of immune susceptibility genes in human lung and breast carcinoma cells treated with poly I:C. *FASEB Journal*. Conference: Experimental Biology. 2018;32(1 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1254. Khaled A, Bassiouni R, Limaye A, Oyer J, Igarashi R, Flores O, et al. Use of a cytotoxic peptide as an immunotherapeutic agent in the treatment of metastatic breast cancer (VAC13P.1134). *Journal of Immunology*. Conference: 102nd Annual Meeting of the American Association of Immunologist, IMMUNOLOGY. 2015;194(1 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1255. Khaled AR, Limaye A, Bassiouni R, Showalter A, Oyer J, Pandey V, et al. Enhancing the immunogenicity of breast cancer cells to stimulate innate immunity and augment the effects of cellular immunotherapy. Cancer Research. Conference: 38th Annual CTRC AACR San Antonio Breast Cancer Symposium. San Antonio, TX United States. Conference Publication: 2016;76(4 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1256. Khan AL, Richardson S, Drew J, Larsen F, Campbell M, Heys SD, et al. Polyadenylic-polyuridylic acid enhances the natural cell-mediated cytotoxicity in patients with breast cancer undergoing mastectomy. *Surgery*. 1995;118(3):531-8.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

1257. Kharkevich DD, Polevaia EB, Kadagidze ZG. [Tumor-induced immunosuppression in breast cancer patients]. *Eksperimentalnaia Onkologiiia*. 1990;12(5):53-6.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1258. Khosravi N, Stoner L, Farajivafa V, Hanson ED. Exercise training, circulating cytokine levels and immune function in cancer survivors: A meta-analysis. *Brain, Behavior, and Immunity*. 2019;81:92-104.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1259. Kieber-Emmons T, Makhoul I, Pennisi A, Emanuel PD, Hutchins LF, Siegel ER, et al. Unleashing natural killer cells upon immunization with a carbohydrate mimetic peptide vaccine. *Journal of Clinical Oncology*. Conference. 2018;36(5 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1260. Kieber-Emmons T. Moving forward with an immunotherapy for the prevention of breast cancer recurrence. *Journal of Cancer Science and Therapy*. 2012;1):68.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1261. Kienle GS, Kiene H. Complementary cancer therapy: A systematic review of prospective clinical trials on anthroposophic mistletoe extracts. *European Journal of Medical Research*. 2007;12(3):103-19.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1262. Kiessling R, Okita R, Mougiakakos D, Mao Y, Sarhan D, Wennerberg E, et al. Opposing consequences of signaling through egf family members: Escape from ctls could be a bait for nk cells. *OncoImmunology*. 2012;1(7):1200-1.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1263. Kikuchi K, Okubo M, Sato T, Sato N. Cytotoxic T cell clones against human autologous cancers: analysis of target antigen and the mechanism of specific target cell destruction. *Princess Takamatsu Symposia*. 1988;19:303-13.

배제사유 : 동물실험 및 전임상시험연구

1264. Killock D. Sequencing cells of the immune TME. *Nature Reviews Clinical Oncology*. 2018;15(9):531.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1265. Kim BJ, Jeong H, Park S, Lee S. Forest adjuvant anti-cancer therapy to enhance natural cytotoxicity in urban women with breast cancer: A preliminary prospective interventional study. European Journal of Integrative Medicine. 2015;7(5):474-8.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

1266. Kim CJ, Hur HK, Kang DH, Kim BH. [The effects of psychosocial interventions to improve stress and coping in patients with breast cancer]. Daehan Ganho Haghoeji. 2006;36(1):169-78.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1267. Kim DS, Jun MH. [Body fat percentage and natural killer cell activity of breast and rectal cancer patients after diagnosis but before treatment]. Daehan Ganho Haghoeji. 2008;38(2):321-31.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

1268. Kim H, Eom HS, Kong SY, Park SR, Kim SY, Ro J, et al. Prognostic significance of immune thrombocytopenic purpura in patients with malignancy. Blood. Conference: 52nd Annual Meeting of the American Society of Hematology, ASH. 2010;116(21).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1269. Kim H, Khanna V, Kucaba TA, Zhang W, Sehgal D, Ferguson DM, et al. TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy. Molecular Pharmaceutics. 2020;17(6):2109-24.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

1270. Kim H, Kim HS, Moon WK. Comparison of transcriptome expression alterations by chronic exposure to low-dose bisphenol A in different subtypes of breast cancer cells. Toxicology and Applied Pharmacology. 2019;385 (114814).

배제사유 : 동물실험 및 전임상시험연구

1271. Kim HW, Kim JE, Hwang MH, Jeon YH, Lee SW, Lee J, et al. Enhancement of natural killer cell cytotoxicity by sodium/iodide symporter gene-mediated radioiodine pretreatment in breast cancer cells. PLoS ONE [Electronic Resource]. 2013;8(8):e70194.

배제사유 : 동물실험 및 전임상시험연구

1272. Kim JI, Kwak BS. Comparative Analysis of Natural Killer Cell Activity between Advanced Breast Cancer and Early Breast Cancer. Breast. 2019;48 (Supplement 2):S41-S2.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1273. Kim JJ, Shin YA, Suk MH. Effect of a 12-week walking exercise program on body composition and immune cell count in patients with breast cancer who are undergoing chemotherapy. Journal of Exercise Nutrition & Biochemistry. 2015;19(3):255-62.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

1274. Kim JY, Bae JH, Lee SH, Lee EY, Chung BS, Kim SH, et al. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide. *Journal of Immunotherapy*. 2008;31(5):475-86.
배제사유 : 동물실험 및 전임상시험연구
1275. Kim KE, Park S, Cheon S, Kim DY, Cho DJ, Park JM, et al. Novel application of radotinib for the treatment of solid tumors via natural killer cell activation. *Journal of Immunology Research*. 2018;2018 (9580561).
배제사유 : 동물실험 및 전임상시험연구
1276. Kim KS, Lee SW, Choe MA, Yi MS, Choi S, Kwon SH. [Effects of abdominal breathing training using biofeedback on stress, immune response and quality of life in patients with a mastectomy for breast cancer]. *Daehan Ganco Haghoeji*. 2005;35(7):1295-303.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1277. Kim KS, Park KS. XRP44X Enhances the Cytotoxic Activity of Natural Killer Cells by Activating the c-JUN N-Terminal Kinase Signaling Pathway. *Balsaenggwa Saengsig*. 2020;24(1):53-62.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1278. Kim KW, Jeong JU, Lee KH, Uong TNT, Rhee JH, Ahn SJ, et al. Combined NK Cell Therapy and Radiation Therapy Exhibit Long-Term Therapeutic and Antimetastatic Effects in a Human Triple Negative Breast Cancer Model. *International Journal of Radiation Oncology, Biology, Physics*. 2019;10:10.
배제사유 : 동물실험 및 전임상시험연구
1279. Kim R, Kawai A, Wakisaka M, Funaoka Y, Ohtani S, Ito M, et al. Differences in immune response to anesthetics used for day surgery versus hospitalization surgery for breast cancer patients. *Clinical and Translational Medicine*. 2017;6(1):34.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1280. Kim R, Kawai A, Wakisaka M, Funaoka Y, Tasaka Y, Yasuda N, et al. Immune response induced by preoperative chemotherapy in breast cancer: Role of peripheral natural killer (pNK) cell activity, tumor-infiltrating lymphocytes (TILs), and tumor microenvironment factors (TMEFs). *Journal of Clinical Oncology Conference*. 2018;36(15 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1281. Kim R, Kawai A, Wakisaka M, Funaoka Y, Yasuda N, Hidaka M, et al. A potential role for peripheral natural killer cell activity induced by preoperative chemotherapy in breast cancer patients. *Cancer Immunology, Immunotherapy*. 2019;68(4):577-85.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1282. Kim R, Kawai A, Wakisaka M, Funaoka Y, Yasuda N, Nishida Y, et al. A potential role for peripheral natural killer (NK) cell activity induced by pre-operative chemotherapy in breast cancer patients. *Annals of Surgical Oncology*. 2018;25 (2 Supplement 1):52-3.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1283. Kim R, Kawai A, Wakisaka M, Garaku H, Yasuda N, Ohtani S, et al. A role for peripheral natural killer (NK) cell activity in the response to neoadjuvant chemotherapy in patients with breast cancer. *Journal of Clinical Oncology. Conference.* 2016;34(Supplement 15).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1284. Kim R, Kawai A, Wakisaka M, Sawada S, Shimoyama M, Yasuda N, et al. Different immune responses to the pathological therapeutic effect of neoadjuvant chemotherapy in the tumor microenvironment of locally-advanced breast cancer. *Breast.* 2019;44 (Supplement 1):S71.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1285. Kim R, Kawai A, Wakisaka M, Sawada S, Shimoyama M, Yasuda N, et al. Immune correlates of the differing pathological and therapeutic effects of neoadjuvant chemotherapy in breast cancer. *European Journal of Surgical Oncology.* 2020;46(1):77-84.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

1286. Kim SW, Yoo JA, Kim SY, Kim JM, Kim SH, Bae KY, et al. Relationship between a hopeful attitude and cellular immunity in patients with breast cancer. *European Neuropsychopharmacology.* 2011;3):S366.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1287. Kim TS, Jung MY, Cho D, Cohen EP. Prolongation of the survival of breast cancer-bearing mice immunized with GM-CSF-secreting syngeneic/allogeneic fibroblasts transfected with a cDNA expression library from breast cancer cells. *Vaccine.* 2006;24(42-43):6564-73.

배제사유 : 동물실험 및 전임상시험연구

1288. Kim Y. No pain, no gain: Bridging the gap from basic science to practice in cancer stress and growth research among cancer patients, survivors, and their family caregivers. *Psycho-Oncology.* 2016;25 (Supplement 3):84-5.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1289. Kim YS, Kaidina AM, Chiang JH, Yarygin KN, Lupatov AY. Cancer stem cell molecular markers verified in vivo. *Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry.* 2017;11(1):43-54.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1290. Kimber I, Moore M, Howell A, Wilkinson MJ. Native and inducible levels of natural cytotoxicity in lymph nodes draining mammary carcinoma. *Cancer Immunology, Immunotherapy.* 1983;15(1):32-8.

배제사유 : 동물실험 및 전임상시험연구

1291. Kimoto Y, Taguchi T. [Adoptive immunotherapy of malignant disease using LAK cells]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy].* 1988;15(4 Pt 2-1):788-96.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1292. Kimoto Y, Tanji Y, Taguchi T. [Blocking factors in human blood which inhibit the cytotoxicity of lymphocytes]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]. 1987;14(2):453-8.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1293. Kimoto Y, Tanji Y, Tanaka T, Taguchi T. [Adoptive immunotherapy of malignant diseases with LAK cells]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]. 1987;14(3 Pt 1):687-92.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1294. Kindzel'skii LP, Zlochevskaia LL, Shabaeva MM, Tolstopiatov BA, Zhukova VM, Rudaia OI, et al. [Possibilities of preclinical and differential diagnosis of malignant neoformations according to the percentage of large granular lymphocytes]. Voprosy Onkologii. 1989;35(12):1441-3.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1295. Kindzel'skii LP, Zlochevskaia LL, Tsyanok TV, Shabaeva MM, Zhukova MM, Rudaia OI. [The count of the large granule-containing lymphocytes of the peripheral blood and the natural killer activity in patients with malignant tumors]. Vrachebnoe Delo. 1990(8):31-2.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1296. Kirkwood JM, Ernstoff MS. Interferons in the treatment of human cancer. Journal of Clinical Oncology. 1984;2(4):336-52.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1297. Kishi A, Takamori Y, Ogawa K, Takano S, Tomita S, Tanigawa M, et al. Differential expression of granzylisin and perforin by NK cells in cancer patients and correlation of impaired granzylisin expression with progression of cancer. Cancer Immunology, Immunotherapy. 2002;50(11):604-14.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1298. Kitamura T, Kato Y, Brownlie D, Soong DYH, Sugano G, Kippen N, et al. Mammary Tumor Cells with High Metastatic Potential Are Hypersensitive to Macrophage-Derived HGF. Cancer Immunology Research. 2019;7(12):2052-64.

배제사유 : 동물실험 및 전임상시험연구

1299. Kitoh T, Shimomura Y, Hori T, Saida S, Yamamoto S, Kikuchi A, et al. Efficacy of l-asparaginase-containing regimen in patients with NK/T-cell lymphoma/leukemia with low asparagine synthetase (ASNS) expression confirmed by human ASNS-specific immunohistochemistry. Annals of Oncology. 2011;9:ix78.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1300. Kiyohara E, Tanemura A, Nishioka M, Yamada M, Tanaka A, Yokomi A, et al. Intratumoral injection of hemagglutinating virus of Japan-envelope vector yielded an antitumor effect for advanced melanoma: a phase I/IIa clinical study. Cancer Immunology, Immunotherapy. 2020;69(6):1131-40.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

1301. Kleeff J, Loos M, Hedderich DM, Friess H. B7-H3 and its role in antitumor immunity. *Clinical and Developmental Immunology*. 2010;2010 (683875).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1302. Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. *OncolImmunology*. 2017;6 (3) (e1277306).
배제사유 : 동물실험 및 전임상시험연구
1303. Klein E, Vankay F, Vose BM. Natural killer and tumor recognizing lymphocyte activity in tumor patients. *Haematologia*. 1978;12(1-4):107-12.
배제사유 : 동물실험 및 전임상시험연구
1304. Klimberg VS, McClellan JL. Glutamine, cancer, and its therapy. *American Journal of Surgery*. 1996;172(5):418-24.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1305. Klimberg VS. Is glutamine effective in enhancing host immune response to tumors? *Journal of Nutrition*. 2005;135(12):2920S.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1306. Klingemann HG. Cellular therapy of cancer with natural killer cells-where do we stand? *Cytotherapy*. 2013;15(10):1185-94.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1307. Klingemann HG. Natural killer cell-based immunotherapeutic strategies. *Cytotherapy*. 2005;7(1):16-22.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1308. Kloss S, Bochennek K, Huenecke S, Zimmermann SY, Kuci S, Muller T, et al. A novel five-colour flow cytometric assay to determine NK cell cytotoxicity against neuroblastoma and other adherent tumour cells. *Journal of Immunological Methods*. 2007;325(1-2):140-7.
배제사유 : 동물실험 및 전임상시험연구
1309. Kmiecik M, Basu D, Payne KK, Toor A, Yacoub A, Wang XY, et al. Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVB/N202 transgenic mouse. *Journal of Immunology*. 2011;187(2):708-17.
배제사유 : 동물실험 및 전임상시험연구
1310. Knight RA, Fitzharris P. Effects of activated T cells on natural killing. *Immunology*. 1982;45(3):513-9.
배제사유 : 동물실험 및 전임상시험연구
1311. Knight RA, Fitzharris P. Separation of spontaneous-killing effector populations by target preference. *British Journal of Cancer*. 1980;42(2):243-51.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1312. Knorr DA, Bachanova V, Verneris MR, Miller JS. Clinical utility of natural killer cells in cancer therapy and transplantation. *Seminars in Immunology*. 2014;26(2):161-72.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1313. Knudson KM, Hicks KC, Alter S, Schlom J, Gameiro SR. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy. *Journal for Immunotherapy of Cancer*. 2019;7(1):82.

배제사유 : 동물실험 및 전임상시험연구

1314. Knudson KM, Hicks KC, Luo X, Chen JQ, Schlom J, Gameiro SR. M7824, a novel bifunctional anti-PD-L1/TGFbeta Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. *OncoImmunology*. 2018;7 (5) (e1426519).

배제사유 : 동물실험 및 전임상시험연구

1315. Knudson KM, Hicks KC, Ozawa Y, Schlom J, Gameiro SR. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist. *Journal for ImmunoTherapy of Cancer*. 2020;8 (1) (e000493).

배제사유 : 동물실험 및 전임상시험연구

1316. Kobayashi S, Sato K, Torikai H, Ogura K, Kobayashi A, Bamba Y, et al. Transformation of myelodysplastic syndrome into myeloid/natural killer cell precursor acute leukemia involving mainly lymph nodes [2]. *Leukemia and Lymphoma*. 2008;49(2):342-5.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1317. Kobayashi Y, Sudo T, Matsushita N, Nakao M, Tanaka Y, Shimizu K, et al. [Preparation of NK-enriched LAK cells--their potential cytotoxic and ADCC activities]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 2003;30(11):1776-9.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1318. Kochan G, Escors D, Breckpot K, Guerrero-Setas D. Role of non-classical MHC class I molecules in cancer immunosuppression. *OncoImmunology*. 2013;2 (11) (e26491).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1319. Kodack DP, Chung E, Yamashita H, Incio J, Duyverman AM, Song Y, et al. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. *Proceedings of the National Academy of Sciences of the United States of America*. 2012;109(45):E3119-27.

배제사유 : 동물실험 및 전임상시험연구

1320. Koelwyn GJ, Jones LW. Exercise as a candidate antitumor strategy: A window into the future. *Clinical Cancer Research*. 2019;25(17):5179-81.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1321. Koepsell SA, Miller JS, McKenna DH. Natural killer cells: A review of manufacturing and clinical utility. *Transfusion*. 2013;53(2):404-10.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1322. Kohrt H, Houot R, Weiskopf K, Goldstein M, Lund P, Czerwinski D, et al. Stimulation of natural killer cells with an anti-CD137 antibody enhances the efficacy trastuzumab, cetuximab, and rituximab in HER2-expressing breast cancer, EGFR+ head and neck cancer, and CD20+ lymphoma. *Cancer Research*. Conference: 103rd Annual Meeting of the American Association for Cancer Research, AACR. 2012;72(8 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1323. Kohrt HE, Houot R, Marabelle A, Cho HJ, Osman K, Goldstein M, et al. Combination strategies to enhance antitumor ADCC. *Immunotherapy*. 2012;4(5):511-27.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1324. Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, et al. Erratum: Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer(J Clin Invest. (2019)129:6 (2595-2595) DOI:10.1172/JCI129688). *Journal of Clinical Investigation*. 2019;129(6):2595.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1325. Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. *Journal of Clinical Investigation*. 2012;122(3):1066-75.
배제사유 : 동물실험 및 전임상시험연구
1326. Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. *Journal of Clinical Investigation*. 2019;129(6):2595.
배제사유 : 동물실험 및 전임상시험연구
1327. Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SEM, Butchar JP, Cheney C, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. *Blood*. 2014;123(12):1957-60.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1328. Koirala P, Roth ME, Gill J, Piperdi S, Chinai JM, Geller DS, et al. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. *Scientific Reports*. 2016;6:30093.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1329. Koivunen JP, Honkanen T, Moilanen T, Karihtala P, Vayrynen J, Makinen M. Spatially positioned tumor infiltrating lymphocytes predict survival in metastatic HER2 positive breast cancer treated with trastuzumab. *Cancer Research*. Conference: American Association for Cancer Research Annual Meeting. 2017;77(13 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1330. Kolbl AC, Jeschke U, Dian D, Friese K, Andergassen U. Glycodelin A - A famous lipocalin and its role in breast cancer. *Anticancer Research*. 2014;34(3):1079-85.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1331. Kolyadina IV, Poddubnaya I, Van De Velde CJH, Kuppen PJK, Bastiaannet E, Davydov M, et al. The prognostic value of the immune profile of breast cancer stage I in Russian and Dutch women. *Journal of Clinical Oncology*. Conference. 2016;34(Supplement 15).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1332. Komarov A, Chenchik A, Makhanov M, Frangou C. Molecular profiling of tumor microenvironment for biomarker discovery. *Journal for ImmunoTherapy of Cancer*. Conference: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer, SITC. 2016;4(Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1333. Komarov A, Chenchik AA, Makhanov M, Diehl P, Frangou C. Board Number: B568 Molecular profiling of tumor microenvironment for biomarker discovery. *Molecular Biology of the Cell*. 2016;27 (25):4985.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1334. Komatsu M, Yee L, Carraway KL. Overexpression of sialomucin complex, a rat homologue of MUC4, inhibits tumor killing by lymphokine-activated killer cells. *Cancer Research*. 1999;59(9):2229-36.
배제사유 : 동물실험 및 전임상시험연구
1335. Konjevic G, Brankovic-Magic M, Nikolic-Vukosavljevic D, Spuzic I. [Steroid receptors and NK cell activity in patients with breast cancer]. *Srpski Arhiv Za Celokupno Lekarstvo*. 1994;122(5-6):139-42.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1336. Konjevic G, Jurisic V, Jovic V, Vuletic A, Mirjacic Martinovic K, Radenkovic S, et al. Investigation of NK cell function and their modulation in different malignancies. *Immunologic Research*. 2012;52(1-2):139-56.
배제사유 : 동물실험 및 전임상시험연구
1337. Konjevic G, Jurisic V, Spuzic I. Association of NK cell dysfunction with changes in LDH characteristics of peripheral blood lymphocytes (PBL) in breast cancer patients. *Breast Cancer Research & Treatment*. 2001;66(3):255-63.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1338. Konjevic G, Radenkovic S, Srdic T, Jurisic V, Stamatovic L, Milovic M. Association of decreased NK cell activity and IFNgamma expression with pSTAT dysregulation in breast cancer patients. *Journal of B.U.On.* 2011;16(2):219-26.
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
1339. Konjevic G, Spuzic I. [Alterations in NK cell activity in the presence of sera of patients with metastases]. *Srpski Arhiv Za Celokupno Lekarstvo*. 1994;122 Suppl 1:78-80.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1340. Konjevic G, Spuzic I. [Immunomodulatory effect of serum on NK cells in vitro in healthy individuals]. *Glas - Srpska Akademija Nauka i Umetnosti, Odeljenje Medicinskih*

Nauka. 1994(44):45-54.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1341. Konjevic G, Spuzic I. [The effect of sera of breast cancer patients on NK cell activity]. Srpski Arhiv Za Celokupno Lekarstvo. 1995;123(9-10):227-31.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1342. Konjevic G, Spuzic I. [The effect of serum on NK cell activity]. Glas - Srpska Akademija Nauka i Umetnosti, Odeljenje Medicinskih Nauka. 1991(41):113-20.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1343. Konjevic G, Spuzic I. [The possibilities of modulation of NK cell activity]. Glas - Srpska Akademija Nauka i Umetnosti, Odeljenje Medicinskih Nauka. 2002(47):89-101.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1344. Konjevic G, Spuzic I. Alterations in NK cell activity in the presence of sera of patients with metastases. [Croatian]. Srpski arhiv za celokupno lekarstvo. 1994;122 Suppl 1:78-80.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1345. Konjevic G, Spuzic I. Evaluation of different effects of sera of breast cancer patients on the activity of natural killer cells. Journal of Clinical & Laboratory Immunology. 1992;38(2):83-93.
배제사유 : 동물실험 및 전임상시험연구
1346. Konjevic G, Spuzic I. Stage dependence of NK cell activity and its modulation by interleukin 2 in patients with breast cancer. Neoplasma. 1993;40(2):81-5.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 갑마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1347. Konjevic G, Spuzic I. Suppressive interaction of breast cancer patients' sera on interleukin-2 induced stimulation of natural killer cells. Journal of Experimental and Clinical Cancer Research. 1995;14(1):31-7.
배제사유 : 동물실험 및 전임상시험연구
1348. Konjevic GM, Radenkovic SS, Srdic T, Jelic S, Stamatovic L, Inic M. Impaired pSTAT3 and pSTAT5 induction by IL-2 does not affect IFNgamma production in NK cells of breast cancer patients. Cancer Research. Conference: 101st Annual Meeting of the American Association for Cancer Research, AACR. 2010;70(8 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1349. Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Research. 2002;62(20):5813-7.
배제사유 : 동물실험 및 전임상시험연구
1350. Kontinen V. Controlled clinical trials in chronic postoperative pain. Acta Anaesthesiologica Scandinavica, Supplement. 2009;53 (119):24-6.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1351. Kontos M, Fentiman IS. Perioperative endocrine status and prognosis in early breast cancer. *Breast Journal*. 2006;12(6):518-25.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1352. Korak T, Ergul E, Sazci A. Nigella sativa and cancer: A review focusing on breast cancer, inhibition of metastasis and enhancement of Natural Killer cell cytotoxicity. *Current Pharmaceutical Biotechnology*. 2020;30:30.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1353. Korbecki J, Siminska D, Kojder K, Grochans S, Gutowska I, Chlubek D, et al. Fractalkine/CX3CL1 in Neoplastic Processes. *International Journal of Molecular Sciences*. 2020;21(10):25.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1354. Korner S, Leibold J, Grosse-Hovest L, Buhring HJ, Jung G, Kanz L, et al. Generation and preclinical characterization of an Fcoptimized CD133 antibody for improved induction of NK cell reactivity against solid tumors. *Oncology Research and Treatment*. 2014;5):112.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1355. Koros AM, Goodwin DG, Siderits RH, Malavasi F. "Natural killer" (NK) cell antigens CD56, CD57 and others are expressed on breast and lung tumor cells as well as sea urchin coelomocytes. *Journal of Biological Regulators & Homeostatic Agents*. 2002;16(3):173-5.
배제사유 : 동물실험 및 전임상시험연구
1356. Koshi S, Egami T, Isogai M, Miyauchi Y. [Breast cancer associated with pregnancy]. *Nippon Geka Gakkai Zasshi. Journal of Japan Surgical Society*. 1989;90(1):127-9.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1357. Koshy S, Wu D, Tajhya R, Hu X, Odejimi A, Yotnda P, et al. Potassium channels on natural killer cells in the presence of breast carcinoma cells. *FASEB Journal. Conference: Experimental Biology*. 2012;26(Meeting Abstracts).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1358. Kosmas C, Epenetos AA, Courtenay-Luck NS. Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens. *British Journal of Cancer*. 1991;64(3):494-500.
배제사유 : 동물실험 및 전임상시험연구
1359. Koval O, Volkova O, Kulemin S, Gorchakov A, Tkachenko A, Nushtaeva A, et al. NK-cell based delivery of anticancer therapeutics. *Annals of Oncology*. 2017;28 (Supplement 11):xi20.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1360. Koval OA, Subrakova VG, Nushtaeva AA, Belovezhets TN, Troitskaya OA, Ermakov MS, et al. CAR-dependent anti-metastatic activity of modified NK cell line YT. [Russian]. *Genes and Cells*. 2019;14(4):66-71.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1361. Krajcovic M, Overholtzer M. Mechanisms of ploidy increase in human cancers: A new role for cell cannibalism. *Cancer Research*. 2012;72(7):1596-601.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1362. Krasnick BA, Gao Q, Goedegebuure P, Ding L, Fields RC. Dissecting the single cell profile of pancreatic ductal adenocarcinoma. *Hpb*. 2019;21 (Supplement 1):S42-S3.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1363. Krebs M, Carter L, Villa S, King A, Massey C, Lorens J, et al. MiST3: A Phase II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in pts with Malignant Mesothelioma. *Journal of Thoracic Oncology*. 2018;13 (10 Supplement):S745.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1364. Kremer L, Garcia-Sanz JA. Editorial: Is the recent burst of therapeutic anti-tumor antibodies the tip of an iceberg? *Frontiers in Immunology*. 2018;9 (MAR) (442).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1365. Kresovich JK, O'Brien KM, Xu Z, Weinberg CR, Sandler DP, Taylor JA. Prediagnostic Immune Cell Profiles and Breast Cancer. *JAMA Network Open*. 2020;3(1):e1919536.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1366. Kreuzer M, Foulds GA, Multhoff G, Pockley AG. Orchestration of NK cell phenotype and function by breast cancerderived factors. *Immunology*. 2012;1):242.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1367. Krivokuca A, Boljevic I, Rakobradovic J, Jovandic S, Brankovic-Magic M. Germline mutations in breast and ovarian cancer cases from Serbia. *International Journal of Gynecological Cancer*. 2017;27 (Supplement 4):1813.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1368. Krneta T, Gillgrass A, Ashkar AA. The influence of macrophages and the tumor microenvironment on natural killer cells. *Current Molecular Medicine*. 2013;13(1):68-79.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1369. Krockenberger M, Engel J, Hausler S, Heuer S, Dietl J, Honig A. Macrophage migration inhibitory factor levels in serum of ovarian cancer patients correlate with prognostic parameters in ovarian cancer. *Archives of Gynecology and Obstetrics*. 2010;1):S204.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1370. Krockenberger M, Engel J, Hausler S, Wischhusen J, Heuer S, Dietl J, et al. Macrophage Migration Inhibitory Factor levels in serum of ovarian cancer patients correlate with poor prognostic parameters in ovarian cancer. *Anticancer Research*. 2011;31 (5):1987-8.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1371. Krohn S, Garin A, Gabay C, Proudfoot AE. The Activity of CCL18 is Principally Mediated through Interaction with Glycosaminoglycans. *Frontiers in Immunology*. 2013;4:193.
배제사유 : 동물실험 및 전임상시험연구

1372. Kroll M, Zurawski S, Gibb M, Su Q, Zurawski G, Iggyarto B. Novel cyclin D1-based DC vaccine inhibits TNBC tumor growth. *European Journal of Immunology*. 2018;48(Supplement 1):71.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1373. Kruckowski K, Eddy J, Janusek L, Mathews H. Role of histone acetylation and deacetylation in psychosocial distress mediated immune dysregulation. *Brain, Behavior, and Immunity*. 2011;25:S226.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1374. Kruckowski K, Eddy JL, Tell D, Janusek L, Mathews HL. Relationships between global epigenetic modifications and NK cell function in women with breast cancer. *Brain, Behavior, and Immunity*. 2012;26 (SUPPL.1):S19.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1375. Kubo M, Morisaki T, Katano M. Combination of chemotherapy and adoptive immunotherapy with herceptin for patients with HER2-overexpressing breast cancer. [Japanese]. *Biotherapy*. 2005;19(5):424-9.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1376. Kubo M, Morisaki T, Matsumoto K, Tasaki A, Yamanaka N, Nakashima H, et al. Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production. *Cancer Immunology, Immunotherapy*. 2005;54(5):468-76.
배제사유 : 동물실험 및 전임상시험연구
1377. Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, et al. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. *Cancer*. 2011;117(1):39-47.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1378. Kuhn S, Hyde EJ, Yang J, Rich FJ, Harper JL, Kirman JR, et al. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents. *Journal of Immunology*. 2013;191(4):1984-92.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1379. Kuiper M, Sanches R, Bignon YJ, Farzaneh F. B7.1 and Cytokines: Synergy in cancer gene therapy. *Advances in Experimental Medicine and Biology*. 2000;465:381-90.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1380. Kumar V, Sinha AK, Makkar HPS, Becker K. Dietary roles of phytate and phytase in human nutrition: A review. *Food Chemistry*. 2010;120(4):945-59.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1381. Kundu N, Beaty TL, Jackson MJ, Fulton AM. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. *Journal of the National Cancer Institute*. 1996;88(8):536-41.
배제사유 : 동물실험 및 전임상시험연구

1382. Kundu N, Ma X, Goloubeva O, Holt D, Kochel T, Fulton AM. A natural plant product to inhibit breast cancer metastasis. *Cancer Research*. Conference: 103rd Annual Meeting of the American Association for Cancer Research, AACR. 2012;72(8 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1383. Kundu N, Ma X, Holt D, Goloubeva O, Ostrand-Rosenberg S, Fulton AM. Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. *Breast Cancer Research and Treatment*. 2009;117(2):235-42.
배제사유 : 동물실험 및 전임상시험연구
1384. Kundu N, Walser TC, Ma X, Fulton AM. Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. *Cancer Immunology, Immunotherapy*. 2005;54(10):981-7.
배제사유 : 동물실험 및 전임상시험연구
1385. Kundu S, Sharma LK, Seth P. Prognostic value of killer cell activity & circulating immune complex levels in patients with breast cancer. *Indian Journal of Medical Research*. 1988;88:330-5.
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
1386. Kunnumakkara AB, Bordoloi D, Sailo BL, Roy NK, Thakur KK, Banik K, et al. Cancer drug development: the missing links. *Experimental biology and medicine*. 2019;244(8):663-89.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1387. Kuribayashi K, Kringsfeld G, Wang W, Xu J, Mayes PA, Dicker DT, et al. TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. *Cancer Biology and Therapy*. 2008;7(12):2034-8.
배제사유 : 동물실험 및 전임상시험연구
1388. Kuroda H, Tamaru J, Sakamoto G, Ohnisi K, Itoyama S. Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast. *Virchows Archiv*. 2005;446(1):10-4.
배제사유 : 동물실험 및 전임상시험연구
1389. Kurosawa S. Anesthesia in patients with cancer disorders. *Current Opinion in Anaesthesiology*. 2012;25(3):376-84.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1390. Kursunel MA, Esenagli G. The untold story of IFN-gamma in cancer biology. *Cytokine and Growth Factor Reviews*. 2016;31:73-81.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1391. Kusmartsev S, Vieweg J. Enhancing the efficacy of cancer vaccines in urologic oncology: New directions. *Nature Reviews Urology*. 2009;6(10):540-9.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1392. Kute T, Stehle JR, Jr., Ornelles D, Walker N, Delbono O, Vaughn JP. Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2

positive breast cancer cells. *Oncoimmunology*. 2012;1(6):810-21.

배제사유 : 동물실험 및 전임상시험연구

1393. Kute TE, Savage L, Stehle Jr JR, Kim-Shapiro JW, Blanks MJ, Wood J, et al. Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing. *Cancer Immunology, Immunotherapy*. 2009;58(11):1889-98.

배제사유 : 동물실험 및 전임상시험연구

1394. Kute TE, Savage L, Stehle JR, Jr., Kim-Shapiro JW, Blanks MJ, Wood J, et al. Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing. *Cancer Immunology, Immunotherapy*. 2009;58(11):1887-96.

배제사유 : 동물실험 및 전임상시험연구

1395. Kute TE, Stehle J, Ornelles D, Walker N, Vaughn J. Significance of ADCC for the action of trastuzumab quantified by novel procedures. *Cancer Research. Conference: 103rd Annual Meeting of the American Association for Cancer Research, AACR*. 2012;72(8 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1396. Kwak JY. Fucoidan as a marine anticancer agent in preclinical development. *Marine Drugs*. 2014;12(2):851-70.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1397. Kwan K, Falting L, Schneider JR, Boockvar JA. Local Immunotherapy for Malignancy: A Role for Brain Tumors? *Clinical Neurosurgery*. 2018;83(1):E5.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1398. Kzhyshkowska J, Mitrofanova I, Liu T, Zavyalova M, Litvyakov N, Buldakov M, et al. Modulation of the immune component of the tumor microenvironment: Perspectives for personalized cancer therapy. *EPMA Journal*. 2017;8 (1 Supplement 1):S11-S2.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1399. Lacour J, Lacour F, Spira A, Michelson M, Petit JY, Delage G, et al. Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: updated results of a randomised trial. *British Medical Journal Clinical Research Ed*. 1984;288(6417):589-92.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1400. Lacour J, Lacour F, Spira A. Adjuvant immunotherapy with polyadenylic-polyuridylic [Poly (A) - Poly (U)] acids in operable breast cancer. Results of a recent controlled therapeutic trial. [French]. *Chirurgie - Memoires de l'Academie de Chirurgie*. 1984;110(4):418-24.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1401. Lacour J. Clinical trials using polyadenylic-polyuridylic acid as an adjuvant to surgery in treating different human tumors. *Journal of Biological Response Modifiers*. 1985;4(5):538-43.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1402. Lafleur EA, Jia SF, Worth LL, Zhou Z, Owen-Schaub LB, Kleinerman ES. Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells. *Cancer Research*. 2001;61(10):4066-71.
배제사유 : 동물실험 및 전임상시험연구
1403. Laguna BA, Tucker ZCG, Delisser H, Singhal S. "Letting the Air In" Can set the stage for tumor recurrences. *Current Cancer Therapy Reviews*. 2012;8(4):293-303.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1404. Lalle M, Minelli M, Tarantini P, Marino M, Cerasoli V, Facciolo F, et al. Cellular and humoral immune alterations in thymectomized patients for thymoma. *Annals of Hematology*. 2009;88(9):847-53.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1405. Lam HY, Yusoff K, Yeap SK, Subramani T, Abd-Aziz S, Omar AR, et al. Immunomodulatory effects of newcastle disease virus AF2240 strain on human peripheral blood mononuclear cells. *International Journal of Medical Sciences*. 2014;11(12):1240-7.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1406. Lamas B, Nachat-Kappes R, Goncalves-Mendes N, Mishellany F, Rossary A, Vasson MP, et al. Dietary fat without body weight gain increases in vivo MCF-7 human breast cancer cell growth and decreases natural killer cell cytotoxicity. *Molecular Carcinogenesis*. 2015;54(1):58-71.
배제사유 : 동물실험 및 전임상시험연구
1407. Landa K, Holl E, Frazier V, Hwang ES, Nair S. Understanding the peripheral cellular immunome in patients with breast cancer. *Journal of Clinical Oncology. Conference*. 2019;37(Supplement 8).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1408. Landuzzi L, Nicoletti G, Palladini A, Ianzano M, Grossi V, Ranieri D, et al. Genetic ablation of lymphoma development in p53 knockout mice reveals a novel model of osteosarcoma and hemangiosarcoma. *Cancer Research. Conference: 104th Annual Meeting of the American Association for Cancer Research, AACR*. 2013;73(8 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1409. Lang I, Feuer L, Nekam K. Effect of treatment with glutaurine on human antibody-dependent cell-mediated cytotoxicity (ADCC). *Immunological Communications*. 1981;10(6):499-509.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1410. Lang K, Ratke J. Leptin and Adiponectin: New players in the field of tumor cell and leukocyte migration. *Cell Communication and Signaling*. 2009;7 (27).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1411. Langer Jacobus T, Nordmeier F, Schmidt RE, Jacobs R. Direct and antibody-dependent NK cell-mediated tumor killing is suppressed by MUC1 in vitro. *European Journal of Immunology*. 2017;47 (Supplement 2):239.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1412. Langsdorf C, Mandavilli B, Hu YZ, Chen A. Evaluating antibody-mediated cellular cytotoxicity and potency of antibody-drug conjugates within three-dimensional tumor models. *Journal for ImmunoTherapy of Cancer*. Conference: 33rd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2018;6(Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1413. Langsdorf C. Development of in vitro immune effector function assays to better approximate the in vivo behavior of biotherapeutics and cell therapies. *Journal for ImmunoTherapy of Cancer*. Conference: 34th Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2019;7(Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1414. Lankester AC, Ball LM, Lang P, Handgretinger R. Immunotherapy in the context of hematopoietic stem cell transplantation: The emerging role of natural killer cells and mesenchymal stromal cells. *Pediatric Clinics of North America*. 2010;57(1):97-121.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1415. Lapinski P, Franklin M, Draper D, Wise S. Treatment of murine mammary carcinoma with focal radiation and immune checkpoint inhibition results in reduced immune suppression and enhanced cytotoxic immune cell activity. *Journal for ImmunoTherapy of Cancer*. Conference: 34th Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2019;7(Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1416. Lapteva N, Aldrich M, Weksberg D, Rollins L, Goltsova T, Chen SY, et al. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. *Journal of Immunotherapy*. 2009;32(2):145-56.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

1417. Lara HH, Turrent LI, Garza-Trevino EN, Tamez-Guerra R, Rodriguez-Padilla C. Clinical and immunological assessment in breast cancer patients receiving anticancer therapy and bovine dialyzable leukocyte extract as an adjuvant. *Experimental & Therapeutic Medicine*. 2010;1(3):425-31.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1418. Larsen SK, Svane IM, Straten PT, Andersen MH. Therapeutic cancer vaccines. *Current Cancer Therapy Reviews*. 2010;6(2):163-74.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1419. Larson MR, Duberstein PR, Talbot NL, Caldwell C, Moynihan JA. A presurgical psychosocial intervention for breast cancer patients. psychological distress and the immune response. *Journal of Psychosomatic Research*. 2000;48(2):187-94.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1420. Lasek W, Zagozdzon R, Jakobisiak M. Interleukin 12: Still a promising candidate for tumor immunotherapy? *Cancer Immunology, Immunotherapy*. 2014;63(5):419-35.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1421. Laszlo J, Hood L, Cox E, Goodwin B. A randomized trial of low doses of alpha interferon in patients with breast cancer. *Journal of Biological Response Modifiers*. 1986;5(3):206-10.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1422. Lau BH. Phytotherapy boosts innate immunity to maximize cancer survival. *Cancer Research*. Conference: 107th Annual Meeting of the American Association for Cancer Research, AACR. 2016;76(14 Supplement).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1423. Lavado-Valenzuela R, Benavides M, Carabantes F, Alonso A, Caballero A. MHC class i chain-related gene A transmembrane polymorphism in Spanish women with breast cancer. *Tissue Antigens*. 2009;74(1):46-9.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1424. Lawry J, Rogers K, Duncan JL, Potter CW. The identification of informative parameters in the flow cytometric analysis of breast carcinoma. *European Journal of Cancer Part A: General Topics*. 1993;29(5):719-23.
배제사유 : 동물실험 및 전임상시험연구
1425. Lawson M, Vasilaras A, De Vries A, Mactaggart P, Nicol D. Urological implications of cyclophosphamide and ifosfamide. *Scandinavian Journal of Urology and Nephrology*. 2008;42(4):309-17.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1426. Lazarova M, Steinle A. Impairment of NKG2D-Mediated Tumor Immunity by TGF-beta. *Frontiers in Immunology*. 2019;10 (2689).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1427. Le Buanc H, Bensussan A, Bagot M, Gallo RC, Zagury D. Active and Passive Anticytokine Immune Therapies: Current Status and Development. *Advances in Immunology*. 2012;115:187-227.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1428. Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: A current perspective. *Cancer Research*. 2012;72(14):3439-44.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1429. Le QT, Shirato H, Giaccia AJ, Koong AC. Emerging treatment paradigms in radiation oncology. *Clinical Cancer Research*. 2015;21(15):3393-401.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1430. Leclercq G. Natural anti-estrogen receptor alpha antibodies able to induce estrogenic responses in breast cancer cells: Hypotheses concerning their mechanisms of action and emergence. *International Journal of Molecular Sciences*. 2018;19 (2) (411).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1431. Lee BN, Gao H, Cohen EN, Andreopoulou E, Jackson SA, Parker C, et al. Patients with inflammatory breast cancer have significant reductions in immune cells responsible for

adaptive immunity. Cancer Research. Conference: 101st Annual Meeting of the American Association for Cancer Research, AACR. 2010;70(8 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1432. Lee HH, Cho H. A blockade of IL-6 released from human breast carcinoma MDA-MB-231 in presence of NK-92 inhibits an invasion of breast carcinoma. FASEB Journal. Conference: Experimental Biology. 2018;32(1 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1433. Lee HH, Cho H. Attenuated anti-tumor activity of NK-92 cells by invasive human breast carcinoma MDA-MB-231 cells. Molecular and Cellular Toxicology. 2020;16(2):139-47.

배제사유 : 동물실험 및 전임상시험연구

1434. Lee HH, Cho H. Improved Anti-Cancer Effect of Curcumin on Breast Cancer Cells by Increasing the Activity of Natural Killer Cells. Journal of Microbiology & Biotechnology. 2018;28(6):874-82.

배제사유 : 동물실험 및 전임상시험연구

1435. Lee HW, Jeon YH, Lee SW, Jeong SY, Ha JH, Rehemtulla A, et al. Real time monitoring of apoptosis mediated by natural killer (NK) cells against cancer using a caspase 3 sensor in vitro. Molecular Imaging and Biology. 2012;1):S1159.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1436. Lee HW, Singh TD, Lee SW, Ha JH, Rehemtulla A, Ahn BC, et al. Evaluation of therapeutic effects of natural killer (NK) cell-based immunotherapy in mice using in vivo apoptosis bioimaging with a caspase-3 sensor. FASEB Journal. 2014;28(7):2932-41.

배제사유 : 동물실험 및 전임상시험연구

1437. Lee J, Gu N, Lee S, Lee Y, Hyun B. Cytotoxic effects of canine nk cells on canine mammary tumor cells. Cytotherapy. 2020;22 (5 Supplement):S128.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1438. Lee J, Kang HA, Bae JS, Kim KD, Lee KH, Lim KJ, et al. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses. mAbs. 2018;10(4):547-71.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1439. Lee JS, Park MH, Yoon JH. High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma. Cancer Research. Conference: 34th Annual CTRC AACR San Antonio Breast Cancer Symposium. San Antonio, TX United States. Conference Publication:. 2011;71(24 SUPPL. 3).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1440. Lee S, Han S, Jeong AL, Park JS, Jung SH, Choi KD, et al. Combined treatment of herbal mixture extract H9 with trastuzumab enhances anti-tumor growth effect. Journal of Microbiology and Biotechnology. 2015;25(7):1036-46.

배제사유 : 동물실험 및 전임상시험연구

1441. Lee S, Son B, Park G, Kim H, Kang H, Jeon J, et al. Immunogenic effect of hyperthermia on enhancing radiotherapeutic efficacy. International Journal of Molecular Sciences. 2018;19 (9) (2795).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1442. Lee SC, Chin SY, Shimasaki N, Tan LK, Koh LP, Lieow JJM, et al. Phase Ib/II trial of expanded and activated autologous natural killer (NK) cells with trastuzumab (Tras) in refractory HER2+ metastatic breast cancer (MBC). Journal of Clinical Oncology. Conference. 2016;34(Supplement 15).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1443. Lee SC, Srivastava RM, Lopez-Albaitero A, Ferrone S, Ferris RL. Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunologic Research. 2011;50(2-3):248-54.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1444. Lee SC, Xu X, Lim YW, Iau P, Sukri N, Lim SE, et al. Chemotherapy-induced tumor gene expression changes in human breast cancers. Pharmacogenetics and Genomics. 2009;19(3):181-92.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1445. Lee SS, Cheah YK. The interplay between microRNAs and cellular components of tumour microenvironment (TME) on non-small-cell lung cancer (NSCLC) progression. Journal of Immunology Research. 2019;2019 (3046379).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1446. Lefebvre S, Antoine M, Uzan S, McMaster M, Dausset J, Carosella ED, et al. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. Journal of Pathology. 2002;196(3):266-74.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1447. Legut M, Cole DK, Sewell AK. The promise of gammadeltaT cells and the gammadeltaT cell receptor for cancer immunotherapy. Cellular and Molecular Immunology. 2015;12(6):656-8.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1448. Lei X, Lei Y, Li JK, Du WX, Li RG, Yang J, et al. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Letters. 2020;470:126-33.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1449. Leischner C, Burkard M, Pfeiffer MM, Lauer UM, Busch C, Venturelli S. Nutritional immunology: Function of natural killer cells and their modulation by resveratrol for cancer prevention and treatment. Nutrition Journal. 2016;15 (1) (47).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1450. Lekander M, Furst C, Rotstein S, Blomgren H, Fredrikson M. Does informed adjuvant placebo chemotherapy for breast-cancer elicit immune changes. Oncology Reports.

1994;1(4):699-703.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

1451. Lemon HM, Rodriguez-Sierra JF, Vollmer RT, Chung M, Chang HR, Wanebo HJ, et al. Younger women with breast carcinoma have a poorer prognosis than older women [3]. *Cancer*. 1996;78(7):1517-8.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1452. Lemon HM, Rodriguez-Sierra JF. Timing of breast cancer surgery during the luteal menstrual phase may improve prognosis. *Nebraska Medical Journal*. 1996;81(3):73-8.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1453. Lengacher CA, Bennett MP, Gonzalez L, Gilvary D, Cox CE, Cantor A, et al. Immune responses to guided imagery during breast cancer treatment. *Biological Research for Nursing*. 2008;9(3):205-14.

배제사유 : 동물실험 및 전임상시험연구

1454. Lengacher CA, Kip KE, Post-White J, Fitzgerald S, Newton C, Barta M, et al. Lymphocyte recovery after breast cancer treatment and mindfulness-based stress reduction (MBSR) therapy. *Biological Research for Nursing*. 2013;15(1):37-47.

배제사유 : 동물실험 및 전임상시험연구

1455. Lennon FE, Moss J, Singleton PA. The mu-opioid receptor in cancer progression: Is there a direct effect? *Anesthesiology*. 2012;116(4):940-5.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1456. Lenzhofer R, Micksche M, Dittrich C. Recombinant human IFN alpha 2 (rHu-IFN-Alpha 2) in advanced breast cancer. *Drugs under Experimental and Clinical Research*. 1984;10(7):463-70.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

1457. Leonardo SM, Fulton RB, Gorden KB, Fraser K, Harrison B, Kangas T, et al. Imprime PGG, a beta-glucan PAMP (pathogen-associated molecular pattern) activates the direct killing functions of innate immune cells in concert with tumor targeting antibodies. *Cancer Research. Conference: 107th Annual Meeting of the American Association for Cancer Research, AACR*. 2016;76(14 Supplement).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1458. Leone K, Poggiana C, Zamarchi R. The interplay between circulating tumor cells and the immune system: From immune escape to cancer immunotherapy. *Diagnostics*. 2018;8 (3) (59).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1459. Leong PP, Mohammad R, Ibrahim N, Ithnin H, Abdullah M, Davis WC, et al. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. *Immunology Letters*. 2006;102(2):229-36.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1460. Leroi N, Sounni NE, Van Overmeire E, Blacher S, Maree R, Van Ginderachter J, et al. The timing of surgery after neoadjuvant radiotherapy influences tumor dissemination in a preclinical model. *Oncotarget*. 2015;6(34):36825-37.
배제사유 : 동물실험 및 전임상시험연구
1461. Lesinski GB, Carson WE, Repasky EA, Wei WZ, Kalinski P, Lotze MT, et al. Meeting report: The 13th annual meeting of the translational research cancer centers consortium (trc3); Immune suppression and the tumor microenvironment, Columbus, Ohio: March 1-2, 2010. *Journal of Immunotherapy*. 2010;33(7):659-62.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1462. Levine KM, Du T, Zhu L, Tasdemir N, Lee AV, Van Houten B, et al. Invasive lobular carcinoma and invasive ductal carcinoma differ in immune response, translation efficiency and metabolic rate. *Cancer Research Conference: San Antonio Breast Cancer Symposium, SABCS*. 2017;78(4 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1463. Levine PH, Fears TR, Cummings P, Hoover RN. Cancer and a fatiguing illness in northern Nevada - A causal hypothesis. *Annals of Epidemiology*. 1998;8(4):245-9.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1464. Levins KJ, Prendeville S, Conlon S, Buggy DJ. The effect of anesthetic technique on micro-opioid receptor expression and immune cell infiltration in breast cancer. *Journal of Anesthesia*. 2018;32(6):792-6.
배제사유 : 동물실험 및 전임상시험연구
1465. Levy N, Paruthiyil S, Zhao X, Vivar OI, Saunier EF, Griffin C, et al. Unliganded estrogen receptor-beta regulation of genes is inhibited by tamoxifen. *Molecular & Cellular Endocrinology*. 2010;315(1-2):201-7.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1466. Levy S, Herberman R, Lippman M, d'Angelo T. Correlation of stress factors with sustained depression of natural killer cell activity and predicted prognosis in patients with breast cancer. *Journal of Clinical Oncology*. 1987;5(3):348-53.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1467. Levy S, Herberman R. CNS-mediated and tumor burden-related factors in the modulation of breast cancer patients' natural killer cell activity. *Proceedings of the american society of clinical oncology*. 1986;5:235, Abstract 919.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1468. Levy SM, Herberman RB, Lee J, Whiteside T, Kirkwood J, McFeeley S. Estrogen receptor concentration and social factors as predictors of natural killer cell activity in early-stage breast cancer patients. Confirmation of a model. *Natural Immunity & Cell Growth Regulation*. 1990;9(5):313-24.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

1469. Levy SM, Herberman RB, Lippman M, D'Angelo T, Lee J. Immunological and psychosocial predictors of disease recurrence in patients with early-stage breast cancer. *Behavioral Medicine*. 1991;17(2):67-75.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1470. Levy SM, Herberman RB, Maluish AM, Schlien B, Lippman M. Prognostic risk assessment in primary breast cancer by behavioral and immunological parameters. *Health Psychology*. 1985;4(2):99-113.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1471. Levy SM, Herberman RB, Whiteside T, Sanzo K, Lee J, Kirkwood J. Perceived social support and tumor estrogen/progesterone receptor status as predictors of natural killer cell activity in breast cancer patients. *Psychosomatic Medicine*. 1990;52(1):73-85.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1472. Lew E, Walsh C, Martin E, Albert A, Li GG, Yokoyama Y. Immuno-oncologic efficacy of RXDX-106, a selective, TAM family small molecule kinase inhibitor. *European Journal of Cancer*. 2016;69 (Supplement 1):S31.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1473. Lewin N. Adjuvant radiation therapy effects systemic immune response cells in female breast cancer patients. *Annals of Oncology*. 2018;29 (Supplement 3):iii26.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1474. Li A, Xing J, Li L, Zhou C, Dong B, He P, et al. A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells. *AMB Express*. 2016;6 (1) (32).
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1475. Li D, Masiero M, Banham AH, Harris AL. The Notch ligand Jagged1 as a target for 1 anti-tumour therapy. *Frontiers in Oncology*. 2014;4 (SEP) (254).
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1476. Li DW. Editorial. *Current Molecular Medicine*. 2012;12(2):111-2.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1477. Li H, Cao MY, Lee Y, Benatar T, Lee V, Feng N, et al. Virulizin, a novel immunotherapy agent, stimulates TNFalpha expression in monocytes/macrophages in vitro and in vivo. *International Immunopharmacology*. 2007;7(10):1350-9.
배제사유 : 동물실험 및 전임상시험연구
1478. Li H, Cao MY, Lee Y, Lee V, Feng N, Benatar T, et al. Virulizin, a novel immunotherapy agent, activates NK cells through induction of IL-12 expression in macrophages. *Cancer Immunology, Immunotherapy*. 2005;54(11):1115-26.
배제사유 : 동물실험 및 전임상시험연구
1479. Li HF, Yang YH, Shi YJ, Wang YQ, Zhu P. Cytokine-induced killer cells showing

multidrug resistance and remaining cytotoxic activity to tumor cells after transfected with mdr1 cDNA. Chinese Medical Journal. 2004;117(9):1348-52.

배제사유 : 동물실험 및 전임상시험연구

1480. Li HX. The role of circadian clock genes in tumors. OncoTargets and Therapy. 2019;12:3645-60.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1481. Li J, Sun D, Wang R, Wang F. The in vitro immunomodulatory and anti-tumor activity of Thymosin alpha1-thymopentin fusion peptide. Latin American Journal of Pharmacy. 2016;35(7):1559-66.

배제사유 : 동물실험 및 전임상시험연구

1482. Li J, Zhu Z. Research and development of next generation of antibody-based therapeutics. Acta Pharmacologica Sinica. 2010;31(9):1198-207.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1483. Li L, Li M, Wang X. Cancer type-dependent correlations between TP53 mutations and antitumor immunity. DNA Repair. 2020;88 (102785).

배제사유 : 동물실험 및 전임상시험연구

1484. Li L, Wang Q, Fu P, Wang Z, Chen R. Effect of citalopram combined with psychological intervention on mental health status and cellular immunity in breast cancer patients. [Chinesel]. Journal of Practical Oncology. 2019;34(3):257-60.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1485. Li M, Zheng H, Duan Z, Liu H, Hu D, Bode A, et al. Promotion of cell proliferation and inhibition of ADCC by cancerous immunoglobulin expressed in cancer cell lines. Cellular & Molecular Immunology. 2012;9(1):54-61.

배제사유 : 동물실험 및 전임상시험연구

1486. Li O, Khan S, Mendoza N, Vanegas S, Tran C, Mirza A. A novel TGFbeta 1/2 specific antibody suppresses 4T1 tumor growth by enhancing NK cell recruitment and function. Cancer Research. Conference: 105th Annual Meeting of the American Association for Cancer Research, AACR. 2014;74(19 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1487. Li R, Liu H, Dilger JP, Lin J. Effect of Propofol on breast Cancer cell, the immune system, and patient outcome. BMC Anesthesiology. 2018;18(1):77.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1488. Li S, Nishikawa T, Kaneda Y. Inactivated Sendai virus particle upregulates cancer cell expression of intercellular adhesion molecule-1 and enhances natural killer cell sensitivity on cancer cells. Cancer Science. 2017;108(12):2333-41.

배제사유 : 동물실험 및 전임상시험연구

1489. Li S. IL-12-Based therapy of malignancies. Drugs of Today. 2001;37(9):629-37.

배제사유 : 동물실험 및 전임상시험연구

1490. Li X, Min M, Du N, Gu Y, Hode T, Naylor M, et al. Chitin, chitosan, and glycated

chitosan regulate immune responses: The novel adjuvants for cancer vaccine. Clinical and Developmental Immunology. 2013;2013 (387023).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1491. Li X, Wang R, Fan P, Yao X, Qin L, Peng Y, et al. A comprehensive analysis of key immune checkpoint receptors on tumor-infiltrating t cells from multiple types of cancer. Frontiers in Oncology. 2019;9 (OCT) (1066).

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1492. Li Y, Chang CW, Fasso M, O'Hear C, Hegde PS, Molinero L. Baseline blood lymphocytes are associated with improved clinical outcome in atezolizumab-treated patients across multiple indications. Cancer Research. Conference. 2018;78(13 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1493. Li Y, Han N, Chen Z, Li X. Systematic review and meta-analysis of shenqi fuzheng and chemotherapy combination in the treatment of breast cancer. Bangladesh Journal of Pharmacology. 2016;11(4):793-801.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1494. Li YR, Gupta P. Immune aspects of the bi-directional neuroimmune facilitator TRPV1. Molecular Biology Reports. 2019;46(1):1499-510.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1495. Li Z. Potential of human gammadelta T cells for immunotherapy of osteosarcoma. Molecular Biology Reports. 2013;40(1):427-37.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1496. Li ZP, Yang Y, Jia CL, Zhang RL, Zhang Y, Bao YX. Clinical efficacy and safety of DC-CIK combined with chemotherapy for the advanced breast cancer: a Meta analysis. Chinese journal of cancer prevention and treatment. 2017;24(10):714?9 and 24.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1497. Liang S, Niu L, Xu K, Wang X, Liang Y, Zhang M, et al. Tumor cryoablation in combination with natural killer cells therapy and Herceptin in patients with HER2-overexpressing recurrent breast cancer. Molecular Immunology. 2017;92:45-53.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1498. Liang S, Xu K, Niu L, Wang X, Liang Y, Zhang M, et al. Comparison of autogeneic and allogeneic natural killer cells immunotherapy on the clinical outcome of recurrent breast cancer. Oncotargets and therapy. 2017;10(pp 4273?4281).

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1499. Liao B, Kamiya-Matsuoka C, Gong Y, Chen M, Wolf BA, Fowler NH. Primary natural killer/T-cell lymphoma presenting as leptomeningeal disease. Journal of the Neurological Sciences. 2014;343(1-2):46-50.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

1500. Lichtenstein A, Berenson J, Gera JF, Waldburger K, Martinez-Maza O, Berek JS. Resistance of human ovarian cancer cells to tumor necrosis factor and

lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes. *Cancer Research*. 1990;50(22):7364-70.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1501. Lichtor T, Glick RP, Feldman LA, Osawa G, Hardman J, I OS, et al. Enhanced immunity to intracerebral breast cancer in mice immunized with a cDNA-based vaccine enriched for immunotherapeutic cells. *Journal of Immunotherapy*. 2008;31(1):18-27.

배제사유 : 동물실험 및 전임상시험연구

1502. Lichtor T, Glick RP, I.S OS, Cohen EP. Antigenic differences between normal and malignant cells as a basis for treatment of intracerebral neoplasms using a DNA-based vaccine. *Current Genomics*. 2006;7(4):253-61.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1503. Lichtor T, Glick RP. Cytokine immuno-gene therapy for treatment of brain tumors. *Journal of Neuro-Oncology*. 2003;65(3):247-59.

배제사유 : 동물실험 및 전임상시험연구

1504. Lichtor T, Glick RP. Immunogene therapy. *Advances in Experimental Medicine & Biology*. 2012;746:151-65.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1505. Lichtor T. Treatment of brain tumors using DNA-based vaccines. *Open Cancer Immunology Journal*. 2010;3:23-9.

배제사유 : 동물실험 및 전임상시험연구

1506. Liebermann HEH, Sietmann R, Bange R, Wazel W, Riebe R. RiV particles are heat stable. *Engineering in Life Sciences*. 2005;5(3):240-6.

배제사유 : 동물실험 및 전임상시험연구

1507. Liikanen I, Tahtinen S, Guse K, Gutmann T, Savola P, Oksanen M, et al. Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer. *Molecular Cancer Therapeutics*. 2016;15(9):2259-69.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1508. Lim JA, Oh CS, Yoon TG, Lee JY, Lee SH, Yoo YB, et al. The effect of propofol and sevoflurane on cancer cell, natural killer cell, and cytotoxic T lymphocyte function in patients undergoing breast cancer surgery: an in vitro analysis. *BMC Cancer*. 2018;18(1):159.

배제사유 : 동물실험 및 전임상시험연구

1509. Lim JKH, Telisinghe PU, Abdullah HMS, Ramasamy R. Tumour infiltrating immune cells in medullary carcinoma of the breast. *European Journal of Immunology*. 2009;1):S730.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1510. Lima LG, Monteiro RQ. Activation of blood coagulation in cancer: Implications for tumour progression. *Bioscience Reports*. 2013;33(5):701-10.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1511. Lima M, Goncalves C, Dos Anjos Teixeira M, Franca M, Canelhas A, Pina R, et al.

Aggressive natural-killer cell lymphoma presenting with skin lesions, breast nodule, suprarenal masses and life-threatening pericardial and pleural effusions. Leukemia and Lymphoma. 2001;42(6):1385-91.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1512. Limaye A, Bassiouni R, Oyer J, Igarashi RW, Flores O, Perez JM, et al. Use of a cytotoxic peptide that induces immunogenic cell death to engage innate immunity in the treatment of metastatic breast cancer. Cancer Immunology Research. Conference: AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter. United States. 2015;3(10 Supplement).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1513. Lin C, Zhang J. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell. Biochimica et Biophysica Acta - Reviews on Cancer. 2018;1869(2):200-15.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1514. Lin Y, Qi X, Liu H, Xue K, Xu S, Tian Z. The anti-cancer effects of fucoidan: A review of both in vivo and in vitro investigations. Cancer Cell International. 2020;20 (1) (154).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1515. Linares I, Berenguer MA, Martinez E, Laplana M, Canas R, Comas S, et al. INTRABEAM: precision hypo-fractionated radiotherapy with a systemic immune response. Radiotherapy and Oncology. 2019;133 (Supplement 1):S596.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1516. Linch SN, Kasiewicz MJ, McNamara MJ, Hilgart-Martiszus IF, Farhad M, Redmond WL. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice. Proceedings of the National Academy of Sciences of the United States of America. 2016;113(3):E319-E27.

배제사유 : 동물실험 및 전임상시험연구

1517. Lind DS. Arginine and cancer. Journal of Nutrition. 2004;134(10 SUPPL.):2837S-41S.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1518. Lindemalm C, Mozaffari F, Choudhury A, Granstrom-Bjorneklett H, Lekander M, Nilsson B, et al. Immune response, depression and fatigue in relation to support intervention in mammary cancer patients. Supportive Care in Cancer. 2008;16(1):57-65.

배제사유 : 동물실험 및 전임상시험연구

1519. Lindeman GJ, Visvader JE. Insights into the cell of origin in breast cancer and breast cancer stem cells. Asia-Pacific Journal of Clinical Oncology. 2010;6(2):89-97.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1520. Linsley PS, Chaussabel D, Speake C. The relationship of immune cell signatures to patient survival varies within and between tumor types. PLoS ONE. 2015;10 (9) (e0138726).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1521. Lion E, Smits ELJM, Berneman ZN, Van Tendeloo VFI. NK Cells: Key to success of DC-based cancer vaccines? *Oncologist*. 2012;17(10):1256-70.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1522. Lipinski B. Mechanism of resistance of cancer cells to immune recognition and destruction. *International Journal of Thymology*. 1997;5(8-9):465-73.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1523. Lissoni P, Barni S, Ardizzoia A, Fossati V, Paolorossi F, Tancini G. Weekly epirubicin plus low-dose interleukin-2 subcutaneous therapy in breast cancer: preliminary immunobiological results. *Journal of Biological Regulators & Homeostatic Agents*. 1994;8(2):53-5.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1524. Lister J, Rybka WB, Donnenberg AD, deMagalhaes-Silverman M, Pincus SM, Bloom EJ, et al. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period. *Clinical Cancer Research*. 1995;1(6):607-14.
배제사유 : 동물실험 및 전임상시험연구
1525. Listinsky JJ, Siegal GP, Listinsky CM. Conventional trastuzumab is an antagonist of natural killer cells: Making the case for fucose-depleted trastuzumab. *Cancer Research Conference: 34th Annual CTRC AACR San Antonio Breast Cancer Symposium*. San Antonio, TX United States. Conference Publication: 2011;71(24 SUPPL. 3).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1526. Listinsky JJ, Siegal GP, Listinsky CM. Glycoengineering in cancer therapeutics: a review with fucose-depleted trastuzumab as the model. *Anti-Cancer Drugs*. 2013;24(3):219-27.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1527. Liu B, Qu L, Yan S. Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. *Cancer Cell International*. 2015;15 (1) (106).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1528. Liu C, Gao H, Lv P, Liu J, Liu G. Extracellular vesicles as an efficient nanoplatform for the delivery of therapeutics. *Human Vaccines and Immunotherapeutics*. 2017;13(11):2678-87.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1529. Liu C, Wang W, Meng X, Sun B, Cong Y, Liu J, et al. Albumin/globulin ratio is negatively correlated with PD-1 and CD25 mRNA levels in breast cancer patients. *OncoTargets and therapy*. 2018;11:2131-9.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1530. Liu D, Tian S, Zhang K, Xiong W, Lubaki NM, Chen Z, et al. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV. *Protein and Cell*. 2017;8(12):861-77.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1531. Liu F, Zheng BR, Lei J, Wang YG, Wang L, Chen Y, et al. Effect of high frequency hyperthermia on the expression of NKG2D ligand in human tumor cell line. [Chinese]. Chinese Journal of Cancer Prevention and Treatment. 2013;20(11):825-9.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1532. Liu G, Guo M, Liu X, Huang N, Li D, Jiang Z, et al. Effective modulation of CD4+CD25+high regulatory T and NK cells in malignant patients by combination of interferon-alpha and interleukin-2. Cancer Immunology, Immunotherapy. 2012;61(12):2357-66.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1533. Liu H, Liu Y, Song Y, Hu B. IL-23 promotes the development of hepatocellular carcinoma through the induction of IL-17producing ILC3 (TUM10P.1044). Journal of Immunology. Conference: 102nd Annual Meeting of the American Association of Immunologists, IMMUNOLOGY. 2015;194(1 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1534. Liu H, Yang B, Sun T, Lin L, Hu Y, Deng M, et al. Specific growth inhibition of ErbB2-expressing human breast cancer cells by genetically modified NK-92 cells. Oncology Reports. 2015;33(1):95-102.
배제사유 : 동물실험 및 전임상시험연구
1535. Liu JT, Yue J, Ren XB, Li H. [Measurement of CD4+CD25+ T cells in breast cancer patients and its significance]. Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]. 2005;27(7):423-5.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1536. Liu LL, Smith MJ, Sun BS, Wang GJ, Redmond HP, Wang JH. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model. Annals of Surgical Oncology. 2009;16(5):1403-11.
배제사유 : 동물실험 및 전임상시험연구
1537. Liu M, Wang H, Liu L, Wang B, Sun G. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy. Journal of Translational Medicine. 2016;14(1):155.
배제사유 : 동물실험 및 전임상시험연구
1538. Liu P, Cao Y, Qiao X. [Clinical study on shenmai injection in promoting postoperative recovery in patients of breast cancer]. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi/Chinese Journal of Integrated Traditional & Western Medicine/Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban. 2000;20(5):328-9.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1539. Liu SL, Qi W, Li H, Wang YF, Yang XF, Li ZM, et al. Recent advances in massage therapy - A review. European Review for Medical and Pharmacological Sciences. 2015;19(20):3843-9.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1540. Liu X, Ran R, Shao B, Rugo HS, Yang Y, Hu Z, et al. Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer. *Chinese Journal of Cancer Research.* 2018;30(3):315-26.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1541. Liu Y, Guo J, Huang L. Modulation of tumor microenvironment for immunotherapy: Focus on nanomaterial-based strategies. *Theranostics.* 2020;10(7):3099-117.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1542. Liu Y, Zhang C. The role of human gammadelta t cells in anti-tumor immunity and their potential for cancer immunotherapy. *Cells.* 2020;9 (5) (1206).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1543. Liu Y, Zhou Y, Huang KH, Fang X, Li Y, Wang F, et al. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor. *Cell Proliferation.* 2020:e12858.
배제사유 : 동물실험 및 전임상시험연구
1544. Liu Z, Zhang Q, Peng H, Zhang WZ. Animal lectins: Potential antitumor therapeutic targets in apoptosis. *Applied Biochemistry and Biotechnology.* 2012;168(3):629-37.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1545. Liveringham CL, Grass GD, Figura NB, Mills MN, Purcell JD, Rosensweig SR, et al. Locoregional recurrence in invasive breast cancer and association with tumor infiltrating leukocyte (TIL) presence. *Cancer Research. Conference.* 2018;79(4 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1546. Lizee G, Radvanyi LG, Overwijk WW, Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. *Clinical Cancer Research.* 2006;12(16):4794-803.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1547. Ljubic B, Milovanovic M, Volarevic V, Murray B, Bugarski D, Przyborski S, et al. Human mesenchymal stem cells creating an immunosuppressive environment and promote breast cancer in mice. *Scientific Reports.* 2013;3:2298.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1548. Llewellyn RA, Gutknecht MF, Thomas KS, Conaway MR, Bouton AH. Focal adhesion kinase (FAK) deficiency in mononuclear phagocytes alters murine breast tumor progression. *American Journal of Cancer Research.* 2018;8(4):675-87.
배제사유 : 동물실험 및 전임상시험연구
1549. Lo A, Alkan S, Huang Q. GATA-3 expression in T/NK cell neoplasms determined by immunohistochemistry. *Laboratory Investigation.* 2016;1):359A-60A.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1550. Lo AKF, Dawson CW, Jin DY, Lo KW. The pathological roles of BART miRNAs in nasopharyngeal carcinoma. *Journal of Pathology*. 2012;227(4):392-403.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1551. Logan RW, Sarkar DK. Circadian nature of immune function. *Molecular and Cellular Endocrinology*. 2012;349(1):82-90.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1552. Loi M, Desideri I, Greto D, Mangoni M, Sottilli M, Meattini I, et al. Radiotherapy in the age of cancer immunology: Current concepts and future developments. *Critical Reviews in Oncology/Hematology*. 2017;112:1-10.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1553. Lokody I. Signalling: Loss of Cbl-b unleashes anti-metastatic natural killer cells. *Nature Reviews Cancer*. 2014;14(4):218.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1554. Lollini PL, Bosco MC, Cavallo F, De Giovanni C, Giovarelli M, Landuzzi L, et al. Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. *International Journal of Cancer*. 1993;55(2):320-9.
배제사유 : 동물실험 및 전임상시험연구
1555. Lollini PL, Nicoletti G, Ianzano M, Croci S, Grosso V, Palladini A, et al. Multioragan metastasis of human HER-2+ breast cancer in immunodeficient mice. *Cancer Research Conference: 103rd Annual Meeting of the American Association for Cancer Research, AACR*. 2012;72(8 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1556. Lollini PL, Nicoletti G, Landuzzi L, Cavallo F, Forni G, de Giovanni C, et al. Vaccines and other immunological approaches for cancer immunoprevention. *Current Drug Targets*. 2011;12(13):1957-73.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1557. Lombardi VRM, Lombardi C, Cacabelos R. Nutrition, immune system activation and anti-cancer strategies in animals and humans. *Current Topics in Pharmacology*. 2008;12(2):1-30.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1558. Lonez C, Hendlisz A, Shaza L, Aftimos P, Vouche M, Donckier V, et al. Celyad's novel CAR T-cell therapy for solid malignancies. *Current Research in Translational Medicine*. 2018;66(2):53-6.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1559. Long X, Gong X. Study of immune function and psychological intervention on patients with malignant tumor after radiotherapy. *Biomedical Research (India)*. 2017;28(5):2375-8.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1560. Long Y, Gao Z, Hu X, Xiang F, Wu Z, Zhang J, et al. Downregulation of MCT4 for

lactate exchange promotes the cytotoxicity of NK cells in breast carcinoma. *Cancer Medicine*. 2018;7(9):4690-700.

배제사유 : 동물실험 및 전임상시험연구

1561. Lopez DM, Handel-Fernandez ME, Cheng X, Charyulu V, Herbert LM, Dinapoli MR, et al. Cytokine production by lymphoreticular cells from mammary tumor bearing mice: The role of tumor-derived factors. *Anticancer Research*. 1996;16(6 C):3923-9.

배제사유 : 동물실험 및 전임상시험연구

1562. Lopez-Gonzalez J, Morales-Estevez C, Alberti-Vargas F, De La Haba-Rodriguez J, Gonzalez-Fernandez R, Cano MT, et al. Analysis of the HLA-I genotypes in patients with solid tumours who were treated with anti-HER therapy. *Journal of Clinical Oncology. Conference*. 2016;34(Supplement 15).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1563. Lopez-Larrea C, Suarez-Alvarez B, Lopez-Soto A, Lopez-Vazquez A, Gonzalez S. The NKG2D receptor: sensing stressed cells. *Trends in Molecular Medicine*. 2008;14(4):179-89.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1564. Lorenzen J, Lewis CE, McCracken D, Horak E, Greenall M, McGee JO. Human tumour-associated NK cells secrete increased amounts of interferon-gamma and interleukin-4. *British Journal of Cancer*. 1991;64(3):457-62.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

1565. Lorenzo-Herrero S, Lopez-Soto A, Sordo-Bahamonde C, Gonzalez-Rodriguez AP, Vitale M, Gonzalez S. NK cell-based immunotherapy in cancer metastasis. *Cancers*. 2019;11(1) (29).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1566. Loriger M, Andreou T, Fife C, James F. Immune Checkpoint Blockade - How Does It Work in Brain Metastases? *Frontiers in Molecular Neuroscience*. 2019;12 (282).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1567. Lotha R, Sivasubramanian A. Flavonoids nutraceuticals in prevention and treatment of cancer: A review. *Asian Journal of Pharmaceutical and Clinical Research*. 2018;11(1):42-7.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1568. Lotze MT, Papamichail M. A primer on cancer immunology and immunotherapy. *Cancer Immunology, Immunotherapy*. 2004;53(3):135-8.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1569. Lotze MT, Wang E, Marincola FM, Hanna N, Bugelski PJ, Burns CA, et al. Workshop on cancer biometrics: Identifying biomarkers and surrogates of cancer in patients - A meeting held at the masur auditorium, national institutes of health. *Journal of Immunotherapy*. 2005;28(2):79-119.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1570. Loumagne L, Baudhuin J, Favier B, Carosella ED, Rouas-Freiss N. Role of the HLA-G

non-classical MHC class I molecule in tumor escape from immunosurveillance. *Tissue Antigens.* 2012;80 (1):94.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1571. Lover RR. Antiestrogens as chemopreventive agents in breast cancer: Promise and issues in evaluation. *Preventive Medicine.* 1989;18(5):661-71.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1572. Lowenfeld L, Xu S, Czerniecki BJ. CD4+ Th1 to the rescue in HER-2+ breast cancer. *OncoImmunology.* 2019;8 (10) (e1078062).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1573. Lu H, Gad E, Yang Y, Chang A, Disis ML. Antitumor immunity induced by toll-like receptor-7 ligation is limited by inflammation-induced immunosuppression but can be restored through interleukin-10 blockade. *Journal of Immunotherapy.* 2009;32 (9):998.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1574. Lu H, Yang Y, Gad E, Inatsuka C, Wenner CA, Disis ML, et al. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. *Clinical Cancer Research.* 2011;17(21):6742-53.

배제사유 : 동물실험 및 전임상시험연구

1575. Lu H, Yang Y, Gad E, Wenner CA, Chang A, Larson ER, et al. Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. *Clinical Cancer Research.* 2011;17(1):67-76.

배제사유 : 동물실험 및 전임상시험연구

1576. Lu P, Zhu XQ, Xu ZL, Zhou Q, Zhang J, Wu F. Increased infiltration of activated tumor-infiltrating lymphocytes after high intensity focused ultrasound ablation of human breast cancer. *Surgery.* 2009;145(3):286-93.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1577. Lucero MA, Fridman WH, Provost MA, Billardon C, Pouillart P, Dumont J, et al. Effect of various interferons on the spontaneous cytotoxicity exerted by lymphocytes from normal and tumor-bearing patients. *Cancer Research.* 1981;41(1):294-9.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

1578. Lucia A, Ramirez M. Muscling in on cancer. *New England Journal of Medicine.* 2016;375(9):892-4.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1579. Luedke E, Jaime-Ramirez AC, Bhave N, Carson IWE. Monoclonal antibody therapy of pancreatic cancer with cetuximab: Potential for immune modulation. *Journal of Immunotherapy.* 2012;35(5):367-73.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1580. Lukac J, Kusic Z, Kordic D, Koncar M, Bolanca A. Natural killer cell activity, phagocytosis, and number of peripheral blood cells in breast cancer patients treated with tamoxifen. *Breast Cancer Research & Treatment.* 1994;29(3):279-85.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지

않은 연구

1581. Lukoseviciene V, Tikuisis R, Dulskas A, Miliauskas P, Ostapenko V. Surgery for triple-negative breast cancer: Does the type of anaesthesia have an influence on oxidative stress, inflammation, molecular regulators, and outcomes of disease? *Journal of B.U.ON.* 2018;23(2):290-5.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1582. Lum LG, Al-Kadhim Z. Development and prospects for bispecific antibody-based therapeutics in cancer and other applications. *Expert Opinion on Drug Discovery.* 2008;3(9):1081-97.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1583. Luna JI, Grossenbacher SK, Murphy WJ, Canter RJ. Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy. *Expert Opinion on Biological Therapy.* 2017;17(3):313-24.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1584. Luo G, He Y, Zhao Q, Yu X. Immune Cells Act as Promising Targets for the Treatment of Bone Metastasis. *Recent Patents on Anti-Cancer Drug Discovery.* 2017;12(3):221-33.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1585. Luo L, Zhang Y. Enhanced metastasis of a mouse mammary adenocarcinoma after in vitro treatment with gamma-interferon. [Chinese]. *Chinese Journal of Oncology.* 1994;16(4):251-4.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1586. Luo Y, Zhou H, Mizutani M, Mizutani N, Reisfeld RA, Xiang R. Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine. *Proceedings of the National Academy of Sciences of the United States of America.* 2003;100(15):8850-5.
배제사유 : 동물실험 및 전임상시험연구
1587. Lutgendorf SK. Individual differences and immune function: Implications for cancer. *Brain, Behavior, and Immunity.* 2003;17(1 SUPPL.):S106-S8.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1588. Luzhna L, Kovalchuk O. Mammary gland and radiation: Knowns and unknowns. *Cell Cycle.* 2016;15(15):1975-6.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1589. Lv Y, Zhang G, Ma Y, Ma M, Liao R, Xiang J, et al. Shenqi Fuzheng Injection Combined with Chemotherapy for Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. *Evidence-based Complementary and Alternative Medicine.* 2015;2015 (635858).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1590. Ma F, Liao YQ, Fan Y, Wang YH, Liang JM, Ma J, et al. [Relationship between P-glycoprotein function in peripheral blood cells and multidrug resistance in breast carcinoma]. Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology].

2010;32(7):529-32.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1591. Ma X, Holt D, Kundu N, Nonomura K, Take Y, Fulton AM. Prostaglandin E receptor EP4 antagonist RQ00015986 inhibits breast cancer metastasis and protects natural killer cells from PGE-mediated immune suppression. *Cancer Research. Conference: 103rd Annual Meeting of the American Association for Cancer Research, AACR.* 2012;72(8 SUPPL. 1).
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1592. Ma X, Holt D, Kundu N, Reader J, Goloubeva O, Take Y, et al. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis. *Oncoimmunology.* 2013;2(1):e22647.
- 배제사유 : 동물실험 및 전임상시험연구
1593. Ma X, Norsworthy K, Kundu N, Rodgers WH, Gimotty PA, Goloubeva O, et al. CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. *Molecular Cancer Therapeutics.* 2009;8(3):490-8.
- 배제사유 : 동물실험 및 전임상시험연구
1594. Ma Y, Aymeric L, Locher C, Kroemer G, Zitvogel L. The dendritic cell-tumor cross-talk in cancer. *Current Opinion in Immunology.* 2011;23(1):146-52.
- 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1595. Macagno M, Rolla S, Iezzi M, Merighi I, Smyth MJ, Forni G, et al. Role of perforin-dependent cytotoxicity in immunosurveillance to ERBB2 carcinogenesis in balb-neut transgenic mice. *European Journal of Immunology.* 2009;1):S601.
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1596. Macchetti AH, Marana HR, Silva JS, de Andrade JM, Ribeiro-Silva A, Bighetti S. Tumor-infiltrating CD4+ T lymphocytes in early breast cancer reflect lymph node involvement. *Clinics (Sao Paulo, Brazil).* 2006;61(3):203-8.
- 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1597. Mackay IR, Goodyear MD, Riglar C, Penschow J. Effect on natural killer and antibody-dependent cellular cytotoxicity of adjuvant cytotoxic chemotherapy including melphalan in breast cancer. *Cancer Immunology, Immunotherapy.* 1983;16(2):98-100.
- 배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1598. Madden KS. Catecholamines, sympathetic innervation, and immunity. *Brain, Behavior, and Immunity.* 2003;17(1 SUPPL.):S5-S10.
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1599. Madhuri S, Pandey G. Anticancer activity of Withania somnifera dunal (Ashwagandha). *Indian Drugs.* 2009;46(8):5-11.
- 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1600. Madjd Z, Spendlove I, Moss R, Bevin S, Pinder SE, Watson NF, et al. Upregulation of

MICA on high-grade invasive operable breast carcinoma. *Cancer Immunology*. 2007;7:17.
배제사유 : 동물실험 및 전임상시험연구

1601. Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. *International Journal of Cancer*. 2005;117(2):248-55.
배제사유 : 동물실험 및 전임상시험연구
1602. Madsen CB, Lavrsen K, Steentoft C, Vester-Christensen MB, Clausen H, Wandall HH, et al. Glycan Elongation Beyond the Mucin Associated Tn Antigen Protects Tumor Cells from Immune-Mediated Killing. *PLoS ONE*. 2013;8 (9) (e72413).
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1603. Madsen CB, Wandall HH, Pedersen AE. Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy. *Immunopharmacology and Immunotoxicology*. 2013;35(6):649-52.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1604. Mahaweni NM, Cloosen S, Bollema M, Senden B, Igarashi R, Lee D, et al. Clinically approved monoclonal antibodies and PM21 particlestimulated ex vivo-expanded alloreactive natural killer cells: A potent combination against cancer cells. *Hla*. 2017;89 (6):341.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1605. Mahmood S, Upreti D, Sow I, Amari A, Nandagopal S, Kung SKP. Bidirectional interactions of NK cells and dendritic cells in immunotherapy: Current and future perspective. *Immunotherapy*. 2015;7(3):301-8.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1606. Mahmoodi S, Nezafat N, Barzegar A, Negahdaripour M, Nikanfar AR, Zarghami N, et al. Harnessing bioinformatics for designing a novel multiepitope peptide vaccine against breast cancer. *Current Pharmaceutical Biotechnology*. 2016;17(12):1100-14.
배제사유 : 동물실험 및 전임상시험연구
1607. Mahoney D. Immunotherapy prolonged survival in stage IV cancers. *Oncology Report*. 2012(MAY):6.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1608. Mahvi DM, Carper SW, Storm FK, Teal SR, Sondel PM. Overexpression of 27-kDa heat-shock protein in MCF-7 breast cancer cells: effects on lymphocyte-mediated killing by natural killer and gamma delta T cells. *Cancer Immunology, Immunotherapy*. 1993;37(3):181-6.
배제사유 : 동물실험 및 전임상시험연구
1609. Maiche AG, Jekunen A, Rissanen P, Virkkunen P, Halavaara J, Turunen JP. Sudden tumour regression with enhanced natural killer cell accumulation in a patient with stage IV breast cancer. *European Journal of Cancer*. 1994;30A(11):1642-6.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1610. Maier G, Fiebig HH. Absence of tumor growth stimulation in a panel of 16 human

tumor cell lines by mistletoe extracts in vitro. *Anti-Cancer Drugs*. 2002;13(4):373-9.
배제사유 : 동물실험 및 전임상시험연구

1611. Maimon Y, Samuels N, Cohen Z, Berger R, Rosenthal DS. Botanical Formula LCS101: A Multi-Targeted Approach to Cancer Care. *Integrative Cancer Therapies*. 2018;17(4):1020-6.

배제사유 : 동물실험 및 전임상시험연구

1612. Maio M, Nicolay HJM, Ascierto PA, Belardelli F, Camerini R, Colombo MP, et al. Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19-22, 2011: New perspectives in the immunotherapy of cancer. *Cancer Immunology, Immunotherapy*. 2012;61(9):1599-608.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1613. Maio M, Nicolay HJM, Ascierto PA, Belardelli F, Camerini R, Colombo MP, et al. Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16-18 October 2008. *Cancer Immunology, Immunotherapy*. 2010;59(6):963-9.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1614. Maitra R, Ghalib MH, Goel S. Reovirus: A targeted therapeutic - Progress and potential. *Molecular Cancer Research*. 2012;10(12):1514-25.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1615. Maj T, Wei S, Welling T, Zou W. T cells and costimulation in cancer. *Cancer Journal (United States)*. 2013;19(6):473-82.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1616. Makhoul I, Jousheghany F, Mohammed S, Siegel E, Pennisi A, Beck JT, et al. Immunization of breast cancer patients in combination with standard-of-care chemotherapy: Results of a phase Ib clinical trial. *Cancer Research Conference: San Antonio Breast Cancer Symposium, SABCS*. 2019;80(4 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1617. Makkouk A, Chester C, Chang S, Sundaram V, Desai M, Sayfer I, et al. A predictive nomogram to determine CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy. *Cancer Immunology Research Conference: CRI CIMT EATI AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival*. United States. 2016;4(1 Supplement).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1618. Makkouk A, Sundaram V, Chester C, Chang S, Colevas AD, Sunwoo JB, et al. Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy. *Annals of Oncology*. 2017;28(2):415-20.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1619. Makkouk A, Sundaram V, Desai M, Chester C, Maecker H, Kohrt HE. Predicting CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy. *Journal for ImmunoTherapy of Cancer. Conference: 30th Annual Scientific Meeting of the Society for Immunotherapy of Cancer, SITC*. 2015;3(SUPPL. 2).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1620. Malaguarnera L. Influence of resveratrol on the immune response. *Nutrients*. 2019;11(5) (946).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1621. Malamas AS, Hammond SA, Schlor J, Hodge JW. Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer. *Oncotarget*. 2017;8(53):90825-41.
배제사유 : 동물실험 및 전임상시험연구
1622. Malhi SK, Saif J, Vadakekolathu JN. The Twelfth International Conference on Progress in Vaccination Against Cancer (PIVAC 12), Nottingham, UK, 11-13 September 2012: Insights into the dynamics of anti-tumour immunity and the development of cancer vaccines. *Cancer Immunology, Immunotherapy*. 2013;62(8):1431-7.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1623. Malladi S, Macalinao DG, Jin X, He L, Basnet H, Zou Y, et al. Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. *Cell*. 2016;165(1):45-60.
배제사유 : 동물실험 및 전임상시험연구
1624. Mallmann P, Dietrich K, Krebs D. Effect of tamoxifen and high-dose medroxyprogesterone acetate (MPA) on cell-mediated immune functions in breast cancer patients. *Methods & Findings in Experimental & Clinical Pharmacology*. 1990;12(10):699-706.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1625. Mallmann P, Krebs D. [Effect of tamoxifen on parameters of cell-mediated immunity in postmenopausal patients with breast carcinoma]. *Zentralblatt fur Gynakologie*. 1991;113(12):689-96.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1626. Mallmann P, Krebs D. [Generation and activation of tumor-infiltrating lymphocytes (TIL) within the scope of lymphokine activated killer cell therapy (LAK-TIL therapy) in patients with advanced breast and ovarian carcinoma]. *Gynakologisch-Geburtshilfliche Rundschau*. 1995;35 Suppl 1:161-5.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1627. Mallmann P, Krebs D. Investigations on cell-mediated immunity in patients with breast and ovarian carcinomas receiving a combination of chemotherapy and immunotherapy with thymopentin. *Methods & Findings in Experimental & Clinical Pharmacology*. 1990;12(5):333-40.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1628. Malyguine A, Umansky V, Kotlan B, Aptsiauri N, Shurin MR. Conference overview: Cancer Immunotherapy and Immunomonitoring (CITIM): Moving forward. *Journal of Immunotoxicology*. 2012;9(3):231-5.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1629. Malyguine AM, Strobl S, Dunham K, Shurin MR, Sayers TJ. ELISPOT assay for

- monitoring cytotoxic T lymphocytes (CTL) activity in cancer vaccine clinical trials. *Cells.* 2012;1(2):111-26.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1630. Mamessier E, Bertucci F, Sabatier R, Birnbaum D, Olive D. "Stealth" tumors: Breast cancer cells shun NK-cells anti-tumor immunity. *Oncoimmunology.* 2012;1(3):366-8.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1631. Mamessier E, Bourgin C, Olive D. When breast cancer cells start to fend the educational process of NK cells off. *Oncoimmunology.* 2013;2(12):e26688.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1632. Mamessier E, Pradel LC, Thibult ML, Drevet C, Zouine A, Jacquemier J, et al. Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets. *Journal of Immunology.* 2013;190(5):2424-36.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1633. Mamessier E, Sylvain A, Bertucci F, Castellano R, Finetti P, Houvenaeghel G, et al. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. *Cancer Research.* 2011;71(21):6621-32.
배제사유 : 동물실험 및 전임상시험연구
1634. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. *Journal of Clinical Investigation.* 2011;121(9):3609-22.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1635. Man YL, Filipovic A, Stebbing J, Giamas G. New and established targets for the treatment of breast cancer. *Advances in Breast Cancer.* 2010;7(3):10-3.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1636. Mandavilli BS, Langsdorf C, Chen A, Hu YZ, Wickett M, Clark ST. Evaluating cellular cytotoxicity and potency of antibody-drug conjugates within 3-dimensional tumor models. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting.* 2019;79(13 Supplement).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1637. Mandl SJ, Rountree R, Dalpozzo K, Do L, Sunkara D, Hu H, et al. Both innate and adaptive effector cells contribute to the antitumor activity of MVA-BN-HER2, a vaccine candidate in development for the treatment of HER-2 - Positive breast cancer. *Journal of Immunotherapy.* 2009;32 (9):959.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1638. Mando P, Rizzo M, Roberti MP, Julia EP, Pampena MB, Perez de la Puente C, et al. High neutrophil to lymphocyte ratio and decreased CD69+ NK cells represent a phenotype of high risk in early-stage breast cancer patients. *OncoTargets and therapy.* 2018;11:2901-10.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1639. Mandriota SJ, Tenan M, Ferrari P, Sappino AP. Aluminium chloride promotes tumorigenesis and metastasis in normal murine mammary gland epithelial cells. *International Journal of Cancer*. 2016;139(12):2781-90.
배제사유 : 동물실험 및 전임상시험연구
1640. Mani A, Roda J, Young D, Caligiuri MA, Fleming GF, Kaufman P, et al. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. *Breast Cancer Research & Treatment*. 2009;117(1):83-9.
배제사유 : 동물실험 및 전임상시험연구
1641. Manjili MH, Egilmez N, Knutson KL, Selvan SR, Ostberg JR. Tumor escape and progression under immune pressure. *Clinical and Developmental Immunology*. 2012;2012 (641079).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1642. Manjili MH, Payne KK. Cancer immunotherapy: Re-programming cells of the innate and adaptive immune systems. *OncoImmunology*. 2012;1(2):201-4.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1643. Manjili MH. Phenotypic plasticity of MDSC in cancers. *Immunological Investigations*. 2012;41(6-7):711-21.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1644. Mansfield AS, Heikkila P, von Smitten K, Vakkila J, Leidenius M. The presence of sinusoidal CD163(+) macrophages in lymph nodes is associated with favorable nodal status in patients with breast cancer. *Virchows Archiv*. 2012;461(6):639-46.
배제사유 : 동물실험 및 전임상시험연구
1645. Mansourabadi Z, Razmkhah M, Mohtasebi M, Talei AR, Ghaderi A. Expression of major histocompatibility complex class i polypeptide-related sequence B in adipose-derived stem cells from breast cancer patients and normal individuals. *Journal of Cancer Research and Therapeutics*. 2019;15(5):1067-72.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1646. Mantovani A, Jerrells TR, Dean JH, Herberman RB. Cytolytic and cytostatic activity on tumor cells of circulating human monocytes. *International Journal of Cancer*. 1979;23(1):18-27.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1647. Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. *Cytokine and Growth Factor Reviews*. 2010;21(1):27-39.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1648. Marchesi F, Locatelli M, Solinas G, Erreni M, Allavena P, Mantovani A. Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer. *Journal of Neuroimmunology*. 2010;224(1-2):39-44.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1649. Marchini A, Bonifati S, Scott EM, Angelova AL, Rommelaere J. Oncolytic parvoviruses: From basic virology to clinical applications. *Virology Journal*. 2015;12 (1) (6).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1650. Margolin KA, Wright C, Forman SJ. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells. *Leukemia*. 1997;11(5):723-8.
배제사유 : 동물실험 및 전임상시험연구
1651. Maria Ayuso J, Truttschel R, Gong MM, Humayun M, Gillette A, Patankar M, et al. Microfluidics to study solid tumor-NK cell interactions: From migration and cytotoxicity to therapeutic antibodies. *Cancer Immunology Research Conference*. 2017;6(9 Supplement).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1652. Mariel GC, Edith CTI, Pilar CR, Elena GDN, Humberto RM, Guadalupe MSM, et al. Expression of NK cell surface receptors in breast cancer tissue as predictors of resistance to antineoplastic treatment. *Technology in Cancer Research and Treatment*. 2018;17.
배제사유 : 동물실험 및 전임상시험연구
1653. Marino F, Cosentino M. Adrenergic modulation of immune cells: An update. *Amino Acids*. 2013;45(1):55-71.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1654. Mariotti FR, Quatrini L, Munari E, Vacca P, Tumino N, Pietra G, et al. Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28. *British Journal of Pharmacology*. 2020;177(13):2889-903.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1655. Market M, Baxter KE, Angka L, Kennedy MA, Auer RC. The potential for cancer immunotherapy in targeting surgery-induced natural killer cell dysfunction. *Cancers*. 2019;11 (1) (2).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1656. Markosyan N, Chen EP, Smyth EM. Targeting COX-2 abrogates mammary tumorigenesis: Breaking cancer-associated suppression of immunosurveillance. *Oncimmunology*. 2014;3:e29287.
배제사유 : 동물실험 및 전임상시험연구
1657. Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WE, 3rd. Myeloid-derived suppressor cells in breast cancer. *Breast Cancer Research & Treatment*. 2013;140(1):13-21.
배제사유 : 동물실험 및 전임상시험연구
1658. Markowska A, Jaszczyńska-Nowinka K, Kaysiewicz J, Makowka A, Markowska J. The role of antioxidant vitamins in gynecologic malignancies. *Current Gynecologic Oncology*. 2016;14(1):39-52.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1659. Marleau AM, Chen CS, Joyce JA, Tullis RH. Exosome removal as a therapeutic adjuvant in cancer. *Journal of Translational Medicine*. 2012;10 (1) (134).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1660. Maroni P. Megakaryocytes in bone metastasis: Protection or progression? *Cells*. 2019;8 (2) (134).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1661. Marotta F, Yadav H, Pathak S, Minelli E, Signorelli P, Lorenzetti A, et al. Inhibition of human breast cancer cell growth and enzymatic activity by a fermented nutraceutical: an in vitro and in vivo study. *Annals of the New York Academy of Sciences*. 2009;1155:273-7.
배제사유 : 동물실험 및 전임상시험연구
1662. Marra A, Curigliano G. T-cell bispecific antibodies to bypass MHC class i loss in breast cancer. *Annals of Oncology*. 2019;30(6):877-9.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1663. Marra P, Mathew S, Grigoriadis A, Wu Y, Kyle-Cezar F, Watkins J, et al. IL15RA drives antagonistic mechanisms of cancer development and immune control in lymphocyte-enriched triple-negative breast cancers. *Cancer Research*. 2014;74(17):4908-21.
배제사유 : 동물실험 및 전임상시험연구
1664. Marrache S, Tundup S, Harn DA, Dhar S. Ex vivo programming of dendritic cells by mitochondria-targeted nanoparticles to produce interferon-gamma for cancer immunotherapy. *Acs Nano*. 2013;7(8):7392-402.
배제사유 : 동물실험 및 전임상시험연구
1665. Marrao G, Habib M, Paiva A, Bicout D, Fallecker C, Franco S, et al. Epstein-Barr virus infection and clinical outcome in breast cancer patients correlate with immune cell TNF-alpha/IFN-gamma response. *BMC Cancer*. 2014;14:665.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1666. Marrufo AM, Mathew SO, Chaudhary P, Malaer JD, Vishwanatha JK, Mathew PA. Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells. *American Journal of Cancer Research*. 2018;8(6):1050-63.
배제사유 : 동물실험 및 전임상시험연구
1667. Marrufo AM, Mathew SO, Chaudhary P, Mathew PA. Enhanced killing of triple-negative breast cancer cells by blocking LLT1-CD161 inhibitory signal to NK cells. *Journal of Immunology. Conference: 105th Annual Meeting of the American Association of Immunologists, IMMUNOLOGY*. 2018;200(1 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1668. Martin C, Kizlik-Masson C, Pelegrin A, Watier H, Viaud-Massuard MC, Joubert N. Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours,

- France. mAbs. 2018;10(2):210-21.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1669. Martin NT, Bell JC. Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones. Molecular Therapy. 2018;26(6):1414-22.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1670. Martin OA, Anderson RL, Narayan K, MacManus MP. Does the mobilization of circulating tumour cells during cancer therapy cause metastasis? Nature Reviews Clinical Oncology. 2017;14(1):32-44.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1671. Martinez Martinez J. An 84% survival of stage C colorectal carcinoma [2]. [Spanish]. Oncologia. 2003;26(8):62-3.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1672. Martiniello-Wilks R, Rasko JEJ. Cell and gene therapy in Australia. Cytotherapy. 2007;9(3):209-21.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1673. Martino A, Poccia F. gammadelta T cells and dendritic cells: Close partners and biological adjuvants for new therapies. Current Molecular Medicine. 2007;7(7):658-73.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1674. Martorelli D, Muraro E, Carli P, Miolo GM, Talamini R, Turchet E, et al. Neoadjuvant trastuzumab and paclitaxel combination induces a high rate of pathological complete responses in locally advanced breast cancer by exploiting host antitumor immunity. European Journal of Cancer. 2012;5):S261.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1675. Marubayashi M, Solana R, Ramirez R, Aranda E, Galan F, Pena J. Sera from patients with colon, breast and lung cancer induce resistance to lysis mediated by NK cytotoxic factors (NKCF). British Journal of Cancer. 1991;63(6):893-6.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1676. Marucha PT, Crespin TR, Shelby RA, Andersen BL. TNF-alpha levels in cancer patients relate to social variables. Brain, Behavior, & Immunity. 2005;19(6):521-5.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1677. Maruyama T, Masuda H, Ono M, Kajitani T, Yoshimura Y. Human uterine stem/progenitor cells: Their possible role in uterine physiology and pathology. Reproduction. 2010;140(1):11-22.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1678. Marzan L. [Flow cytometry study of the sets and subsets of normal and pathologic human lymphocytes]. Bacteriologia, Virusologia, Parazitologia, Epidemiologia. 2003;48(1):47-58.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1679. Mascitelli L, Goldstein MR. Do the immunosuppressive effects of statins increase merkel cell carcinoma risk? *International Journal of Dermatology*. 2014;53(9):406-9.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1680. Mascitelli L, Goldstein MR. Menopause, estrogen, statins, and the immune system. *Maturitas*. 2011;68(2):197.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1681. Massa C, Schneeweiss A, Karn T, Hanusch CA, Blohmer JU, Fasching PA, et al. Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy with durvalumab-Results from the prospectively randomized GeparNuevo trial. *Cancer research*. 2019;79(4).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1682. Massague J. Latency and immune evasion of metastatic stem cells. *Cancer Research*. Conference: AACR Special Conference on The Function of Tumor Microenvironment in Cancer Progression. 2016;76(15 Supplement).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1683. Massague J. Metastatic latency and immune evasion by cancer stem cells. *Cancer Research*. Conference: 107th Annual Meeting of the American Association for Cancer Research, AACR. 2016;76(14 Supplement).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1684. Massaia M, Fiore F, Castella B, Pantaleoni F, Mariani S, Peola S, et al. Unconventional properties of zoledronic acid. *Haematologica Reports*. 2006;2(7):106-8.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1685. Mastini C, Becker PD, Iezzi M, Curcio C, Musiani P, Forni G, et al. Intramammary application of non-methylated-CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB/c Her-2/neu transgenic mice. *Current Cancer Drug Targets*. 2008;8(3):230-42.
배제사유 : 동물실험 및 전임상시험연구
1686. Mathenge EG, Dean C, Clements D, Vagharkashani A, Photopoulos S, Coyle K, et al. Biopsy induced metastasis: Role of SOX4/TGF-beta driven EMT and immunosuppressive microenvironment. *Cancer Research*. Conference: 105th Annual Meeting of the American Association for Cancer Research, AACR. 2014;74(19 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1687. Mathews H, Janusek L. Epigenetic mechanism of immune dysregulation. *Brain, Behavior, and Immunity*. 2009;2):S48-S9.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1688. Mathews H, Janusek L. Immune dysregulation by psychological distress. *Journal of Immunology*. Conference: 98th Annual Meeting of the American Association of Immunologists, IMMUNOLOGY. 2011;186(1 MeetingAbstracts).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1689. Mathews HL, Konley T, Kosik KL, Krukowski K, Eddy J, Albuquerque K, et al. Epigenetic patterns associated with the immune dysregulation that accompanies psychosocial distress. *Brain, Behavior, & Immunity*. 2011;25(5):830-9.
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
1690. Matias BF, de Oliveira TM, Rodrigues CM, Abdalla DR, Montes L, Murta EFC, et al. Influence of immunotherapy with autologous dendritic cells on innate and adaptive immune response in cancer. *Clinical Medicine Insights: Oncology*. 2013;7:165-72.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1691. Matic I, Grujic M, Kolundzija B, Damjanovic Velickovic A, Tomasevic Z, Bozovic Spasojevic I, et al. Changes of the white blood cells subsets in HER2 positive breast cancer patients treated with trastuzumab. *European Journal of Cancer*. 2014;5:S214.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1692. Matsueda S, Graham DY. Immunotherapy in gastric cancer. *World Journal of Gastroenterology*. 2014;20(7):1657-66.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1693. Mattarollo SR, Steegh K, Li M, Duret H, Foong Ngiow S, Smyth MJ. Transient Foxp3 + regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells. *Immunology and Cell Biology*. 2013;91(1):105-14.
배제사유 : 동물실험 및 전임상시험연구
1694. Matyszewski A, Czarnecka AM, Solarek W, Korzen P, Safir IJ, Kukwa W, et al. Molecular basis of carcinogenesis in diabetic patients (Review). *International Journal of Oncology*. 2015;46(4):1435-43.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1695. Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH. Adoptive immunotherapy for cancer or viruses. *Annual Review of Immunology*. 2014;32:189-225.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1696. Mayes K, Elsayed Z, Alhazmi A, Waters M, Alkhattib SG, Roberts M, et al. BPTF inhibits NK cell activity and the abundance of natural cytotoxicity receptor co-ligands. *Oncotarget*. 2017;8(38):64344-57.
배제사유 : 동물실험 및 전임상시험연구
1697. Mayor S. Role for natural-killer cells in monoclonal-antibody treatment. *Lancet Oncology*. 2006;7(2):114.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1698. Mazumder A. Experimental evidence of interleukin-2 activity in bone marrow transplantation. *Cancer Journal from Scientific American*. 1997;3(SUPPL. 1):S37-S42.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1699. Mazzarino C, Nicosia A, Monte V, Petralia S, Garraffo C, Girlando A, et al. IL-2 receptors, NK and LAK cytotoxicity of lymphocytes in breast carcinoma during

prolonged thymopentin therapy. Journal of Nuclear Medicine & Allied Sciences. 1990;34(4 Suppl):161-2.

배제사유 : 동물실험 및 전임상시험연구

1700. McArdle SE, Foulds G, Vadakekolathu JN, Abdel-Fatah TMA, Johnson C, Hood S, et al. Effects of neoadjuvant chemotherapy on immune cell subsets in patients with breast cancer: A transcriptomic and phenotypic analysis. Journal for ImmunoTherapy of Cancer. 2017;5 (Supplement 1):10-1.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1701. McCain NL. Psychoneuroimmunology, spirituality, and cancer. Gynecologic Oncology. 2005;99(3 SUPPL.):S121.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1702. McCormick SM, Heller NM. Commentary: IL-4 and IL-13 receptors and signaling. Cytokine. 2015;75(1):38-50.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

1703. McCulloch PG, MacIntyre A. Effects of surgery on the generation of lymphokine-activated killer cells in patients with breast cancer. British Journal of Surgery. 1993;80(8):1005-7.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

1704. McCullough J, Key N, Gee A, Rooney C, Whiteside T, Donnenberg A, et al. Production assistance for cellular therapies [3]. Transfusion. 2004;44(12):1793-5.

배제사유 : 동물실험 및 전임상시험연구

1705. McElroy JA, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, Hampton JM, Egan KM. Duration of sleep and breast cancer risk in a large population-based case-control study. Journal of Sleep Research. 2006;15(3):241-9.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1706. McHale D, Francisco-Anderson L, Sandy P, Shariffudin S, Goldberg M, Gardner H, et al. P-325 Oral delivery of a single microbial strain, EDP1503, induces anti-tumor responses via gut-mediated activation of both innate and adaptive immunity. Annals of Oncology. 2020;31 (Supplement 3):S195.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1707. McKay MJ, Langlands AO, Evans RA, Morsch HHC, Clark GM, Osborne CK, et al. Prognostic factors in breast cancer [2]. New England Journal of Medicine. 1992;327(18):1317-8.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1708. McMichael EL, Courtney NB, Duggan MC, Wesolowski R, Quiroga D, Kondadasula SV, et al. Activation of the FcgammaReceptorIIIa on human natural killer cells leads to increased expression of functional interleukin-21 receptor. OncoImmunology. 2017;6 (5) (e1312045).

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

1709. McMillan A. Central nervous system-directed preventative therapy in adults with lymphoma. *British Journal of Haematology*. 2005;131(1):13-21.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1710. McNerney KO, Karageorgos SA, Hogarty MD, Bassiri H. Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells. *Frontiers in Immunology*. 2020;11 (873).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1711. Mead MN. Estrogens shield breast cancer cells. *Environmental Health Perspectives*. 2007;115(6):A297.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1712. Medeiros B, Allan AL. Molecular mechanisms of breast cancer metastasis to the lung: Clinical and experimental perspectives. *International Journal of Molecular Sciences*. 2019;20 (9) (2272).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1713. Medon M, Vidacs E, Vervoort SJ, Li J, Jenkins MR, Ramsbottom KM, et al. HDAC inhibitor panobinostat engages host innate immune defenses to promote the tumoricidal effects of trastuzumab in HER2+ Tumors. *Cancer Research*. 2017;77(10):2594-606.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1714. Meehan KR, Wu A, Hassan R, Miao Y, Chawla J, Slack R, et al. Ex vivo cytokine activation of peripheral blood stem cells: a potential role for adoptive cellular immunotherapy. *Journal of Hematology & Stem Cell Research*. 2001;10(2):283-90.
배제사유 : 동물실험 및 전임상시험연구
1715. Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Tin S, et al. Circulating tumor cells (CTC) are associated with defects in innate and adaptive immunity in inflammatory breast cancer (IBC) patients. *Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium*. San Antonio, TX United States. Conference Publication: 2015;75(9 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1716. Meier R, Muller Y, Dietrich PY, Villard J, De Picciotto N, Labidi-Galy I, et al. Immunologic rejection of a metastatic donor-derived bellini duct carcinoma in a kidney transplant recipient. *Tissue Antigens*. 2015;85 (5):305.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1717. Meier RPH, Muller YD, Dietrich PY, Tille JC, Nikolaev S, Sartori A, et al. Immunologic Clearance of a BK Virus-associated Metastatic Renal Allograft Carcinoma. *Transplantation*. 2020;21.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1718. Melendez K, Wallen ES, Edwards BS, Mobarak CD, Bear DG, Moseley PL. Heat shock protein 70 and glycoprotein 96 are differentially expressed on the surface of malignant and nonmalignant breast cells. *Cell Stress & Chaperones*. 2006;11(4):334-42.

배제사유 : 동물실험 및 전임상시험연구

1719. Melichar B, Touskova M, Hornychova H, Vokurkova D, Solichova D, Vesely P, et al. Systemic immune activation and peripheral blood lymphocytes during primary chemotherapy with the combination of doxorubicin and paclitaxel in patients with breast carcinoma. *Pteridines*. 2007;18(1):25-34.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

1720. Mellios T, Ko HL, Beuth J. Impact of adjuvant chemo- and radiotherapy on the cellular immune system of breast cancer patients. *In Vivo*. 2010;24(2):227-30.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1721. Menard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E. Role of HER2/neu in tumor progression and therapy. *Cellular and Molecular Life Sciences*. 2004;61(23):2965-78.

배제사유 : 동물실험 및 전임상시험연구

1722. Menard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. *Oncogene*. 2003;22(42):6570-8.

배제사유 : 동물실험 및 전임상시험연구

1723. Meneghini AJ, Saddi VA, De Cassia Goncalves Alencar R, Correa R, Wastowski IJ. The non-classical class-I histocompatibility HLA-G antigen expression in papillary ductal thyroid carcinoma. *Tissue Antigens*. 2012;80 (1):93.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1724. Menendez P, Caballero MD, Prosper F, Del Canizo MC, Perez-Simon JA, Mateos MV, et al. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen. *Transfusion*. 2002;42(9):1159-72.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

1725. Menendez P, Prosper F, Bueno C, Arbona C, San Miguel JF, Garcia-Conde J, et al. Sequential analysis of CD34+ and CD34- cell subsets in peripheral blood and leukapheresis products from breast cancer patients mobilized with SCF plus G-CSF and cyclophosphamide. *Leukemia*. 2001;15(3):430-9.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1726. Meneses G, Delgado MA, Perez-Machado MA, Prieto A, Alonso R, Carrion F, et al. Thymostimulin increases natural cytotoxic activity in patients with breast cancer. *International Journal of Immunopharmacology*. 1997;19(4):187-93.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

1727. Menetrier-Caux C, Bain C, Favrot MC, Duc A, Blay JY. Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes. *British Journal of Cancer*. 1999;79(1):119-30.

배제사유 : 동물실험 및 전임상시험연구

1728. Menetrier-Caux C, Faget J, Biota C, Gobert M, Blay JY, Caux C. Innate immune

recognition of breast tumor cells mediates CCL22 secretion favoring Treg recruitment within tumor environment. *OncoImmunology*. 2012;1(5):759-61.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1729. Meng LX, Yu J, Zheng YX, Zhou CY, Ding ZJ. Clinical effect of cyclophosphamide-taxinol therapy on breast cancer. *Biomedical Research (India)*. 2017;28(19):8461-3.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1730. Meraviglia S, Caccamo N, Guggino G, Tolomeo M, Siragusa S, Stassi G, et al. Optimizing tumor-reactive gammadelta T cells for antibody-based cancer immunotherapy. *Current Molecular Medicine*. 2010;10(8):719-26.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1731. Merker M, Rettinger E, Oelsner S, Pfirrmann V, Wagner J, Ullrich E, et al. ErB2-chimeric antigen receptor engineering of cytokineinduced killer cells against soft tissue sarcomas: Highly increased cytotoxicity in vitro and effective prevention of tumor engraftment in in vivo mouse models. *Bone Marrow Transplantation*. 2016;1):S317.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1732. Mesker WE, Vangangelt K, Tollenaar L, Van Pelt G, Dekker T, Kuppen P, et al. The prognostic value of the tumour-stroma ratio in invasive breast carcinoma. *Virchows Archiv*. 2018;473 (Supplement 1):s52.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1733. Mesker WE, Vangangelt K, Tollenaar R. The prognostic value of the tumour-stroma ratio in invasive breast carcinoma. *European Journal of Cancer*. 2018;92 (Supplement 3):S48.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1734. Messina G, Lissoni P, Bartolacelli E, Tancini G, Villa S, Gardani GS, et al. A psychoncological study of lymphocyte subpopulations in relation to pleasure-related neurobiochemistry and sexual and spiritual profile to Rorschach's test in early or advanced cancer patients. *Journal of Biological Regulators & Homeostatic Agents*. 2003;17(4):322-6.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

1735. Meulendijks D, Jacob W, Martinez-Garcia M, Taus A, Lolkema MP, Voest EE, et al. First-in-human phase i study of lumretuzumab, a glycoengineered humanized anti-HER3 monoclonal antibody, in patients with metastatic or advanced HER3-positive solid tumors. *Clinical Cancer Research*. 2016;22(4):877-85.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1736. Michelin MA, Murta EFC. Potential therapeutic vaccine strategies and relevance of the immune system in uterine cervical cancer. *European Journal of Gynaecological Oncology*. 2008;29(1):10-8.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1737. Micksche M, Colot M, Uchida A. Immunomodulation in cancer patients by synthetic

- biological response modifiers. *Cancer Treatment Symposia*. 1985;VOL. 1:27-35.
- 배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1738. Mikamo S. [Adoptive immunotherapy using immobilized anti-CD3 mAb-activated autologous lymphocytes: the strong cytotoxicity was supported by CD16+ cells which proliferated in prolonged cultures]. *Human Cell*. 1992;5(3):256-66.
- 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1739. Milanese JS, Tibiche C, Zou J, Meng Z, Nantel A, Drouin S, et al. Germline variants associated with leukocyte genes predict tumor recurrence in breast cancer patients. *npj Precision Oncology*. 2019;3 (1) (28).
- 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1740. Milanese JS, Wang E. Germline mutations and their clinical applications in cancer. *Breast Cancer Management*. 2019;8 (1) (BMT23).
- 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1741. Miller JS, Tessmer-Tuck J, Pierson BA, Weisdorf D, McGlave P, Blazar BR, et al. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. *Biology of Blood & Marrow Transplantation*. 1997;3(1):34-44.
- 배제사유 : 동물실험 및 전임상시험연구
1742. Mills KC, Gross TG, Varney ML, Heimann DG, Reed EC, Kessinger A, et al. Immunologic phenotype and function in human bone marrow, blood stem cells and umbilical cord blood. *Bone Marrow Transplantation*. 1996;18(1):53-61.
- 배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1743. Milovanovic M, Volarevic V, Radosavljevic G, Jovanovic I, Pejnovic N, Arsenijevic N, et al. IL-33/ST2 axis in inflammation and immunopathology. *Immunologic Research*. 2012;52(1-2):89-99.
- 배제사유 : 동물실험 및 전임상시험연구
1744. Minarovits J. Recent advances in the pathogenesis of EBV infection. *Clinical Microbiology and Infection*. 2011;4):S74.
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1745. Mine T, Matsueda S, Li Y, Tokumitsu H, Gao H, Danes C, et al. Breast cancer cells expressing stem cell markers CD44+ CD24lo are eliminated by Numb-1 peptide-activated T cells. *Cancer Immunology, Immunotherapy*. 2009;58(8):1185-94.
- 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1746. Minetto P, Guolo F, Pesce S, Greppi M, Obino V, Ferretti E, et al. Harnessing NK Cells for Cancer Treatment. *Frontiers in Immunology*. 2019;10 (2836).
- 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1747. Minton K. Enhancing antitumour eosinophils. *Nature Reviews Immunology*. 2019;19(4):202-3.
- 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1748. Misale MS, Janusek L, Mathews H. Epigenetic basis for psychological stress-induced IFNg production in women diagnosed with breast cancer. *Brain, Behavior, and Immunity*. 2015;49 (Supplement 1):e11-e2.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1749. Mishima M, Toh U, Fukushima T, Fukunaga M, Nakagawa S, Yahara T, et al. Augmentation of the clinical effect of immunotherapy using trastuzumab combined adoptive cell therapy for refractory breast cancer. [Japanese]. *Biotherapy*. 2008;22(5):322-6.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1750. Mita Y, Kimura MY, Hayashizaki K, Koyama-Nasu R, Ito T, Motohashi S, et al. Crucial role of CD69 in anti-tumor immunity through regulating the exhaustion of tumor-infiltrating T cells. *International Immunology*. 2018;30(12):559-67.
배제사유 : 동물실험 및 전임상시험연구
1751. Mitchell MS. Chemotherapy in combination with biomodulation: a 5-year experience with cyclophosphamide and interleukin-2. *Seminars in Oncology*. 1992;19(2 Suppl 4):80-7.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1752. Mitchell MS. Combinations of anticancer drugs and immunotherapy. *Cancer Immunology, Immunotherapy*. 2003;52(11):686-92.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1753. Mitri Z, Ueno NT, Yang W, Valero V, Litton JK, Murthy R, et al. Women's triple-negative, first-line treatment: improving outcomes in triple-negative breast cancer using molecular triaging and diagnostic imaging to guide neoadjuvant therapy. *Cancer research*. 2016;76(14).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1754. Mitsuhashi M, Liu J, Cao S, Shi X, Ma X. Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas. *Journal of Leukocyte Biology*. 2004;76(2):322-32.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1755. Mittal D, Caramia F, Michiels S, Joensuu H, Kellokumpu-Lehtinen PL, Sotiriou C, et al. Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells. *Cancer Research*. 2016;76(2):264-74.
배제사유 : 동물실험 및 전임상시험연구
1756. Mittal D, Vijayan D, Putz EM, Aguilera AR, Markey KA, Straube J, et al. Interleukin-12 from CD103+ Batf3-dependent dendritic cells required for NK-cell suppression of metastasis. *Cancer Immunology Research*. 2017;5(12):1098-108.
배제사유 : 동물실험 및 전임상시험연구
1757. Mittal D, Young A, Stannard K, Teng MW, Allard B, Stagg J, et al. Anti-metastatic activity via co-blockade of PD-1 and adenosine A2A receptor. *European Journal of Cancer*. 2014;6):40-1.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1758. Mittal D, Young A, Stannard K, Yong M, Teng MWL, Allard B, et al. Antimetastatic effects of blocking PD-1 and the adenosine A_{2A} receptor. *Cancer Research*. 2014;74(14):3652-8.

배제사유 : 동물실험 및 전임상시험연구

1759. Mittal K, Ebos J, Rini B. Angiogenesis and the tumor microenvironment: Vascular endothelial growth factor and beyond. *Seminars in Oncology*. 2014;41(2):235-51.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1760. Mittendorf BA, Schneble EJ, Ibrahim NK, Greene JM, Berry JS, Trappey AF, et al. Combination immunotherapy with trastuzumab and the HER2 vaccine E75 (nelipepimut-S) in high-risk HER2+ breast cancer patients to prevent recurrence. *Cancer research*. 2015;75(9 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1761. Miura D, Yoneyama K, Furuhata Y, Shimizu K. Paclitaxel enhances antibody-dependent cell-mediated cytotoxicity of trastuzumab by rapid recruitment of natural killer cells in HER2-positive breast cancer. *Journal of Nippon Medical School = Nihon Ika Daigaku Zasshi*. 2014;81(4):211-20.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1762. Miya K, Saji S, Furuta T, Azuma S, Umemoto T, Takao H, et al. [Significance of antitumor effects and immunological response on endogenously induced LAK therapy for primary or metastatic liver tumor]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1992;19(10 Suppl):1453-6.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1763. Miyazono K. Transforming growth factor-beta signaling and cancer: The 28th Sapporo Cancer Seminar, 25-27 June 2008. *Cancer Science*. 2009;100(2):363-5.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1764. Mobergslien A, Peng Q, Vasovic V, Sioud M. Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth. *Oncotarget*. 2016;7(46):75940-53.

배제사유 : 동물실험 및 전임상시험연구

1765. Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D. Part I: Vaccines for solid tumours. *Lancet Oncology*. 2004;5(11):681-9.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1766. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM. The dual role of IL-10. *Trends in Immunology*. 2003;24(1):36-43.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1767. Mohamad NE, Abu N, Yeap SK, Lim KL, Romli MF, Sharifuddin SA, et al. Apoptosis and metastasis inhibitory potential of pineapple vinegar against mouse mammary gland cells in vitro and in vivo. *Nutrition and Metabolism*. 2019;16 (1) (49).

배제사유 : 동물실험 및 전임상시험연구

1768. Mohamed MM, El-Shinawi M, Cavallo-Medved D, Sobhy M, Nouh MA, Abdelwahab SF, et al. Monocytes/macrophages and natural killer cells characterize the tumor microenvironment of inflammatory breast cancer in Egyptian patients. *Cancer Research*. Conference: 31st Annual San Antonio Breast Cancer Symposium. San Antonio, TX United States. Sponsor: UT Health Science Center San Antonio School of Medicine, American Association for Cancer Research, Baylor College of Medicine. Conference Publication: 2009;69(2 Suppl. S).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1769. Mohamedali KA, Cheung LH, Alvarez-Cienfuegos A, Rosenblum MG. Genomic differential expression analysis of fusion proteins incorporating the pro-apoptotic molecule Granzyme B reveals new potential targets for treatment of breast cancer. *Cancer Research*. Conference: American Association for Cancer Research Annual Meeting. 2017;77(13 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1770. Moheno PBB. Calcium pterin as an antitumor agent. *International Journal of Pharmaceutics*. 2004;271(1-2):293-300.
배제사유 : 동물실험 및 전임상시험연구
1771. Mohme M, Riethdorf S, Pantel K. Circulating and disseminated tumour cells-mechanisms of immune surveillance and escape. *Nature Reviews Clinical Oncology*. 2017;14(3):155-67.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1772. Moiseeva EV, Semushina SG, Svirshchevskaya EV. Phenotypic and histopathologic characteristics of tumor infiltrates in spontaneous mouse mammary cancer. *European Journal of Immunology*. 2009;1):S602.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1773. Mokbel K, Reed MJ, Kunkler IH. Benefits of post-mastectomy radiotherapy (multiple letters) [12]. *Lancet*. 1998;351(9097):219.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1774. Molgora M, Supino D, Mantovani A, Garlanda C. Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8. *Immunological Reviews*. 2018;281(1):233-47.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1775. Molling JW, Kolgen W, van der Vliet HJ, Boomsma MF, Kruizinga H, Smorenburg CH, et al. Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. *International Journal of Cancer*. 2005;116(1):87-93.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1776. Moloudizargari M, Asghari MH, Mortaz E. Inhibiting exosomal MIC-A and MIC-B shedding of cancer cells to overcome immune escape: new insight of approved drugs. *DARU, Journal of Pharmaceutical Sciences*. 2019;27(2):879-84.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1777. Monteiro HP, Rodrigues EG, Amorim Reis AKC, Longo LS, Ogata FT, Moretti AIS, et al. Nitric oxide and interactions with reactive oxygen species in the development of melanoma, breast, and colon cancer: A redox signaling perspective. *Nitric Oxide - Biology and Chemistry*. 2019;89:1-13.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1778. Mooney R, Hammad M, Batalla-Covello J, Abdul Majid A, Aboody KS. Concise Review: Neural Stem Cell-Mediated Targeted Cancer Therapies. *Stem Cells Translational Medicine*. 2018;7(10):740-7.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1779. Morales-Estevez C, De la Haba-Rodriguez J, Manzanares-Martin B, Porras-Quintela I, Rodriguez-Ariza A, Moreno-Vega A, et al. KIR Genes and Their Ligands Predict the Response to Anti-EGFR Monoclonal Antibodies in Solid Tumors. *Frontiers in Immunology*. 2016;7:561.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1780. Morales-Estevez C, Manzanares-Martin B, Gonzalez-Fernandez R, Porras I, Gomez-Espana MA, Cano MT, et al. Association of Killer cell immunoglobulin-like receptors (KIRs) polymorphisms and advanced cancer in a Caucasian population. *Journal of Clinical Oncology. Conference*. 2015;33(15 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1781. Morales-Estevez C, Manzanares-Martln B, De la Haba-Rodrlguez J, Gonzalez-Fernandez R, Lopez-Gonzalez J, Moreno A, et al. Killer-cell Inmunoglobulin-like Receptor (KIR) genes as a predictor of response to the anti-HER therapy in solid tumors. *Journal of Clinical Oncology. Conference*. 2016;34(Supplement 15).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1782. Morandi F, Pistoia V. Interactions between HLA-G and HLA-E in physiological and pathological conditions. *Frontiers in Immunology*. 2014;5 (AUG) (Article 394).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1783. Mordoh J, Levy EM, Roberti MP. Natural killer cells in human cancer: From biological functions to clinical applications. *Journal of Biomedicine and Biotechnology*. 2011;2011 (676198).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1784. Moreno M, Bontkes HJ, Scheper RJ, Kenemans P, Verheijen RH, von Mensdorff-Pouilly S. High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). *Cancer Letters*. 2007;257(1):47-55.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1785. Morini M, Albini A, Lorusso G, Moelling K, Lu B, Cilli M, et al. Prevention of angiogenesis by naked DNA IL-12 gene transfer: Angioprevention by immunogene therapy. *Gene Therapy*. 2004;11(3):284-91.
배제사유 : 동물실험 및 전임상시험연구

1786. Morokuma A, Saeki Y, Nakamura A, Sakuma H, Ishihara Y, Abe M. Assessing antitumor and T cell immune responses by cytokine assay in cancer patients treated with immunotherapy - A pilot study. Personalized Medicine Universe. 2018;7:28-33.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1787. Morre M, Beq S. Interleukin-7 and immune reconstitution in cancer patients: A new paradigm for dramatically increasing overall survival. Targeted Oncology. 2012;7(1):55-68.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1788. Morris JC, Ramlogan-Steel CA, Yu P, Black BA, Mannan P, Allison JP, et al. Vaccination with tumor cells expressing IL-15 and IL-15Ralpha inhibits murine breast and prostate cancer. Gene Therapy. 2014;21(4):393-401.
배제사유 : 동물실험 및 전임상시험연구
1789. Morse MA, Lyerly HK, Clay TM, Abdel-Wahab O, Chui SY, Garst J, et al. How does the immune system attack cancer? Current Problems in Surgery. 2004;41(1):15-132.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1790. Morton BA, Ramey WG, Paderon H, Miller RE. Monoclonal antibody-defined phenotypes of regional lymph node and peripheral blood lymphocyte subpopulations in early breast cancer. Cancer Research. 1986;46(4 Pt 2):2121-6.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1791. Moss J, Magenheim J, Neiman D, Zemmour H, Loyfer N, Korach A, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nature Communications. 2018;9 (1) (5068).
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1792. Mossner E, Tuffin G, Colombetti S, Freytag O, Moser S, Dunn C, et al. M4-3-ML2, a novel glycoengineered humanized IgG1 antibody, targeting a membrane-proximal epitope of MCSP/CSPG4 exhibits potent ADCC induction in vitro and in vivo anti-tumoral efficacy in disseminated melanoma models. Cancer Research. Conference: 103rd Annual Meeting of the American Association for Cancer Research, AACR. 2012;72(8 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1793. Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu EF, Engreitz JM, et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nature Medicine. 2016;22(12):1402-10.
배제사유 : 동물실험 및 전임상시험연구
1794. Mozaffari F, Lindemalm C, Choudhury A, Granstam-Bjorneklett H, Helander I, Lekander M, et al. NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy. British Journal of Cancer. 2007;97(1):105-11.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1795. Mozaffari F, Lindemalm C, Choudhury A, Granstam-Bjorneklett H, Lekander M, Nilsson B, et al. Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil,

- epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: A longitudinal study. *Cancer Immunology, Immunotherapy*. 2009;58(1):111-20.
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
1796. Mroz P, Hashmi JT, Huang YY, Lange N, Hamblin MR. Stimulation of anti-tumor immunity by photodynamic therapy. *Expert Review of Clinical Immunology*. 2011;7(1):75-91.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1797. Mueller C, Triebel F. AIPAC (Active Immunotherapy PAClitaxel): A phase IIb trial in hormone receptor-positive metastatic breast carcinoma patients receiving IMP321 (LAG-3Ig fusion protein) or placebo as adjunctive to a standard chemotherapy regimen of paclitaxel. *Annals of Oncology*. 2016;27 (Supplement 8):viii14.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1798. Muenst S, Laubli H, Soysal SD, Zippelius A, Tzankov A, Hoeller S. The immune system and cancer evasion strategies: Therapeutic concepts. *Journal of Internal Medicine*. 2016;279(6):541-62.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1799. Mufudza C, Sorofa W, Chiyaka ET. Assessing the effects of estrogen on the dynamics of breast cancer. *Computational and Mathematical Methods in Medicine*. 2012;2012 (473572).
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1800. Mukaida N, Sasaki SI, Baba T. Two-faced roles of tumor-associated neutrophils in cancer development and progression. *International Journal of Molecular Sciences*. 2020;21 (10) (3457).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1801. Mukohyama J, Shimono Y, Funakoshi Y, Kono S, Yamashita K, Mukohara T, et al. [Effect of Natural Killer Cell Infiltration on the Growth of Breast Cancer Patient-Derived Tumor Xenografts]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 2015;42(10):1252-5.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1802. Mullin GE. Folate: Is too much of a good thing harmful? *Nutrition in Clinical Practice*. 2011;26(1):84-7.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1803. Mundy BL, Thornton LM, Andersen BL, Carson WE. Relationship between psychological stress and immunosuppressive cell populations in breast cancer patients. *Journal of Immunotherapy*. 2009;32 (9):983.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1804. Mundy-Bosse BL, Thornton LM, Yang HC, Andersen BL, Carson WE. Psychological stress is associated with altered levels of myeloid-derived suppressor cells in breast cancer patients. *Cellular Immunology*. 2011;270(1):80-7.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1805. Munoz DP, Yannone SM, Daemen A, Sun Y, Vakar-Lopez F, Kawahara M, et al. Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging. *JCI Insight*. 2019;4 (14) (e124716).
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1806. Muntasell A, Cabo M, Servitja S, Tusquets I, Martinez-Garcia M, Rovira A, et al. Interplay between Natural killer cells and Anti-HER2 antibodies: Perspectives for breast cancer immunotherapy. *Frontiers in Immunology*. 2017;8 (NOV) (1544).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1807. Muntasell A, Rojo F, Servitja S, Rubio-Perez C, Cabo M, Tamborero D, et al. NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival. *Clinical Cancer Research*. 2019;25(5):1535-45.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1808. Muntasell A, Servitja S, Cabo M, Bermejo B, Perez-Buira S, Rojo F, et al. High Numbers of Circulating CD57(+) NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2(+) Primary Breast Cancer. *Cancer Immunology Research*. 2019;7(8):1280-92.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1809. Muraro E, Comaro E, Talamini R, Turchet E, Miolo G, Scalzone S, et al. Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy. *Journal of Translational Medicine*. 2015;13:204.
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
1810. Muraro E, Furlan C, Avanzo M, Martorelli D, Comaro E, Rizzo A, et al. Local high-dose radiotherapy induces systemic immunomodulating effects of potential therapeutic relevance in oligometastatic breast cancer. *Frontiers in Immunology*. 2017;8 (1476).
배제사유 : 동물실험 및 전임상시험연구
1811. Muraro E, Furlan C, Berretta M, Militello L, Del Conte A, Spazzapan S, et al. Stereotactic ablative radiation therapy (SABR) for oligometastatic breast cancer patients: Investigating the immune profile to identify predictive biomarkers. *International Journal of Radiation Oncology Biology Physics*. 2014;1:S769.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1812. Murphy WJ, Longo DL. The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation. *Immunological Reviews*. 1997;157:167-76.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1813. Murta EF, de Andrade JM, Falcao RP, Bighetti S. Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy. *Tumori*. 2000;86(5):403-7.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

1814. Musiani P, Allione A, Modica A, Lollini PL, Giovarelli M, Cavallo F, et al. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. *Laboratory Investigation*. 1996;74(1):146-57.

배제사유 : 동물실험 및 전임상시험연구

1815. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. *Journal of Clinical Oncology*. 2008;26(11):1789-96.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1816. N.M EL-D, H.I EL-A, A.E.A EL-w, Haddad AM, H.A ELE, He YW, et al. Modulation of NKG2D, KIR2DL and Cytokine Production by Pleurotus ostreatus Glucan Enhances Natural Killer Cell Cytotoxicity Toward Cancer Cells. *Frontiers in Cell and Developmental Biology*. 2019;7 (165).

배제사유 : 동물실험 및 전임상시험연구

1817. Na YM, Lim KB, Lee HJ, Kim YK, Lee YJ, Lee HD. Effects of Exercise Therapy on Natural Killer Cell Cytotoxic Activity in Breast Cancer Patients after Curative Surgery. *Journal of korean academy of rehabilitation medicine*. 2003;27(2):250?4.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

1818. Nabavinia MS, Ghooobi A, Charbgoo F, Nabavinia M, Ramezani M, Abnous K. Anti-MUC1 aptamer: A potential opportunity for cancer treatment. *Medicinal Research Reviews*. 2017;37(6):1518-39.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1819. Naden J. Cell line xenograft growth in the B6:129-Rag2tm1Fwa IL2rgtm1Rsky/DwlHsd (R2G2) mouse model. *FASEB Journal*. 2019;33(S1):lb1-872.4.

배제사유 : 동물실험 및 전임상시험연구

1820. Nagalla S, Chou JW, Ruiz J, Vaughn JP, Black MA, Miller LD. Novel interactions between immunity and proliferation in breast cancer prognosis. *Cancer Research Conference: 34th Annual CTRC AACR San Antonio Breast Cancer Symposium*. San Antonio, TX United States. Conference Publication: 2011;71(24 SUPPL. 3).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1821. Nagalla S, Chou JW, Willingham MC, Ruiz J, Vaughn JP, Dubey P, et al. Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. *Genome Biology*. 2013;14(4):R34.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1822. Nagamine T, Kadena K, Tomori M, Nakajima K, Iha M. Activation of NK cells in male cancer survivors by fucoidan extracted from cladosiphon okamuranus. *Molecular and Clinical Oncology*. 2020;12(1):81-8.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

1823. Nagashima Y, Maeda N, Yamamoto S, Yoshino S, Oka M. Evaluation of host quality of life and immune function in breast cancer patients treated with combination of adjuvant chemotherapy and oral administration of Lentinula edodes mycelia extract. *OncoTargets and Therapy*. 2013;6:853-9.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

1824. Nagashima Y, Sanpei N, Yamamoto S, Yoshino S, Tangoku A, Oka M. [Evaluation of host immunity and side effects in breast cancer patients treated with adjuvant chemotherapy (FEC therapy)]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 2005;32(11):1550-2.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1825. Nagashima Y, Yoshino S, Yamamoto S, Maeda N, Azumi T, Komoike Y, et al. Lentinula edodes mycelia extract plus adjuvant chemotherapy for breast cancer patients: Results of a randomized study on host quality of life and immune function improvement. *Molecular and Clinical Oncology*. 2017;7(3):359-66.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1826. Naik A, Monjazeb AM, Decock J. The obesity paradox in cancer, tumor immunology, and immunotherapy: Potential therapeutic implications in triple negative breast cancer. *Frontiers in Immunology*. 2019;10 (AUG) (1940).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1827. Nair VR, Malladi S. Mouse Models to Study Natural Killer Cell-Mediated Immunosurveillance and Metastatic Latency. *Methods in Molecular Biology*. 2019;1884:141-50.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1828. Najafi M, Shirazi A, Motevaseli E, Geraily G, Norouzi F, Heidari M, et al. The melatonin immunomodulatory actions in radiotherapy. *Biophysical Reviews*. 2017;9(2):139-48.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1829. Nakagawa S, Matsuoka Y, Ichihara H, Yoshida H, Yoshida K, Ueoka R. New cancer immunotherapy using autologous lymphocytes activated with trastuzumab. *Biological & Pharmaceutical Bulletin*. 2012;35(8):1213-5.

배제사유 : 동물실험 및 전임상시험연구

1830. Nakagawa S, Matsuoka Y, Ichihara H, Yoshida H, Yoshida K, Ueoka R. Therapeutic effects of autologous lymphocytes activated with trastuzumab for xenograft mouse models of human breast cancer. *Biological & Pharmaceutical Bulletin*. 2013;36(5):861-5.

배제사유 : 동물실험 및 전임상시험연구

1831. Nakajima Y, Akimoto M, Kimura M, Matano S, Hirakawa H, Kasai M. [Interferon production in lymph nodes draining breast carcinoma and its augmentation by OK-432]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1986;13(9):2766-71.

배제사유 : 동물실험 및 전임상시험연구

1832. Nakajima Y, Akimoto M, Kimura M, Sawano A, Iwasaki H, Abe R, et al. [Modified radical mastectomy and lymphocyte subsets of regional lymph nodes]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]. 1986;13(6):2182-6.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

1833. Nakao A, Kasuya H, Sahin TT, Nomura N, Kanzaki A, Misawa M, et al. A phase i dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer. Cancer Gene Therapy. 2011;18(3):167-75.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

1834. Nakao R, Nelson OL, Park JS, Mathison BD, Thompson PA, Chew BP. Effect of dietary astaxanthin at different stages of mammary tumor initiation in BALB/c mice. Anticancer Research. 2010;30(6):2171-5.

배제사유 : 동물실험 및 전임상시험연구

1835. Nakau M, Imanishi J, Watanabe S, Imanishi A, Baba T, Hirai K, et al. Spiritual care of cancer patients by integrated medicine in urban green space: A pilot study. Explore: The Journal of Science and Healing. 2013;9(2):87-90.

배제사유 : 동물실험 및 전임상시험연구

1836. Nan X, Wang J, Liu HN, Wong STC, Zhao H. Epithelial-mesenchymal plasticity in organotropism metastasis and tumor immune escape. Journal of Clinical Medicine. 2019;8 (5) (747).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1837. Nangia C, Soon-Shiong P, Rabizadeh S, Lee JH, Sender L, Jones F, et al. Complete responses in patients with second-line or greater metastatic triple negative breast cancer (TNBC) following first-in-human immunotherapy combining NK and T cell activation with off-the-shelf high-affinity CD16 NK cell line (haNK). Annals of Oncology. 2019;30 (Supplement 5):v130.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1838. Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Ianzano ML, et al. Multiorgan metastasis of human HER-2+ breast cancer in Rag2^{-/-};Il2rg^{-/-} mice and treatment with PI3K inhibitor. PLoS ONE [Electronic Resource]. 2012;7(6):e39626.

배제사유 : 동물실험 및 전임상시험연구

1839. Narvaiza I, Mazzolini G, Qian C, Prieto J, Melero I. First generation adenoviral vectors, the vector par excellence for immuno-gene therapy of cancer. [Spanish]. Inmunología. 2003;22(2):225-42.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1840. Natoli C, Iacobelli S, Kohn L. The immune stimulatory protein 90K increases major histocompatibility complex class I expression in a human breast cancer cell line. Biochemical and Biophysical Research Communications. 1996;225(2):617-20.

배제사유 : 동물실험 및 전임상시험연구

1841. Naucler CS, Geisler J, Vetvik K. The emerging role of human cytomegalovirus infection in human carcinogenesis: A review of current evidence and potential therapeutic implications. *Oncotarget*. 2019;10(42):4333-47.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1842. Naukkarinen A, Syrjanen KJ. Quantitative immunohistochemical analysis of mononuclear infiltrates in breast carcinomas--correlation with tumour differentiation. *Journal of Pathology*. 1990;160(3):217-22.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1843. Nava-Castro KE, Palacios-Arreola MI, Ostoa-Saloma P, Muniz-Hernandez S, Cerbon MA, Gomez-Icazbalceta G, et al. The immunoendocrine network in breast cancer. *Advances in Neuroimmune Biology*. 2014;5(2):109-31.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1844. Nct. Analgesia and Pancreatic Cancer Surgery. <https://clinicaltrials.gov/show/NCT01929915>. 2013.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1845. Nct. Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patient With Breast Cancer. <https://clinicaltrials.gov/show/NCT02567929>. 2015.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1846. Nct. Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica. <https://clinicaltrials.gov/show/NCT00351520>. 2006.
배제사유 : 동물실험 및 전임상시험연구
1847. Nct. Impact of Anesthesia Maintenance Methods on Long-term Survival Rate. <https://clinicaltrials.gov/show/NCT02660411>. 2016.
배제사유 : 동물실험 및 전임상시험연구
1848. Nct. Intra-Peritoneal Local Anaesthetics in Ovarian Cancer. <https://clinicaltrials.gov/show/NCT04065009>. 2019.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1849. Nct. IRB-HSR# 13957: IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery: effects on Postoperative Recovery and Cancer Recurrence. <https://clinicaltrials.gov/show/NCT01204242>. 2010.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1850. Nct. Perioperative Administration of COX 2 Inhibitors and Beta Blockers to Women Undergoing Breast Cancer Surgery. <https://clinicaltrials.gov/show/NCT00502684>. 2007.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1851. Nct. Regional Anesthesia and Breast Cancer Recurrence. <https://clinicaltrials.gov/show/NCT00418457>. 2007.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1852. Nct. Understanding and Addressing Patient and Provider Preferences Around Discussions

- of Cost of Breast Cancer Care. <https://clinicaltrials.gov/show/NCT03780491>. 2018.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1853. Nct. Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy. <https://clinicaltrials.gov/show/NCT01922921>. 2013.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1854. Neefe JR, Sreevalsan T, Bash JA. Phase I trial of immunomodulatory activities of human leukocyte interferon in advanced cancer patients. Proceedings of the American Association for Cancer Research. 1982;Vol. 23:No. 969.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1855. Neefe JR, Sullivan JE, Ayoob M. Augmented immunity in cancer patients treated with alpha-interferon. Cancer Research. 1985;45(2):874-8.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1856. Neeman E, Zmora O, Ben-Eliyahu S. A new approach to reducing postsurgical cancer recurrence: Perioperative targeting of catecholamines and prostaglandins. Clinical Cancer Research. 2012;18(18):4895-902.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1857. Neilson HK, Conroy SM, Friedenreich CM. The Influence of Energetic Factors on Biomarkers of Postmenopausal Breast Cancer Risk. Current Nutrition Reports. 2014;3(1):22-34.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1858. Neises M, Ditz S, Scheck T, Schiller A, Nebe CT. [Consenting and declining patients for an intervention group after breast cancer surgery differ in terms of quality of life, coping and immunological functional assays]. Zentralblatt fur Gynakologie. 2001;123(1):27-36.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1859. Neises M, Nebe T, Schiller A, Ditz S, Wischnik A, Melchert F. [Coping with illness/quality of life and immunologic parameters of patients with breast carcinoma and benign tumors]. Gynakologisch-Geburtshilfliche Rundschau. 1995;35 Suppl 1:166-71.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1860. Nemunaitis JM, Nemunaitis J. Potential of Advexin: A p53 gene-replacement therapy in Li-Fraumeni syndrome. Future Oncology. 2008;4(6):759-68.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1861. Neo SY, Yang Y, Record J, Ma R, Chen X, Chen Z, et al. CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. Journal of Clinical Investigation. 2020;130(3):1185-98.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1862. Nesaretnam K, Radhakrishnan A, Selvadurai KR, Reimann K, Pailoor J, Razak G, et al. Effect of palm oil carotene on breast cancer tumorigenicity in nude mice. Lipids. 2002;37(6):557-60.

배제사유 : 동물실험 및 전임상시험연구

1863. Ng S, Galipeau J. Concise review: Engineering the fusion of cytokines for the modulation of immune cellular responses in cancer and autoimmune disorders. *Stem Cells Translational Medicine*. 2014;4(1):66-73.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1864. Ngiow SF, Teng MWL, Smyth MJ. A balance of interleukin-12 and -23 in cancer. *Trends in Immunology*. 2013;34(11):548-55.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1865. Nguyen A, Sanborn JZ, Vaske CJ, Rabizadeh S, Niazi K, Soon-Shiong P, et al. High-throughput identification of neoepitopes for the development of patient-specific cancer immunotherapies. *Cancer Research Conference: 107th Annual Meeting of the American Association for Cancer Research, AACR*. 2016;76(14 Supplement).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1866. Nguyen AW, Liu Y, Maynard J. Enhancing the immunotherapeutic Trastuzumab for selective activity in the low pH tumor microenvironment. *Journal of Immunology Conference: 105th Annual Meeting of the American Association of Immunologists, IMMUNOLOGY*. 2018;200(1 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1867. Nguyen K, Sun JC, Hortobagyi GN, Andreeff M, Battula VL. GD2-mediated FAK signaling regulates breast cancer stem cell function in triple negative breast cancer. *Cancer Research Conference: 39th Annual CTRC AACR San Antonio Breast Cancer Symposium. United States*. 2017;77(4 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1868. Nham T, Poznanski SM, Fan IY, Vahedi F, Shenouda MM, Lee AJ, et al. Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells. *Journal of Immunotherapy*. 2018;41(2):64-72.

배제사유 : 동물실험 및 전임상시험연구

1869. Niavarani SR, Lawson C, Boudaud M, Simard C, Tai LH. Oncolytic vesicular virus-based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8+ T-cell functionality. *Journal for ImmunoTherapy of Cancer*. 2020;8 (1) (e000465).

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

1870. Nicol AJ, Tazbirkova A, Nieda M. Comparison of clinical and immunological effects of intravenous and intradermal administration of alpha-GalactosylCeramide (KRN7000)-pulsed dendritic cells. *Clinical Cancer Research*. 2011;17(15):5140-51.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

1871. Nicolini A, Carpi A, Rossi G. Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. *Cancer Letters*. 2007;251(2):330-8.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1872. Nicolini A, Ferrari P, Spinelli R, Carpi A, Sagripanti A, Ambrogi F. Cell-mediated immunity in breast cancer patients. *Biomedicine & Pharmacotherapy*. 1996;50(8):337-43.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1873. Nicolini A, Mancini PA, Ferrari P, Anselmi L, Sagripanti A, Carpi A. Immunological and side effects of low sc recombinant interleukin-2 dose in addition to conventional treatment in relapsed breast and colorectal cancer patients. *Biomedicine & Pharmacotherapy*. 1996;50(8):344-9.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1874. Nicolini A, Rossi G, Ferrari P, Carpi A. Clinical and laboratory patterns during immune stimulation in hormone responsive metastatic breast cancer. *Biomedicine & Pharmacotherapy*. 2014;68(2):171-8.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1875. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K, et al. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. *Blood*. 2004;103(2):383-9.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1876. Nieland JD, Loviscek K, Kono K, Albain KS, McCall AR, Potkul RK, et al. PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCRzeta expression but are functionally impaired. *Journal of Immunotherapy*. 1998;21(4):317-22.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1877. Nielsen LL. NK cells mediate the anti-tumor effects of E1-deleted, type 5 adenovirus in a human tumor xenograft model. *Oncology Reports*. 2000;7(1):151-5.
배제사유 : 동물실험 및 전임상시험연구
1878. Nieman DC, Cook VD, Henson DA, Suttles J, Rejeski WJ, Ribisl PM, et al. Moderate exercise training and natural killer cell cytotoxic activity in breast cancer patients. *International Journal of Sports Medicine*. 1995;16(5):334-7.
배제사유 : 동물실험 및 전임상시험연구
1879. Nieto-Sampedro M, Valle-Argos B, Gomez-Nicola D, Fernandez-Mayoralas A, Nieto-Diaz M. Inhibitors of glioma growth that reveal the tumour to the immune system. *Clinical Medicine Insights: Oncology*. 2011;5:265-314.
배제사유 : 월저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1880. Nieto-Velazquez NG, Torres-Ramos YD, Munoz-Sanchez JL, Espinosa-Godoy L, Gomez-Cortes S, Moreno J, et al. Altered Expression of Natural Cytotoxicity Receptors and NKG2D on Peripheral Blood NK Cell Subsets in Breast Cancer Patients. *Translational Oncology*. 2016;9(5):384-91.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지

않은 연구

1881. Nikitin D, Garazha A, Sorokin M, Penzar D, Tkachev V, Markov A, et al. Retroelement-linked transcription factor binding patterns point to quickly developing molecular pathways in human evolution. *Cells.* 2019;February 2019. 8 (2) (130).
배제사유 : 동물실험 및 전임상시험연구
1882. Ning H, Lei HE, Xu YD, Guan RL, Venstrom JM, Lin G, et al. Conversion of adipose-derived stem cells into natural killer-like cells with anti-tumor activities in nude mice. *PLoS ONE.* 2014;9 (8) (e106246).
배제사유 : 동물실험 및 전임상시험연구
1883. Nishihira T, Hirayama K, Akimoto M, Sato S, Shineha R, Tan M, et al. [Significance of active nutritional support for maintenance of immunopotentiation on the surgical treatment of esophageal cancer]. *Nippon Geka Gakkai Zasshi. Journal of Japan Surgical Society.* 1985;86(9):1104-7.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1884. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. *International Journal of Cancer.* 2010;127(4):759-67.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1885. Nishikawa T, Kaneda Y. Systemic administration of platelet vector containing inactivated sendai virus particle eradicates melanoma in mice. *Molecular Therapy.* 2012;1):S264.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1886. Nishikawa T, Li S, Kaneda Y. Inactivated sendai virus particles upregulate cancer cell ICAM-1 expression with enhancing NK cell sensitivity on cancer cell. *Molecular Therapy.* 2018;26 (5 Supplement 1):339.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1887. Niwa Y, Kainuma T, Morita S, Itami J, Yokoro K. Anti-cancer effect in vitro and clinical efficacy of a cancer therapeutic containing natural herbs (BG-104), exposed to far infrared-ray heating and fermentation process using Aspergillus oryzae. [Japanese]. *Pharmacometrics.* 1994;47(5):465-77.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1888. Nocera NF, Lee MC, Czerniecki BJ. Boosting anti-HER2 CD4 T-helper responses in HER2 expressing ductal carcinoma in situ. *Future Oncology.* 2017;13(17):1459-62.
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
1889. Noguchi A, Kaneko T, Naitoh K, Saito M, Iwai K, Maekawa R, et al. Impaired and imbalanced cellular immunological status assessed in advanced cancer patients and restoration of the T cell immune status by adoptive T-cell immunotherapy. *International Immunopharmacology.* 2014;18(1):90-7.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1890. Nordstrom J. Development of an Fc-domain-optimized monoclonal antibody with enhanced potency against HER2-expressing tumors. *Cancer Research. Conference:* 101st

Annual Meeting of the American Association for Cancer Research, AACR. 2010;70(8 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1891. Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties. *Breast Cancer Research*. 2011;13 (6) (R123).

배제사유 : 동물실험 및 전임상시험연구

1892. Nordstrom JL, Huang L, Yang Y, Tuailon N, Stavenhagen JB, Stewart S, et al. Preclinical antitumor activity of an Fc domain-optimized HER2 monoclonal antibody (mAb). *Journal of Clinical Oncology. Conference*. 2010;28(15 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1893. Norton N, Olson RM, Pegram M, Tenner K, Ballman KV, Clynes R, et al. Association studies of Fcgamma receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831. *Cancer Immunology Research*. 2014;2(10):962-9.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1894. Obeid E, Zhou C, McFarlane A, Cornfeld A, Davis E, Bealin L, et al. T-cell response parallels clinical responses in patients with metastatic triple-negative breast cancer receiving platinum-based chemotherapy combined with PD-1 blockade. *JNCCN Journal of the National Comprehensive Cancer Network*. 2018;16 (5 Supplement 1):590.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1895. Oberg HH, Kellner C, Gonnermann D, Sebens S, Bauerschlag D, Gramatzki M, et al. Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing gammadelta T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells. *Frontiers in Immunology*. 2018;9:814.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1896. Oberoi P, Jabulowsky RA, Wels WS. Selective induction of cancer cell death by targeted granzyme B. *Antibodies*. 2013;2(1):130-51.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1897. O'Brien DI, Nally K, Kelly RG, O'Connor TM, Shanahan F, O'Connell J. Targeting the Fas/Fas ligand pathway in cancer. *Expert Opinion on Therapeutic Targets*. 2005;9(5):1031-44.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1898. Odeh A, McKee C, McCauley L, Jones H, Hodge L. Is lymphatic pumping safe for breast cancer patients?: The role of lymphatic flow in tumor formation and metastasis. *Journal of Immunology. Conference: 99th Annual Meeting of the American Association of Immunologists, IMMUNOLOGY*. 2012;188(1 MeetingAbstracts).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1899. Ogata S, Maimonis PJ, Itzkowitz SH. Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity. *Cancer Research*.

1992;52(17):4741-6.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

1900. Ogmundsdottir HM. Immune reaction to breast cancer: for better or for worse? *Archivum Immunologiae et Therapiae Experimentalis*. 2001;49 Suppl 2:S75-81.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1901. Oh CS, Lee J, Yoon TG, Seo EH, Park HJ, Piao L, et al. Effect of Equipotent Doses of Propofol versus Sevoflurane Anesthesia on Regulatory T Cells after Breast Cancer Surgery. *Anesthesiology*. 2018;129(5):921-31.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1902. Oh S, Lee JH, Kwack K, Choi SW. Natural killer cell therapy: A new treatment paradigm for solid tumors. *Cancers*. 2019;11 (10) (1534).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1903. Ohlsson-Wilhelm BM, Wang G. Circulating killer cells in women undergoing needle-directed excisional breast biopsy. *European Journal of Histochemistry*. 1994;38 Suppl 1:77-82.
배제사유 : 동물실험 및 전임상시험연구
1904. Ohshima K, Haraoka S, Ishihara S, Ohgami A, Yoshioka S, Suzumiya J, et al. Analysis of chromosome 6q deletion in EBV-associated NK cell leukemia/lymphoma. *Leukemia and Lymphoma*. 2002;43(2):293-300.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1905. Oka K, Nagayama R, Yonekawa N, Koyamatsu S, Mori N. A case report on a patient who presented with myelofibrosis, developed breast cancer with myeloid metaplasia, and finally showed immature NK-cell leukemia or AML without maturation with CD56 expression transformation in the pleura with extramedullary hematopoiesis: a 25-year course. *Pathology, Research & Practice*. 2013;209(5):319-22.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1906. Oka S. A review of clinical studies of bestatin. *Recent Results in Cancer Research*. 1980;75:126-32.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1907. Okada S, Vaeteewoottacharn K, Kariya R. Application of highly immunocompromised mice for the establishment of patient-derived xenograft (PDX) models. *Cells*. 2019;8 (8) (889).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1908. Okano F, Tachibana H, Akiyama K, Murakami H. The detection of a breast cancer antigen on MCF-7 cells reactive with the TCR (alpha) of a specific killer T cell line. *Biotherapy*. 1993;6(3):195-203.
배제사유 : 동물실험 및 전임상시험연구
1909. Okano F, Yamada K. Canine interleukin-18 induces apoptosis and enhances fas ligand mRNA expression in a canine carcinoma cell line. *Anticancer Research*. 2000;20(5)

B):3411-5.

배제사유 : 동물실험 및 전임상시험연구

1910. Okino T, Kan N, Nakanishi M, Satoh K, Mise K, Teramura Y, et al. The therapeutic effect of OK-432-combined adoptive immunotherapy against liver metastases from breast cancer. *Journal of Cancer Research & Clinical Oncology*. 1990;116(2):197-202.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1911. Okino T, Kan N, Nakanishi M, Satoh K, Mise K, Yamasaki S, et al. [The therapeutic effects of OK-432 combined adoptive immunotherapy (AIT) against liver metastases of breast cancer]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1989;16(4 Pt 2-3):1913-9.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
1912. Okita R, Ando T, Mougiakakos D, Mao Y, Lundqvist A, Kiessling R. HER2-HER3 signaling pathway regulates NK cell-mediated cytotoxicity via MHC class I-related chain A/ B in human breast cancer cells. *European Journal of Cancer*. 2011;1):S331.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1913. Okita R, Mougiakakos D, Ando T, Mao Y, Sarhan D, Wennerberg E, et al. HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines. *Journal of Immunology*. 2012;188(5):2136-45.
배제사유 : 동물실험 및 전임상시험연구
1914. Okita R, Mougiakakos D, Yasuda K, Maeda A, Yukawa T, Saisho S, et al. Her signaling effects on the NK cell-mediated cytotoxicity via regulation of mhc class i-related chain A/ B in cancer cells. *Annals of Oncology*. 2012;9):ix541.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1915. Okubo M, Sato N, Wada Y, Takahashi S, Torimoto K, Takahashi N, et al. Identification by monoclonal antibody of the tumor antigen of a human autologous breast cancer cell that is involved in cytotoxicity by a cytotoxic T-cell clone. *Cancer Research*. 1989;49(14):3950-4.
배제사유 : 동물실험 및 전임상시험연구
1916. Oleksowicz L, Dutcher JP. A Review of the New Cytokines: IL-4, IL-6, IL-11, and IL-12. *American Journal of Therapeutics*. 1994;1(2):107-15.
배제사유 : 동물실험 및 전임상시험연구
1917. Olive D, Savoldo B, Pastorino F, Castriconi R. Immunotherapy in the Treatment of Human Solid Tumors: Basic and Translational Aspects. *Journal of Immunology Research*. 2016;2016 (7853028).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1918. Oliver AJ, Davey AS, Keam SP, Mardiana S, Chan JD, von Scheidt B, et al. Tissue-specific tumor microenvironments influence responses to immunotherapies. *Clinical & Translational Immunology*. 2019;8(11):e1094.
배제사유 : 동물실험 및 전임상시험연구

1919. Olkhanud PB, Baatar D, Bodogai M, Hakim F, Gress R, Anderson RL, et al. Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. *Cancer Research*. 2009;69(14):5996-6004.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1920. Olson RM, Ward TM, Jegg AM, Liu X, Pegram MD. In vitro resistance to ERBB2-targeted therapies does not bestow cross-resistance to antibody dependent cellular cytotoxicity. *Cancer Research Conference: 36th Annual CTRC AACR San Antonio Breast Cancer Symposium*. San Antonio, TX United States. Conference Publication: 2013;73(24 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1921. Opdenakker G, Van Damme J. The countercurrent principle in invasion and metastasis of cancer cells. Recent insights on the roles of chemokines. *International Journal of Developmental Biology*. 2004;48(5-6):519-27.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1922. Orecchioni S, Talarico G, Labanca V, Calleri A, Mancuso P, Bertolini F. Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma. *British Journal of Cancer*. 2018;118(10):1329-36.
배제사유 : 동물실험 및 전임상시험연구
1923. Ortiz-Andrellucchi A, Sánchez-Villegas A, Rodríguez-Gallego C, Lemes A, Molero T, Soria A, et al. Immunomodulatory effects of the intake of fermented milk with *Lactobacillus casei* DN114001 in lactating mothers and their children. *British journal of nutrition*. 2008;100(4):834-45.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1924. Ortona E, Pierdominici M, Bernstein L. Autoantibodies to estrogen receptors and their involvement in autoimmune diseases and cancer. *Journal of Steroid Biochemistry and Molecular Biology*. 2014;B. 144(PART B):260-7.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1925. Oruc MT, Soran A, Jain AK, Wilson JW, Fung J. De novo breast cancer in patients with liver transplantation: University of Pittsburgh's experience and review of the literature. *Liver Transplantation*. 2004;10(1):1-6.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1926. Osborne RH, Sali A, Aaronson NK, Elsworth GR, Mdzewski B, Sinclair AJ. Immune function and adjustment style: do they predict survival in breast cancer? *Psycho-Oncology*. 2004;13(3):199-210.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1927. O'Shaughnessy J, Young RR, Levin MK, Baisch J, Timis R, Muniz LS, et al. Safety and immunologic activity of anakinra in HER2-negative metastatic breast cancer (MBC). *Journal of Clinical Oncology Conference*. 2016;34(Supplement 15).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1928. Oshimi K, Wakasugi H, Seki H, Kano S. Streptococcal preparation OK-432 augments cytotoxic activity against an erythroleukemic cell line in humans. *Cancer Immunology, Immunotherapy*. 1980;9(3):187-92.
배제사유 : 동물실험 및 전임상시험연구
1929. Ostapchuk Y, Cetin EA, Perfilyeva Y, Yilmaz A, Belyaev N, Deniz G. HLA-G expressing NK cell subset with suppressive properties is expanded in breast cancer (TUM10P.1043). *Journal of Immunology. Conference: 102nd Annual Meeting of the American Association of Immunologist, IMMUNOLOGY*. 2015;194(1 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1930. Ostapchuk YO, Cetin EA, Perfilyeva YV, Yilmaz A, Skiba YA, Chirkin AP, et al. Peripheral blood NK cells expressing HLA-G, IL-10 and TGF-beta in healthy donors and breast cancer patients. *Cellular Immunology*. 2015;298(1-2):37-46.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1931. Othman N, Jamal R, Abu N. Cancer-Derived Exosomes as Effectors of Key Inflammation-Related Players. *Frontiers in Immunology*. 2019;10 (2103).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1932. Oucherif O, Naimi D. Function of HLA-G in cancer immunoediting and its clinical benefits. *Journal Africain du Cancer*. 2015;7(3):132-9.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1933. Ouni N, Ben Chaaben A, Kablouti G, Lajnef M, Ayari F, Abaza H, et al. MIC-129Met/Val Polymorphism Is Associated with Early-Onset Breast Cancer Risk. *Immunological Investigations*. 2017;46(6):603-14.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1934. Owen JL, Iragavarapu-Charyulu V, Lopez DM. T cell-derived matrix metalloproteinase-9 in breast cancer: Friend or foe? *Breast Disease*. 2004;20:145-53.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1935. Ozkan A, Ayhan A, Fiskin K. Combined effect of epirubicin and lymphokine-activated killer cells on the resistant human breast cancer cells. *Cell Biology & Toxicology*. 2004;20(5):261-71.
배제사유 : 동물실험 및 전임상시험연구
1936. Ozzello L, Habif DV, De Rosa CM, Cantell K. Cellular events accompanying regression of skin recurrences of breast carcinomas treated with intralesional injections of natural interferons alpha and gamma. *Cancer Research*. 1992;52(17):4571-81.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1937. Pacey AA. On the shoulders of giants. *Human Fertility*. 2016;19(3):150.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1938. Pachynski RK, Wang P, Salazar N, Zheng Y, Nease L, Rosalez J, et al. Chemerin Suppresses Breast Cancer Growth by Recruiting Immune Effector Cells Into the Tumor

Microenvironment. *Frontiers in Immunology*. 2019;10:983.

배제사유 : 동물실험 및 전임상시험연구

1939. Pachynski RK, Zabel BA, Tejeda N, Butcher EC. Leukocyte chemoattractant chemerin as a novel immunotherapeutic agent. *Cancer Research*. Conference: 101st Annual Meeting of the American Association for Cancer Research, AACR. 2010;70(8 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1940. Paciotti GF, Tamarkin L. Interleukin-2 differentially affects the proliferation of a hormone-dependent and a hormone-independent human breast cancer cell line in vitro and in vivo. *Anticancer Research*. 1988;8(6):1233-9.

배제사유 : 동물실험 및 전임상시험연구

1941. Paciucci PA, Bekesi JG, Ryder JS, Odchimar R, Chahinian PA, Holland JF. Immunotherapy with IL2 by constant infusion and weekly doxorubicin. *American Journal of Clinical Oncology*. 1991;14(4):341-8.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1942. Page DB, Pucilowska J, Berinstein NL, Egan JE. Tumor infiltrating lymphocyte recruitment in patients with early stage breast cancer after intramammary IRX-2 cytokine immunotherapy. *Journal of Clinical Oncology*. Conference: 2018;36(5 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1943. Page DB, Pucilowska J, Moxon N, Mellinger S, Conlin A, Imatani J, et al. Tumor immune infiltration in patients with early stage breast cancer after preoperative treatment with IRX-2. *Journal for ImmunoTherapy of Cancer*. Conference: 32nd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2017;5(Supplement 2).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1944. Pal A, Zimmer P, Schmidt ME, Hummel M, Ulrich CM, Wiskemann J, et al. No Evidence for Effect of Exercise on Transcriptome of NK Cells in Breast Cancer Patients Undergoing Adjuvant Therapy: Results From a Pilot Study. *Frontiers in Physiology*. 2019;10:959.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1945. Palacios-Arreola MI, Nava-Castro KE, Rio-Araiza VHD, Perez-Sanchez NY, Morales-Montor J. A single neonatal administration of Bisphenol A induces higher tumour weight associated to changes in tumour microenvironment in the adulthood. *Scientific Reports*. 2017;7(1):10573.

배제사유 : 동물실험 및 전임상시험연구

1946. Palazon A, Dubrot J, Martinez-Forero I, Rouzaut-Subira A, Ochoa C, Perez-Gracia JL, et al. Polly Matzinger's "danger model" finds its predicted danger-denoting self moieties. *Inmunologia*. 2008;27(4):205-11.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1947. Palena C, Gulley JL, Schlom J. Brachyury and the interleukin-8 axis in tumor progression. *Molecular Cancer Therapeutics*. Conference: AACR NCI EORTC

International Conference: Molecular Targets and Cancer Therapeutics. 2017;17(1 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1948. Palmer SC, Stefanek ME, Thombs BD, Coyne JC. Psychologic intervention and survival: Wishing does not make it so - letter. Clinical Cancer Research. 2010;16(21):5364-5.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1949. Palmisano GL, Pistillo MP, Fardin P, Capanni P, Nicolo G, Salvi S, et al. Analysis of HLA-G expression in breast cancer tissues. Human Immunology. 2002;63(11):969-76.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1950. Pan CL, Chen FC. Patent trend and competitive analysis of cancer immunotherapy in the United States. Human Vaccines and Immunotherapeutics. 2017;13(11):2583-93.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

1951. Pan J, Shen J, Si W, Du C, Chen D, Xu L, et al. Resveratrol promotes MICA/B expression and natural killer cell lysis of breast cancer cells by suppressing c-Myc/miR-17 pathway. Oncotarget. 2017;8(39):65743-58.

배제사유 : 동물실험 및 전임상시험연구

1952. Pande K, Cayatte C, Banerjee A, Ueda R, Gorman D, Beaumont M, et al. Sustained IFNalpha treatment inhibits metastasis in 4T1 mammary adenocarcinoma and correlates with decreasing tumor-induced myeloid-derived suppressor cells. Cytokine. 2010;52 (1-2):94.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1953. Pant S, Mulder I, Shah AY, Msaouel P, Altan M, Weinberg J, et al. A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy. Journal of Clinical Oncology. Conference. 2019;37(Supplement 15).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1954. Pantic JM, Jovanovic IP, Radosavljevic GD, Gajovic NM, Arsenijevic NN, Conlon JM, et al. The frog skin host-defense peptide frenatin 2.1S enhances recruitment, activation and tumoricidal capacity of NK cells. Peptides. 2017;93:44-50.

배제사유 : 동물실험 및 전임상시험연구

1955. Papadimitrakopoulou V, Tannir N, Bernatchez C, Haymaker C, Bentebibel S, Curti B, et al. Pivot-02: Phase 1/2 study of NKTR-214 and nivolumab in patients with locally advanced or metastatic solid tumor malignancies. Journal of Thoracic Oncology. 2017;12 (11 Supplement 2):S2153.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1956. Papadopoulos NG, Dedoussis GV, Spanakos G, Gritzapis AD, Baxevanis CN, Papamichail M. An improved fluorescence assay for the determination of lymphocyte-mediated cytotoxicity using flow cytometry. Journal of Immunological Methods. 1994;177(1-2):101-11.

배제사유 : 동물실험 및 전임상시험연구

1957. Papamichail M, Baxevanis CN. Gamma-interferon enhances the cytotoxic activity of interleukin-2-induced peripheral blood lymphocyte (LAK) cells, tumor infiltrating lymphocytes (TIL), and effusion associated lymphocytes. *Journal of Chemotherapy*. 1992;4(6):387-93.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1958. Papamichos SI. NKG2E comprises an immunogenic peptide, derived from an alu-retrotransposon: An attractive novel target for immunotherapeutic approaches. *Annals of Oncology*. 2019;30 (Supplement 11):xi53.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1959. Papila C, Papila I, Bilir M, Cagatay T, Yanardag H, Koksal S. Effect of vitamin E supplementation on natural killer cell activity in patients with solid tumors. *Journal of B.U.ON.* 1999;4(4):435-7.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1960. Pardali K, Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. *Biochimica et Biophysica Acta - Reviews on Cancer*. 2007;1775(1):21-62.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1961. Parihar R, Nadella P, Lewis A, Jensen R, De Hoff C, Dierksheide JE, et al. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. *Clinical Cancer Research*. 2004;10(15):5027-37.
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
1962. Park HC, Kim SH, Choi HY, Kim H, Lee JE, Kim HJ. Peripheral natural killer cell activity as a tool to screen for malignancy in hemodialysis patients. *Nephrology Dialysis Transplantation*. 2018;33 (Supplement 1):i260-i1.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1963. Park IH, Kong SY, Kang JH, Mo HJ, Kim TS, Lee KS, et al. Decreased functions of natural killer cells in peripheral blood of advanced triple negative breast cancer patients. *Cancer Research Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium*. San Antonio, TX United States. Conference Publication: 2015;75(9 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1964. Park IH, Yang HN, Lee KJ, Kim TS, Lee ES, Jung SY, et al. Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer. *Oncotarget*. 2017;8(20):32722-30.
배제사유 : 동물실험 및 전임상시험연구
1965. Park MH, Lee JS, Yoon JH. High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma. *Journal of Surgical Oncology*. 2012;106(4):386-92.
배제사유 : 동물실험 및 전임상시험연구

1966. Park NJ, Kang DH, Weaver MT. Objective and subjective breast cancer risk: relationships with natural killer cell activity and psychological distress in healthy women. *Cancer Nursing*. 2010;33(6):411-20.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
1967. Park NJ, Kang DH. Breast cancer risk and immune responses in healthy women. *Oncology Nursing Forum*. 2006;33(6):1151-9.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1968. Park SM, Ahn JW, Lee SW, Kim DY, Kim JH, Kim YM, et al. The antiproliferative and antiviral effect of interferon-beta on breast cancer cell line and its mutants. *Journal of Immunotherapy*. 2009;32 (9):1007-8.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1969. Park SW, Bae JH, Kim SD, Son YO, Park HJ, Lee CH, et al. Comparison of level of NKG2D ligands between normal and tumor tissue using multiplex RT-PCR. *Cancer Investigation*. 2007;25(5):299-307.
배제사유 : 동물실험 및 전임상시험연구
1970. Park YK, Shin DJ, Cho D, Kim SK, Lee JJ, Shin MG, et al. Interleukin-21 increases direct cytotoxicity and IFN-gamma production of ex vivo expanded NK cells towards breast cancer cells. *Anticancer Research*. 2012;32(3):839-46.
배제사유 : 동물실험 및 전임상시험연구
1971. Parodi PW. A role for milk proteins and their peptides in cancer prevention. *Current Pharmaceutical Design*. 2007;13(8):813-28.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1972. Pascutti F, Cunha LL, Rizzatti EG, Colleoni GW. Understanding myeloma cancer stem cells. *Immunotherapy*. 2013;5(12):1291-4.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1973. Pasero C, Gravis G, Rocchi P, Sylvaine JL, Livrati P, Thomassin J, et al. Alterations of natural killer cell receptors as biomarkers associated with the severity of the disease in prostate cancer. *Journal of Clinical Oncology Conference*. 2012;30(15 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1974. Pasto A, Consonni FM, Sica A. Influence of innate immunity on cancer cell stemness. *International Journal of Molecular Sciences*. 2020;21 (9) (3352).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1975. Patel SA, Meyer JR, Greco SJ, Corcoran KE, Bryan M, Rameshwar P. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. *Journal of Immunology*. 2010;184(10):5885-94.
배제사유 : 동물실험 및 전임상시험연구
1976. Paterso Y. Searching for the ideal cancer vaccine. *Cancer Biology and Therapy*. 2009;8(2):104-5.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1977. Paul S, Lal G. The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. *Frontiers in Immunology*. 2017;8 (SEP) (1124).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1978. Pavlakis GN, Ng SM, Dimas K, Valentin A, Nagy B, Alicea C, et al. hetIL-15 therapy results in tumor control by promoting tumor infiltration of CD8+ T cells with increased cytotoxic potential and decreased PD-1 expression. *Journal of Immunology*. Conference: 103rd Annual Meeting of the American Association of Immunologist, IMMUNOLOGY. 2016;196(SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1979. Pavletic Z, Benyunes MC, Thompson JA, Lindgren CG, Massumoto C, Alderson MR, et al. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy. *Experimental Hematology*. 1993;21(10):1371-8.

배제사유 : 동물실험 및 전임상시험연구

1980. Pawelec G, Perez S. Translating immunity into cancer therapy: New findings from the first conference of the European Society for Cancer Immunology and Immunotherapy, an ESMO-EIS held in Athens, 15-17 November 2007. *Cancer Immunology, Immunotherapy*. 2008;57(10):1505-9.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1981. Pawlik A, Anisiewicz A, Filip-Psurska B, Nowak M, Turlej E, Trynda J, et al. Calcitriol and its analogs establish the immunosuppressive microenvironment that drives metastasis in 4T1 mouse mammary gland cancer. *International Journal of Molecular Sciences*. 2018;19 (7) (2116).

배제사유 : 동물실험 및 전임상시험연구

1982. Pawlowska E, Szczepanska J, Blasiak J. Pro- And antioxidant effects of Vitamin C in cancer in correspondence to its dietary and pharmacological concentrations. *Oxidative Medicine and Cellular Longevity*. 2019;2019 (7286737).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1983. Payne KK, Zoon CK, Wan W, Marlar K, Keim RC, Kenari MN, et al. Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells. *Breast Cancer Research & Treatment*. 2013;142(1):45-57.

배제사유 : 동물실험 및 전임상시험연구

1984. Peace KM, Hale DF, Vreeland TJ, Jackson DO, Berry JS, Trappey AF, et al. Phase Ib trial of two folate binding protein peptide booster vaccines (E39 and J65) in breast and ovarian cancer patients. *Journal for immunotherapy of cancer*. 2016;4.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1985. Peakman M. Broadening the translational immunology landscape. *Clinical and Experimental Immunology*. 2012;170(3):249-53.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

1986. Peighambarzadeh F, Najafalizadeh A, Esmaeil N, Rezaei A, Ashrafi F, Ganjalikhani Hakemi M. Optimization of In Vitro Expansion and Activation of Human Natural Killer Cells against Breast Cancer Cell Line. *Avicenna Journal of Medical Biotechnology*. 2020;12(1):17-23.
배제사유 : 동물실험 및 전임상시험연구
1987. Peipp M, Derer S, Lohse S, Staudinger M, Klausz K, Valerius T, et al. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity. *Oncotarget*. 2015;6(31):32075-88.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
1988. Pejawar-Gaddy S, Finn OJ. Cancer vaccines: Accomplishments and challenges. *Critical Reviews in Oncology/Hematology*. 2008;67(2):93-102.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1989. Pellegrino B, Llop-Guevara A, Pedretti F, Cruz C, Castroviejo M, Cedro-Tanda A, et al. PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors. *Annals of Oncology*. 2019;30 (Supplement 5):v760.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
1990. Pellegrino B, Musolino A, Llop-Guevara A, Serra V, De Silva P, Hlavata Z, et al. Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review. *Translational Oncology*. 2020;13(2):410-22.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1991. Pelley RP, Strickland FM. Plants, polysaccharides, and the treatment and prevention of neoplasia. *Critical Reviews in Oncogenesis*. 2000;11(3-4):189-225.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
1992. Peng Q, Zhao L, Hou Y, Sun Y, Wang L, Luo H, et al. Biological Characteristics and Genetic Heterogeneity between Carcinoma-Associated Fibroblasts and Their Paired Normal Fibroblasts in Human Breast Cancer. *PLoS ONE*. 2013;8 (4) (e60321).
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1993. Perez S, Sotiriadou R, Missitzis G, Trangas T, Giannoulis N, Mavroudeas D, et al. delta IK17 antigen: a possible early marker of cancer development. *International Journal of Biological Markers*. 1996;11(4):190-7.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1994. Perillo A, Pierelli L, Battaglia A, Salerno MG, Rutella S, Cortesi E, et al. Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer. *Bone Marrow Transplantation*. 2002;30(9):571-8.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
1995. Pernas S, Goel S, Harrison BT, Hu J, Johnson N, Regan M, et al. Assessment of the tumor immune environment in inflammatory breast cancer treated with neoadjuvant dual-HER2 blockade. *Cancer Research Conference*. 2018;79(4 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1996. Peske J, Thompson E, Gemta L, Baylis R, Fu Y, Engelhard V. Effector lymphocytes induce lymph node-like vasculature in tumors, which enables naive T cell infiltration and enhanced anti-tumor immunity (TUM7P.1020). *Journal of Immunology*. Conference: 102nd Annual Meeting of the American Association of Immunologist, IMMUNOLOGY. 2015;194(1 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

1997. Peske JD, Thompson ED, Gemta L, Baylis RA, Fu YX, Engelhard VH. Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. *Nature Communications*. 2015;6 (7114).

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

1998. Peters C, Lotzerich H, Niemeier B, Schule K, Uhlenbruck G. Influence of a moderate exercise training on natural killer cytotoxicity and personality traits in cancer patients. *Anticancer Research*. 1994;14(3A):1033-6.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

1999. Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy: When aspecificity becomes an advantage. *Current Medicinal Chemistry*. 2008;15(5):422-32.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2000. Petricevic B, Laengle J, Singer J, Sachet M, Fazekas J, Steger G, et al. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. *Journal of Translational Medicine*. 2013;11:307.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2001. Petricevic L, Langle J, Singer J, Steger G, Bartsch R, Jensen-Jarolim E, et al. Evaluation of trastuzumab mediated antibody dependent cellular cytotoxicity in HER2/neu positive breast cancer patient using a rapid FACS-based analysis. *European Surgery - Acta Chirurgica Austriaca*. 2012;248):8.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2002. Petrini B, Wasserman J, Blomgren H. T-cell subsets in patients treated with pelvic irradiation for cancer. *Journal of Clinical & Laboratory Immunology*. 1985;17(3):147-8.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2003. Petrosiute A, Auletta JJ, Lazarus HM. Achieving graft-versus-tumor effect in brain tumor patients: From autologous progenitor cell transplant to active immunotherapy. *Immunotherapy*. 2012;4(11):1139-51.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2004. Petticrew M, Sutton A, Jacobs JR, Bovasso G. Letter to the editor (multiple letters). *Psychological Medicine*. 2001;31(3):565-8.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2005. Peyrin-Biroulet L, Christopher R, Behan D, Lassen C. Modulation of sphingosine-1-phosphate in inflammatory bowel disease. *Autoimmunity Reviews*.

2017;16(5):495-503.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2006. Phalke S, Badwe R, Parmar V, Chiplunkar S. Zoledronate induced gammadelta T cells activation: A potential cell based therapy. European Journal of Cancer. 2016;1):S63-S4.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2007. Pham DH, Kim JS, Kim SK, Shin DJ, Uong NT, Hyun H, et al. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells In Vitro. Anticancer Research. 2017;37(10):5507-13.

배제사유 : 동물실험 및 전임상시험연구

2008. Phan TG, Long GV, Scolyer RA. Multiple checkpoints on the long road towards cancer immunotherapy. Immunology and Cell Biology. 2015;93(4):323-5.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2009. Philippe A, Rassy M, Craciun L, Naveaux C, Willard-Gallo K, Larsimont D, et al. Inflammatory Stroma of Lymphoepithelioma-like Carcinoma of the Cervix: Immunohistochemical Study of 3 Cases and Review of the Literature. International Journal of Gynecological Pathology. 2018;37(5):482-7.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2010. Piccart M, Saini K, Azim H, Metzger O, De Azambuja E. Beyond trastuzumab: New anti-HER2 agents. Breast. 2011;1):S1-S2.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2011. Pierelli L, Perillo A, Ferrandina G, Salerno G, Rutella S, Fattorossi A, et al. The role of growth factor administration and T-cell recovery after peripheral blood progenitor cell transplantation in the treatment of solid tumors: Results from a randomized comparison of G-CSF and GM-CSF. Transfusion. 2001;41(12):1577-85.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2012. Pignata C, Amorosi S, Russo I, Capalbo D, Lettieri T, Adriani M, et al. Shared signaling pathways between endocrine and immune system receptors: The model of gamma chain. Current Signal Transduction Therapy. 2008;3(3):206-14.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2013. Pinkas J, Teicher BA. TGF-beta in cancer and as a therapeutic target. Biochemical Pharmacology. 2006;72(5):523-9.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2014. Pinte S, Soncin F. Egfl7 promotes tumor escape from immunity. OncoImmunology. 2012;1(3):375-6.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2015. Pires BRB, Silva RCMC, Ferreira GM, Abdelhay E. NF-kappaB: Two sides of the same coin. Genes. 2018;9 (1) (24).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2016. Piroozmand A, Hassan ZM. Evaluation of natural killer cell activity in pre and post treated breast cancer patients. *Journal of Cancer Research & Therapeutics*. 2010;6(4):478-81.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2017. Pirttikangas CO, Perttilä J, Salo M, Vainio O, Liukko-Sipi S. Propofol infusion anaesthesia and immune response in minor surgery. *Anaesthesia*. 1994;49(1):13-6.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2018. Plunkett TA, Miles DW. Immunotherapy and breast cancer. *Cancer Treatment Reviews*. 1998;24(1):55-67.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2019. Poggi A, Zocchi MR. Mesenchymal stromal cells as regulators of anti-tumour immune response. *Indian Journal of Medical Research*. 2015;142(FEB):139-42.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2020. Pol JG, Marguerie M, Arulanandam R, Bell JC, Lichty BD. Panorama from the oncolytic virotherapy summit. *Molecular Therapy*. 2013;21(10):1814-8.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2021. Polakova K, Russ G. Expression of the non-classical HLA-G antigen in tumor cell lines is extremely restricted. *Neoplasma*. 2000;47(6):342-8.
배제사유 : 동물실험 및 전임상시험연구
2022. Pollack SB, Lee MY, Cohen E, Lottfeldt JL, Rosse C. Modulation of murine natural killer cells by a granulocytosis-inducing tumor. *Cancer Research*. 1989;49(1):174-8.
배제사유 : 동물실험 및 전임상시험연구
2023. Pollard JW. Defining Metastatic Cell Latency. *New England Journal of Medicine*. 2016;375(3):280-2.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2024. Popkov M, Sidrac-Ghali S, Lusignan Y, Lemieux S, Mandeville R. Inhibition of tumour growth and metastasis of human fibrosarcoma cells HT-1080 by monoclonal antibody BCD-F9. *European Journal of Cancer*. 2001;37(18):2484-92.
배제사유 : 동물실험 및 전임상시험연구
2025. Porrata LF, Markovic SN. Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation. *Clinical and Experimental Medicine*. 2004;4(2):78-85.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2026. Porta C, Larghi P, Rimoldi M, Grazia Totaro M, Allavena P, Mantovani A, et al. Cellular and molecular pathways linking inflammation and cancer. *Immunobiology*. 2009;214(9-10):761-77.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2027. Pouillart P, Palangie T, Jouve M, Garcia-Giralt E, Fridman WH, Magdelenat H, et al. Administration of fibroblast interferon to patients with advanced breast cancer: possible effects on skin metastasis and on hormone receptors. European Journal of Cancer & Clinical Oncology. 1982;18(10):929-35.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2028. Pradere JP, Dapito DH, Schwabe RF. The Yin and Yang of Toll-like receptors in cancer. Oncogene. 2014;33(27):3485-95.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2029. Prestwich RJ, Errington F, Hatfield P, Merrick AE, Ilett EJ, Selby PJ, et al. The Immune System - is it Relevant to Cancer Development, Progression and Treatment? Clinical Oncology. 2008;20(2):101-12.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2030. Prestwich RJD, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F. Oncolytic viruses: A novel form of immunotherapy. Expert Review of Anticancer Therapy. 2008;8(10):1581-8.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2031. Price GB, Teh HS, Miller RG. Specific spontaneous cytotoxic activity in human T cell colonies. Journal of Immunology. 1980;124(5):2352-5.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2032. Price JE. Xenograft models in immunodeficient animals : I. Nude mice: spontaneous and experimental metastasis models. Methods in Molecular Medicine. 2001;58:205-13.
배제사유 : 동물실험 및 전임상시험연구
2033. Pross HF, Sterns E, MacGillis DR. Natural killer cell activity in women at "high risk" for breast cancer, with and without benign breast syndrome. International Journal of Cancer. 1984;34(3):303-8.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2034. Provinciali M, Re F, Donnini A, Orlando F, Bartozzi B, Di Stasio G, et al. Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. International Journal of Cancer. 2005;115(1):36-45.
배제사유 : 동물실험 및 전임상시험연구
2035. Puchalapalli M, Zeng X, Mu L, Anderson A, Glickman LH, Zhang M, et al. NSG mice provide a better spontaneous model of breast cancer metastasis than athymic (nude) mice. PLoS ONE. 2016;11 (9) (e0163521).
배제사유 : 동물실험 및 전임상시험연구
2036. Pucilowska J, Egan JE, Berinstein NL, Moxon N, Aliabadi-Wahle S, Imatani JH, et al. Perilymphatic IRX-2 cytokine therapy to enhance tumor infiltrating lymphocytes (TILs) and PD-L1 expression preceding curative-intent therapy in early stage breast cancer (ESBC). Cancer Research Conference. 2018;79(4 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2037. Pucilowska J, Rajamanickam V, Moxon N, Sanchez K, Shah M, Imatani J, et al. Tumor infiltrating lymphocyte recruitment after peri-lymphatic IRX-2 cytokine immunotherapy in resectable breast cancer and head and neck carcinoma. *Journal for ImmunoTherapy of Cancer*. Conference: 33rd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2018;6(Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2038. Puglisi F, Minisini AM, De Angelis C, Arpino G. Overcoming treatment resistance in HER2-positive breast cancer: Potential strategies. *Drugs*. 2012;72(9):1175-93.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2039. Puiggros A, Blanco G, Muntasell A, Rodriguez-Rivera M, Nonell L, Puigdecanet E, et al. Reduced expression of the CD94/NKG2C NK cell receptor in chronic lymphocytic leukemia (CLL) and CLL-like monoclonal B-cell lymphocytosis (MBL). *Blood*. Conference: 61st Annual Meeting of the American Society of Hematology, ASH. 2019;134(Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2040. Pulaski BA, Clements VK, Pipeling MR, Ostrand-Rosenberg S. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. *Cancer Immunology Immunotherapy*. 2000;49(1):34-45.
배제사유 : 동물실험 및 전임상시험연구
2041. Pulaski BA, Smyth MJ, Ostrand-Rosenberg S. Interferon-gamma-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma. *Cancer Research*. 2002;62(15):4406-12.
배제사유 : 동물실험 및 전임상시험연구
2042. Punt KC, Jansen RL, De Mulder PH, Batchelor D, Galazka A, Bolhuis RL, et al. Repetitive weekly cycles of 4-day continuous infusion of recombinant interleukin-2: a phase I study. *Journal of Immunotherapy*. 1992;12(4):277-84.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2043. Putz E, Gotthardt D, Hoermann G, Csiszar A, Wirth S, Berger A, et al. CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. *Cell Reports*. 2013;4(3):437-44.
배제사유 : 동물실험 및 전임상시험연구
2044. Putz EM, Mayfosh AJ, Kos K, Barkauskas DS, Nakamura K, Town L, et al. NK cell heparanase controls tumor invasion and immune surveillance. *Journal of Clinical Investigation*. 2017;127(7):2777-88.
배제사유 : 동물실험 및 전임상시험연구
2045. Qi CJ, Ning YL, Han YS, Min HY, Ye H, Zhu YL, et al. Autologous dendritic cell vaccine for estrogen receptor (ER)/ progestin receptor (PR) double-negative breast cancer. *Cancer Immunology, Immunotherapy*. 2012;61(9):1415-24.
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

2046. Qi L, Zhang Q, Miao Y, Kang W, Tian Z, Xu D, et al. Interleukin-33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development. *International Journal of Cancer*. 2020;146(5):1421-34.
배제사유 : 동물실험 및 전임상시험연구
2047. Qi L, Zhang QY, Miao YH, Fang F, Xu DM, Xiao WH. Interleukin-33 activates and recruits natural killer cells to inhibit cancer pulmonary metastasis. *European Journal of Immunology*. 2019;49 (Supplement 3):480.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2048. Qian X, Chen H, Wu X, Hu L, Huang Q, Jin Y. Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis. *Cytokine*. 2017;89:34-44.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2049. Qian X, Shi Z, Qi H, Zhao M, Huang K, Han D, et al. A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors. *Theranostics*. 2019;9(25):7616-27.
배제사유 : 동물실험 및 전임상시험연구
2050. Qian Z, Wang X, Song Z, Zhang H, Zhou S, Zhao J, et al. A phase i trial to evaluate the multiple-dose safety and antitumor activity of ursolic acid liposomes in subjects with advanced solid tumors. *BioMed Research International*. 2015;2015 (809714).
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2051. Qiao H, Chen X, Chen E, Zhang J, Huang D, Yang D, et al. Folated pH-degradable nanogels for the simultaneous delivery of docetaxel and an IDO1-inhibitor in enhancing cancer chemo-immunotherapy. *Biomaterials Science*. 2019;7(7):2749-58.
배제사유 : 동물실험 및 전임상시험연구
2052. Qiao N, Chawla A, Alatrash G, Philips A, Peoples G, Ponniah S, et al. A novel method to identify HER2-derived HLA-A2 epitopes for use in combination immunotherapy with Trastuzumab. *Cancer Research. Conference: 104th Annual Meeting of the American Association for Cancer Research, AACR*. 2013;73(8 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2053. Qiao Y, Zheng P, Liu Y. Harnessing the regulatory feedback to T cells to enhance antitumor immune responses. *Drug Discovery Today: Therapeutic Strategies*. 2006;3(1):31-4.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2054. Qin H, Liu L, Sun S, Zhang D, Sheng J, Li B, et al. The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment. *PeerJ*. 2018;2018 (6) (e5092).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2055. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. *Nature Medicine*. 2013;19(11):1423-37.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2056. Quesada JR, Guterman JU, Hersh EM. Clinical and immunological study of beta

interferon by intramuscular route in patients with metastatic breast cancer. *Journal of Interferon Research*. 1982;2(4):593-9.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2057. Quirk K, Ganapathy-Kanniappan S. Is There an Opportunity for Current Chemotherapeutics to Up-regulate MIC-A/B Ligands? *Frontiers in Pharmacology*. 2017;8:732.

배제사유 : 동물실험 및 전임상시험연구

2058. Quist J, Mirza H, Cheang MCU, Telli ML, O'Shaughnessy JA, Lord CJ, et al. A four-gene decision tree signature classification of triple-negative breast cancer: Implications for targeted therapeutics. *Molecular Cancer Therapeutics*. 2019;18(1):204-12.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2059. Raab S, Hilpert J, Grosse-Hovest L, Schmiedel BJ, Steinle A, Kanz L, et al. Fc-engineered NKG2D-Ig fusion proteins for induction of NK cell ADCC against breast cancer. *Onkologie*. 2012;6:169.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2060. Raab S, Steinbacher J, Grosse-Hovest L, Schmiedel BJ, Steinle A, Kanz L, et al. Induction of NK cell reactivity in breast cancer by FC-engineered NKG2D-ig fusion proteins. *Blood Conference: 54th Annual Meeting of the American Society of Hematology, ASH*. 2012;120(21).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2061. Raab S, Steinbacher J, Schmiedel BJ, Kousis PC, Steinle A, Jung G, et al. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status. *Journal of Immunology*. 2014;193(8):4261-72.

배제사유 : 동물실험 및 전임상시험연구

2062. Rabinovich GA, Conejo-Garcia JR. Shaping the Immune Landscape in Cancer by Galectin-Driven Regulatory Pathways. *Journal of Molecular Biology*. 2016;428(16):3266-81.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2063. Rabizadeh S, Simon B, Klingemann H, Sims D, Weiss R, Soon-Shiong P. Novel protocol combining metronomic nant-paclitaxel with HER2-targeted natural killer cells (innate immunotherapy) for HER2-positive metastatic breast cancer. *Cancer Research Conference: 38th Annual CTRC AACR San Antonio Breast Cancer Symposium. San Antonio, TX United States. Conference Publication*: 2016;76(4 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2064. Rachel H, Chang-Chun L. Recent advances toward the development of inhibitors to attenuate tumor metastasis via the interruption of lectin-ligand interactions. *Advances in Carbohydrate Chemistry and Biochemistry*. 2013;69:125-207.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2065. Radenkovic S, Gopcevic K, Nikitovic M, Jurisic V, Konjevic G. Clinical stage-dependent down-regulation of STAT 1, 3 and 5 expression and induction by Th1 cytokines in

- breast cancer patients. Annals of Oncology. 2013;3):iii39.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2066. Radenkovic S, Konjevic G, Srdic Rajic T, Stamatovic L, Milovic M, Jurisic V. Association of decreased NK cell activity and IFNgamma expression with pstat dysregulation in breast cancer patients. European Journal of Cancer. 2011;1):S362.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2067. Radenkovic S, Nikitovic M, Vucicevic S, Milovic M, Srdic-Rajic T, Konjevic G. Impairment of IFN gamma production and NK cell cytotoxicity of advanced breast cancer patients. Breast. 2013;3):S59.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2068. Radenkovic SS, Jurisic V, Dzodic R, Konjevic G. Association of IFNg production and NK cytotoxicity in PBL of breast cancer patients. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO. 2016;27(Supplement 6).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2069. Rady M, Watzl C, Claus M, Khorshid O, Mahran L, Abou-Aisha K. Altered expression of miR-181a and miR-146a does not change the expression of surface NCRs in human NK cells. Scientific Reports. 2017;7:41381.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2070. Rafei H, Mehta RS, Rezvani K. Editorial: Cellular Therapies in Cancer. Frontiers in Immunology. 2019;10 (2788).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2071. Raghavendra RM, Ajaikumar BS, Vadiraja HS, Patil S, Diwakar RB, Sashidhara P, et al. Role of yoga in modulating fatigue, sleep disturbances, salivary cortisol, and immune measures in breast cancer survivors: A randomized controlled trial. Journal of Clinical Oncology. Conference. 2010;28(15 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2072. Rahman S, Archana A, Jan AT, Dutta D, Shankar A, Kim J, et al. Molecular insights into the relationship between autoimmune thyroid diseases and breast cancer: A critical perspective on autoimmunity and ER stress. Frontiers in Immunology. 2019;10 (MAR) (344).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2073. Rahman S, Islam R, Swaraz AM, Ansari A, Parvez AK, Paul DK. An insight on genistein as potential pharmacological and therapeutic agent. Asian Pacific Journal of Tropical Biomedicine. 2012;2(3 SUPPL.):S1924-S37.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2074. Raigon-Ponferrada A, Recio MED, Guerrero-Orriach JL, Malo-Manso A, Escalona-Belmonte JJ, Aliaga MR, et al. Breast Cancer and Anesthesia. Current Pharmaceutical Design. 2019;25(28):2998-3004.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2075. Rajalingam R. Meta analyses revealed overrepresentation of centromeric or telomeric KIR gene-clusters in aborigines and in patients with inflammatory disorders. *Human Immunology*. 2009;1):S9.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2076. Rajasekaran N, Sadaram M, Hebb J, Sagiv-Barfi I, Ambulkar S, Rajapaksa A, et al. Three BTK-specific inhibitors, in contrast to ibrutinib, do not antagonize rituximab-dependent NK-Cell mediated cytotoxicity. *Blood*. Conference: 56th Annual Meeting of the American Society of Hematology, ASH. 2014;124(21).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2077. Rajayi H, Tavasolian P, Rezalotfi A, Ebrahimi M. Cancer Stem Cells Targeting; the Lessons from the Interaction of the Immune System, the Cancer Stem Cells and the Tumor Niche. *International Reviews of Immunology*. 2019;38(6):267-83.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2078. Rakhmilevich AL, Janssen K, Hao Z, Sondel PM, Yang NS. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell- independent mechanism. *Cancer Gene Therapy*. 2000;7(6):826-38.
배제사유 : 동물실험 및 전임상시험연구
2079. Ralff MD, Wagner J, El-Deiry WS. ONC201 sensitizes resistant breast cancer cells to TRAIL through death receptor 5 upregulation. *Cancer Research*. Conference. 2018;78(13 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2080. Raman D, Baugher PJ, Thu YM, Richmond A. Role of chemokines in tumor growth. *Cancer Letters*. 2007;256(2):137-65.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2081. Raman K, Kuberan B. Chemical tumor biology of heparan sulfate proteoglycans. *Current Chemical Biology*. 2010;4(1):20-31.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2082. Ramirez MF, Ai D, Bauer M, Vauthey JN, Gottumukkala V, Kee S, et al. Innate immune function after breast, lung, and colorectal cancer surgery. *Journal of Surgical Research*. 2015;194(1):185-93.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2083. Ramnath N, Tan D, Li Q, Hylander BL, Bogner P, Ryes L, et al. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? *Cancer Immunology, Immunotherapy*. 2006;55(8):891-9.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2084. Ramstead AG, Jutila MA. Complex role of gammadelta T-cell-derived cytokines and growth factors in cancer. *Journal of Interferon and Cytokine Research*. 2012;32(12):563-9.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2085. Randall TD, Kern JA. Tertiary lymphoid structures target the antitumor immune response to lung cancer. *American Journal of Respiratory and Critical Care Medicine*. 2014;189(7):767-9.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2086. Randhwala MA, Alghamdi MS. Anticancer activity of Nigella sativa (Black Seed) - A review. *American Journal of Chinese Medicine*. 2011;39(6):1075-91.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2087. Rao RM, Nagendra HR, Raghuram N, Vinay C, Chandrashekara S, Gopinath KS, et al. Influence of yoga on mood states, distress, quality of life and immune outcomes in early stage breast cancer patients undergoing surgery. *International Journal of Yoga*. 2008;1(1):11-20.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2088. Rao RM, Telles S, Nagendra HR, Nagarathna R, Gopinath K, Srinath S, et al. Effects of yoga on natural killer cell counts in early breast cancer patients undergoing conventional treatment. Comment to: recreational music-making modulates natural killer cell activity, cytokines, and mood states in corporate employees Masatada Wachi, Masahiro Koyama, Masanori Utsuyama, Barry B. Bittman, Masanobu Kitagawa, Katsuiku Hirokawa *Med Sci Monit*, 2007; 13(2): CR57-70. *Medical Science Monitor*. 2008;14(2):LE3-4.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2089. Rao RM, Vadiraja HS, Nagarathna R, Gopinath KS, Patil S, Diwakar RB, et al. Effect of Yoga on Sleep Quality and Neuroendocrine Immune Response in Metastatic Breast Cancer Patients. *Indian Journal of Palliative Care*. 2017;23(3):253-60.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2090. Rao XQ, Yu RC, Zhang JH. [Sheng xue tang on immunological functions of cancer patients with spleen-deficiency syndrome]. *Chung Hsi i Chieh Ho Tsa Chih Chinese Journal of Modern Developments in Traditional Medicine*. 1991;11(4):218-9.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
2091. Rasoul-Rockenschaub S, Zielinski CC, Muller C, Tichatschek E, Popow-Kraupp T, Kunz C. Viral reactivation as a cause of unexplained fever in patients with progressive metastatic breast cancer. *Cancer Immunology, Immunotherapy*. 1990;31(3):191-5.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2092. Rathore AS, Goel MM, Makker A, Kumar S, Srivastava AN. Is the tumor infiltrating natural killer cell (NK-TILs) count in infiltrating ductal carcinoma of breast prognostically significant? *Asian Pacific Journal of Cancer Prevention: Apjcp*. 2014;15(8):3757-61.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2093. Rautela J, Anderson R, Hertzog P, Parker B. Type I interferon agonists as potent

- anti-metastatic cancer therapeutics. European Journal of Immunology. 2016;46 (Supplement 1):203-4.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2094. Rautela J, Baschuk N, Jayatilleke K, Hertzog P, Parker B. Exploiting the type-1 interferon pathway as a biomarker and therapeutic target for metastatic cancer. Cytokine. 2014;70 (1):25.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2095. Ravelli A, Reuben JM, Lanza F, Anfossi S, Cappelletti MR, Zanotti L, et al. Immune-related strategies driving immunotherapy in breast cancer treatment: A real clinical opportunity. Expert Review of Anticancer Therapy. 2015;15(6):689-702.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2096. Ray A, Ficek M. Immunomodulatory effects of anti-estrogenic drugs. Acta Pharmaceutica. 2012;62(2):141-55.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2097. Ray M, Ruffalo MM, Bar-Joseph Z. Construction of integrated microRNA and mRNA immune cell signatures to predict survival of patients with breast and ovarian cancer. Genes, Chromosomes & Cancer. 2019;58(1):34-42.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2098. Razali FN, Sinniah SK, Hussin H, Zainal Abidin N, Shuib AS. Tumor suppression effect of Solanum nigrum polysaccharide fraction on Breast cancer via immunomodulation. International Journal of Biological Macromolecules. 2016;92:185-93.
배제사유 : 동물실험 및 전임상시험연구
2099. Rebmann V, Regel J, Stolke D, Grosse-Wilde H. Secretion of sHLA-G molecules in malignancies. Seminars in Cancer Biology. 2003;13(5):371-7.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2100. Recchia F, Candeloro G, Desideri G, Necozione S, Rea S. Extended phase II study of maintenance immunotherapy in advanced cancer. Cancer Research. Conference: 103rd Annual Meeting of the American Association for Cancer Research, AACR. 2012;72(8 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2101. Recchia F, Candeloro G, Necozione S, Accorsi P, Recchia CO, Tombolini V, et al. Prolonged disease control after myeloablative chemotherapy, autologous transplantation and immunotherapy in high-risk early breast cancer. Anticancer Research. 2010;30(1):209-15.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2102. Recchia F, Candeloro G, Rea S. High-dose chemotherapy and immunotherapy in premenopausal breast cancer patients with more than 10 axillary nodes (PBC+10N). Long-term follow-up of a phase II study. Cancer Research. Conference. 2018;79(4 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2103. Recchia F, Candeloro G, Rea S. Maintenance immunotherapy in estrogen receptor negative (ER-) locally advanced (LA) and/or metastatic breast cancer (MBC). Longterm follow-up of a phase II study. *Cancer Research*. Conference: 39th Annual CTRC AACR San Antonio Breast Cancer Symposium. United States. 2017;77(4 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2104. Recchia F, Candeloro G, Rea S. Maintenance immunotherapy in stage IV cancer patients who have a clinical benefit from chemotherapy. *Journal of Clinical Oncology*. Conference. 2017;35(15 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2105. Recchia F, De Filippis S, Rosselli M, Saggio G, Cesta A, Fumagalli L, et al. Phase 1B study of subcutaneously administered interleukin 2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer. *Clinical Cancer Research*. 2001;7(5):1251-7.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2106. Recchia F, Sica G, Candeloro G, Necozione S, Bisegna R, Bratta M, et al. Maintenance immunotherapy in metastatic breast cancer. *Oncology Reports*. 2008;20(5):1173-9.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2107. Reddy GK, Tyagi P, Jain VK. Histone deacetylase inhibitors show promising activity in the treatment of cutaneous T-cell lymphoma. *Clinical Lymphoma*. 2005;6(1):4-10.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2108. Reddy SP, Harwood RM, Moore DF, Grimm EA, Murray JL, Vadhan-Raj S. Recombinant interleukin-2 in combination with recombinant interferon-gamma in patients with advanced malignancy: A phase 1 study. *Journal of Immunotherapy*. 1997;20(1):79-87.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2109. Red-Horse K, Drake PM, Fisher SJ. Human pregnancy: The role of chemokine networks at the fetal-maternal interface. *Expert Reviews in Molecular Medicine*. 2004;6(11).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2110. Redzovic A, Laskarin G, Dominovic M, Haller H, Rukavina D. Mucins help to avoid alloreactivity at the maternal fetal interface. *Clinical and Developmental Immunology*. 2013;2013 (542152).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2111. Regan D, Guth A, Coy J, Dow S. Cancer immunotherapy in veterinary medicine: Current options and new developments. *Veterinary Journal*. 2016;207:20-8.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2112. Reiche EMV, Morimoto HK, Nunes SOV. Stress and depression-induced immune dysfunction: Implications for the development and progression of cancer. *International Review of Psychiatry*. 2005;17(6):515-27.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2113. Reif M, Bromba M. Association between fatigue and laboratory parameters in a longitudinal randomized controlled mistletoe trial in breast cancer patients. *Phytomedicine*. 2019;61 (Supplement 1):2.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2114. Reim F, Dombrowski Y, Ritter C, Buttmann M, Hausler S, Ossadnik M, et al. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. *Cancer Research*. 2009;69(20):8058-66.
배제사유 : 동물실험 및 전임상시험연구
2115. Reisfeld RA, Niethammer AG, Luo Y, Xiang R. DNA vaccines suppress tumor growth and metastases by the induction of anti-angiogenesis. *Immunological Reviews*. 2004;199:181-90.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2116. Reisser D, Arnould L, Maynadie M, Belichard C, Coudert B, Jeannin JF. Lipid A OM-174 increases the natural killer activity of peripheral blood cells from breast cancer patients. *Journal of Endotoxin Research*. 1999;5(4):189-95.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2117. Reiter Z, Chen L, Revel M, Rubinstein M. Interleukin-6 protects ductal breast carcinoma cells from MHC-unrestricted cell-mediated cytotoxicity. *Lymphokine & Cytokine Research*. 1992;11(3):175-81.
배제사유 : 동물실험 및 전임상시험연구
2118. Ren X, Alamri A, Hipolito J, Lin F, Kung SKP. Applications of microfluidic devices in advancing NK-cell migration studies. *Methods in Enzymology*. 2020;631:357-70.
배제사유 : 동물실험 및 전임상시험연구
2119. Renner C, Pfreundshuh M. Tumor therapy by immune recruitment with bispecific antibodies. *Immunological Reviews*. 1995(145):179-209.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2120. Reome JB, Hylind JC, Dutton RW, Dobrzanski MJ. Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer. *Clinical Immunology*. 2004;111(1):69-81.
배제사유 : 동물실험 및 전임상시험연구
2121. Repka T, Chiorean EG, Gay J, Herwig KE, Kohl VK, Yee D, et al. Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. *Clinical Cancer Research*. 2003;9(7):2440-6.
배제사유 : 동물실험 및 전임상시험연구
2122. Rescigno M, Avogadro F, Curigliano G. Challenges and prospects of immunotherapy as cancer treatment. *Biochimica et Biophysica Acta - Reviews on Cancer*. 2007;1776(1):108-23.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2123. Resnick IB, Shapira MY, Slavin S. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases. *Transplant Immunology*. 2005;14(3-4 SPEC. ISS.):207-19.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2124. Rezaeifard S, Safaei A, Talei A, Faghah Z, Erfani N. NK, NKT and Invariant-NKT Cells in Tumor Draining Lymph Nodes of Patients with Breast Cancer. *Iranian Journal Of Immunology: IJI*. 2019;16(4):291-8.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2125. Ribatti D, Crivellato E, Vacca A. Inflammation and antiangiogenesis in cancer. *Current Medicinal Chemistry*. 2012;19(7):955-60.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2126. Ribatti D, Nico B, Crivellato E, Vacca A. Macrophages and tumor angiogenesis. *Leukemia*. 2007;21(10):2085-9.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2127. Ricart E, Bouma G, Salvador Pena A. The therapeutic spectrum of infliximab and tumor necrosis factor immunomodulation in chronic inflammatory diseases. *Drugs of Today*. 2002;38(11):725-44.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2128. Ricciardi M, Zanotto M, Malpeli G, Bassi G, Bifari F, Perbellini O, et al. Epithelial to mesenchymal transition (EMT) increases immunomodulatory properties of cancer cells. *Cyotherapy*. 2014;4:S20-S1.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2129. Ricciardi M, Zanotto M, Malpeli G, Bassi G, Perbellini O, Chilos M, et al. Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells. *British Journal of Cancer*. 2015;112(6):1067-75.
배제사유 : 동물실험 및 전임상시험연구
2130. Ricciardi M, Zanotto M, Malpeli G, Pedica F, Bassi G, Perbellini O, et al. Epithelial-to-mesenchymal transition (EMT) elicits mesenchymal stromal cell-like immune modulatory properties in cancer cells. *Haematologica*. 2014;2):S48.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2131. Richards JO, Albers AJ, Smith TS, Tjoe JA. Erratum to: NK cell-mediated antibody-dependent cellular cytotoxicity is enhanced by tamoxifen in HER2/neu non-amplified, but not HER2/neu-amplified, breast cancer cells. *Cancer Immunology, Immunotherapy*. 2016;65(11):1337.
배제사유 : 동물실험 및 전임상시험연구
2132. Richards JO, Albers AJ, Smith TS, Tjoe JA. NK cell-mediated antibody-dependent cellular cytotoxicity is enhanced by tamoxifen in HER2/neu non-amplified, but not HER2/neu-amplified, breast cancer cells. *Cancer Immunology, Immunotherapy*.

2016;65(11):1325-35.

배제사유 : 동물실험 및 전임상시험연구

2133. Richards JO, Chang X, Blaser BW, Caligiuri MA, Zheng P, Liu Y. Tumor growth impedes natural-killer-cell maturation in the bone marrow. *Blood*. 2006;108(1):246-52.
배제사유 : 동물실험 및 전임상시험연구
2134. Richardson MA, Post-White J, Grimm EA, Moye LA, Singletary SE, Justice B. Coping, life attitudes, and immune responses to imagery and group support after breast cancer treatment. *Alternative Therapies in Health & Medicine*. 1997;3(5):62-70.
배제사유 : 동물실험 및 전임상시험연구
2135. Riether C, Schurcza C, Ochsenbeina AF. From 'magic bullets' to specific cancer immunotherapy. *Swiss Medical Weekly*. 2013;143 (w13734).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2136. Rihova B, Strohalm J, Prausova J, Kubackova K, Jelinkova M, Rozprimova L, et al. Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data. *Journal of Controlled Release*. 2003;91(1-2):1-16.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2137. Rihova B. Clinical experience with anthracycline antibiotics-HPMA copolymer-human immunoglobulin conjugates. *Advanced Drug Delivery Reviews*. 2009;61(13):1149-58.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2138. Ringden O. Immunotherapy by Allogeneic Stem Cell Transplantation. *Advances in Cancer Research*. 2007;97:25-60.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2139. Rittenhouse-Olson K. Jaa-f11: extending the life of mice with breast cancer. *Expert Opinion on Biological Therapy*. 2007;7(7):923-8.
배제사유 : 동물실험 및 전임상시험연구
2140. Rivera A, Zavala-Ruiz Z. Expression and purification of the human lymphocyte activation gene-3 for structural studies. *FASEB Journal*. Conference: Experimental Biology. 2010;24(Meeting Abstracts).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2141. Robert Siemens D, Hamilton T, Barsoum I, Li X, Miles E, Graham C. A mechanism of hypoxia-induced immune escape in prostate cancer cells. *Journal of Urology*. 2011;1:e509-e10.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2142. Roberti MP, Barrio MM, Bravo AI, Rocca YS, Arriaga JM, Bianchini M, et al. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR. *Breast Cancer Research & Treatment*. 2011;130(2):465-75.
배제사유 : 동물실험 및 전임상시험연구
2143. Roberti MP, Julia EP, Rocca YS, Amat M, Bravo AI, Loza J, et al. Overexpression of

CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade. European Journal of Immunology. 2015;45(5):1560-9.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2144. Roberti MP, Mordoh J, Levy EM. Biological role of NK cells and immunotherapeutic approaches in breast cancer. *Frontiers in Immunology*. 2012;3:375.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2145. Roberti MP, Rocca YS, Amat M, Pampena MB, Loza J, Colo F, et al. IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients. *Breast Cancer Research & Treatment*. 2012;136(3):659-71.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2146. Roberts LK. Cancer vaccines: Asymptotically approaching product approval. *BioPharm International*. 2007;20(8 SUPPL.):69-77.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2147. Robinson E, Rubin D, Mekori T, Segal R, Pollack S. In vivo modulation of natural killer cell activity by tamoxifen in patients with bilateral primary breast cancer. *Cancer Immunology, Immunotherapy*. 1993;37(3):209-12.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2148. Roda JM, Parihar R, Lehman A, Mani A, Tridandapani S, Carson WE, 3rd. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. *Journal of Immunology*. 2006;177(1):120-9.

배제사유 : 동물실험 및 전임상시험연구

2149. Roda JM, Parihar R, Magro C, Nuovo GJ, Tridandapani S, Carson WE, 3rd. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. *Cancer Research*. 2006;66(1):517-26.

배제사유 : 동물실험 및 전임상시험연구

2150. Rodeck U, Williams JC. Nature's design: A blueprint for engineered therapeutic antibodies. *Cancer Biology and Therapy*. 2008;7(11):1751-2.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2151. Rodrigues NV, Correia DV, Mensurado S, Nobrega-Pereira S, deBarros A, Kyle-Cezar F, et al. Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vgamma9Vdelta2 T Cells. *Cancer Immunology Research*. 2018;6(4):448-57.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2152. Rodriguez E, Schettters STT, Van Kooyk Y. The tumour glyco-code as a novel immune checkpoint for immunotherapy. *Nature Reviews Immunology*. 2018;18(3):204-11.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2153. Rogers D, Vila-Leahy A, Pessoa AC, Oldford S, Marignani PA, Marshall JS. Ranitidine Inhibition of Breast Tumor Growth Is B Cell Dependent and Associated With an Enhanced Antitumor Antibody Response. *Frontiers in Immunology*. 2018;9:1894.
배제사유 : 동물실험 및 전임상시험연구
2154. Roghanian A, Hu G, Fraser C, Singh M, Foxall RB, Meyer MJ, et al. Cyclophosphamide enhances cancer antibody immunotherapy in the resistant bone marrow niche by modulating macrophage Fc γ R expression. *Cancer Immunology Research*. 2019;7(11):1876-90.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2155. Rosental B, Appel MY, Yossef R, Hadad U, Brusilovsky M, Porgador A. The effect of chemotherapy/radiotherapy on cancerous pattern recognition by NK cells. *Current Medicinal Chemistry*. 2012;19(12):1780-91.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2156. Rosental B, Hadad U, Brusilovsky M, Campbell KS, Porgador A. A novel mechanism for cancer cells to evade immune attack by NK cells: The interaction between NKp44 and proliferating cell nuclear antigen. *OncolImmunology*. 2012;1(4):572-4.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2157. Rosewell Shaw A, Suzuki M. Recent advances in oncolytic adenovirus therapies for cancer. *Current Opinion in Virology*. 2016;21:9-15.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2158. Roshani R, Boroujerdnia MG, Talaiezadeh AH, Khodadadi A. Assessment of changes in expression and presentation of NKG2D under influence of MICA serum factor in different stages of breast cancer. *Tumour Biology*. 2016;37(5):6953-62.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2159. Rosillo MC, Ortuno F, Moraleda JM, Lozano ML, Heras I, De Arriba F, et al. Immune recovery after autologous or rhG-CSF primed PBSC transplantation. *European Journal of Haematology*. 1996;56(5):301-7.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2160. Rossi E, Fabbri F. CTCs 2020: Great expectations or unreasonable dreams. *Cells*. 2019;8 (9) (989).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2161. Rossin A, Miloro G, Hueber AO. TRAIL and FasL functions in cancer and autoimmune diseases: Towards an increasing complexity. *Cancers*. 2019;11 (5) (639).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2162. Rossman ML. Guided imagery in cancer care. *Seminars in Integrative Medicine*. 2004;2(3):99-106.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2163. Roszkowski PI, Hyc A, Stopinska-Gluszak U, Malejczyk J. Natural killer cell activity and sex hormone levels in mastopathy. *Gynecological Endocrinology*. 1997;11(6):399-404.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2164. Roth C, Rochlitz C, Kourilsky P. Immune response against tumors. *Advances in Immunology*. 1994;57:281-351.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2165. Rothammer A, Sage EK, Werner C, Combs SE, Multhoff G. Increased heat shock protein 70 (Hsp70) serum levels and low NK cell counts after radiotherapy - potential markers for predicting breast cancer recurrence? *Radiation Oncology*. 2019;14(1):78.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2166. Rothfelder K, Leibold J, Grosse-Hovest L, Buehring HJ, Jung G, Kanz L, et al. An FC-engineered CD133 antibody for induction of NK cell reactivity against cancer cells. *Blood*. Conference: 56th Annual Meeting of the American Society of Hematology, ASH. 2014;124(21).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2167. Rothwell WT, Bell P, Richman LK, Limberis MP, Tretiakova AP, Li M, et al. Intrathecal Viral Vector Delivery of Trastuzumab Prevents or Inhibits Tumor Growth of Human HER2-Positive Xenografts in Mice. *Cancer Research*. 2018;78(21):6171-82.

배제사유 : 동물실험 및 전임상시험연구

2168. Rotstein S, Blomgren H, Petrini B, Wasserman J, von Stedingk LV. Influence of adjuvant tamoxifen on blood lymphocytes. *Breast Cancer Research & Treatment*. 1988;12(1):75-9.

배제사유 : 동물실험 및 전임상시험연구

2169. Rouas-Freiss N, Moreau P, Menier C, Carosella ED. HLA-G in cancer: A way to turn off the immune system. *Seminars in Cancer Biology*. 2003;13(5):325-36.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2170. Roufas C, Chasiotis D, Makris A, Efthathiades C, Dimopoulos C, Zaravinos A. The expression and prognostic impact of immune cytolytic activity-related markers in human malignancies: A comprehensive meta-analysis. *Frontiers in Oncology*. 2018;8 (FEB) (27).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2171. Routes JM, Ryan S, Morris K, Takaki R, Cerwenka A, Lanier LL. Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection. *Journal of Experimental Medicine*. 2005;202(11):1477-82.

배제사유 : 동물실험 및 전임상시험연구

2172. Rovati B, Mariucci S, Delfanti S, Grasso D, Tinelli C, Torre C, et al. Simultaneous detection of circulating immunological parameters and tumor biomarkers in early stage breast cancer patients during adjuvant chemotherapy. *Cellular Oncology*. 2016;39(3):211-28.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2173. Roy D, Morgan M, Yoo C, Deoraj A, Roy S, Yadav VK, et al. Integrated bioinformatics, environmental epidemiologic and genomic approaches to identify environmental and molecular links between endometriosis and breast cancer. *International Journal of Molecular Sciences*. 2015;16(10):25285-322.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2174. Rozenblit M, Heguy A, Chiriboga L, Loomis C, Darvishian F, Egeblad M, et al. Identification of differentially expressed genes associated with clinical response after treatment of breast cancer skin metastases with imiquimod. *Journal of Clinical Oncology. Conference*. 2017;35(15 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2175. Rugo HS, Pegram MD, Gradishar WJ, Cortes J, Curigliano G, Hong S, et al. SOPHIA: A phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2+ metastatic breast cancer. *Cancer Research. Conference: 39th Annual CTRC AACR San Antonio Breast Cancer Symposium*. United States. 2017;77(4 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2176. Rugo HS, Pegram MD, Gradishar WJ, Cortes J, Curigliano G, Wigginton JM, et al. SOPHIA: A phase 3, randomized study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of patients with HER2+ metastatic breast cancer (MBC). *Journal of Clinical Oncology. Conference*. 2016;34(Supplement 15).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2177. Ruiz-Manzano RA, Palacios-Arreola MI, Hernandez-Cervantes R, Del Rio-Araiza VH, Nava-Castro KE, Ostoa-Saloma P, et al. Potential Novel Risk Factor for Breast Cancer: *Toxocara canis* Infection Increases Tumor Size Due to Modulation of the Tumor Immune Microenvironment. *Frontiers in Oncology*. 2020;10 (736).
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2178. Rupeshkumar M, Chettri U, Jaikumar S, Rathi Bai M, Paarakh PM. *Ganoderma lucidum*: A review with special emphasis on the treatment of various cancer. *Journal of Applied Pharmacy*. 2016;8(4):1-5.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2179. Russnes HG, Rye IH, Huse K, Schlichting E, Garred O, Mykelbust JH. Tumor cell detection and immune profiling of lymph nodes from breast cancer patients by mass cytometry. *Cancer Research. Conference*. 2018;79(4 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2180. Russo M, Spagnuolo C, Tedesco I, Bilotto S, Russo GL. The flavonoid quercetin in disease prevention and therapy: Facts and fancies. *Biochemical Pharmacology*. 2012;83(1):6-15.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2181. Rutella S, Pierelli L, Sica S, Rumi C, Leone G. Transplantation of autologous peripheral blood progenitor cells: impact of CD34-cell selection on immunological reconstitution. *Leukemia & Lymphoma*. 2001;42(6):1207-20.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2182. Ruuschen CJ, Boermeester MA, Butzelaar RMJM. Interaction between breast carcinoma, psychosocial stress and immune response [1] (multiple letters). [Dutch]. Nederlands Tijdschrift voor Geneeskunde. 1999;143(24):1280.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2183. Ruvolo P, Bright E, Kennedy MJ, Morris L, Fischer A, Vogelsang G, et al. Cyclosporine-induced autologous graft versus host disease: assessment of cytolytic effector mechanisms and the V beta T-cell receptor repertoire. Transplantation Proceedings. 1995;27(1):1363-5.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2184. Sabbatino F, Ferrone S. Can the "right" EGFR-specific mAb dramatically improve EGFR-targeted therapy? Clinical Cancer Research. 2013;19(5):958-60.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2185. Sabbioni ME, Bernhard J, Siegrist HP, Schmitz SF, Gertsch MC, Thurlimann B, et al. Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy? Breast Cancer Research & Treatment. 2004;87(1):75-86.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2186. Sabbioni ME, Siegrist HP, Bacchi M, Bernhard J, Castiglione M, Thurlimann B, et al. Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment. Breast Cancer Research & Treatment. 2000;59(3):279-87.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2187. Sabbioni MEE, Castiglione M, Hurny C, Siegrist HP, Bacchi M, Bernhard J, et al. Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients. Supportive Care in Cancer. 1999;7(3):149-53.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2188. Sabel MS, Nehs MA, Su G, Lowler KP, Ferrara JL, Chang AE. Immunologic response to cryoablation of breast cancer. Breast Cancer Research & Treatment. 2005;90(1):97-104.

배제사유 : 동물실험 및 전임상시험연구

2189. Sachs G, Rasoul-Rockenschaub S, Aschauer H, Spiess K, Gober I, Staffen A, et al. Lytic effector cell activity and major depressive disorder in patients with breast cancer: a prospective study. Journal of Neuroimmunology. 1995;59(1-2):83-9.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2190. Sage EK, Schmid TE, Sedelmayr M, Gehrmann M, Geinitz H, Duma MN, et al. Comparative analysis of the effects of radiotherapy versus radiotherapy after adjuvant chemotherapy on the composition of lymphocyte subpopulations in breast cancer

- patients. *Radiotherapy & Oncology*. 2016;118(1):176-80.
- 배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2191. Sage EK, Schmied TE, Geinitz H, Gehrmann M, Sedelmayr M, Duma MN, et al. Effects of local radiotherapy on the composition of lymphocyte subpopulations in prostate and breast cancer patients. *Strahlentherapie und Onkologie*. 2017;193 (1 Supplement 1):S180-S1.
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2192. Sage EK, Sedelmayr M, Gehrmann M, Bayer C, Schilling D, Duma MN, et al. Radiation-induced modulation in the distribution of lymphocytes in breast cancer patients. *Oncology Research and Treatment*. 2014;1):12.
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2193. Sage EK, Sedelmayr M, Gehrmann M, Bayer C, Schilling D, Duma MN, et al. Radiation-induced modulation in the distribution of lymphocytes in breast cancer patients. *Radiotherapy and Oncology*. 2014;1):S301.
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2194. Sage EK, Sedelmayr M, Geinitz H, Gehrmann M, Bayer C, Schilling D, et al. Radiation-induced modulation in the distribution of lymphocytes in breast cancer patients. *Tumor Biology*. 2014;1):S26.
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2195. Saglam A, Hayran M, Uner AH. Immunohistochemical expression of multidrug resistance proteins in mature T/NK-cell lymphomas. *APMIS*. 2008;116(9):791-800.
- 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2196. Sahm C, Schonfeld K, Wels WS. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. *Cancer Immunology, Immunotherapy*. 2012;61(9):1451-61.
- 배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2197. Salaun B, Romero P, Lebecque S. Toll-like receptor's two-edged sword: When immunity meets apoptosis. *European Journal of Immunology*. 2007;37(12):3311-8.
- 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2198. Salazar LG, Higgins D, Childs J, Coveler AL, Liao J, Stanton S, et al. Phase I/II randomized study of combination immunotherapy with or without polysaccharide krestin (PSK) concurrently with a HER2 ICD peptide-based vaccine in patients with stage IV breast cancer receiving HER2-targeted monoclonal antibody therapy. *Cancer Research. Conference: 38th Annual CTRC AACR San Antonio Breast Cancer Symposium*. San Antonio, TX United States. Conference Publication: 2016;76(4 SUPPL. 1).
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2199. Saligan LN, Kim HS. A systematic review of the association between immunogenomic markers and cancer-related fatigue. *Brain, Behavior, & Immunity*. 2012;26(6):830-48.
- 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2200. Salimi M, Wang R, Yao X, Li X, Wang X, Hu Y, et al. Activated innate lymphoid cell populations accumulate in human tumour tissues. *BMC Cancer*. 2018;18(1):341.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2201. Samara P, Skopeliti M, Tsiantas ML, Georgaki S, Gouloumis C, Voelter W, et al. A Cytokine Cocktail Augments the Efficacy of Adoptive NK-92 Cell Therapy Against Mouse Xenografts of Human Cancer. *Anticancer Research*. 2016;36(7):3373-82.
배제사유 : 동물실험 및 전임상시험연구
2202. Sanchez AP, Angel M. Potentialities of the effects of acupuncture on natural killer cell activity in patients with breast cancer. [Spanish]. *Revista Internacional de Acupuntura*. 2012;6(2):58-62.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
2203. Sanchez-Margalef V, Barco-Sanchez A, Vilarino-Garcia T, Jimenez-Cortegana C, Perez-Perez A, Henao-Carrasco F, et al. Circulating regulatory T cells from breast cancer patients in response to neoadjuvant chemotherapy. *Translational Cancer Research*. 2019;8(1):59-65.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2204. Sanders AJ, Ye L, Wei XQ, Mansel RE, Jiang WG. Expression of interleukin-15 (IL-15) and the IL-15 receptor in human breast cancer. *Cancer Research Conference*: 34th Annual CTRC AACR San Antonio Breast Cancer Symposium. San Antonio, TX United States. Conference Publication: 2011;71(24 SUPPL. 3).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2205. Sandhu D, Kochupillai V, Sharma A, Das SN. Prospective non-randomized controlled study of the effect of mind-body relaxation on T-cell subsets and NK cell population in cancer patients. *Journal International Medical Sciences Academy*. 2017;30(1):13-8.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2206. Sandmaier BM, Oparin DV, Holmberg LA, Reddish MA, MacLean GD, Longenecker BM. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with theratope STn-KLH cancer vaccine. *Journal of Immunotherapy*. 1999;22(1):54-66.
배제사유 : 동물실험 및 전임상시험연구
2207. Sanduzzi-Zamparelli M, Boix L, Leal C, Reig M. Hepatocellular carcinoma recurrence in HCV patients treated with direct antiviral agents. *Viruses*. 2019;11 (5) (406).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2208. Sangiolo D, Valabrega G, Cavalloni G, Capellero S, Mesiano G, Todorovic M, et al. MIC A/B protein expression associates with trastuzumab-resistant breast cancer cells leading to effective immunotherapy by cytokine induced killer cells. *Blood Conference*: 51st Annual Meeting of the American Society of Hematology, ASH. New Orleans, LA United States. Conference Publication: 2009;114(22).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2209. Sanikommu SR, Clemente MJ, Chomczynski P, Afable MG, Jerez A, Thota S, et al. Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). *Leukemia and Lymphoma*. 2018;59(2):416-22.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2210. Santamaria LB, Schifilliti D, La Torre D, Fodale V. Drugs of anaesthesia and cancer. *Surgical Oncology*. 2010;19(2):63-81.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2211. Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, et al. Overexpression of HER-2/neu in uterine serous papillary cancer. *Clinical Cancer Research*. 2002;8(5):1271-9.
배제사유 : 동물실험 및 전임상시험연구
2212. Santini D, Stumbo L, Spoto C, D'Onofrio L, Pantano F, Iuliani M, et al. Bisphosphonates as anticancer agents in early breast cancer: Preclinical and clinical evidence. *Breast Cancer Research*. 2015;17 (1) (121).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2213. Santos MF, Mannam VK, Craft BS, Puneky LV, Sheehan NT, Lewis RE, et al. Comparative analysis of innate immune system function in metastatic breast, colorectal, and prostate cancer patients with circulating tumor cells. *Experimental & Molecular Pathology*. 2014;96(3):367-74.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2214. Saraswathi J, Venkatesh K, Baburao N, Hilal MH, Rani AR. Phytopharmacological importance of pelargonium species. *Journal of Medicinal Plants Research*. 2011;5(13):2587-98.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2215. Sarhan D, D'Arcy P, Lundqvist A. Regulation of TRAIL-receptor expression by the ubiquitin-proteasome system. *International Journal of Molecular Sciences*. 2014;15(10):18557-73.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2216. Sarkar DK, Murugan S, Zhang C, Boyadjieva N. Regulation of cancer progression by beta-endorphin neuron. *Cancer Research*. 2012;72(4):836-40.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2217. Sarkar DK, Zhang C, Dokur M, Boyadjieva NI, Ortiguela M, Rafferty N, et al. Beta-endorphin neuron transplants suppress mammary tumor growth and progression via neuroimmune activation. *Cancer Research Conference: 102nd Annual Meeting of the American Association for Cancer Research, AACR*. 2011;71(8 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2218. Satge D, Seidel MG. The pattern of malignancies in down syndrome and its potential context with the immune system. *Frontiers in Immunology*. 2018;9 (3058).
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2219. Sato T, Okubo M, Wada Y, Sato N, Kikuchi K. Identification of a human T cell clone with the cytotoxic T lymphocyte and natural killer-like cytotoxic function against autologous mammary carcinoma and K562 line. Japanese Journal of Cancer Research. 1989;80(7):655-61.
배제사유 : 동물실험 및 전임상시험연구
2220. Sato T, Sato N, Cho J, Takahashi S, Toda K, Asaishi K, et al. Heterogeneity of human breast cancer cell clones with respect to cytotoxic susceptibility detected by cytotoxic T-lymphocytes and natural killer cells. Tumor Research. 1991;26:29-41.
배제사유 : 동물실험 및 전임상시험연구
2221. Sato T, Sato N, Takahashi S, Koshiba H, Kikuchi K. Specific cytotoxicity of a long-term cultured T-cell clone on human autologous mammary cancer cells. Cancer Research. 1986;46(9):4384-9.
배제사유 : 동물실험 및 전임상시험연구
2222. Satta A, Mezzanzanica D, Turatti F, Canevari S, Figini M. Redirection of T-cell effector functions for cancer therapy: Bispecific antibodies and chimeric antigen receptors. Future Oncology. 2013;9(4):527-39.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2223. Savani BN. Can we modify transplant outcome by improving lymphocyte recovery? Cytotherapy. 2011;13(8):900-2.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2224. Savard J, Simard S, Giguere I, Ivers H, Morin CM, Maunsell E, et al. Randomized clinical trial on cognitive therapy for depression in women with metastatic breast cancer: psychological and immunological effects. Palliative & Supportive Care. 2006;4(3):219-37.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2225. Savas B, Kerr PE, Pross HF. Lymphokine-activated killer cell susceptibility and adhesion molecule expression of multidrug resistant breast carcinoma. Cancer Cell International. 2006;6:24.
배제사유 : 동물실험 및 전임상시험연구
2226. Sawada R, Wu X, Sun SM, Ragupathi G, Livingston PO, Scholz WW. Potent CDC, ADCC, and antitumor activity of human monoclonal antibodies to Sialyl Lewisa. Molecular Cancer Therapeutics. Conference: AACR NCI EORTC International Conference: Molecular Targets and Cancer. 2011;10(11 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2227. Sawant A, Chanda D, Hensel J, Ponnazhagan S. Characterization of immune response during osteolytic progression of breast cancer. Journal of Immunotherapy. 2009;32 (9):999.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2228. Saxena M, Balan S, Roudko V, Bhardwaj N. Towards superior dendritic-cell vaccines for cancer therapy. Nature Biomedical Engineering. 2018;2(6):341-4.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2229. Saxton JM, Scott EJ, Daley AJ, Woodroffe M, Mutrie N, Crank H, et al. Effects of an exercise and hypocaloric healthy eating intervention on indices of psychological health status, hypothalamic-pituitary-adrenal axis regulation and immune function after early-stage breast cancer: a randomised controlled trial. *Breast Cancer Research*. 2014;16(2):R39.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2230. Scallan BJ, Snyder LA, Mark Anderson G, Chen Q, Yan L, Weiner LM, et al. A review of antibody therapeutics and antibody-related technologies for oncology. *Journal of Immunotherapy*. 2006;29(4):351-64.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2231. Scaneay J, Parker BS, Smyth MJ, Moller A. Hypoxia-driven immunosuppression contributes to the pre-metastatic niche. *Oncoimmunology*. 2013;2(1):e22355.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2232. Schaffner F, Ruf W. Tissue factor and PAR2 signaling in the tumor microenvironment. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2009;29(12):1999-2004.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2233. Scheid C. Allogeneic stem cell transplantation or novel agents for the treatment of relapsed/refractory Hodgkin's lymphoma? *International Journal of Hematologic Oncology*. 2012;1(2):103-5.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2234. Schena G, Caplan MJ. Everything you always wanted to know about beta3-ar * (* But were afraid to ask). *Cells*. 2019;8 (4) (357).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2235. Schenk A, Baumann F, Koliamitra C, Bloch W, Schollmayer F, Beulertz J, et al. Changes of epigenetic modifications in natural killer cells of breast cancer patients in follow-up care by enhanced physical activity. *Oncology Research and Treatment*. 2014;1):122.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2236. Scheper RJ, Dalton WS, Grogan TM, Schlosser A, Bellamy WT, Taylor CW, et al. Altered expression of P-glycoprotein and cellular adhesion molecules on human multi-drug-resistant tumor cells does not affect their susceptibility to NK- and LAK-mediated cytotoxicity. *International Journal of Cancer*. 1991;48(4):562-7.

배제사유 : 동물실험 및 전임상시험연구

2237. Scherpereel A, Grigoriu BD, Noppen M, Gey T, Chahine B, Baldacci S, et al. Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid. *BMC Cancer*. 2013;13 (324).

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2238. Schilling D, Kuhnel A, Tetzlaff F, Konrad S, Multhoff G. NZ28-induced inhibition of HSF1, SP1 and NF-kappaB triggers the loss of the natural killer cell-activating ligands MICA/B on human tumor cells. *Cancer Immunology, Immunotherapy*.

2015;64(5):599-608.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2239. Schink M, Troger W, Goyert A, Scheuerecker H, Selbmann HK, Glaser F. [Correlation of NK cell activity against autologous tumour cells and K562 cells with the clinical outcome during therapy with mistletoe extracts]. *Forschende Komplementarmedizin* (2006). 2006;13(3):147-55.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
2240. Schirrmacher V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: Improvement of patient survival based on improved antitumor immune memory. *Cancer Immunology, Immunotherapy*. 2005;54(6):587-98.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2241. Schlapfer M, Piegeler T, Eugster P, Beck-Schimmer B. Sevoflurane supports cell-differentiation of NK-cells towards mature cells in patients undergoing breast cancer surgery. *Swiss Medical Weekly*. 2016;146 (Supplement 220):3S.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2242. Schlitz PM, Beutel LD, Nayak SK, Dillman RO. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer. *Journal of Immunotherapy*. 1997;20(5):377-86.
배제사유 : 동물실험 및 전임상시험연구
2243. Schlom J. Multimodal approach to cancer immunotherapy. *Journal of Acquired Immune Deficiency Syndromes*. 2019;81 (Supplement 1):37.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2244. Schmidt T, Jonat W, Wesch D, Oberg HH, Adam-Klages S, Keller L, et al. Influence of physical activity on the immune system in breast cancer patients during chemotherapy. *Journal of Cancer Research & Clinical Oncology*. 2018;144(3):579-86.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2245. Schmidt T, van Mackelenbergh M, Wesch D, Mundhenke C. Physical activity influences the immune system of breast cancer patients. *Journal of Cancer Research & Therapeutics*. 2017;13(3):392-8.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2246. Schmidt T, Weisser B, Jonat W, Maass N, Wesch D, Keller L, et al. Influence of strength and endurance training on the immune system in breast cancer patients during chemotherapy. *Oncology Research and Treatment*. 2017;40 (Supplement 3):226.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2247. Schmiedel BJ, Baessler T, Azuma M, Kanz L, Salih HR. Expression and immunomodulatory function of RANKL in leukemia. *Blood. Conference: 53rd Annual Meeting of the American Society of Hematology, ASH*. 2011;118(21).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2248. Schmittgen TD. Exosomal miRNA cargo as mediator of immune escape mechanisms in neuroblastoma. *Cancer Research*. 2019;79(7):1293-4.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2249. Schoenhals JE, Skrepnik T, Selek U, Cortez MA, Li A, Welsh JW. Optimizing radiotherapy with immunotherapeutic approaches. *Advances in Experimental Medicine and Biology*. 2017;995:53-71.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2250. Scholl SM, Mosseri V, Tang R, Beuvon F, Palud C, Lidereau R, et al. Expression of colony-stimulating factor-1 and its receptor (the protein product of c-fms) in invasive breast tumor cells. Induction of urokinase production via this pathway? *Annals of the New York Academy of Sciences*. 1993;698:131-5.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2251. Scholz C, Toth B, Barthell E, Mylonas I, Weissenbacher T, Friese K, et al. Immunohistochemical expression of glycodelin in breast cancer correlates with estrogen-receptor alpha and progesterone-receptor A positivity. *Histology & Histopathology*. 2009;24(4):467-71.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2252. Schondorf T, Engel H, Lindemann C, Kolhagen H, von Rucker AA, Mallmann P. Cellular characteristics of peripheral blood lymphocytes and tumour-infiltrating lymphocytes in patients with gynaecological tumours. *Cancer Immunology, Immunotherapy*. 1997;44(2):88-96.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2253. Schonfeld K, Knopp C, Brendel C, Kohler S, Naundorf S, Odendahl M, et al. Retargeted natural killer cells for adoptive cancer immunotherapy. *Journal of Immunotherapy*. 2011;34 (9):682.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2254. Schonfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. *Molecular Therapy: the Journal of the American Society of Gene Therapy*. 2015;23(2):330-8.
배제사유 : 동물실험 및 전임상시험연구
2255. Schrader J. The role of MDSCs in hepatocellular carcinoma - In vivo veritas? *Journal of Hepatology*. 2013;59(5):921-3.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2256. Schraven B. CD148. *Journal of Biological Regulators and Homeostatic Agents*. 2001;14(3):220-2.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2257. Schreiber RD. Cancer Vaccines 2004 opening address: The molecular and cellular basis of cancer immuno surveillance and immunoediting. *Cancer Immunity*. 2005;5(SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2258. Schroder W, Vering A, Stegmuller M, Strohmeier R. Lymphocyte subsets in patients with ovarian and breast cancer. European Journal of Gynaecological Oncology. 1997;18(6):474-7.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2259. Schulenburg A, Kalhs P, Worel N, Hocker P, Knobl P, Greinix HT. Immunologic recovery of patients given CD34-selected peripheral blood progenitor cell transplantation for malignant diseases. Bone Marrow Transplantation. 2000;25(2):223-4.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2260. Schuler J, Avrutskaya A, Lashuk K, Heins M, Tschuch C, Jensen A, et al. CRISPR CAS9 mediated BRCA1 knockout modulates the tumor infiltrating lymphocytes landscape and cytokine profile in a murine breast cancer model. Journal for ImmunoTherapy of Cancer. Conference: 34th Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2019;7(Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2261. Schuler TA, Andersen BL, Carson IWE. Depressive symptoms moderate the covariation of marital distress with five-year endocrine/immunity trajectories in breast cancer patients. Psychosomatic Medicine. 2012;74 (3):A28.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2262. Schutz F, Marme F, Domschke C, Sohn C, Von Au A. Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies. Breast Care. 2018;13(1):22-6.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2263. Schwartz G, Kaufman P, Tretter C, Arrick B, Mulrooney T, Connelly E, et al. Vinorelbine and trastuzumab enhance effector cell function in patients with HER-2/neu overexpressing metastatic breast cancer. 2004.
배제사유 : 동물실험 및 전임상시험연구
2264. Scigliano MG, Storti G, D'Amico F, Gentile P, Kim BS, Cervelli V, et al. Adipose-derived stem cells in cancer progression: New perspectives and opportunities. International Journal of Molecular Sciences. 2019;20 (13) (3296).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2265. Sconocchia G, Eppenberger S, Spagnoli GC, Tornillo L, Drosler R, Caratelli S, et al. NK cells and T cells cooperate during the clinical course of colorectal cancer. Oncoimmunology. 2014;3(8):e952197.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2266. Scarpanti I, Felli MP, Toniato E, Meco D, Martinotti S, Frati L, et al. Enhancement of natural-killer-cell susceptibility of human breast-cancer cells by estradiol and v-Ha-ras oncogene. International Journal of Cancer. 1991;47(3):445-9.
배제사유 : 동물실험 및 전임상시험연구
2267. Sebastian M, Kuemmel A, Schmidt M, Schmittel A. Catumaxomab: a bispecific trifunctional antibody. Drugs of Today. 2009;45(8):589-97.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2268. See D, Mason S, Roshan R. Increased Tumor Necrosis Factor alpha (TNF-alpha) and Natural Killer Cell (NK) function using an integrative approach in late stage cancers. *Immunological Investigations*. 2002;31(2):137-53.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2269. Segerer SE, Kapp M, Hahne JC, Dietl J, Engel JB. Mechanisms of tumor immune escape in triplenegative breast cancers (TNBC) with and without mutated BRCA 1. *Cancer Research Conference*: 34th Annual CTRC AACR San Antonio Breast Cancer Symposium. San Antonio, TX United States. Conference Publication: 2011;71(24 SUPPL. 3).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2270. Segler A, Tsimberidou AM. Lenalidomide in solid tumors. *Cancer Chemotherapy and Pharmacology*. 2012;69(6):1393-406.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2271. Segovia-Mendoza M, Morales-Montor J. Immune tumor microenvironment in breast cancer and the participation of estrogens and its receptors into cancer physiopathology. *Frontiers in Immunology*. 2019;10 (MAR) (348).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2272. Segui E, Pare L, Adamo B, Pineda E, Marin-Aguilera M, Reig O, et al. Immune gene expression, survival outcome and response to PD-1/PD-L1 blockade: A TCGA pan-cancer analysis. *Journal of Clinical Oncology Conference*. 2016;34(Supplement 15).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2273. Seidel UJE, Schlegel P, Lang P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. *Frontiers in Immunology*. 2013;4 (MAR) (Article 76).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2274. Sek K, Molck C, Stewart GD, Kats L, Darcy PK, Beavis PA. Targeting adenosine receptor signaling in cancer immunotherapy. *International Journal of Molecular Sciences*. 2018;19 (12) (3837).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2275. Selhub J, Rosenberg IH. Excessive folic acid intake and relation to adverse health outcome. *Biochimie*. 2016;126:71-8.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2276. Seliger B, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer JU, et al. Correlation of the tumor mutational burden with the composition of the immune cell subpopulations in peripheral blood of triple-negative breast cancer patients undergoing neoadjuvant therapy with durvalumab: results from the prospectively randomized GeparNuevo trial. *Journal of clinical oncology*. 2019;37.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2277. Seliger B. Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy (GBG89, Geparnuevo trial). *Annals of Oncology*. 2018;29 (Supplement 8):viii74.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2278. Sellami M, Gasmi M, Denham J, Hayes LD, Stratton D, Padulo J, et al. Effects of acute and chronic exercise on immunological parameters in the elderly aged: Can physical activity counteract the effects of aging? *Frontiers in Immunology*. 2018;9 (OCT) (2187).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2279. Semenza GL, Ruvolo PP. Introduction to tumor microenvironment regulation of cancer cell survival, metastasis, inflammation, and immune surveillance. *Biochimica et Biophysica Acta - Molecular Cell Research*. 2016;1863(3):379-81.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2280. Senovilla L, Galluzzi L, Marino G, Vitale I, Castedo M, Kroemer G. Immunosurveillance against cancer-associated hyperploidy. *Oncotarget*. 2012;3(11):1270-1.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2281. Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, et al. Trial watch prognostic and predictive value of the immune infiltrate in cancer. *OncolImmunology*. 2012;1(8):1323-43.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2282. Sensebe L, Krampera M, Schrezenmeier H, Bourin P, Giordano R. Mesenchymal stem cells for clinical application. *Vox Sanguinis*. 2010;98(2):93-107.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2283. Sensi M, Pietra G, Molla A, Nicolini G, Vegetti C, Bersani I, et al. Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5. *International Immunology*. 2009;21(3):257-68.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2284. Sephton S, Spiegel D. Circadian disruption in cancer: A neuroendocrine-immune pathway from stress to disease? *Brain, Behavior, and Immunity*. 2003;17(5):321-8.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2285. Sephton SE, Koopman C, Schaal M, Thoresen C, Spiegel D. Spiritual expression and immune status in women with metastatic breast cancer: an exploratory study. *Breast Journal*. 2001;7(5):345-53.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2286. Sephton SE, Kraemer HC, Neri E, Stites DP, Weissbecker I, Spiegel D. Improving methods of assessing natural killer cell cytotoxicity. *International Journal of Methods in Psychiatric Research*. 2006;15(1):12-21.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2287. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. *Journal of the National Cancer Institute*. 2000;92(12):994-1000.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지

않은 연구

2288. Sessler DI. Long-term consequences of anesthetic management. *Anesthesiology*. 2009;111(1):1-4.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2289. Seth P, Bose M, Katyal P, Kundu SK, Sharma LK. Natural killer cell & killer cell activities & circulating immune complexes in patients with breast cancer. *Indian Journal of Medical Research*. 1987;85:404-14.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2290. Seth R, Seth P. Circulating immune complex and NK-cell activity in progressive breast cancer. *Breast Cancer Research & Treatment*. 1984;4(1):54-5.
배제사유 : 동물실험 및 전임상시험연구
2291. Seth TK, Bai S, Hu M, Sei E, Wood A, Wiley J, et al. Towards a human breast cell atlas. *Cancer Research. Conference*. 2018;79(4 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2292. Sethi G, Sung B, Aggarwal BB. Therapeutic potential of VEGI/TL1A in autoimmunity and cancer. *Therapeutic Targets of the TNF Superfamily*. 2009;Advances in Experimental Medicine and Biology. 647:207-15.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2293. Sethuraman J, Santiago L, Chen JQ, Dai Z, Wardell S, Bender J, et al. Successful expansion and characterization of tumor infiltrating lymphocytes (TILs) from non-melanoma tumors. *Journal for ImmunoTherapy of Cancer. Conference: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer, SITC*. 2016;4(Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2294. Seton-Rogers S. Immunotherapy: Combinations that work. *Nature Reviews Cancer*. 2012;12(4):231.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2295. Setti M, Bignardi D, Ballestrero A, Ferrando F, Musselli C, Blanchi S, et al. The induction of distinct cytokine cascades correlates with different effects of granulocyte-colony stimulating factor and granulocyte/macrophage-colony-stimulating factor on the lymphocyte compartment in the course of high-dose chemotherapy for breast cancer. *Cancer Immunology, Immunotherapy*. 1999;48(6):287-96.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2296. Sewell HF, Halbert CF, Robins RA, Galvin A, Chan S, Blamey RW. Chemotherapy-induced differential changes in lymphocyte subsets and natural-killer-cell function in patients with advanced breast cancer. *International Journal of Cancer*. 1993;55(5):735-8.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2297. Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, et al. Strategies for combining immunotherapy with radiation for anticancer therapy. *Immunotherapy*. 2015;7(9):967-80.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2298. Sfikakis PP, Gourgoulis GM, Moulopoulos LA, Kouvatsseas G, Theofilopoulos AN, Dimopoulos MA. Age-related thymic activity in adults following chemotherapy-induced lymphopenia. *European Journal of Clinical Investigation*. 2005;35(6):380-7.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2299. Sfondrini L, Sommariva M, Tortoreto M, Meini A, Piconese S, Calvaruso M, et al. Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases. *International Journal of Cancer*. 2013;133(2):383-93.
배제사유 : 동물실험 및 전임상시험연구
2300. Sforzin JM. Propolis and the immune system: a review. *Journal of Ethnopharmacology*. 2007;113(1):1-14.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2301. Sgagias MK, Nieroda C, Yannelli JR, Cowan KH, Danforth DN, Jr. Upregulation of DF3, in association with ICAM-1 and MHC class II by IFN-gamma in short-term human mammary carcinoma cell cultures. *Cancer Biotherapy & Radiopharmaceuticals*. 1996;11(3):177-85.
배제사유 : 동물실험 및 전임상시험연구
2302. Shaashua L, Satchi-Fainaro R, Sloan E, Ben-Eliyahu S. Surgical excision of a primary tumor enhances spontaneous metastasis of breast cancer through cox-2 and beta-adrenergic pathways. *Cancer Microenvironment*. 2015;1):S116-S7.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2303. Shaashua L, Shabat-Simon M, Haldar R, Matzner P, Zmora O, Shabtai M, et al. Perioperative COX-2 and beta-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a phase-II randomized trial. *Clinical Cancer Research*. 2017;23(16):4651-61.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2304. Shaashua L, Shabat-Simon M, Haldar R, Shabtai M, Sharon E, Alweis T, et al. Perioperative COX-2 inhibition and beta-adrenoceptor blockade in breast cancer patients improve markers of immunity and reduce inflammation and primary tumor epithelial-to-mesenchymal transition (EMT). *Brain, Behavior, and Immunity*. 2016;57 (Supplement 1):e8.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2305. Shabani N, Mylonas I, Kunert-Keil C, Briese V, Janni W, Gerber B, et al. Expression of glycodelin in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastases. *Anticancer Research*. 2005;25(3A):1761-4.
배제사유 : 동물실험 및 전임상시험연구

2306. Shabo I, Olsson H, Stal O, Svanvik J. Breast cancer expression of DAP12 is associated with skeletal and liver metastases and poor survival. *Clinical Breast Cancer*. 2013;13(5):371-7.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2307. Shahid A, Bharadwaj M. The connection between the Th17 cell related cytokines and cancer stem cells in cancer: Novel therapeutic targets. *Immunology Letters*. 2019;213:9-20.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2308. Shaked Y, Pham E, Hariharan S, Magidey K, Beyar-Katz O, Xu P, et al. Evidence implicating immunological host effects in the efficacy of metronomic low-dose chemotherapy. *Cancer Research*. 2016;76(20):5983-93.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2309. Shakhar K, Shakhar G, Rosenne E, Ben-Eliyahu S. Timing within the menstrual cycle, sex, and the use of oral contraceptives determine adrenergic suppression of NK cell activity. *British Journal of Cancer*. 2000;83(12):1630-6.
배제사유 : 동물실험 및 전임상시험연구
2310. Shakhar K, Valdimarsdottir HB, Bovbjerg DH. Heightened risk of breast cancer following pregnancy: could lasting systemic immune alterations contribute? *Cancer Epidemiology, Biomarkers & Prevention*. 2007;16(6):1082-6.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2311. Shamilov FA, Elshina GA, Burov DA, Vishnevskaya Ya V, Chkhikvadze NV, Zernov DI, et al. The impact of polyoxidonium on a subpopulation intratumorale lymphocytes in patients with breast cancer. [Russian]. *Immunologiya*. 2013;34(4):207-11.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
2312. Shao B, Li HP, Di LJ, Song GH, Jiang HF, Liang X, et al. [Predictive and prognostic value of monitoring lymphocyte subsets in peripheral blood before and after chemotherapy in patients with metastatic breast cancer]. Beijing da Xue Xue Bao. Yi Xue Ban/Journal of Peking University. Health Sciences. 2016;48(2):304-9.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
2313. Shapira MY. Elucidation of the biology of multi-donor transplantation. *Bone Marrow Transplantation*. 2016;1):S163.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2314. Share SM, Laws MA, Sherwood NT, Silverman JF, Ru K. Evaluating the specificity of CD56 as a neuroendocrine immunohistochemical marker. *Laboratory Investigation*. 2009;1):120A.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2315. Shariat S, Jalali SA, Jafari MR, Alimohammadi R. MPL adjuvant encapsulated in liposome coated with P5 HER2/neu peptide: A potent prophylactic vaccine for breast cancer. *European Journal of Immunology*. 2016;46 (Supplement 1):228.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2316. Sharma B. In vitro immunization against human tumor cells with tumor cell fractions. *Cancer Research*. 1977;37(12):4660-8.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2317. Sharma C, Wang HX, Li Q, Knoblich K, Reisenbichler ES, Richardson AL, et al. Protein Acyltransferase DHHC3 Regulates Breast Tumor Growth, Oxidative Stress, and Senescence. *Cancer Research*. 2017;77(24):6880-90.
배제사유 : 동물실험 및 전임상시험연구
2318. Shatova Y, Zlatnik E, Novikova I, Bakhtin A. Characteristics of the local immunity of breast cancer patients with different reproductive function statuses. *European Journal of Cancer*. 2015;3):S298-S9.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2319. Shaw D. Chinese herbs as immune stimulants in cancer treatment. Focus on Alternative and Complementary Therapies. 2009;14(4):291-2.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2320. Sheard CR, Reilly F, Tee DE, Vergani D, Lowe D, Baum M, et al. The effect of adjuvant cyclophosphamide or tamoxifen on the numbers of lymphocytes bearing T cell or NK cell markers. *British Journal of Cancer*. 1986;54(4):705-9.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2321. Sheen YY, Kim MJ, Park SA, Park SY, Nam JS. Targeting the transforming growth factor-beta signaling in cancer therapy. *Biomolecules and Therapeutics*. 2013;21(5):323-31.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2322. Sheikhpour E, Noorbakhsh P, Foroughi E, Farahnak S, Nasiri R, Neamatzadeh H. A Survey on the Role of Interleukin-10 in Breast Cancer: A Narrative. *Reports of Biochemistry & Molecular Biology*. 2018;7(1):30-7.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2323. Shelley CS, Fu Q, Cash SE, Andersen JJ, Kennedy CR, Dietrich LL, et al. CD43 normally expressed on the surface of leukocytes is expressed in the cytoplasm and nucleus of breast cancer and is a novel therapeutic target. *Cancer Research Conference: 103rd Annual Meeting of the American Association for Cancer Research, AACR*. 2012;72(8 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2324. Shen G, Huang H, Zhang A, Zhao T, Hu S, Cheng L, et al. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models. *Cancer Immunology, Immunotherapy*. 2011;60(3):339-48.
배제사유 : 동물실험 및 전임상시험연구
2325. Shen H, Kuo WH, Chang WC, Yang IJ, Wu CJ, Wei LH, et al. Clinical significance of tumor-infiltrating lymphocytes in overall survival of human breast cancer: A long term follow-up study. *International Journal of Gynecological Cancer*. 2018;28 (Supplement

2):563.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2326. Shen J, Pan J, Du C, Si W, Yao M, Xu L, et al. Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer. *Cell Death & Disease*. 2017;8(4):e2740.

배제사유 : 동물실험 및 전임상시험연구

2327. Shen J, Tanida M, Fujisaki Y, Horii Y, Hashimoto K, Nagai K. Effect of the culture extract of *Lentinus edodes* mycelia on splenic sympathetic activity and cancer cell proliferation. *Autonomic Neuroscience: Basic and Clinical*. 2009;145(1-2):50-4.

배제사유 : 동물실험 및 전임상시험연구

2328. Shen L, Li J, Liu Q, Song W, Zhang X, Tiruthani K, et al. Local Blockade of Interleukin 10 and C-X-C Motif Chemokine Ligand 12 with Nano-Delivery Promotes Antitumor Response in Murine Cancers. *Acs Nano*. 2018;12(10):9830-41.

배제사유 : 동물실험 및 전임상시험연구

2329. Shen M, Wang J, Ren X. New insights into tumor-infiltrating B lymphocytes in breast cancer: Clinical impacts and regulatory mechanisms. *Frontiers in Immunology*. 2018;9 (MAR) (470).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2330. Shen X. Hmgb1 induced anti-cancer effect of dendritic cells (DCs) in vitro. *Respirology*. 2011;2):157-9.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2331. Shenouda MM, Gillgrass A, Nham T, Hogg R, Lee AJ, Chew MV, et al. Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours. *Breast Cancer Research*. 2017;19(1):76.

배제사유 : 동물실험 및 전임상시험연구

2332. Shepro D, Miller M. Gemcitabine in blastic plasmacytoid dendritic cell neoplasm (CD4+CD56+ hematodermic neoplasm). *Blood. Conference: 56th Annual Meeting of the American Society of Hematology, ASH*. 2014;124(21).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2333. Sherman AC, Leszcz M, Mosier J, Burlingame GM, Cleary T, Ulman KH, et al. Group Interventions for Patients with Cancer and HIV Disease: Part II. Effects on Immune, Endocrine, and Disease Outcomes at Different Phases of Illness. *International Journal of Group Psychotherapy*. 2004;54(2):203-33.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2334. Sheu JJC, Shih IM. Clinical and biological significance of HLA-G expression in ovarian cancer. *Seminars in Cancer Biology*. 2007;17(6):436-43.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2335. Shevde LA, Joshi NN, Advani SH, Nadkarni JJ. Impaired T lymphocyte function and differential cytokine response pattern in members from cancer families. *Natural*

Immunity. 1998;16(4):146-56.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2336. Shevde LA, Joshi NN, Dudhat SB, Hawaldar RW, Nadkarni JJ. Immune functions, clinical parameters and hormone receptor status in breast cancer patients. *Journal of Cancer Research & Clinical Oncology*. 1999;125(5):313-20.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2337. Shevde LA, Joshi NN, Shinde SR, Nadkarni JJ. Studies on functional status of circulating lymphocytes in unaffected members from cancer families. *Human Immunology*. 1998;59(6):373-81.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2338. Shevde LA, Rao NM, Joshi NN, Shinde SR, Ghosh SN, Nadkarni JJ. Natural killer cell function and genetic instability in unaffected individuals from breast cancer families. *European Journal of Cancer Prevention*. 1998;7(2):141-8.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2339. Shi B, Vinyals A, Alia P, Broceno C, Chen F, Adrover M, et al. Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription: Implication of CIITA in tumor and metastasis development. *International Journal of Biochemistry and Cell Biology*. 2006;38(4):544-62.
배제사유 : 동물실험 및 전임상시험연구
2340. Shi X, Cao S, Mitsuhashi M, Xiang Z, Ma X. Genome-Wide Analysis of Molecular Changes in IL-12-Induced Control of Mammary Carcinoma via IFN-gamma-Independent Mechanisms. *Journal of Immunology*. 2004;172(7):4111-22.
배제사유 : 동물실험 및 전임상시험연구
2341. Shi X, Liu J, Xiang Z, Mitsuhashi M, Wu RS, Ma X. Gene expression analysis in interleukin-12-induced suppression of mouse mammary carcinoma. *International Journal of Cancer*. 2004;110(4):570-8.
배제사유 : 동물실험 및 전임상시험연구
2342. Shi Y, Fan X, Deng H, Brezski RJ, Ryczyn M, Jordan RE, et al. Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcgamma receptors on macrophages. *Journal of Immunology*. 2015;194(9):4379-86.
배제사유 : 동물실험 및 전임상시험연구
2343. Shi YJ, Ren HY, Cen XN, Zhu Q, Yu JR. [Immunological effector cells enhance apoptosis induced by adriamycin in a multi-drug resistant human breast cancer cell line]. Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]. 2006;28(3):188-91.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
2344. Shi YJ, Yu JR, Cen XN, Zhu Q, Ren HY. [Influence of HSP70 on combined method of hyperthermia and immunologic effector cells to treat cancer]. Beijing da Xue Xue Bao. Yi Xue Ban/Journal of Peking University. Health Sciences. 2005;37(2):175-8.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

2345. Shiiba K, Suzuki R, Kawakami K, Ohuchi A, Kumagai K. Interleukin 2-activated killer cells: generation in collaboration with interferon gamma and its suppression in cancer patients. *Cancer Immunology, Immunotherapy*. 1986;21(2):119-28.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

2346. Shimizu C, Mogushi K, Koizumi F, Tamura K, Yunokawa M, Fujiwara Y, et al. FcGR2A genotype and change in gene expression of effector cells in peripheral blood after administration of trastuzumab (T). *Journal of Clinical Oncology. Conference*. 2012;30(15 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2347. Shin WJ, Zabel BA, Pachynski RK. Mechanisms and functions of chemerin in cancer: Potential roles in therapeutic intervention. *Frontiers in Immunology*. 2018;9 (NOV) (02772).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2348. Shinde P, Bharat V, Rodriguez-Oquendo A, Zhou B, Vella AT. Understanding how combinatorial targeting of TLRs and TNFR family costimulatory members promote enhanced T cell responses. *Expert Opinion on Biological Therapy*. 2018;18(10):1073-83.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2349. Shinohara Y, Takahashi N, Nishiwaki K, Hino M, Kashimura M, Wakita H, et al. A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction. *Haematologica*. 2013;98(9):1407-13.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2350. Shirakawa T, Tokunaga A, Onda M. Release of immunosuppressive substances after gastric resection is more prolonged than after mastectomy in humans. *International Surgery*. 1998;83(3):210-4.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2351. Shishkova N, Kuznetsova O, Berezov T. Photodynamic therapy for gynecological diseases and breast cancer. *Cancer Biology and Medicine*. 2012;9(1):9-17.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2352. Shou D, Wen L, Song Z, Yin J, Sun Q, Gong W. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies. *Oncotarget*. 2016;7(39):64505-11.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2353. Sideras K, Kwekkeboom J. Cancer inflammation and inflammatory biomarkers: Can neutrophil, lymphocyte, and platelet counts represent the complexity of the immune system? *Transplant International*. 2014;27(1):28-31.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2354. Siegers GM, Dutta I, Lai R, Postovit LM. Functional plasticity of Gamma delta T cells and breast tumor targets in hypoxia. *Frontiers in Immunology*. 2018;9 (JUN) (1367).
배제사유 : 동물실험 및 전임상시험연구
2355. Sikora J, Dworacki G, Trybus M, Batura-Gabryel H, Zeromski J. Correlation between DNA content, expression of Ki-67 antigen of tumor cells and immunophenotype of lymphocytes from malignant pleural effusions. *Tumour Biology*. 1998;19(3):196-204.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2356. Silva MR, Parreira A, Ascensao JL. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion. *Experimental Hematology*. 1995;23(14):1676-81.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2357. Silver HK, Connors JM, Karim KA, Kong S, Spinelli JJ, de Jong G, et al. Effect of lymphoblastoid interferon on lymphocyte subsets in cancer patients. *Journal of Biological Response Modifiers*. 1983;2(5):428-40.
배제사유 : 동물실험 및 전임상시험연구
2358. Silver HK, Connors JM, Kong S, Karim KA, Spinelli JJ. Survival, response and immune effects in a prospectively randomized study of dose strategy for alpha-N1 interferon. *British Journal of Cancer*. 1988;58(6):783-7.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2359. Silverio KA, Patel SA. Harnessing antitumor immunity: Employment of tumor recall antigens to optimize the inflammatory response to cancer (Review). *Oncology Letters*. 2017;13(4):2015-20.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2360. Sim GC, Grimm E, Dai ZM, Overwijk W, Hwu P, Radvanyi L. IL-2 analogues: Novel agents circumventing the expansion of T regulatory cells while promoting NK cell activation during IL-2 therapy. *Journal for ImmunoTherapy of Cancer. Conference: 28th Annual Scientific Meeting of the Society for Immunotherapy of Cancer, SITC*. 2013;1(SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2361. Sima P, Richter J, Vetticka V. Glucans as new anticancer agents. *Anticancer Research*. 2019;39(7):3373-8.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2362. Simmons O, Magee M, Nemunaitis J. Current vaccine updates for lung cancer. *Expert Review of Vaccines*. 2010;9(3):323-35.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2363. Simo Camps E, Pinas Forcadell I, Garcia Llorente F, Vich Pascuchi JM, Ribera del Pueyo M, Claret Godo A. [Intralymphatic administration of adoptive (LAK) immunotherapy in the treatment of patients with metastatic cancer resistant to conventional therapies]. *Anales de Medicina Interna*. 1992;9(5):217-24.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구

2364. Simonson WTN, Allison KH. Tumour-infiltrating lymphocytes in cancer: Implications for the diagnostic pathologist. *Diagnostic Histopathology*. 2011;17(2):80-90.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2365. Simpson A, Caballero O. Monoclonal antibodies for the therapy of cancer. *BMC Proceedings*. Conference: 5th Congress of the Brazilian Biotechnology Society, SBBIOTEC. 2013;8(SUPPL. 4).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2366. Singh M, Quispe-Tintaya W, Chandra D, Jahangir A, Venkataswamy MM, Ng TW, et al. Direct incorporation of the NKT-cell activator alpha-galactosylceramide into a recombinant Listeria monocytogenes improves breast cancer vaccine efficacy. *British Journal of Cancer*. 2014;111(10):1945-54.
배제사유 : 동물실험 및 전임상시험연구
2367. Singh S, Fatima Z, Hameed S. Predisposing factors endorsing Candida infections. *Infezioni in Medicina*. 2015;23(3):211-23.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2368. Singha NC, Nekoroski T, Zhao C, Symons R, Jiang P, Frost G, et al. Hyaluronan (HA) depletion sensitizes HAhigh tumors to antibody-dependent cell-mediated cytotoxicity. *Cancer Research*. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium. San Antonio, TX United States. Conference Publication: 2015;75(9 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2369. Singha NC, Nekoroski T, Zhao C, Symons R, Jiang P, Frost GI, et al. Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy. *Molecular Cancer Therapeutics*. 2015;14(2):523-32.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2370. Singha NC, Nekoroski T, Zimmerman S, Zhao C, Jiang P, Connor R, et al. Hyaluronan-rich ECM contributes to resistance to antibody-dependent cell-mediated cytotoxicity in solid tumors. *Cancer Research*. Conference: 104th Annual Meeting of the American Association for Cancer Research, AACR. 2013;73(8 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2371. Sinkovics JG. Adult human sarcomas. I. Basic science. *Expert Review of Anticancer Therapy*. 2007;7(1):31-56.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2372. Sinkovics JG. Molecular biology of oncogenic inflammatory processes. I. Non-oncogenic and oncogenic pathogens, intrinsic inflammatory reactions without pathogens, and microRNA/DNA interactions (Review). *International Journal of Oncology*. 2012;40(2):305-49.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2373. Sioud M, Westby P, Olsen JKE, Mobergslien A. Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of

cancer cells. Molecular Therapy - Methods and Clinical Development. 2015;2:15043.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2374. Sioud M, Westby P, Vasovic V, Floisand Y, Peng Q. Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies. FASEB Journal. 2018;32(9):5063-77.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2375. Sitkovsky MV. Lessons from the A2A adenosine receptor antagonist- enabled tumor regression and survival in patients with treatment-refractory renal cell cancer. Cancer Discovery. 2020;10(1):16-9.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2376. Sivik T, Kot A, Stal O, Fornander T, Skoog L, Nordenskjold B, et al. Expression of C-X-C motif chemokine 10 (CXCL10) in breast cancer. Cancer Research. Conference: 102nd Annual Meeting of the American Association for Cancer Research, AACR. 2011;71(8 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2377. Skak K, Kragh M, Hausman D, Smyth MJ, Sivakumar PV. Interleukin 21: Combination strategies for cancer therapy. Nature Reviews Drug Discovery. 2008;7(3):231-40.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2378. Skeate R, Singh C, Cooley S, Geller M, Northouse J, Welbig J, et al. Hemolytic anemia due to passenger lymphocyte syndrome in solid malignancy patients treated with allogeneic natural killer cell products. Transfusion. 2013;53(2):419-23.
배제사유 : 동물실험 및 전임상시험연구
2379. Skeate RC, Singh C, Northouse JM, Welbig J, Miller JS, Slungaard A, et al. Two cases of passenger lymphocyte syndrome from contaminating B-Cells after allogeneic natural killer cell infusion. Transfusion. 2010;2):24A.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2380. Skotarenko L, Kadagidze Z, Korotkova O, Vorotnikov I, Chkhikvadze N, Rodionova M. Lymphocyte subpopulations in peripheral blood of breast cancer patients. Breast. 2011;4):S25.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2381. Slaney CY, Bidwell BN, Rautela J, Anderson RL, Hertzog PJ, Parker BS. Tumor cell derived type I IFN stimulates tumor immunosurveillance, suppressing metastasis to bone. Cytokine. 2012;59 (3):537.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2382. Slaney CY, Rautela J, Bidwell BN, Anderson RL, Hertzog PJ, Parker BS. Th role of type I interferons in suppressing breast cancer metastasis to bone. Cytokine. 2013;63 (3):302.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2383. Slaney CY, Rautela J, Parker BS. The emerging role of immunosurveillance in dictating metastatic spread in breast cancer. Cancer Research. 2013;73(19):5852-7.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2384. Slattery K, Gardiner CM. NK Cell Metabolism and TGFbeta - Implications for Immunotherapy. *Frontiers in Immunology*. 2019;10 (2915).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2385. Slavin S. Potential elimination of multi-drug resistant cancer cells by targeted non-engrafting intentionally mismatched activated donor lymphocytes. *Journal of Clinical Oncology. Conference*. 2019;37(Supplement 15).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2386. Slota M, Lim JB, Dang Y, Disis ML. ELISpot for measuring human immune responses to vaccines. *Expert Review of Vaccines*. 2011;10(3):299-306.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2387. Small S. Hem/Onc. *Clinical Advances in Hematology and Oncology*. 2013;11(2):84-5.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2388. Smalley M, Shanthappa B, Gertje H, Lawson M, Ulaganathan B, Thayakumar A, et al. Characterizing immunotherapy-induced lymphocyte infiltration at the single patient level using CANscriptTM, an ex-vivo human tumor model. *Journal for ImmunoTherapy of Cancer. Conference: 32nd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC*. 2017;5(Supplement 2).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2389. Smalley M, Shanthappa B, Gertje H, Lawson M, Ulaganathan B, Thayakumar A, et al. Therapy-induced priming of natural killer cells predicts patient-specific tumor rejection in multiple breast cancer indications. *Annals of Oncology*. 2017;28(Supplement 11):xi9.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2390. Smalley M, Shanthappa BU, Gertje H, Lawson M, Biswas M, Thiagarajan S, et al. Spatial re-distribution of natural killer cells targets drug resistance and anti-tumor response, ex-vivo. *Cancer Research. Conference*. 2018;78(13 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2391. Smalley M, Shanthappa BU, Gertje H, Lawson M, Ulaganathan B, Thayakumar A, et al. Therapy-induced priming of natural killer cells predicts patientspecific tumor rejection in multiple breast cancer indications. *Cancer Research. Conference: San Antonio Breast Cancer Symposium, SABCS*. 2017;78(4 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2392. Smalley RV, Borden EC. Interferons: current status and future directions of this prototypic biological. *Springer Seminars in Immunopathology*. 1986;9(1):73-83.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2393. Smida T, Bruno TC, Stabile LP. Influence of Estrogen on the NSCLC Microenvironment: A Comprehensive Picture and Clinical Implications. *Frontiers in Oncology*. 2020;10 (137).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2394. Smith LP, Harrell LM, Christenson JL, Bitler B, Slansky J, Richer JK. Tryptophan

catabolism in ovarian cancer. Cancer Research. Conference. 2018;78(13 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2395. Smith RA, Dzugan SA, Rafique S, Fumagalli L, Lissoni P. Peripheral blood natural killer cell increase as a predictor of survival in metastatic cancer patients treated by neuroimmunotherapy with subcutaneous low-dose interleukin-2 plus melatonin. International Journal of Immunotherapy. 1999;15(3-4):131-5.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2396. Smyth MJ, Stagg J. Her 2 in 1. Cancer Cell. 2010;18(2):101-2.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2397. Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, Verstraeten AA, Livingston PO, Hilgers J, et al. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. International Journal of Cancer. 2001;93(1):97-106.
배제사유 : 동물실험 및 전임상시험연구
2398. Snyder GL, Greenberg S. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. British Journal of Anaesthesia. 2010;105(2):106-15.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2399. So S, Zhao B. The effect of NK cell immunotherapy on cancer prognosis through its booster role on cellular (Th1) immunity and its compensator role to maintain the CD4 T-cell subset. Journal of Clinical Oncology. Conference: ASCO Annual Meeting. 2011;29(15 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2400. Sobol RE, Scanlon KJ. Improved cancer vaccines through gene transfer. Cancer Gene Therapy. 2005;12(6):515.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2401. Soda H, Koda K, Yasutomi J, Oda K, Takiguchi N, Saito N, et al. Adoptive immunotherapy for advanced cancer patients using in vitro activated cytotoxic T lymphocytes. Journal of Surgical Oncology. 1999;72(4):211-7.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2402. Soejima K, Rollins BJ. A functional IFN-gamma-inducible protein-10/CXCL10-specific receptor expressed by epithelial and endothelial cells that is neither CXCR3 nor glycosaminoglycan. Journal of Immunology. 2001;167(11):6576-82.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2403. Sohn S, Tiper I, Japp E, Sun W, Tkaczuk K, Webb TJ. Development of a qPCR method to rapidly assess the function of NKT cells. Journal of Immunological Methods. 2014;407:82-9.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2404. Soiffer RJ, Murray C, Cochran K, Cameron C, Wang E, Schow PW, et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood.

1992;79(2):517-26.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2405. Solinas C, Migliori E, De Silva P, Willard-Gallo K. LAG3: The biological processes that motivate targeting this immune checkpoint molecule in human cancer. *Cancers*. 2019;11 (8) (1213).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2406. Solomayer EF, Feuerer M, Bai L, Umansky V, Beckhove P, Meyberg GC, et al. Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer. *Clinical Cancer Research*. 2003;9(1):174-80.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2407. Soltan Dallal MM, Yazdi MH, Holakuyee M, Hassan ZM, Abolhassani M, Mahdavi M. Lactobacillus casei ssp.casei induced Th1 cytokine profile and natural killer cells activity in invasive ductal carcinoma bearing mice. *Iranian Journal of Allergy Asthma & Immunology*. 2012;11(2):183-9.

배제사유 : 동물실험 및 전임상시험연구

2408. Sommaggio R, Cappuzzello E, Dalla Pieta A, Tosi A, Palmerini P, Carpanese D, et al. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells. *Oncogen Immunology*. 2020;9 (1) (1777046).

배제사유 : 동물실험 및 전임상시험연구

2409. Sondel PM, Hank JA, Gan J, Neal Z, Albertini MR. Preclinical and clinical development of immunocytokines. *Current Opinion in Investigational Drugs*. 2003;4(6):696-700.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2410. Song E, Su S, Zhao J. Antibody-dependent tumor phagocytosis enhances PD-L1 and IDOs expression on macrophages, which mediate trastuzumab resistance in Her2 breast cancer. *Journal of Immunology. Conference: 104th Annual Meeting of the American Association of Immunologists, AAI*. 2017;198(1 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2411. Song N, Guo H, Ren J, Hao S, Wang X. Synergistic anti-tumor effects of dasatinib and dendritic cell vaccine on metastatic breast cancer in a mouse model. *Oncology Letters*. 2018;15(5):6831-8.

배제사유 : 동물실험 및 전임상시험연구

2412. Song PY. Liquid biopsy testing in monitoring TNBC. *Mlo: Medical Laboratory Observer*. 2017;49(1):26.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2413. Song Y, Wang Q, Feng H, Dong Y, Chen J. Epirubicin sequential natural killer cells enhanced the cytotoxicity to breast cancer cells in vitro. *Journal for ImmunoTherapy of Cancer. Conference: 30th Annual Scientific Meeting of the Society for Immunotherapy of Cancer, SITC*. 2015;3(SUPPL. 2).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2414. Sonoda K, Miyamoto S, Nakashima M, Wake N. Receptor-binding cancer antigen expressed on SiSo cells induces apoptosis via ectodomain shedding. *Experimental Cell Research.* 2010;316(11):1795-803.
배제사유 : 동물실험 및 전임상시험연구
2415. Sonoda K. RCAS1, which induces apoptosis via ectodomain shedding, is a novel therapeutic target against human malignancies. *Cancer Research. Conference: 101st Annual Meeting of the American Association for Cancer Research, AACR.* 2010;70(8 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2416. Sony K, Revathi R, Rajalingam R, Jayalakshmi M. Synergistic role of activating killer cell immunoglobulin-like receptor genes in breast cancer. *Human Immunology.* 2017;78 (Supplement 1):173.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2417. Soon G, Lee SY, Wang S. Aggressive MLL gene rearranged CD7+ CD56+ myeloid / natural killer cell precursor acute leukaemia with extramedullary relapse in the uterus and breast. *Pathology.* 2015;47(6):588-91.
배제사유 : 동물실험 및 전임상시험연구
2418. Soriani A, Vulpis E, Cuollo L, Santoni A, Zingoni A. Cancer extracellular vesicles as novel regulators of NK cell response. *Cytokine and Growth Factor Reviews.* 2020;51:19-26.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2419. Sorrelle N, Ganguly D, Dominguez ATA, Zhang Y, Huang H, Dahal LN, et al. Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues. *Journal of Immunology.* 2019;202(1):292-9.
배제사유 : 동물실험 및 전임상시험연구
2420. Sosman JA, Stiff P, Moss SM, Sorokin P, Martone B, Bayer R, et al. Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. *Journal of Clinical Oncology.* 2001;19(3):634-44.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2421. Sounni NE, Noel A. Targeting the tumor microenvironment for cancer therapy. *Clinical Chemistry.* 2013;59(1):85-93.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2422. Souza BDO, Diaz BF, Guidugli GS, Ferraz LS, Amarante MK, Rocha SPD, et al. Natural killer cells: Prospects in cancer immunotherapy. *Current Immunology Reviews.* 2018;14(2):100-4.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2423. Spallanzani RG, Dalotto-Moreno T, Raffo Iraolagoitia XL, Ziblat A, Domaica CI, Avila

DE, et al. Expansion of CD11b⁺Ly6G⁺Ly6C^{int} cells driven by medroxyprogesterone acetate in mice bearing breast tumors restrains NK cell effector functions. *Cancer Immunology, Immunotherapy*. 2013;62(12):1781-95.

배제사유 : 동물실험 및 전임상시험연구

2424. Sparano JA, Fisher RI, Weiss GR, Margolin K, Aronson FR, Hawkins MJ, et al. Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors. *Journal of Immunotherapy with Emphasis on Tumor Immunology*. 1994;16(3):216-23.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2425. Spencer CM, Faulds D. Paclitaxel: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. *Drugs*. 1994;48(5):794-847.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2426. Spiegel D, Giese-Davis J. Depression and cancer: Mechanisms and disease progression. *Biological Psychiatry*. 2003;54(3):269-82.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2427. Spiegel D. Minding the body: psychotherapy and cancer survival. *British Journal of Health Psychology*. 2014;19(3):465-85.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2428. Spiegel S, Milstien S. Sphingosine-1-phosphate gradient and Spns2 transporter in lymphocyte trafficking and breast cancer metastasis. *FEBS Journal*. 2017;284 (Supplement 1):287.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2429. Spina CA, Fahey JL, Durkos-Smith D, Dorey F, Sarna G. Suppression of natural killer cell cytotoxicity in the peripheral blood of patients receiving interferon therapy. *Journal of Biological Response Modifiers*. 1983;2(5):458-69.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2430. Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, et al. Systemic Immunity Is Required for Effective Cancer Immunotherapy. *Cell*. 2017;168(3):487-502.e15.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2431. Springer GF, Desai PR, Robinson MK, Tegtmeyer H, Scanlon EF. The fundamental and diagnostic role of T and Tn antigens in breast carcinoma at the earliest histologic stage and throughout. *Progress in Clinical & Biological Research*. 1986;204:47-70.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2432. Spuzic I, Konjevic G, Djarmati D. [Selenium, immunity and tumors]. *Srpski Arhiv Za Celokupno Lekarstvo*. 1994;122 Suppl 1:75-7.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

2433. Spuzic I, Konjevic G. [The significance of determination of NK cell activity in

malignant diseases]. Glas - Srpska Akademija Nauka i Umetnosti, Odeljenje Medicinskih Nauka. 1990(39):153-60.

배제사유 : 동물실험 및 전임상시험연구

2434. Spuzic I. [Accomplishments and perspectives in tumor diagnostics and treatment]. Glas - Srpska Akademija Nauka i Umetnosti, Odeljenje Medicinskih Nauka. 2002(47):21-32.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2435. Sran S, Taborga M, Friari M. Psoriasisiform spongiotic dermatitis and autoimmune disease. Annals of Allergy, Asthma and Immunology. 2014;1:A115-A6.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2436. Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. Therapeutic actions of melatonin in cancer: possible mechanisms. Integrative Cancer Therapies. 2008;7(3):189-203.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2437. Srivastava RM, Khar A. Dendritic cells and their receptors in antitumor immune response. Current Molecular Medicine. 2009;9(6):708-24.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2438. Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proceedings of the National Academy of Sciences of the United States of America. 2011;108(17):7142-7.

배제사유 : 동물실험 및 전임상시험연구

2439. Stagg J, Smyth MJ. NK cell-based cancer immunotherapy. Drug News and Perspectives. 2007;20(3):155-63.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2440. Standish L, Sweet E, Wenner C, Martzen M, Torkelson C. Phase i dose-escalation trial of *Trametes versicolor* in women with breast cancer. Journal of the Society for Integrative Oncology. 2010;8 (4):160.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2441. Standish LJ, Sweet ES, Novack J, Wenner CA, Bridge C, Nelson A, et al. Breast cancer and the immune system. Journal Of The Society For Integrative Oncology. 2008;6(4):158-68.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2442. Standish LJ, Torkelson C, Hamill FA, Yim D, Hill-Force A, Fitzpatrick A, et al. Immune defects in breast cancer patients after radiotherapy. Journal Of The Society For Integrative Oncology. 2008;6(3):110-21.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2443. Stanek L, Tesarova P, Vocka M, Musil Z, Kasparova K, Petruzelka L. Immunoprofile of TIL, genetics of Fc-receptor gama and apoptosis activation in patients with Her2-positive breast cancer-pilot study. Cancer Research. Conference: 38th Annual

CTRC AACR San Antonio Breast Cancer Symposium. San Antonio, TX United States.
Conference Publication: 2016;76(4 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2444. Stanojevic-Bakic N, Vuckovic-Dekic L, Radomirovic S, Juranic Z, Jovanovic N. The influence of surgery and anesthesia on lymphocyte functions in breast cancer patients: in vitro effects of indomethacin. *Neoplasma*. 1999;46(1):54-60.

배제사유 : 동물실험 및 전임상시험연구

2445. Stanzer S, Andritsch E, Zloklikovits S, Ladinek V, Farkas C, Augustin T, et al. A Pilot Randomized Trial Assessing the Effect of a Psychoeducational Intervention on Psychoneuroimmunological Parameters Among Patients With Nonmetastatic Breast Cancer. *Psychosomatic Medicine*. 2019;81(2):165-75.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2446. Starink TM, van der Veen JP, Goldschmeding R. Decreased natural killer cell activity in Cowden's syndrome. *Journal of the American Academy of Dermatology*. 1986;15(2 Pt 1):294-6.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2447. Stathopoulos GP, Baxevanis CN, Papadopoulos NG, Zarkadis IK, Papacostas P, Michailakis E, et al. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters. *Anticancer Research*. 1996;16(6B):3855-60.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2448. Stauber H, Kreuser ED. Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: Current state of clinical research. *Onkologie*. 2002;25(4):374-80.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2449. Steel JC, Ramlogan CA, Yu P, Sakai Y, Forni G, Waldmann TA, et al. Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help. *Cancer Research*. 2010;70(3):1072-81.

배제사유 : 동물실험 및 전임상시험연구

2450. Stein MN, Shin J, Gudzowaty O, Bernstein AM, Liu JM. Antibody-dependent cell cytotoxicity to breast cancer targets despite inhibitory KIR signaling. *Anticancer Research*. 2006;26(3A):1759-63.

배제사유 : 동물실험 및 전임상시험연구

2451. Steinbacher J, Raab S, Grosse-Hovest L, Schmiedel BJ, Steinle A, Kanz L, et al. An Fc-optimized NKG2D-Ig fusion protein for induction of NK cell reactivity against breast cancer. *Journal of Clinical Oncology*. Conference. 2013;31(15 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2452. Steingrimsdottir H, Gruber A, Bjorkholm M, Svensson A, Hansson M. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.

Haematologica. 2000;85(8):832-8.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2453. Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW. Tachykinins and their receptors: Contributions to physiological control and the mechanisms of disease. *Physiological Reviews*. 2014;94(1):265-301.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2454. Steinman RA, Brufsky AM, Oesterreich S. Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment? *Breast Cancer Research*. 2012;14 (5) (213).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2455. Sterle HA, Nicoud MB, Massari NA, Taquez Delgado MA, Herrero Ducloux MV, Cremaschi GA, et al. Immunomodulatory role of histamine H4 receptor in breast cancer. *British Journal of Cancer*. 2019;120(1):128-38.
배제사유 : 동물실험 및 전임상시험연구
2456. Stevanovic S. Identification of tumour-associated T-cell epitopes for vaccine development. *Nature Reviews Cancer*. 2002;2(7):514-20.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2457. Steven A, Seliger B. The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer. *Breast Care*. 2018;13(1):16-21.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2458. Stewart DA, Guo D, Luider J, Auer I, Klassen J, Morris D, et al. The CD3- 16+ 56+ NK cell count independently predicts autologous blood stem cell mobilization. *Bone Marrow Transplantation*. 2001;27(12):1237-43.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2459. Stewart LD, Ades EW. Prospective study of natural cytotoxicity in peripheral blood of patients with nonlymphoid solid malignancies. *Clinical Immunology & Immunopathology*. 1984;31(1):78-86.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2460. Stiff A, Trikha P, Mundy-Bosse B, McMichael E, Mace TA, Benner B, et al. Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function. *Clinical Cancer Research*. 2018;24(8):1891-904.
배제사유 : 동물실험 및 전임상시험연구
2461. Stolzel F, Hackmann K, Kuithan F, Mohr B, Fussel M, Oelschlagel U, et al. Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation. *Transplantation*. 2012;93(7):744-9.
배제사유 : 동물실험 및 전임상시험연구
2462. Stovgaard ES, Nielsen D, Hogdall E, Balslev E. Triple negative breast cancer - prognostic role of immune-related factors: a systematic review. *Acta Oncologica*.

2018;57(1):74-82.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2463. Strange KS, Kerr LR, Andrews HN, Emerman JT, Weinberg J. Psychosocial stressors and mammary tumor growth: an animal model. *Neurotoxicology & Teratology*. 2000;22(1):89-102.
배제사유 : 동물실험 및 전임상시험연구
2464. Strayer DR, Carter WA, Brodsky I. Familial occurrence of breast cancer is associated with reduced natural killer cytotoxicity. *Breast Cancer Research & Treatment*. 1986;7(3):187-92.
배제사유 : 동물실험 및 전임상시험연구
2465. Street SEA, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. *Blood*. 2001;97(1):192-7.
배제사유 : 동물실험 및 전임상시험연구
2466. Strohlein MA, Heiss MM. Perspective of immunotherapy in cancer treatment. [German]. *Viszeralchirurgie*. 2006;41(4):231-6.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
2467. Strome SE, Sausville EA, Mann D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. *Oncologist*. 2007;12(9):1084-95.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2468. Stryjkowska-Gora A, Karczmarek-Borowska B, Gora T, Krawczak K. Statins and cancers. *Wspolczesna Onkologia*. 2015;19(3):167-75.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2469. Su N, Ojeifo JO, MacPherson A, Zwiebel JA. Breast cancer gene therapy: Transgenic immunotherapy. *Breast Cancer Research and Treatment*. 1994;31(2-3):349-56.
배제사유 : 동물실험 및 전임상시험연구
2470. Su S, Zhao J, Xing Y, Zhang X, Liu J, Ouyang Q, et al. Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages. *Cell*. 2018;175(2):442-57.e23.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2471. Su X, Liang B, Li H, Wang Y, Yan B, Kong J, et al. The repairing mechanism of Rushi decoction on cellular immunofunction in patients with breast cancer. [Chinese]. *Chinese Journal of Lung Cancer*. 2009;12(6):651-3.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2472. Su Z, Ni P, She P, Liu Y, Richard SA, Xu W, et al. Bio-HMGB1 from breast cancer contributes to M-MDSC differentiation from bone marrow progenitor cells and facilitates conversion of monocytes into MDSC-like cells. *Cancer Immunology, Immunotherapy*. 2017;66(3):391-401.
배제사유 : 동물실험 및 전임상시험연구
2473. Suarez-Kelly LP, Rampersaud IV, Albertson D, Morris E, Noel TC, Buteyn NJ, et al.

- Antibody conjugation of fluorescent nanodiamonds for targeted innate immune cell activation. Annals of Surgical Oncology. 2018;25 (1 Supplement 1):S13.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2474. Sucher R, Kurz K, Margreiter R, Fuchs D, Brandacher G. Antiviral activity of interferon-gamma involved in impaired immune function in infectious diseases. Pteridines. 2013;24(3-4):149-64.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2475. Sugie T, Kaoru MH, Iwasaki M, Morita CT, Li W, Okamura H, et al. Activation by zoledronic acid and IL-18 of T cells from early-stage breast cancer patients in the context of helper NK cells. Journal of Clinical Oncology. Conference. 2012;30(15 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2476. Sugie T, Murata-Hirai K, Iwasaki M, Morita CT, Li W, Okamura H, et al. Zoledronic acid-induced expansion of gammadelta T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells. Cancer Immunology, Immunotherapy. 2013;62(4):677-87.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2477. Sullivan R. Understanding the practice and politics of cancer immunotherapy. Scrip Clinical Research. 2009;16(5):9-12.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2478. Sun B, Wu SK, Song ST. Progress of cancer experimental research in NOD/SCID mice. [Chinesel]. Chinese Journal of Cancer Prevention and Treatment. 2008;15(4):307-10.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2479. Sun DL, Xie HB, Xia YZ. A study on the inhibitory effect of polysaccharides from Radix ranunculus ternati on human breast cancer MCF-7 cell lines. African journal of traditional, complementary, & alternative medicines. 2013;10(6):439-43.
배제사유 : 동물실험 및 전임상시험연구
2480. Sun H, Sun C, Xiao W, Sun R. Tissue-resident lymphocytes: from adaptive to innate immunity. Cellular and Molecular Immunology. 2019;16(3):205-15.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2481. Sun J, Tao H, Li X, Wang L, Yang J, Wu P, et al. Clinical significance of novel costimulatory molecule B7-H6 in human breast cancer. Oncology Letters. 2017;14(2):2405-9.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2482. Sun W, Lv S, Li H, Cui W, Wang L. Enhancing the anticancer efficacy of immunotherapy through combination with histone modification inhibitors. Genes. 2018;9 (12) (633).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2483. Sun X, Jiang R, Przepiorski A, Reddy S, Palmano KP, Krissansen GW. "Iron-saturated" bovine lactoferrin improves the chemotherapeutic effects of tamoxifen in the treatment

of basal-like breast cancer in mice. *BMC Cancer*. 2012;12:591.

배제사유 : 동물실험 및 전임상시험연구

2484. Sun Y, Rao E, Yan F, Li Q, Zhang Y, Silverstein KAT, et al. Fatty acid-binding protein E-FABP restricts tumor growth by promoting IFN- β responses in tumor-associated macrophages. *Cancer Research*. 2014;74(11):2986-98.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2485. Sun Y. Translational horizons in the tumor microenvironment: Harnessing breakthroughs and targeting cures. *Medicinal Research Reviews*. 2015;35(2):408-36.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2486. Sun Z, Shi L, Zhang H, Shao Y, Wang Y, Lin Y, et al. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer. *Clinical Immunology*. 2011;138(1):23-32.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2487. Suresh K, Scheid E, Klotz L, Venkateswaran V, Gauldie J, Foley R. Induction of specific human cytotoxic T cells using dendritic cells transduced with an adenovector encoding rat epidermal growth factor receptor 2. *International Journal of Oncology*. 2011;39(4):907-13.
배제사유 : 동물실험 및 전임상시험연구
2488. Surico N, Tavassoli K. Effect of immunostimulating therapy on the immunocompetent system in breast carcinoma. *Panminerva Medica*. 1992;34(4):172-80.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2489. Surman M, Drozdz A, Stepień E, Przybylo M. Extracellular vesicles as drug delivery systems - Methods of production and potential therapeutic applications. *Current Pharmaceutical Design*. 2019;25(2):132-54.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2490. Suzuki A, Leland P, Joshi BH, Puri RK. Targeting of IL-4 and IL-13 receptors for cancer therapy. *Cytokine*. 2015;75(1):79-88.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2491. Suzuki E, Kataoka TR, Hirata M, Kawaguchi K, Nishie M, Haga H, et al. Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients. *BMC Cancer*. 2015;15:39.
배제사유 : 동물실험 및 전임상시험연구
2492. Suzuki E, Niwa R, Saji S, Muta M, Hirose M, Iida S, et al. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. *Clinical Cancer Research*. 2007;13(6):1875-82.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2493. Suzuki E, Sato F, Kawaguchi K, Sugie T, Toi M. Upregulation of neuropilin-1 in human monocyte is induced by RANKL and may be associated with trastuzumab mediated antibody dependent cellular cytotoxicity in breast cancer cells. *Cancer Research*.

Conference: 104th Annual Meeting of the American Association for Cancer Research, AACR. 2013;73(8 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2494. Suzuki H, Abo S, Kitamura M, Hashimoto M, Izumi K. The intrapleural administration of recombinant interleukin-2 (rIL-2) to patients with malignant pleural effusion: clinical trials. *Surgery Today*. 1993;23(12):1053-9.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2495. Suzuki H. [Experimental and clinical studies on intrapleural instillations of interleukin-2 (IL-2) in patients with malignant pleural effusion]. *Nippon Geka Gakkai Zasshi. Journal of Japan Surgical Society*. 1989;90(11):1922-31.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

2496. Suzuki M, Cheung NV. Disialoganglioside GD2 as a therapeutic target for human diseases. *Expert Opinion on Therapeutic Targets*. 2015;19(3):349-62.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2497. Swann J, Crowe NY, Hayakawa Y, Godfrey DI, Smyth MJ. Regulation of antitumour immunity by CD1d-restricted NKT cells. *Immunology and Cell Biology*. 2004;82(3):323-31.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2498. Swoboda A, Nanda R. Immune Checkpoint Blockade for Breast Cancer. *Cancer Treatment & Research*. 2018;173:155-65.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2499. Syed Najmuddin SU, Romli MF, Hamid M, Alitheen NB, Nik Abd Rahman NM. Anti-cancer effect of Annona Muricata Linn Leaves Crude Extract (AMCE) on breast cancer cell line. *BMC Complementary & Alternative Medicine*. 2016;16(1):311.

배제사유 : 동물실험 및 전임상시험연구

2500. Szeifert GT, Salmon I, Rorive S, Massager N, Devriendt D, Simon S, et al. Does gamma knife surgery stimulate cellular immune response to metastatic brain tumors? A histopathological and immunohistochemical study. *Journal of Neurosurgery*. 2005;102 Suppl:180-4.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2501. Szekely B, Bossuyt V, Li X, Baine M, Silber A, Sanft T, et al. Immunological differences between primary and metastatic breast cancer. *Cancer Research. Conference: San Antonio Breast Cancer Symposium, SABCS*. 2017;78(4 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2502. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. *Clinical Cancer Research*. 2013;19(5):1021-34.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2503. Taghian A, Budach W, Zietman A, Freeman J, Gioioso D, Ruka W, et al. Quantitative comparison between the transplantability of human and murine tumors into the subcutaneous tissue of NCr/Sed-nu/nu nude and severe combined immunodeficient

mice. *Cancer Research.* 1993;53(20):5012-7.

배제사유 : 동물실험 및 전임상시험연구

2504. Tagliabue E, Sfondrini L, Regondi V, Casalini P, Pupa SM, Sommariva M, et al. Chemotherapy can enhance trastuzumab-mediated ADCC. *Cancer Research. Conference: 35th Annual CTRC AACR San Antonio Breast Cancer Symposium.* San Antonio, TX United States. Conference Publication: 2012;72(24 SUPPL. 3).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2505. Tagliaferri P, Tortora G, Guerrasi R, Damiano V, Ruggiero A, Morelli D, et al. Differential sensitivity to non-major histocompatibility complex-restricted recombinant interleukin 2-activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or protein kinase A subunits. *Clinical Cancer Research.* 1996;2(1):207-14.

배제사유 : 동물실험 및 전임상시험연구

2506. Taguchi T, Domoto K. [Adoptive immunotherapy of cancer patients with lymphokine-activated killer cells]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy].* 1987;14(3 Pt 2):914-21.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

2507. Tahbaz-Lahafi B, Akbari ME, Amir-Rassouli H, Rahimipour A, Azargashb E, Nafissi N, et al. Granzyme h serum levels variations with both reproductive hormone receptors, and related hormone receptors in breast cancer patients. *Iranian Journal of Cancer Prevention.* 2014;7(1):48-52.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2508. Tai LH, Alkayyal AA, De Souza CT, Leslie AL, Sahi S, Bennett S, et al. Phosphodiesterase-5 inhibition augments postoperative natural killer cell antitumor immunity by reducing myeloid-derived suppressor cell function. *Cancer Immunology Research. Conference: CRI CIMT EATI AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival.* United States. 2016;4(1 Supplement).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2509. Tai LH, Zhang J, Auer RC. Preventing surgery-induced NK cell dysfunction and cancer metastases with influenza vaccination. *OncoImmunology.* 2013;2 (11) (e26618).

배제사유 : 동물실험 및 전임상시험연구

2510. Tai LH, Zhang J, Scott KJ, De Souza CT, Alkayyal AA, Ananth AA, et al. Perioperative influenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells. *Clinical Cancer Research.* 2013;19(18):5104-15.

배제사유 : 동물실험 및 전임상시험연구

2511. Tajiri M, Yamamoto O, Suenaga Y, Asahi M, Yoshinaga K, Hayashi M. A case of Stewart-Treves syndrome. [Japanese]. *Nishinihon Journal of Dermatology.* 2000;62(5):620-5.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

2512. Takada M, Terunuma H, Deng X, Dewan MZ, Saji S, Kuroi K, et al. Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. *Breast Cancer*. 2011;18(1):64-7.
배제사유 : 동물실험 및 전임상시험연구
2513. Takahashi H, Oshi M, Asaoka M, Yan L, Endo I, Takabe K. Molecular Biological Features of Nottingham Histological Grade 3 Breast Cancers. *Annals of Surgical Oncology*. 2020;20:20.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2514. Takahashi H, Oshi M, Asaoka M, Yan L, Takabe K. The biology and tumor immune microenvironment of nottingham grade 3 breast cancer. *Annals of Surgical Oncology*. 2020;27 (Supplement 1):S15.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2515. Takahashi T, Makiguchi Y, Hinoda Y, Kakiuchi H, Nakagawa N, Imai K, et al. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. *Journal of Immunology*. 1994;153(5):2102-9.
배제사유 : 동물실험 및 전임상시험연구
2516. Takanami I, Onishi H. Clinical Effects of Ninjin-Yoei-To as the Immunopotentiator. *Kiso to rinsho (the clinical report)*. 1988;22(7):1835?46.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
2517. Takaoka A, Tamura T, Taniguchi T. Interferon regulatory factor family of transcription factors and regulation of oncogenesis. *Cancer Science*. 2008;99(3):467-78.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2518. Tallerico R, Conti L, Lanzardo S, Sottile R, Garofalo C, Wagner AK, et al. NK cells control breast cancer and related cancer stem cell hematological spread. *Oncoimmunology*. 2017;6(3):e1284718.
배제사유 : 동물실험 및 전임상시험연구
2519. Talmadge JE, Alvord WG. Stress factors and breast cancer outcome. *Journal of Clinical Oncology*. 1987;5(3):333-4.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2520. Tan X, Chen W, Jiao C, Liang H, Yun H, He C, et al. Anti-tumor and immunomodulatory activity of the aqueous extract of *Sarcodon imbricatus* in vitro and in vivo. *Food & Function*. 2020;11(1):1110-21.
배제사유 : 동물실험 및 전임상시험연구
2521. Tanaka H, Hori M, Ohki T. High endothelial venule and immunocompetent cells in typical medullary carcinoma of the breast. *Virchows Archiv - A, Pathological Anatomy & Histopathology*. 1992;420(3):253-61.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2522. Tanaka H, Shimoda T, Uchida K, Suzuki T, Ishikawa E. Immunohistochemical study on the distribution and significance of mononuclear cells in human breast carcinoma. *Acta*

Pathologica Japonica. 1986;36(10):1455-68.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2523. Tanaka H, Watanabe M, Zeniya M, Takahashi H. Ultrastructure of IL2-stimulated tumor-infiltrating lymphocytes showing cytolytic activity against tumor cells. *Acta Pathologica Japonica*. 1991;41(2):94-105.

배제사유 : 동물실험 및 전임상시험연구

2524. Tanaka M, Honda J, Imamura Y, Shiraishi K, Tanaka K, Oizumi K. Effect of heat-pretreatment on interleukin-2-activated killer cells for in vitro purging. *Pathobiology*. 2000;68(3):124-8.

배제사유 : 동물실험 및 전임상시험연구

2525. Tang R, Beuvon F, Ojeda M, Mosseri V, Pouillart P, Scholl S. M-CSF (monocyte colony stimulating factor) and M-CSF receptor expression by breast tumour cells: M-CSF mediated recruitment of tumour infiltrating monocytes? *Journal of Cellular Biochemistry*. 1992;50(4):350-6.

배제사유 : 동물실험 및 전임상시험연구

2526. Tang X, Huang Y, Lei J, Luo H, Zhu X. The single-cell sequencing: New developments and medical applications. *Cell and Bioscience*. 2019;9 (1) (53).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2527. Tang X, Shu Z, Zhang W, Cheng L, Yu J, Zhang M, et al. Clinical significance of the immune cell landscape in hepatocellular carcinoma patients with different degrees of fibrosis. *Annals of Translational Medicine*. 2019;7(20):528.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2528. Taouk G, Hussein O, Zekak M, Abouelghar A, Al-Sarrat Y, Abdelalim EM, et al. CD56 expression in breast cancer induces sensitivity to natural killer-mediated cytotoxicity by enhancing the formation of cytotoxic immunological synapse. *Scientific Reports*. 2019;9(1):8756.

배제사유 : 동물실험 및 전임상시험연구

2529. Tardaguila M, Manes S. CX3CL1 at the crossroad of EGF signals: Relevance for the progression of ERBB2+ breast carcinoma. *Oncoimmunology*. 2013;2(9):e25669.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2530. Tarner IH, Muller-Ladner U, Fathman CG. Targeted gene therapy: Frontiers in the development of 'smart drugs'. *Trends in Biotechnology*. 2004;22(6):304-10.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2531. Taylor MA, Yong-Hun LEE, Schiemann WP. Role of TGF-beta and the tumor microenvironment during mammary tumorigenesis. *Gene Expression*. 2011;15(3):117-32.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2532. Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: Couples therapy. *Nature Reviews Cancer*. 2013;13(9):663-73.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2533. Teichman A, Lamerant-Fayel N, Jacquinet JC, Bielawska-Pohl A, Mleczko-Sanecka K, Grillon C, et al. Tumor hypoxia modulates podoplanin/CCL21 interactions in CCR7+ NK cell recruitment and CCR7+ tumor cell mobilization. *Oncotarget*. 2017;8(19):31876-87.
배제사유 : 동물실험 및 전임상시험연구
2534. Tekewe A. Vaccines and antibodies for cancer immunotherapy a review. *Pharmacophore*. 2012;3(1):1-17.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2535. Teng MWL, Sharkey J, McLaughlin NM, Exley MA, Smyth MJ. CD1d-based combination therapy eradicates established tumors in mice. *Journal of Immunology*. 2009;183(3):1911-20.
배제사유 : 동물실험 및 전임상시험연구
2536. Tentori L, Fuggetta MP, D'Atri S, Aquino A, Nunziata C, Roselli M, et al. Influence of low-dose beta-interferon on natural killer cell activity in breast cancer patients subjected to chemotherapy. *Cancer Immunology, Immunotherapy*. 1987;24(1):86-91.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2537. Teo HMV, Goh SW, Sari IP, Chew WL, Lim HE, Dasgupta R, et al. Generation of personalized tumor Biopsy-Derived Natural Killer (BDNK) cells. *Journal of Global Oncology*. 2019;5 (Supplement):86.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2538. Teramura Y, Watanabe Y, Kan N, Masuda T, Kuribayashi K. Interferon-gamma-producing tumor induces host tumor-specific T cell responses. *Japanese Journal of Cancer Research*. 1993;84(6):689-96.
배제사유 : 동물실험 및 전임상시험연구
2539. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L. Natural killer cell-directed therapies: Moving from unexpected results to successful strategies. *Nature Immunology*. 2008;9(5):486-94.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2540. Terunuma H, Deng X, Nishino N, Watanabe K. NK cell-based autologous immune enhancement therapy (AIET) for cancer. *Journal of Stem Cells and Regenerative Medicine*. 2013;9(1):9-13.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2541. Terunuma H. Autologous Immune Enhancement Therapy for Cancer - Our experience since 2004. *Journal of Stem Cells & Regenerative Medicine*. 2012;8(3):205-6.
배제사유 : 동물실험 및 전임상시험연구
2542. Tesniere A, Kroemer G, Tursz T, Zitvogel L. Personalized immunotherapy: A siren myth? *Personalized Medicine*. 2009;6(5):469-73.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2543. Thakur A, Schalk D, Tomaszewski E, Kondadasula SV, Yano H, Sarkar FH, et al. Microenvironment generated during EGFR targeted killing of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through COX2 and PGE2 dependent pathway. *Journal of Translational Medicine*. 2013;11:35.
배제사유 : 동물실험 및 전임상시험연구
2544. Thein MS, Chumsri S, Eeast J, Li J, Kesmodel S, Bao T, et al. Levels of circulating natural killer T and natural killer cells in breast cancer patients. *Journal of Clinical Oncology. Conference*. 2013;31(15 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2545. Theodoro TR, Matos LL, Cavalheiro RP, Justo GZ, Nader HB, Pinhal MAS. Crosstalk between tumor cells and lymphocytes modulates heparanase expression. *Journal of Translational Medicine*. 2019;17 (1) (103).
배제사유 : 동물실험 및 전임상시험연구
2546. Thisoda P, Ketsa-Ard K, Thongprasert S, Vongsakul M, Picha P, Karbwang J, et al. Immunostimulating effect of a well-known Thai folkloric remedy in breast cancer patients. *Asian Pacific Journal of Cancer Prevention: Apjcp*. 2013;14(4):2599-605.
배제사유 : 동물실험 및 전임상시험연구
2547. Thompson B. Oncolytics Biotech♦ Inc.: REOLYSIN♦ for melanoma therapy. *Melanoma Management*. 2015;2(2):105-7.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2548. Thornton LM, Andersen BL, Carson WE, 3rd. Immune, endocrine, and behavioral precursors to breast cancer recurrence: a case-control analysis. *Cancer Immunology, Immunotherapy*. 2008;57(10):1471-81.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2549. Thornton LM, Andersen BL, Crespin TR, Carson WE. Individual trajectories in stress covary with immunity during recovery from cancer diagnosis and treatments. *Brain, Behavior, & Immunity*. 2007;21(2):185-94.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2550. Thurnher M, Nussbaumer O, Gruenbacher G. Novel aspects of mevalonate pathway inhibitors as antitumor agents. *Clinical Cancer Research*. 2012;18(13):3524-31.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2551. Thyagarajan S, Felten DL. Modulation of neuroendocrine-immune signaling by L-deprenyl and L-desmethyldeprenyl in aging and mammary cancer. *Mechanisms of Ageing and Development*. 2002;123(8):1065-79.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2552. Thyagarajan S, Madden KS, Boehm GW, Stevens SY, Felten DL, Bellinger DL. L-Deprenyl reverses age-associated decline in splenic norepinephrine, interleukin-2 and interferon-gamma production in old female F344 rats. *Neuroimmunomodulation*. 2013;20(2):72-8.

배제사유 : 동물실험 및 전임상시험연구

2553. Thyagarajan S, Madden KS, Stevens SY, Felten DL. Anti-tumor effect of L-deprenyl is associated with enhanced central and peripheral neurotransmission and immune reactivity in rats with carcinogen-induced mammary tumors. *Journal of Neuroimmunology*. 2000;109(2):95-104.

배제사유 : 동물실험 및 전임상시험연구

2554. Thyagarajan S, Madden KS, Stevens SY, Felten DL. Inhibition of tumor growth by L-deprenyl involves neural-immune interactions in rats with spontaneously developing mammary tumors. *Anticancer Research*. 1999;19(6 B):5023-8.

배제사유 : 동물실험 및 전임상시험연구

2555. ThyagaRajan S, Tran L, Molinaro CA, Gridley DS, Felten DL, Bellinger DL. Prevention of mammary tumor development through neuroimmunomodulation in the spleen and lymph nodes of old female sprague-dawley rats by L-deprenyl. *NeuroImmunoModulation*. 2013;20(3):141-51.

배제사유 : 동물실험 및 전임상시험연구

2556. Thyphronitis G, Koutsilieris M. Boosting the immune response: An alternative combination therapy for cancer patients. *Anticancer Research*. 2004;24(4):2443-53.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2557. Tian T, Ren GS, Li XT. Effect of transfection of REGgamma gene on the growth of xenografted human breast cancer in nude mice. [Chinese]. *Tumor*. 2009;29(3):226-30.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

2558. Tian W, Wang L, Yuan L, Duan W, Zhao W, Wang S, et al. A prognostic risk model for patients with triple negative breast cancer based on stromal natural killer cells, tumor-associated macrophages and growth-arrest specific protein 6. *Cancer Science*. 2016;107(7):882-9.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2559. Tian X, Wei F, Wang L, Yu W, Zhang N, Zhang X, et al. Herceptin enhances the antitumor effect of natural killer cells on breast cancer cells expressing human epidermal growth factor receptor-2. *Frontiers in Immunology*. 2017;8 (OCT) (1426).

배제사유 : 동물실험 및 전임상시험연구

2560. Tian Y, Li M, Song W, Jiang R, Li YQ. Effects of probiotics on chemotherapy in patients with lung cancer. *Oncology letters*. 2019;17(3):2836?48.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2561. Tian Y, Liu Z, Tan H, Hou J, Wen X, Yang F, et al. New aspects of ultrasound-mediated targeted delivery and therapy for cancer. *International Journal of Nanomedicine*. 2020;15:401-18.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2562. Tichatschek E, Zielinski CC, Muller C, Sevelda P, Kubista E, Czerwenka K, et al. Long-term influence of adjuvant therapy on natural killer cell activity in breast cancer. *Cancer Immunology, Immunotherapy*. 1988;27(3):278-82.

배제사유 : 동물실험 및 전임상시험연구

2563. Tiriveedhi V, Tucker N, Herndon J, Li L, Sturmoski M, Ellis M, et al. Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer. *Clinical Cancer Research.* 2014;20(23):5964-75.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2564. Todorova VK, Klimberg VS, Hennings L, Kieber-Emmons T, Pashov A. Immunomodulatory effects of radiofrequency ablation in a breast cancer model. *Immunological Investigations.* 2010;39(1):74-92.

배제사유 : 동물실험 및 전임상시험연구

2565. Toge T, Yamaguchi Y, Sawamura A. The role of lymphocyte surface binding sites for wheat germ agglutinin in the negative regulation of cancer patients. *Surgery Today.* 1993;23(9):765-70.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2566. Toh U, Saku S, Iwakuma N, Okabe M, Shichijo S, Yamada A, et al. Feasibility study of multiple HLA-class IA restricted peptide vaccines (KRM-19) for metastatic triple negative breast cancer (TNBC). *Journal of Clinical Oncology.* 2017;35 (7 Supplement 1):164.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2567. Toh U, Yamana H, Kido K, Mine T, Fujii T, Horiuchi H, et al. [Autologous tumor specific immunotherapy of refractory cancers with ex vivo-generated T cells stimulated by autologous tumor cell]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy].* 2003;30(11):1566-70.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

2568. Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, So HF, et al. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab. *International Journal of Cancer.* 2008;122(11):2526-34.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2569. Tolaney SM, Ziehr DR, Guo H, Ng MR, Barry WT, Higgins MJ, et al. Phase II and biomarker study of cabozantinib in metastatic triple-negative breast cancer patients. *Oncologist.* 2017;22(1):25?32.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2570. Tomida M, Yamamoto Y, Hozumi M, Kawade Y. Interferon production in mixed cultures of mouse spleen cells and tumor cells: IFN-gamma as the main component. *Journal of Interferon Research.* 1982;2(2):271-83.

배제사유 : 동물실험 및 전임상시험연구

2571. Tomiyama T, Uchida K, Yoshida K, Muto T, Saito H, Nemoto K, et al. Giant cavernous hemangioma of the liver and multiple primary malignant tumors in a patient with suspected familial inhibition of natural killer cell activity--a case report. *Japanese Journal of Surgery.* 1989;19(2):216-22.

배제사유 : 동물실험 및 전임상시험연구

2572. Tonini G, Nunziata C, Prete SP, Pepponi R, Turriziani M, Masci G, et al. Adjuvant treatment of breast cancer: a pilot immunochemotherapy study with CMF, interleukin-2 and interferon alpha. *Cancer Immunology, Immunotherapy*. 1998;47(3):157-66.
배제사유 : 동물실험 및 전임상시험연구
2573. Topalian SL, Solomon D, Avis FP, Chang AE, Freerksen DL, Linehan WM, et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. *Journal of Clinical Oncology*. 1988;6(5):839-53.
배제사유 : 동물실험 및 전임상시험연구
2574. Torabi A, Welder D, Perry C, Wians FH. Cd206 positive macrophages in axillary lymph nodes of patients with breast adenocarcinoma express PD-l1. *Laboratory Investigation*. 2017;97 (Supplement 1):74A.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2575. Torkelson CJ, Sweet E, Martzen MR, Sasagawa M, Wenner CA, Gay J, et al. Phase 1 Clinical Trial of Trametes versicolor in Women with Breast Cancer. *Ismr Oncology Print*. 2012;2012:251632.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2576. Toth G, Szoor A, Simon L, Yarden Y, Szollosi J, Vereb G. The best is not enough-when it is alone: Current clinical doses of humanized anti-Her2 antibodies should be applied in combination to delay development of trastuzumab resistance by additively enhancing ADCC. *Cancer Immunology Research*. Conference: 2nd CRI CIMT EATI AACR International Cancer Immunotherapy Conference: Translating Science into Survival. United States. 2016;4(11 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2577. Toth G, Szoor A, Simon L, Yarden Y, Szollosi J, Vereb G. The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity. *mAbs*. 2016;8(7):1361-70.
배제사유 : 동물실험 및 전임상시험연구
2578. Travis Clifton G, Litton JK, Arrington K, Ponniah S, Ibrahim NK, Gall V, et al. Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients. *Annals of surgical oncology*. 2017;1?7.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2579. Triki H, Charfi S, Bouzidi L, Ben Kridis W, Daoud J, Chaabane K, et al. CD155 expression in human breast cancer: Clinical significance and relevance to natural killer cell infiltration. *Life Sciences*. 2019;231:116543.
배제사유 : 동물실험 및 전임상시험연구
2580. Trintinaglia L, Bandinelli LP, Grassi-Oliveira R, Petersen LE, Anzolin M, Correa BL, et al. Features of Immunosenescence in Women Newly Diagnosed With Breast Cancer.

Frontiers in Immunology. 2018;9:1651.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2581. Tripathi P, Tran N, Padmanabhan R, Hartsfield R, Moler EJ, Hoe N, et al. Measurement of immune infiltration in ER, PR, and HER2 IHC subtypes reveals populations that may benefit from immunotherapy. Cancer Immunology Research. Conference: CRI CIMT EATI AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival. United States. 2016;4(1 Supplement).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2582. Trivedi S, Jie HB, Ferris RL. Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity. Seminars in Oncology. 2014;41(5):678-84.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2583. Troger W. Cancer therapy with mistletoe extracts. short overview of 100 year experiences and recent clinical results. BMC Complementary and Alternative Medicine. Conference: World Congress Integrative Medicine and Health. 2017;17(Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2584. Tsang KY, Fundenberg HH, Pan JF. An in vitro study on the effects of isoprinosine on immune responses in cancer patients. International Journal of Immunopharmacology. 1983;5(6):481-90.
배제사유 : 동물실험 및 전임상시험연구
2585. Tsang KY, Hynes JB, Fudenberg HH, Pan JF. Effects of three new folate antagonists on human breast adenocarcinoma cells in vitro and on immune responses in vivo. Chemotherapy. 1984;30(1):61-8.
배제사유 : 동물실험 및 전임상시험연구
2586. Tsang YW, Chi KH, Hu CJ, Tseng CL, Tseng FW, Wang YS. Chemotherapy-induced immunosuppression is restored by a fermented soybean extract: a proof of concept clinical trial. Nutrition Research. 2007;27(11):679-84.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2587. Tsao L, Draoua HY, Mansukhani M, Bhagat G, Alobeid B. EBV-associated, extranodal NK-cell lymphoma, nasal type of the breast, after heart transplantation. Modern Pathology. 2004;17(1):125-30.
배제사유 : 동물실험 및 전임상시험연구
2588. Tsao LC, Crosby EJ, Trotter TN, Agarwal P, Hwang BJ, Acharya C, et al. CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. Jci Insight. 2019;4(24):19.
배제사유 : 동물실험 및 전임상시험연구
2589. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. British Journal of Cancer. 2002;87(1):21-7.
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
2590. Tseng D, Jones CD, Anderson M, Warnke R, Zehnder JL, Miklos DB. Clonally identical

- Hodgkin's disease develops after allogeneic hematopoietic cell transplant for CLL. *Bone Marrow Transplantation*. 2011;46(12):1576-8.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2591. Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. *Cancer Treatment Reviews*. 2020;86 (102019).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2592. Tu H, Zhang L, Ding L, Jin Y, Zhou F. Effect of compound kushen injection on immune function for patients with newly diagnosed multiple myeloma undergoing chemotherapy. *HemaSphere*. 2018;2 (Supplement 2):970-1.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2593. Tu MM, Rahim MMA, Sayed C, Mahmoud AB, Makrigiannis AP. Immunosurveillance and immunoediting of breast cancer via class I MHC receptors. *Cancer Immunology Research*. 2017;5(11):1016-28.
배제사유 : 동물실험 및 전임상시험연구
2594. Turaj AH, Dahal LN, Beers SA, Cragg MS, Lim SH. TLR-3/9 agonists synergize with anti-ErbB2 mAb - Letter. *Cancer Research*. 2017;77(12):3376-8.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2595. Turini M, Chames P, Bruhns P, Baty D, Kerfelec B. A FcgammaRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy. *Oncotarget*. 2014;5(14):5304-19.
배제사유 : 동물실험 및 전임상시험연구
2596. Turnbull AK, Larionov AA, Renshaw L, Kay C, Sims AH, Dixon JM. Lack of response to aromatase inhibitors involves distinct mechanisms. *Cancer Research Conference: 35th Annual CTRC AACR San Antonio Breast Cancer Symposium*. San Antonio, TX United States. Conference Publication:. 2012;72(24 SUPPL 3).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2597. Turriziani M, Fantini M, Benvenuto M, Izzi V, Masuelli L, Sacchetti P, et al. Carcinoembryonic antigen (CEA)-based cancer vaccines: Recent patents and antitumor effects from experimental models to clinical trials. *Recent Patents on Anti-Cancer Drug Discovery*. 2012;7(3):265-96.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2598. Tuve S, Liu Y, Tragoolpua K, Jacobs JD, Yumul RC, Li ZY, et al. In situ adenovirus vaccination engages T effector cells against cancer. *Vaccine*. 2009;27(31):4225-39.
배제사유 : 동물실험 및 전임상시험연구
2599. Tydeman-Edwards R. Glutamine and its use in selected oncology settings. *South African Journal of Clinical Nutrition*. 2017;30(4):109-17.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2600. Tyutyunyk L, Gewirtz DA, Landry J, Dao N. Suppression of epigenetic regulator NURF leads to autophagy mediated chemo- and immune sensitization of triple negative breast

cancer. Cancer Research. Conference: American Association for Cancer Research Annual Meeting. 2019;79(13 Supplement).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2601. Tyutyunyk L, Landry J, Saleh T, Gewirtz D. Synergistic effects of chemotherapy-induced autophagy and epigenetic remodeling. Cancer Research. Conference: American Association for Cancer Research Annual Meeting. 2017;77(13 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2602. Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. European Journal of Immunology. 2006;36(10):2566-73.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2603. Uchida A, Kolb R, Micksche M. Generation of suppressor cells for natural killer activity in cancer patients after surgery. Journal of the National Cancer Institute. 1982;68(5):735-41.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2604. Ueda S, Roblyer D, Cerussi A, Saeki T, Tromberg B. Tissue oxyhemoglobin dynamics measured with functional optical imaging immediately after starting chemotherapy correlates with markers of cellular proliferation and inflammation in a rat breast tumor model. Cancer Research. Conference: 35th Annual CTRC AACR San Antonio Breast Cancer Symposium. San Antonio, TX United States. Conference Publication: 2012;72(24 SUPPL. 3).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2605. Ueno Y, Kohgo Y, Sasagawa Y, Kanisawa Y, Nojiri S, Mahara K, et al. [A case of pericarditis carcinomatosa showing good response following local transfer of lymphokine-activated killer (LAK) cells]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]. 1987;14(8):2579-82.

배제사유 : 동물실험 및 전임상시험연구

2606. Ueshima C, Kataoka TR, Hirata M, Furuhat A, Suzuki E, Toi M, et al. The Killer Cell Ig-like Receptor 2DL4 Expression in Human Mast Cells and Its Potential Role in Breast Cancer Invasion. Cancer Immunology Research. 2015;3(8):871-80.

배제사유 : 동물실험 및 전임상시험연구

2607. Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, et al. Retargeting of natural killer-cell cytolytic activity to Erbb2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood. 2002;100(4):1265-73.

배제사유 : 동물실험 및 전임상시험연구

2608. Ullrich A, Sures I, D'Egidio M, Jallal B, Powell TJ, Herbst R, et al. The secreted tumor-associated antigen 90K is a potent immune stimulator. Journal of Biological Chemistry. 1994;269(28):18401-7.

배제사유 : 동물실험 및 전임상시험연구

2609. Ullrich E, Bonmort M, Mignot G, Kroemer G, Zitvogel L. Tumor stress, cell death and the ensuing immune response. Cell Death and Differentiation. 2008;15(1):21-8.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2610. Umansky V, Guinn BA. ESCII-PIVAC meeting "Recent advances in cancer immunotherapy with an emphasis on cancer vaccines" held in Athens, 9-11 October 2008. *Cancer Immunology, Immunotherapy*. 2010;59(4):635-40.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2611. Underwood JC, Giri DD, Rooney N, Lonsdale R. Immunophenotype of the lymphoid cell infiltrates in breast carcinomas of low oestrogen receptor content. *British Journal of Cancer*. 1987;56(6):744-6.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2612. Uong TNT, Lee KH, Ahn SJ, Kim KW, Min JJ, Hyun H, et al. Real-time tracking of ex vivo-expanded natural killer cells toward human triple-negative breast cancers. *Frontiers in Immunology*. 2018;9 (MAY) (825).

배제사유 : 동물실험 및 전임상시험연구

2613. Urbanska K, Poussin M, Stashwick C, Smith JB, Powell DJ. Overcoming resistance to antibody targeted therapy in ovarian cancer. *Clinical Cancer Research. Conference: 10th Biennial Ovarian Cancer Research Symposium*. United States. 2015;21(16 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2614. Urbanska K, Poussin M, Stashwick C, Smith JB, Powell Jr DJ. Overcoming resistance to antibody targeted therapy in cancer using gene-modified T cells. *Molecular Therapy*. 2014;1):S297-S8.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2615. Urosevic M, Trojan A, Dummer R. HLA-G and its KIR ligands in cancer--another enigma yet to be solved? *Journal of Pathology*. 2002;196(3):252-3.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2616. Ursini-Siegel J. Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies? *Frontiers in Oncology*. 2013;3 FEB (Article 00023).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2617. Vacca P, Martini S, Garelli V, Passalacqua G, Moretta L, Mingari MC. NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation. *European Journal of Immunology*. 2013;43(2):550-61.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2618. Vacchelli E, Michels J, Hadoux J, Lotz JP. American Association for Cancer Research - AACR congress 2014. [French]. *Oncologie*. 2014;16(7-8):341-66.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

2619. Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, et al. Trial watch: Immunostimulatory cytokines in cancer therapy. *OncoImmunology*. 2014;3 (6) (e29030).

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2620. Vadiraja HS, Rao RM, Nagarathna R, Nagendra HR, Patil S, Diwakar RB, et al. Effects of Yoga in Managing Fatigue in Breast Cancer Patients: A Randomized Controlled Trial. Indian Journal of Palliative Care. 2017;23(3):247-52.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2621. Valavaara R, Tuominen J, Toivanen A. The immunological status of breast cancer patients during treatment with a new antiestrogen, toremifene. Cancer Immunology, Immunotherapy. 1990;31(6):381-6.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2622. Valdes-Zayas A, Gonzalez Z, Mulens V, Vega AM, Perez K, Lorenzo-Luaces P, et al. Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy. Journal of immunotherapy. 2017;40(8):289-301.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2623. Valdimarsdottir HB, Zakowski SG, Gerin W, Mamakos J, Pickering T, Bovbjerg DH. Heightened psychobiological reactivity to laboratory stressors in healthy women at familial risk for breast cancer. Journal of Behavioral Medicine. 2002;25(1):51-65.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2624. Vallera DA, Zhang B, Gleason MK, Oh S, Weiner LM, Kaufman DS, et al. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biotherapy & Radiopharmaceuticals. 2013;28(4):274-82.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2625. Valsesia-Wittmann S, Clemenceau B, Jallas AC, Blay JY, Marabelle A, Caux C, et al. Overcoming therapeutic MAb resistance in aggressive HER2 positive breast carcinomas by adoptive immunotherapy using optimized effector cells. Journal for ImmunoTherapy of Cancer. Conference: 28th Annual Scientific Meeting of the Society for Immunotherapy of Cancer, SITC. 2013;1(SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2626. Van De Ven R, Oerlemans R, Van Der Heijden JW, Scheffer GL, De Gruyl TD, Jansen G, et al. ABC drug transporters and immunity: Novel therapeutic targets in autoimmunity and cancer. Journal of Leukocyte Biology. 2009;86(5):1075-87.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2627. Van den Bergh JM, Van Tendeloo VF, Smits ELJM. Interleukin-15: New kid on the block for antitumor combination therapy. Cytokine and Growth Factor Reviews. 2015;26(1):15-24.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2628. van der Haar Avila I, Marmol P, Cany J, Kiessling R, Pico de Coana Y. Evaluating Antibody-Dependent Cell-Mediated Cytotoxicity by Flow Cytometry. Methods in Molecular Biology. 2019;1913:181-94.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2629. van der Haar Avila I, Marmol P, Kiessling R, Pico de Coana Y. Evaluating Antibody-Dependent Cell-Mediated Cytotoxicity by Chromium Release Assay. *Methods in Molecular Biology*. 2019;1913:167-79.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2630. van der Most RG, Currie AJ, Robinson BWS, Lake RA. Decoding dangerous death: How cytotoxic chemotherapy invokes inflammation, immunity or nothing at all. *Cell Death and Differentiation*. 2008;15(1):13-20.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2631. van der Pompe G, Antoni M, Visser A, Garssen B. Adjustment to breast cancer: the psychobiological effects of psychosocial interventions. *Patient Education & Counseling*. 1996;28(2):209-19.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2632. van der Pompe G, Antoni MH, Duivenvoorden HJ, Heijnen CJ. Relations of plasma ACTH and cortisol levels with the distribution and function of peripheral blood cells in response to a behavioral challenge in breast cancer: an empirical exploration by means of statistical modeling. *International Journal of Behavioral Medicine*. 1997;4(2):145-69.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2633. van der Pompe G, Antoni MH, Duivenvoorden HJ, de Graeff A, Simonis RF, van der Vegt SG, et al. An exploratory study into the effect of group psychotherapy on cardiovascular and immunoreactivity to acute stress in breast cancer patients. *Psychotherapy & Psychosomatics*. 2001;70(6):307-18.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2634. van der Pompe G, Antoni MH, Visser A, Heijnen CJ. Effect of mild acute stress on immune cell distribution and natural killer cell activity in breast cancer patients. *Biological Psychology*. 1998;48(1):21-35.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2635. van der Pompe G, Duivenvoorden HJ, Antoni MH, Visser A, Heijnen CJ. Effectiveness of a short-term group psychotherapy program on endocrine and immune function in breast cancer patients: an exploratory study. *Journal of Psychosomatic Research*. 1997;42(5):453-66.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2636. van der Wall E, Horn T, Bright E, Passos-Coehlo JL, Bond S, Clarke B, et al. Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells. *British Journal of Cancer*. 2000;83(11):1405-11.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2637. van Egmond M. Neutrophils in antibody-based immunotherapy of cancer. *Expert*

Opinion on Biological Therapy. 2008;8(1):83-94.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2638. Van Elsen CHMJ, Oth T, Germeraad WTV, Bos GMJ, Vanderlocht J. Natural killer cells: The secret weapon in dendritic cell vaccination strategies. *Clinical Cancer Research*. 2014;20(5):1095-103.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2639. van Gumeren MM, Willemse PH, Mulder NH, Limburg PC, Groen HJ, Vellenga E, et al. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. *Blood*. 1994;84(5):1434-41.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2640. Van Gelder M, Frings P, Matos C, Schouten HC, Bos GMJ. Effective alloreactive NK cell therapy for breast cancer in mice requires conditioning with cyclophosphamide and total body irradiation but not bone marrow engraftment. *Blood*. Conference: 52nd Annual Meeting of the American Society of Hematology, ASH. 2010;116(21).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2641. Van Slambrouck S, Parmar VS, Sharma SK, De Bondt B, Fore F, Coopman P, et al. Tangeretin inhibits extracellular-signal-regulated kinase (ERK) phosphorylation. *FEBS Letters*. 2005;579(7):1665-9.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2642. Vangangelt KMH, van Pelt GW, Engels CC, Putter H, Liefers GJ, Smit V, et al. Prognostic value of tumor-stroma ratio combined with the immune status of tumors in invasive breast carcinoma. *Breast Cancer Research & Treatment*. 2018;168(3):601-12.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2643. Vanmeerbeek I, Sprooten J, De Ruysscher D, Teijpar S, Vandenberghe P, Fucikova J, et al. Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. *OncolImmunology*. 2020;9 (1) (1703449).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2644. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. *Nature Reviews Cancer*. 2012;12(4):237-51.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2645. Vanni G, Materazzo M, Perretta T, Meucci R, Anemona L, Buonomo C, et al. Impact of Awake Breast Cancer Surgery on Postoperative Lymphocyte Responses. *In Vivo*. 2019;33(6):1879-84.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2646. Vantourout P, Willcox C, Turner A, Swanson CM, Haque Y, Sobolev O, et al. Immunological visibility: Posttranscriptional regulation of human NKG2D ligands by the EGF receptor pathway. *Science Translational Medicine*. 2014;6 (231) (231ra49).
배제사유 : 동물실험 및 전임상시험연구
2647. Varadhachary A, Wolf JS, Pettrak K, O'Malley Jr BW, Spadaro M, Curcio C, et al. Oral

lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. International Journal of Cancer. 2004;111(3):398-403.

배제사유 : 동물실험 및 전임상시험연구

2648. Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Research. 2007;67(24):11991-9.

배제사유 : 동물실험 및 전임상시험연구

2649. Vari F, Hart DNJ. Loading DCs with Ag. Cytotherapy. 2004;6(2):111-21.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2650. Varker KA, Terrell CE, Welt M, Suleiman S, Thornton L, Andersen BL, et al. Impaired natural killer cell lysis in breast cancer patients with high levels of psychological stress is associated with altered expression of killer immunoglobulin-like receptors. Journal of Surgical Research. 2007;139(1):36-44.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2651. Varn FS, Andrews EH, Mullins DW, Cheng C. Integrative analysis of breast cancer reveals prognostic haematopoietic activity and patient-specific immune response profiles. Nature Communications. 2016;7 (10248).

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2652. Vartuli RL, Zhou H, Zhang L, Powers RK, Klarquist J, Rudra P, et al. Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation. Journal of Clinical Investigation. 2018;128(6):2535-50.

배제사유 : 동물실험 및 전임상시험연구

2653. Vazquez B, Rebollo J, Martinez E, Sureda M, Gonzalez Manzano R. Long-term low-dose interleukin-2 (IL-2), alfa-interferon (alpha-IFN) and 13-cis-retinoic acid (RA) as maintenance therapy in cancer patients. A preliminary study. European Journal of Immunology. 2009;1):S525-S6.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2654. Vazquez-Lombardi R, Roome B, Christ D. Molecular engineering of therapeutic cytokines. Antibodies. 2013;2(3):426-51.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2655. Veldwijk M, Botma A, Helmbold I, Gurth N, Kirchner A, Behrens S, et al. Association of T lymphocyte apoptosis after in vitro irradiation with normal tissue late toxicity after radiation therapy in 252 breast cancer patients with 10-year clinical follow-up. International Journal of Radiation Oncology. 2016;96 (2 Supplement 1):S64-S5.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2656. Veldwijk MR, Seibold P, Botma A, Helmbold I, Sperk E, Giordano FA, et al. Association of CD4+ radiation-induced lymphocyte apoptosis with fibrosis and telangiectasia after radiotherapy in 272 breast cancer patients with >10-year follow-up. Clinical Cancer Research. 2019;25(2):562-72.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2657. Velica P, Rundqvist H, Gojkovic M, Johnson RS. The immune composition of a spontaneous mouse breast cancer. *Cancer Research*. Conference: AACR Special Conference on The Function of Tumor Microenvironment in Cancer Progression. 2016;76(15 Supplement).
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2658. Vendramini-Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. *Current Pharmaceutical Design*. 2012;18(26):3831-52.
- 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2659. Verma B, Aftimos PG, Awada A, Machiels JPH, Brayer JB, Sallman DA, et al. A NKG2D-based CAR-T therapy in a multinational phase I dose escalation and expansion study targeting multiple solid and hematologic tumor types. *Journal of Clinical Oncology*. Conference. 2017;35(15 Supplement 1).
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2660. Verma B, Awada A, Aftimos P, Lewalle P, Meuleman N, Machiels JP, et al. A phase I global trial targeting multiple solid and hematologic malignancies through a NKG2D receptor-based CAR-T immunotherapy. *Annals of Oncology*. 2017;28 (Supplement 5):v426.
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2661. Verma C, Kaewkangsdan V, Eremin JM, Cowley GP, Ilyas M, El-Sheemy MA, et al. Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): Differential restoration of blood profiles by NAC and surgery. *Journal of Translational Medicine*. 2015;13 (1) (180).
- 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2662. Verma R, Foster RE, Horgan K, Mounsey K, Nixon H, Smalle N, et al. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. *Breast Cancer Research*. 2016;18(1):10.
- 배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2663. Verma R, Rajan SS, Smalle N, McCurtin RE, Horgan K, Hughes TA, et al. Determinants of B cell depletion and repopulation after chemotherapy for breast cancer. *European Journal of Surgical Oncology*. 2012;38 (11):1134-5.
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2664. Verma R, Smalle N, McCurtin RE, Horgan K, Carter CRD, Hughes TA. Chemotherapy for breast cancer causes sustained alteration in number and type of b lymphocytes. *Cancer Research*. Conference: 35th Annual CTRC AACR San Antonio Breast Cancer Symposium. San Antonio, TX United States. Conference Publication:. 2012;72(24 SUPPL. 3).
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2665. Veronesi U, Luini A, Mariani L, Del Vecchio M, Alvez D, Andreoli C, et al. Effect of

menstrual phase on surgical treatment of breast cancer. *Lancet.* 1994;343(8912):1545-7.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2666. Verrone E, Delgado A, Valladeau-Guilemond J, Garin G, Guillemaut S, Tredan O, et al. Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay. *OncoImmunology.* 2016;5(3).
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
2667. Vetzicka V, Thornton BP, Wieman TJ, Ross GD. Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18). *Journal of Immunology.* 1997;159(2):599-605.
배제사유 : 동물실험 및 전임상시험연구
2668. Vetzicka V, Vetzickova J. beta 1, 3-glucan in cancer treatment. *American Journal of Immunology.* 2012;8(2):38-43.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2669. Vetzicka V, Yvin JC. Effects of marine beta-1,3 glucan on immune reactions. *International Immunopharmacology.* 2004;4(6):721-30.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2670. Vey N, Karlin L, Sadot-Lebouvier S, Broussais F, Berton-Rigaud D, Rey J, et al. A phase 1 study of lirilumab (antibody against killer immunoglobulinlike receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies. *Oncotarget.* 2018;9(25):17675-88.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2671. Vgenopoulou S, Lazaris AC, Markopoulos C, Boltetsou E, Kyriakou V, Kavantzas N, et al. Immunohistochemical evaluation of immune response in invasive ductal breast cancer of not-otherwise-specified type. *Breast.* 2003;12(3):172-8.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2672. Vidal-Vanaclocha F, Mendoza L, Telleria N, Salado C, Valcarcel M, Gallot N, et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. *Cancer and Metastasis Reviews.* 2006;25(3):417-34.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2673. Vilalta M, Rafat M, Graves EE. Effects of radiation on metastasis and tumor cell migration. *Cellular and Molecular Life Sciences.* 2016;73(16):2999-3007.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2674. Villa ML, Ferrario E, Trabattoni D, Formelli F, De Palo G, Magni A, et al. Retinoids, breast cancer and NK cells. *British Journal of Cancer.* 1993;68(5):845-50.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2675. Villasboas J, McGrath K, Amir EAD, Leon-Ferre R, Goetz M, Boughey J, et al. High dimensional immune monitoring of peripheral blood samples from breast cancer patients using mass cytometry (CyTOF. *Journal for ImmunoTherapy of Cancer.* Conference: 34th Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer Part. 2019;7(Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2676. Viry E, Baginska J, Berchem G, Noman MZ, Medves S, Chouaib S, et al. Autophagic degradation of GZMB/granzyme B: a new mechanism of hypoxic tumor cell escape from natural killer cell-mediated lysis. *Autophagy*. 2014;10(1):173-5.

배제사유 : 동물실험 및 전임상시험연구

2677. Vishnubhotla P, Khaled A, Showalter A, Oyer J, Igarshi R, Copik A, et al. A novel therapeutic to enhance the immunogenicity of breast cancer cells. *Journal of Clinical Oncology*. 2017;35 (7 Supplement 1):119.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2678. Visonneau S, Cesano A, Porter DL, Luger SL, Schuchter L, Kamoun M, et al. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer. *Clinical Cancer Research*. 2000;6(5):1744-54.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2679. Visser O, van Leeuwen FE. Cancer risk in first generation migrants in North-Holland/Flevoland, The Netherlands, 1995-2004. *European Journal of Cancer*. 2007;43(5):901-8.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2680. Vo JN. Intratumoral chitosan/interleukin-12 immunotherapy reduces breast cancer metastasis. *Cancer Research*. Conference: 103rd Annual Meeting of the American Association for Cancer Research, AACR. 2012;72(8 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2681. Vodala S, Nguyen A, Rodriguez N, Sieling P, Vaske C, Van Lew J, et al. TCR repertoires from peripheral blood correlate with prognostic response in TNBC cancer vaccine immunotherapy. *Journal for ImmunoTherapy of Cancer*. Conference: 34th Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer Part. 2019;7(Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2682. Vojdani A, Campbell A, Brautbar N. Immune functional impairment in patients with clinical abnormalities and silicone breast implants. *Toxicology and Industrial Health*. 1992;8(6):415-29.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2683. Volaklis KA, Halle M, Tokmakidis SP. Exercise in the prevention and rehabilitation of breast cancer. *Wiener Klinische Wochenschrift*. 2013;125(11-12):297-301.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2684. Von Ah D, Kang DH, Carpenter JS. Stress, optimism, and social support: impact on immune responses in breast cancer. *Research in Nursing & Health*. 2007;30(1):72-83.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

2685. Von Ah DM, Kang DH, Carpenter JS. Predictors of cancer-related fatigue in women with breast cancer before, during, and after adjuvant therapy. *Cancer Nursing*. 2008;31(2):134-44.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2686. von der Lippe Gythfeldt H, Lien T, Tekpli X, Silwal-Pandit L, Borgen E, Garred O, et al. Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer. International Journal of Cancer. 2020;03:03.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2687. von Kleist S, Berling J, Bohle W, Wittekind C. Immunohistological analysis of lymphocyte subpopulations infiltrating breast carcinomas and benign lesions. International Journal of Cancer. 1987;40(1):18-23.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2688. Von Minckwitz G. Anti-HER2 therapy treatment after progression. European Journal of Cancer, Supplement. 2009;7 (2-3):34-5.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2689. Vora T, de Azambuja E, Awada A, Piccart M. Novel therapeutics in breast cancer-Looking to the future. Update on Cancer Therapeutics. 2009;3(4):189-205.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2690. Vose BM, Moore M. Suppressor cell activity of lymphocytes infiltrating human lung and breast tumors. International Journal of Cancer. 1979;24(5):579-85.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2691. Votta-Velis G. Refresher course: Cancer recurrence and regional anesthesia: An update of the evidence! Regional Anesthesia and Pain Medicine. 2015;1):e47-e9.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2692. Voutsas IF, Mahaira LG, Fotopoulou K, Kapranos N, Reclos JG, Gritzapis AD, et al. Gamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab. International Journal of Radiation Biology. 2013;89(5):319-25.

배제사유 : 동물실험 및 전임상시험연구

2693. Vučenik I, Stains J. Cancer preventive and therapeutic properties of IP6: Efficacy and mechanisms. Periodicum Biologorum. 2010;112(4):451-8.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2694. Vujanovic NL, Yasumura S, Hirabayashi H, Lin WC, Watkins S, Herberman RB, et al. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues. Journal of Immunology. 1995;154(1):281-9.

배제사유 : 동물실험 및 전임상시험연구

2695. Wagner J, Rapsomaniki MA, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, et al. A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. Cell. 2019;177(5):1330-45.e18.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2696. Wahid B, Ali A, Rafique S, Waqar M, Wasim M, Wahid K, et al. An overview of cancer immunotherapeutic strategies. *Immunotherapy*. 2018;10(11):999-1010.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2697. Wahlberg BJ, Burholt DR, Kornblith P, Richards TJ, Bruffsky A, Herberman RB, et al. Measurement of NK activity by the microcytotoxicity assay (MCA): a new application for an old assay. *Journal of Immunological Methods*. 2001;253(1-2):69-81.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2698. Wajchman HJ, Pierce CW, Varma VA, Issa MM, Petros J, Dombrowski KE. Ex vivo expansion of CD8+CD56+ and CD8+CD56- natural killer T cells specific for MUC1 mucin. *Cancer Research*. 2004;64(3):1171-80.
배제사유 : 동물실험 및 전임상시험연구
2699. Wakasugi H, Oshimi K, Miyata M, Morioka Y. Augmentation of natural killer (NK) cell activity by a streptococcal preparation, OK-432, in patients with malignant tumors. *Journal of Clinical Immunology*. 1981;1(3):154-62.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2700. Waldhauer I, Nicolini V, Freimoser-Grundschober A, Codarri-Deak L, Nayak T, Boerman O, et al. Proffered Paper: FAP-IL2V (RG7461), a novel targeted immunocytokine for cancer immunotherapy. *European Journal of Cancer*. 2016;55 (Supplement 1):S1-S2.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2701. Waldmann TA. Immunotherapy: Past, present and future. *Nature Medicine*. 2003;9(3):269-77.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2702. Waldner M, Fantus D, Solari M, Thomson AW. New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation. *British Journal of Clinical Pharmacology*. 2016;1158-70.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2703. Wallerius M, Wallmann T, Bartish M, Ostling J, Mezheyevski A, Tobin NP, et al. Guidance Molecule SEMA3A Restricts Tumor Growth by Differentially Regulating the Proliferation of Tumor-Associated Macrophages. *Cancer Research*. 2016;76(11):3166-78.
배제사유 : 동물실험 및 전임상시험연구
2704. Walser TC, Rifat S, Ma X, Kundu N, Ward C, Goloubanova O, et al. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. *Cancer Research*. 2006;66(15):7701-7.
배제사유 : 동물실험 및 전임상시험연구
2705. Walsh RJ, Soo RA. Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies. *Therapeutic Advances in Medical Oncology*. 2020;12.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2706. Walton R, Brown M, Holl E, Boczkowski D, Chandramohan V, Nair S, et al. PVSRIPO is an interferon-resistant, immunotherapeutic oncolytic virus. *Journal for ImmunoTherapy of Cancer*. Conference: 32nd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2017;5(Supplement 2).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2707. Wang B, Wang Q, Wang Z, Jiang J, Yu SC, Ping YF, et al. Metastatic consequences of immune escape from NK cell cytotoxicity by human breast cancer stem cells. *Cancer Research*. 2014;74(20):5746-57.
배제사유 : 동물실험 및 전임상시험연구
2708. Wang BX, Rahbar R, Fish EN. Interferon: current status and future prospects in cancer therapy. *Journal of Interferon & Cytokine Research*. 2011;31(7):545-52.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2709. Wang F, Zhang X, Wang H, Liu Y. Effects of dezocine and sufentanil for postoperative analgesia on activity of NK, CD4+ and CD8+ cells in patients with breast cancer. *Oncology Letters*. 2019;17(3):3392-8.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2710. Wang H. [Influence of extirpative surgery on the natural killer cell activity in peripheral blood in cancer patients]. Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery]. 1990;28(10):622-4, 38.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
2711. Wang J, Feng H, Wang Q, He Y, Song Y, Zhu J. Killer effect of natural killer cells combined with tamoxifen on breast cancer cells in vitro and its mechanism. [Chinesel]. *Journal of Jilin University Medicine Edition*. 2017;43(2):281-7.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
2712. Wang K, Shen T, Siegal GP, Wei S. Cd4/cd8 ratio of tumor-infiltrating lymphocytes (TIL) at the tumor-host interface (THI) has prognostic value in triple negative breast cancer (TNBC). *Laboratory Investigation*. 2017;97 (Supplement 1):77A-8A.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2713. Wang K, Shi Y, Li H. Development and validation of nomograms integrating immune-related genomic signatures with clinicopathologic features to improve prognosis and predictive prediction of triple negative breast cancer: a gene-expression-based retrospective study. *Breast*. 2019;44 (Supplement 1):S95-S6.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2714. Wang L, Wang PL, Zhu Q. Effect of perioperative psychological intervention on immune function of patients with breast cancer after modified radical mastectomy. [Chinesel]. *Chinese Journal of Cancer Prevention and Treatment*. 2019;26(19):1468-72.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
2715. Wang M, Cattaruzza F, Yeung P, Brunner A, LeScolan E, Liu Y, et al. Prevalence of GITR expression and pharmacodynamic (PD) biomarkers in syngeneic tumor models

treated by a GITR agonist (GITRL-Fc). Cancer Research. Conference: American Association for Cancer Research Annual Meeting. 2017;77(13 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2716. Wang M, Zhang C, Song Y, Wang Z, Wang Y, Luo F, et al. Mechanism of immune evasion in breast cancer. *OncoTargets and Therapy*. 2017;10:1561-73.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2717. Wang Q, Gao X, Yuan Z, Wang Z, Meng Y, Cao Y, et al. Methionine enkephalin (MENK) improves lymphocyte subpopulations in human peripheral blood of 50 cancer patients by inhibiting regulatory T cells (Tregs). *Human Vaccines and Immunotherapeutics*. 2014;10(7):1836-40.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2718. Wang S, Balasundaram G. Potential cancer gene therapy by baculoviral transduction. *Current Gene Therapy*. 2010;10(3):214-25.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2719. Wang S, Zhang Y, Cong W, Liu J, Zhang Y, Fan H, et al. Breast cancer stem-like cells can promote metastasis by activating platelets and down-regulating antitumor activity of natural killer cells. *Journal of Traditional Chinese Medicine*. 2016;36(4):530-7.

배제사유 : 동물실험 및 전임상시험연구

2720. Wang T, Ge Y, Xiao M, Lopez-Coral A, Li L, Roesch A, et al. SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathway. *Journal of Investigative Dermatology*. 2014;134(4):1108-18.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2721. Wang T, Shen Y, Luyten S, Yang Y, Jiang X. Tissue-resident memory CD8+ T cells in cancer immunology and immunotherapy. *Pharmacological Research*. 2020;159 (104876).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2722. Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM. NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy. *Frontiers in Immunology*. 2015;6:368.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2723. Wang W, Xiao J, Shen S, Wang S, Chen M, Hu Y. Emerging effect of anesthesia on post-operative tumor recurrence and metastasis. *Journal of International Medical Research*. 2019;47(8):3550-8.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2724. Wang X, Yu J, Li H, Yu W, Ren X, Cao S. Effect of combinatorial culture protocol (IL-2 and IL-5) on the proliferation of NK cells in the peripheral blood of breast cancer patients in vitro. [Chinese]. *Chinese Journal of Cancer Biotherapy*. 2013;20(6):654-60.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

2725. Wank R, Song X, Gu S, Laumbacher B. Benefits of a continuous therapy for cancer patients with a novel adoptive cell therapy by cascade priming (CAPRI).

- Immunotherapy. 2014;6(3):269-82.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2726. Ware WR. Raising concerns about unmetabolized folic acid. Journal of Orthomolecular Medicine. 2008;23(1):43-51.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2727. Wasser SP. Medicinal mushrooms in human clinical studies. Part I. anticancer, oncoimmunological, and immunomodulatory activities: A review. International Journal of Medicinal Mushrooms. 2017;19(4):279-317.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2728. Wasserman J, Blomgren H, Petrini B, Baral E, Strender LE, Jarstrand C, et al. Effect of radiation therapy and in vitro x-ray exposure on lymphocyte subpopulations and their functions. American Journal of Clinical Oncology. 1982;5(2):195-208.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2729. Wasserman J, Blomgren H, Rotstein S, Petrini B, Hammarstrom S. Immunosuppression in irradiated breast cancer patients: in vitro effect of cyclooxygenase inhibitors. Bulletin of the New York Academy of Medicine. 1989;65(1):36-44.
배제사유 : 동물실험 및 전임상시험연구
2730. Waslylyshyn ML, Cochran AJ, Golub SH. Influence of alpha and gamma interferon on lymphokine-activated killing of lymph node lymphocytes. Proceedings of the American Association for Cancer Research. 1985;VOL. 26:No. 1201.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2731. Watanabe D, Goshima F. Oncolytic virotherapy by HSV. Advances in Experimental Medicine and Biology. 2018;1045:63-84.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2732. Watanabe T, Niedermann G. IDO inhibition strongly enhances effects of combined hRT and PD1/PD-L1 checkpoint blockade. Radiotherapy and Oncology. 2019;133 (Supplement 1):***-***.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2733. Watkins-Schulz R, Tiet P, Galloovic MD, Junkins RD, Batty C, Bachelder EM, et al. A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8+ T cell-mediated anti-tumor immunity. Biomaterials. 2019;205:94-105.
배제사유 : 동물실험 및 전임상시험연구
2734. Wattenberg MM, Kwilas AR, Gameiro SR, Dicker AP, Hodge JW. Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets. British Journal of Cancer. 2014;110(6):1472-80.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2735. Waumans Y, Baerts L, Kehoe K, Lambeir AM, De Meester I. The dipeptidyl peptidase family, prolyl oligopeptidase and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis. Frontiers in Immunology. 2015;6 (JUL) (387).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2736. Wculek SK, Malanchi I. Neutrophils support lung colonization of metastasis-initiating breast cancer cells. *Nature*. 2015;528(7582):413-7.

배제사유 : 동물실험 및 전임상시험연구

2737. Wege AK, Ernst W, Eckl J, Frankenberger B, Vollmann-Zwerenz A, Mannel DN, et al. Humanized tumor mice--a new model to study and manipulate the immune response in advanced cancer therapy. *International Journal of Cancer*. 2011;129(9):2194-206.

배제사유 : 동물실험 및 전임상시험연구

2738. Wege AK, Schmidt M, Ueberham E, Ponnath M, Ortmann O, Brockhoff G, et al. Co-transplantation of human hematopoietic stem cells and human breast cancer cells in NSG mice: a novel approach to generate tumor cell specific human antibodies. *mAbs*. 2014;6(4):968-77.

배제사유 : 동물실험 및 전임상시험연구

2739. Wege AK, Weber F, Kroemer A, Ortmann O, Nimmerjahn F, Brockhoff G. IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM). *Oncotarget*. 2017;8(2):2731-44.

배제사유 : 동물실험 및 전임상시험연구

2740. Wei HC. Mathematical modeling of tumor growth: the MCF-7 breast cancer cell line. *Mathematical Biosciences & Engineering: MBE*. 2019;16(6):6512-35.

배제사유 : 동물실험 및 전임상시험연구

2741. Wei WZ, Heppner G. Natural killer activity of lymphocytic infiltrates in mouse mammary lesions. *British Journal of Cancer*. 1987;55(6):589-94.

배제사유 : 동물실험 및 전임상시험연구

2742. Wei WZ. Introduction. *Breast Disease*. 2004;20:1.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2743. Weibel S, Raab V, Yu YA, Worschel A, Wang E, Marincola FM, et al. Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection. *BMC Cancer*. 2011;11 (68).

배제사유 : 동물실험 및 전임상시험연구

2744. Weihe P, Spielmann J, Kielstein H, Henning-Klusmann J, Weihrauch-Bluher S. Childhood Obesity and Cancer Risk in Adulthood. *Current Obesity Reports*. 2020;09:09.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2745. Weinberg G. Non-anesthetic effects of local anesthetics. *Regional Anesthesia and Pain Medicine*. 2011;2):E62.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2746. Weiner LM, Clark JI, Davey M, Li WS, De Palazzo IG, Ring DB, et al. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and FcgammaRIII. *Cancer Research*. 1995;55(20):4586-93.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2747. Weiner LM, Clark JI, Ring DB, Alpaugh RK. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. *Journal of Hematology*. 1995;4(5):453-6.
배제사유 : 동물실험 및 전임상시험연구
2748. Weiner LM. Building better magic bullets - Improving unconjugated monoclonal antibody therapy for cancer. *Nature Reviews Cancer*. 2007;7(9):701-6.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2749. Weis Bjerrum O, Gjedde S, Bendtzen K, Enk C, Pedersen BK, Munch-Petersen B, et al. An unusual case of multiple malignancy in an adult. *Tumori*. 1984;70(6):575-7.
배제사유 : 동물실험 및 전임상시험연구
2750. Wels W, Biburger M, Muller T, Dalken B, Giesubel U, Tonn T, et al. Recombinant immunotoxins and retargeted killer cells: Employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors. *Cancer Immunology, Immunotherapy*. 2004;53(3):217-26.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2751. Wen SW, Scaneay J, Lima LG, Wong CS, Becker M, Krumeich S, et al. The Biodistribution and Immune Suppressive Effects of Breast Cancer-Derived Exosomes. *Cancer Research*. 2016;76(23):6816-27.
배제사유 : 동물실험 및 전임상시험연구
2752. Weng H, Morimoto K. Differential responses to mutagens among human lymphocyte subpopulations. *Mutation Research - Genetic Toxicology and Environmental Mutagenesis*. 2009;672(1):1-9.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2753. Wesa AK, Storkus WJ. Killer dendritic cells: Mechanisms of action and therapeutic implications for cancer. *Cell Death and Differentiation*. 2008;15(1):51-7.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2754. West CE, Kvistgaard AS, Peerson JM, Donovan SM, Peng YM, L?nnnerdal B. Effects of osteopontin-enriched formula on lymphocyte subsets in the first 6 months of life: a randomized controlled trial. *Pediatric research*. 2017;82(1):63-71.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2755. Wey S. 14 years fever-range whole body hyperthermia in adjuvant recurrence prophylaxis of breast cancer. *Strahlentherapie und Onkologie*. 2018;194 (5):495.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2756. White D, Jones DB, Cooke T, Kirkham N. Natural killer (NK) activity in peripheral blood lymphocytes of patients with benign and malignant breast disease. *British Journal of Cancer*. 1982;46(4):611-6.
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구
2757. Wiegele J, Gastl G, Niederwieser D. Effects of instillation of interferon on local and

systemic natural killing (NK). [German]. Langenbecks Archiv fur Chirurgie. 1983;359(Suppl.):93-7.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

2758. Wierz M, Janji B, Berchem G, Moussay E, Paggetti J. High-dimensional mass cytometry analysis revealed microenvironment complexity in chronic lymphocytic leukemia. *Oncogen Immunology*. 2018;7 (8) (e1465167).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2759. Wieten L, Boumans EE, Reichardt A, Sinelnikov E, Sarkar S, Tilanus MGJ, et al. NK cells expanded with the ZRP cultivation system retain their alloreactive and cytotoxic capacity. *Tissue Antigens*. 2014;84 (1):33-4.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2760. Wigginton JM, Komschlies KL, Green JE, Cox GW, Jorcyk CL, Back TC, et al. Evaluation of the antitumor activity of the interleukin-12/pulse interleukin-2 combination. *Annals of the New York Academy of Sciences*. 1996;795:434-9.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2761. Wijayahadi N, Haron MR, Stanslas J, Yusuf Z. Changes in cellular immunity during chemotherapy for primary breast cancer with anthracycline regimens. *Journal of Chemotherapy*. 2007;19(6):716-23.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2762. Wilczynski JR. Modulation of immune functions by oestrogens. Part II. *Przeglad Menopauzalny*. 2010;14(3):128-31.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2763. Wilkerson A, Kim J, Huang AY, Zhang M. Nanoparticle systems modulating myeloid-derived suppressor cells for cancer immunotherapy. *Current Topics in Medicinal Chemistry*. 2017;17(16):1843-57.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2764. Willer A. Reduction of the individual cancer risk by physical exercise. *Onkologie*. 2003;26(3):283-9.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2765. Williams P, Galipeau J. GMCSF-Interleukin fusion cytokines induce novel immune effectors that can serve as biopharmaceuticals for treatment of autoimmunity and cancer. *Journal of Internal Medicine*. 2011;269(1):74-84.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2766. Wiltschke C, Tyl E, Speiser P, Steininger A, Zeillinger R, Kury F, et al. Increased natural killer cell activity correlates with low or negative expression of the HER-2/neu oncogene in patients with breast cancer. *Cancer*. 1994;73(1):135-9.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2767. Wischhusen J, Diessner J, Becker K, Honig A. Targeting of pre-existing and induced breast cancer stem cells with HER2-specific immunotherapeutics and NK cells. *Journal of Immunology*. Conference: 98th Annual Meeting of the American Association of

Immunologist, IMMUNOLOGY. 2011;186(1 MeetingAbstracts).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2768. Witek Janusek L, Tell D, Albuquerque K, Mathews HL. Childhood adversity increases vulnerability for behavioral symptoms and immune dysregulation in women with breast cancer. *Brain, Behavior, & Immunity*. 2013;30 Suppl:S149-62.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2769. Witek Janusek L, Tell D, Mathews HL. Mindfulness based stress reduction provides psychological benefit and restores immune function of women newly diagnosed with breast cancer: A randomized trial with active control. *Brain, Behavior, and Immunity*. 2019;80:358-73.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

2770. Witek-Janusek L, Albuquerque K, Chroniak KR, Chroniak C, Durazo-Arvizu R, Mathews HL. Effect of mindfulness based stress reduction on immune function, quality of life and coping in women newly diagnosed with early stage breast cancer. *Brain, Behavior, and Immunity*. 2008;22(6):969-81.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

2771. Witek-Janusek L, Gabram S, Mathews HL. Psychologic stress, reduced NK cell activity, and cytokine dysregulation in women experiencing diagnostic breast biopsy. *Psychoneuroendocrinology*. 2007;32(1):22-35.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

2772. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. *Clinical Cancer Research*. 2003;9(2):606-12.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2773. Wolfson B, Schlom J, Hodge J. Exploiting off-target effects of estrogen receptor-targeting drugs to sensitize breast cancer to immune killing. *Cancer Immunology Research*. Conference: AACR Special Conference on Tumor Immunology and Immunotherapy. United States. 2020;8(3 SUPPL).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2774. Wong BR, Grossbard EB, Payan DG, Masuda ES. Targeting Syk as a treatment for allergic and autoimmune disorders. *Expert Opinion on Investigational Drugs*. 2004;13(7):743-62.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2775. Wong PY, Staren ED, Tereshkova N, Braun DP. Functional analysis of tumor-infiltrating leukocytes in breast cancer patients. *Journal of Surgical Research*. 1998;76(1):95-103.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2776. Woo JH, Baik HJ, Kim CH, Chung RK, Kim DY, Lee GY, et al. Effect of Propofol and Desflurane on Immune Cell Populations in Breast Cancer Patients: A Randomized Trial. *Journal of Korean Medical Science*. 2015;30(10):1503-8.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2777. Wootla B, Denic A, Rodriguez M. Polyclonal and monoclonal antibodies in clinic. *Methods in Molecular Biology*. 2014;1060:79-110.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2778. Workenhe ST, Verschoor ML, Mossman KL. The role of oncolytic virus immunotherapies to subvert cancer immune evasion. *Future Oncology*. 2015;11(4):675-89.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2779. Wotschel N, Eitler J, Miller N, Tonn T. Live cell imaging of the immune synapse of CAR-expressing NK-92 cells and breast cancer cells as a tool to evaluate combination therapies. *Transfusion Medicine and Hemotherapy*. 2017;44 (Supplement 1):16-7.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2780. Wright SE, Quinlin IS, Rewers-Felkins KA, Dombrowski KE, Phillips CA. Retention of immunogenicity produced by mucin 1 peptides with glycosylation site substitutions. *Immunopharmacology & Immunotoxicology*. 2010;32(4):647-55.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2781. Wright SE, Rewers-Felkins KA, Quinlin IS, Phillips CA, Townsend M, Philip R, et al. Number of treatment cycles influences development of cytotoxic T cells in metastatic breast cancer patients a phase III study. *Immunological Investigations*. 2010;39(6):570-86.
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
2782. Wu F, Zhou L, Chen WR. Host antitumor immune responses to HIFU ablation. *International Journal of Hyperthermia*. 2007;23(2):165-71.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2783. Wu J, Zhao Y, Zhang J, Wu Q, Wang W. Development and validation of an immune-related gene pairs signature in colorectal cancer. *OncoImmunology*. 2019;8 (7) (1596715).
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2784. Wu L, Parton A, Lu L, Adams M, Schafer P, Bartlett JB. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: Influence of host immune and tumor markers. *Cancer Immunology, Immunotherapy*. 2011;60(1):61-73.
배제사유 : 동물실험 및 전임상시험연구
2785. Wu MR, Zhang T, DeMars LR, Sentman CL. B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity. *Gene Therapy*. 2015;22(8):675-84.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2786. Wu SY, Guo P, Peng T, Xu J, Hou QQ, Sun X, et al. HSF1: A potential target for therapeutic intervention in cancer. *International Journal of Clinical and Experimental Medicine*. 2017;10(3):5637-48.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2787. Wu T, Qiao Q, Qin X, Zhang D, Zhang Z. Immunostimulatory cytokine and doxorubicin co-loaded nanovesicles for cancer immunochemotherapy. *Nanomedicine*. 2019;18:66-77.
배제사유 : 동물실험 및 전임상시험연구
2788. Wu T, Wang X, Li J, Song X, Wang Y, Zhang L, et al. Identification of personalized chemoresistance genes in subtypes of basal-like breast cancer based on functional differences using pathway analysis. *PLoS ONE*. 2015;10 (6) (e0131183).
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2789. Wu W, Deng H, Rao N, You N, Yang Y, Cao M, et al. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial. *Trials [Electronic Resource]*. 2017;18(1):497.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2790. Wu Y, Kyle-Cezar F, Woolf RT, Naceur-Lombardelli C, Owen J, Biswas D, et al. An innate-like Vdelta1+ gammadelta T cell compartment in the human breast is associated with remission in triple-negative breast cancer. *Science Translational Medicine*. 2019;11 (513) (eaax9364).
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2791. Wu Y, Li J, Jabbarzadeh Kaboli P, Shen J, Wu X, Zhao Y, et al. Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy. *Pharmacological Research*. 2020;155 (104691).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2792. Wu Y, Wei J, Chen X, Qin Y, Mao R, Song J, et al. Comprehensive transcriptome profiling in elderly cancer patients reveals aging-altered immune cells and immune checkpoints. *International Journal of Cancer*. 2019;144(7):1657-63.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2793. Wu YG, Ma QL, Liu GF. [Influence of ⁸⁹Sr on the cell immune function in patients with multiple bone metastases]. *Bulletin of Hunan Medical University*. 2002;27(3):277-8.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
2794. Wu ZZ, Liu F, Li N, Zhang HY, Jin FJ, Lan L, et al. Effect of fractalkine, IP-10 and different signal pathway inhibitors on NK cells in the tumor microenvironment. [Chinese]. *Medical Journal of Chinese People's Liberation Army*. 2015;40(7):547-53.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
2795. Wurzer H, Absi AA, Hoffmann C, Thomas C. Do tumor cells escape from natural killer cell cytotoxicity by mimicking dendritic cells? *Oncotarget*. 2019;10(25):2419-20.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2796. Xia Q, Zhang FF, Geng F, Liu CL, Wang YQ, Xu P, et al. Improvement of anti-tumor immunity of fibroblast activation protein alpha based vaccines by combination with cyclophosphamide in a murine model of breast cancer. *Cellular Immunology*. 2016;14.

배제사유 : 동물실험 및 전임상시험연구

2797. Xiang D, Li Z. Epigenetic deregulation in LSD1-deficient luminal mammary tumor cells leads to their increased metastasis via reprogramming of the immune microenvironment. *Cancer Immunology Research.* Conference: AACR Special Conference on Tumor Immunology and Immunotherapy. United States. 2020;8(3 SUPPL).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2798. Xiang R, Luo Y, Niethammer AG, Reisfeld RA. Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis. *Immunological Reviews.* 2008;222(1):117-28.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2799. Xiao H, Woods EC, Vukojicic P, Bertozzi CR. Precision glycocalyx editing as a strategy for cancer immunotherapy. *Proceedings of the National Academy of Sciences of the United States of America.* 2016;113(37):10304-9.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2800. Xie HY, Shao ZM, Li DQ. Tumor microenvironment: Driving forces and potential therapeutic targets for breast cancer metastasis. *Chinese Journal of Cancer.* 2017;36 (1) (36).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2801. Xie J, Gallagher G. Transforming growth factor-beta is not the major soluble immunosuppressor in the microenvironments of human breast tumours. *Anticancer Research.* 1992;12(6B):2117-21.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2802. Xie W, Liu F, Wang Y, Ren X, Wang T, Chen Z, et al. VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer. *Oncotarget.* 2016;7(13):16445-61.

배제사유 : 동물실험 및 전임상시험연구

2803. Xie X, Brunner N, Jensen G, Albrechtsen J, Gotthardsen B, Rygaard J. Comparative studies between nude and scid mice on the growth and metastatic behavior of xenografted human tumors. *Clinical & Experimental Metastasis.* 1992;10(3):201-10.

배제사유 : 동물실험 및 전임상시험연구

2804. Xie Z, Shi M, Feng J, Yu M, Sun Y, Shen B, et al. A trivalent anti-erbB2/anti-CD16 bispecific antibody retargeting NK cells against human breast cancer cells. *Biochemical & Biophysical Research Communications.* 2003;311(2):307-12.

배제사유 : 동물실험 및 전임상시험연구

2805. Xiong Z, Ohlfest JR. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors. *Journal of Immunotherapy.* 2011;34(3):264-9.

배제사유 : 동물실험 및 전임상시험연구

2806. Xu C, Zhang Y, Alexander Rolfe P, Hernandez VM, Guzman W, Kradjian G, et al. Combination therapy with NHS-muIL12 and avelumab (anti-PD-L1) enhances antitumor efficacy in preclinical cancer models. *Clinical Cancer Research.* 2017;23(19):5869-80.

배제사유 : 동물실험 및 전임상시험연구

2807. Xu C, Zhang Y, Kradjian G, Qin G, Qi J, Xu X, et al. Enhanced anti-tumor effect of combination therapy with NHS-muLL-12 and anti-PD-L1 antibody (avelumab) in a preclinical cancer model. *Journal for ImmunoTherapy of Cancer*. Conference: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer, SITC. 2016;4(Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2808. Xu F, Bian L, Zhou Y, Du G, Li J, Wang T, et al. Germline mutation in the KLRC2 gene to inform intrinsic resistance and inferior responses to trastuzumab in breast cancer. *Journal of Clinical Oncology*. Conference. 2016;34(Supplement 15).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2809. Xu F, Sunderland A, Zhou Y, Schulick RD, Edil BH, Zhu Y. Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions. *Cancer Immunology, Immunotherapy*. 2017;66(10):1367-75.

배제사유 : 동물실험 및 전임상시험연구

2810. Xu H, Bai X, Yu S, Liu Q, Pestell RG, Wu K. MAT1 correlates with molecular subtypes and predicts poor survival in breast cancer. *Chinese Journal of Cancer Research*. 2018;30(3):351-63.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2811. Xu J, Jiang L, Cao H, Jia Y, Wu S, Jiang C, et al. Predictive Value of CD4+/CD8+ Ratio in Patients with Breast Cancer Receiving Recombinant Human Thrombopoietin. *Journal of Interferon & Cytokine Research*. 2018;38(5):213-20.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2812. Xu P, Sun Y, Song Y, Jiao J, Shen B, Li W, et al. ATM kinase regulates tumor immunoreactions in lymphocyte-predominant breast cancer through modulation of NKG2D ligand and TNF cytokines on tumor cells. *Medical Molecular Morphology*. 2020.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2813. Xu S, Yan J, Xu W, Wang Z. [Increased serum IL-6 and soluble IL-6 receptor in breast cancer patients after radiotherapy are correlated with proportions of immune cells]. *Xibao Yu Fenzi Mianyixue Zazhi*. 2019;35(8):738-43.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

2814. Xu X, Li J, Zou J, Feng X, Zhang C, Zheng R, et al. Association of Germline Variants in Natural Killer Cells with Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk. *JAMA Network Open*. 2019;2 (9) (e199292).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2815. Xu X, Rao G, Li Y. Xanthine oxidoreductase is required for genotoxic stress-induced NKG2D ligand expression and gemcitabine-mediated antitumor activity. *Oncotarget*. 2016;7(37):59220-35.

배제사유 : 동물실험 및 전임상시험연구

2816. Xu Y, Zhou S, Lam YW, Pang SW. Dynamics of Natural Killer Cells Cytotoxicity in Microwell Arrays with Connecting Channels. *Frontiers in Immunology*. 2017;8:998.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2817. Xu Y. DNA damage: A trigger of innate immunity but a requirement for adaptive immune homeostasis. *Nature Reviews Immunology*. 2006;6(4):261-70.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2818. Xu Z, Cui Y, Li Y, Guo Y. [Research progress on nonspecific immune microenvironment in breast cancer]. *Zhejiang da Xue Xue Bao. Yi Xue Ban/Journal of Zhejiang University. Medical Sciences*. 2018;47(4):426-34.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2819. Xue M, Liang H, Tang Q, Xue C, He X, Zhang Z, et al. The Protective and Immunomodulatory Effects of Fucoidan Against 7,12-Dimethyl benz[a]anthracene-Induced Experimental Mammary Carcinogenesis Through the PD1/PDL1 Signaling Pathway in Rats. *Nutrition and Cancer*. 2017;69(8):1234-44.
배제사유 : 동물실험 및 전임상시험연구
2820. Yaacoby-Bianu K, Hakim F. Sleep Disturbance and Cancer-Animal Models. *Current Sleep Medicine Reports*. 2017;3(2):31-7.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2821. Yagi H, Soto-Gutierrez A, Parekkadan B, Kitagawa Y, Tompkins RG, Kobayashi N, et al. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. *Cell Transplantation*. 2010;19(6-7):667-79.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2822. Yagita M, Seppo A, Renkonen O, Saksela E. Deacetylase activity of human tumor cells producing immunosuppressive aminosugars: its possible role in resistance to cell-mediated cytotoxicity. *Cancer Research*. 1993;53(23):5600-4.
배제사유 : 동물실험 및 전임상시험연구
2823. Yahaya R, Dash GK, Abdullah MS, Mathews A. Clinacanthus nutans (burm. F.) Lindau: An useful medicinal plant of south-east Asia. *International Journal of Pharmacognosy and Phytochemical Research*. 2015;7(6):1244-50.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2824. Yakkala C, Chiang CLL, Kandalaft L, Denys A, Duran R. Cryoablation and immunotherapy: An enthralling synergy to confront the tumors. *Frontiers in Immunology*. 2019;10 (SEP) (2283).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2825. Yamaguchi R, Perkins G. An Emerging Model for Cancer Development from a Tumor Microenvironment Perspective in Mice and Humans. *Advances in experimental medicine and biology*. 2020;1225:19-29.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2826. Yamaguchi Y, Hironaka K, Okawaki M, Okita R, Matsuura K, Ohshita A, et al.

HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab. *Anticancer Research*. 2005;25(2A):827-32.

배제사유 : 동물실험 및 전임상시험연구

2827. Yamaguchi Y, Miyahara E, Hihara J. Efficacy and safety of orally administered Lentinula edodes mycelia extract for patients undergoing cancer chemotherapy: a pilot study. *American Journal of Chinese Medicine*. 2011;39(3):451-9.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2828. Yamasaki S, Kan N, Harada T, Ichinose Y, Moriguchi Y, Li L, et al. Relationship between immunological parameters and survival of patients with liver metastases from breast cancer given immuno-chemotherapy. *Breast Cancer Research & Treatment*. 1993;26(1):55-65.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2829. Yamashita M, Kitano S, Aikawa H, Kuchiba A, Hayashi M, Yamamoto N, et al. A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells. *Scientific Reports*. 2016;6:19772.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2830. Yamauchi C, Fujii S, Kimura T, Kuwata T, Wada N, Mukai H, et al. E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells. *International Journal of Cancer*. 2011;128(9):2125-37.

배제사유 : 동물실험 및 전임상시험연구

2831. Yan C, Brunson DC, Tang Q, Do D, Iftimia NA, Moore JC, et al. Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish. *Cell*. 2019;177(7):1903-14.e14.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2832. Yan J, Li XY, Aguilera AR, Xiao C, Jacobberger-Foissac C, Nowlan B, et al. Control of metastases via myeloid CD39 and NK cell effector function. *Cancer Immunology Research*. 2020;8(3):356-67.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2833. Yan WH. HLA-G expression in cancers: Potential role in diagnosis, prognosis and therapy. *Endocrine, Metabolic and Immune Disorders - Drug Targets*. 2011;11(1):76-89.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2834. Yanagawa E, Uchida A, Micksche M. Natural cytotoxicity of lymphocytes from lymph nodes draining breast carcinoma and its augmentation by interferon and OK432. *Cancer Immunology, Immunotherapy*. 1984;17(1):1-6.

배제사유 : 동물실험 및 전임상시험연구

2835. Yaneva MP, Botushanova AD, Grigorov LA, Kokov JL, Todorova EP, Krachanova MG. Evaluation of the immunomodulatory activity of Aronia in combination with apple pectin in patients with breast cancer undergoing postoperative radiation therapy. *Folia Medica (Plovdiv)*. 2002;44(1-2):22-5.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2836. Yanez-Munoz RJ, Grupp SA. CAR-T in the clinic: Drive with care. *Gene Therapy*. 2018;25(3):157-61.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2837. Yang CY, Meng CL, Shen KL, Wong PY, Lee HK. Regulation of eicosanoid-like compound biosynthesis by IFN-gamma, IL-6, and EPA in human breast cancer cell line. *Advances in Experimental Medicine & Biology*. 1997;407:179-84.

배제사유 : 동물실험 및 전임상시험연구

2838. Yang F, Jin H, Wang J, Sun Q, Yan C, Wei F, et al. Adoptive cellular therapy (ACT) for cancer treatment. *Advances in Experimental Medicine and Biology*. 2016;909:169-239.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2839. Yang L, Lou M, Liu W, Feng D, Cheng T, Ma J. [Amplification of immune cells derived from human peripheral blood and cytotoxicity on MDA-MB-231 breast cancer cells in vitro]. *Xibao Yu Fenzi Mianyixue Zazhi*. 2019;35(8):682-8.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

2840. Yang L, Sun L, Wu X, Wei H, Wan M, Zhang P, et al. Therapeutic injection of C-class CpG ODN in draining lymph node area induces potent activation of immune cells and rejection of established breast cancer in mice. *Clinical Immunology*. 2009;131(3):426-37.

배제사유 : 동물실험 및 전임상시험연구

2841. Yang L, Wu X, Wan M, Yu Y, Yu Y, Wang L. CpG oligodeoxynucleotides with double stem-loops show strong immunostimulatory activity. *International Immunopharmacology*. 2013;15(1):89-96.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2842. Yang L, Yu H, Dong S, Zhong Y, Hu S. Recognizing and managing on toxicities in cancer immunotherapy. *Tumor Biology*. 2017;39(3).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2843. Yang N, Cao Y, Li X, Li S, Yan H, Geng Q. Mediating effects of patients' stigma and self-efficacy on relationships between doctors' empathy abilities and patients' cellular immunity in male breast cancer patients. *Medical Science Monitor*. 2018;24:3978-86.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2844. Yang N, Huang B, Tsinkalovsky O, Brekka N, Zhu H, Leiss L, et al. A novel GFP nude rat model to investigate tumor-stroma interactions. *Cancer Cell International*. 2014;14(1) (541).

배제사유 : 동물실험 및 전임상시험연구

2845. Yang YQ, Li JC. Progress of Research in Cell-in-Cell Phenomena. *Anatomical Record*. 2012;295(3):372-7.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2846. Yang ZZ, Ansell SM. The role of Treg cells in the cancer immunological response.

American Journal of Immunology. 2009;5(1):17-28.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2847. Yazdi MH, Mahdavi M, Kheradmand E, Shahverdi AR. The preventive oral supplementation of a selenium nanoparticle-enriched probiotic increases the immune response and lifespan of 4T1 breast cancer bearing mice. *Arzneimittel-Forschung/Drug Research*. 2012;62(11):525-31.

배제사유 : 동물실험 및 전임상시험연구

2848. Yazdi MH, Mahdavi M, Setayesh N, Esfandyar M, Shahverdi AR. Selenium nanoparticle-enriched Lactobacillus brevis causes more efficient immune responses in vivo and reduces the liver metastasis in metastatic form of mouse breast cancer. *DARU, Journal of Pharmaceutical Sciences*. 2013;21 (1) (33).

배제사유 : 동물실험 및 전임상시험연구

2849. Ye YB, Zhou ZF, Chen Q, Li JY, Chen X, Huang WW. [The roles of soluble MICA in immune escape of breast tumor]. *Xibao Yu Fenzi Mianyixue Zazhi*. 2008;24(9):904-7.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

2850. Yea K, Zhang H, Xie J, Jones TM, Lin CW, Francesconi W, et al. Agonist antibody that induces human malignant cells to kill one another. *Proceedings of the National Academy of Sciences of the United States of America*. 2015;112(45):E6158-E65.

배제사유 : 동물실험 및 전임상시험연구

2851. Yerushalmi R, Lubin I, Lipovettzky J, Hardy B, Raiter A. Cell surface GRP78 expression on T and NK cell sub-populations of breast cancer patients. *Journal of Clinical Oncology. Conference*. 2017;35(15 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2852. Yiang GT, Chou PL, Tsai HF, Chen LA, Chang WJ, Yu YL, et al. Immunotherapy for SV40 T/t antigen-induced breast cancer by recombinant adeno-associated virus serotype 2 carrying interleukin-15 in mice. *International Journal of Molecular Medicine*. 2012;29(5):809-14.

배제사유 : 동물실험 및 전임상시험연구

2853. Yin J, Albers AJ, Smith TS, Riddell GT, Richards JO. Differential regulation of human monocytes and NK cells by antibody-opsonized tumors. *Cancer Immunology, Immunotherapy*. 2018;67(8):1239-50.

배제사유 : 동물실험 및 전임상시험연구

2854. Yin T, Wang G, He S, Liu Q, Sun J, Wang Y. Human cancer cells with stem cell-like phenotype exhibit enhanced sensitivity to the cytotoxicity of IL-2 and IL-15 activated natural killer cells. *Cellular Immunology*. 2016;300:41-5.

배제사유 : 동물실험 및 전임상시험연구

2855. Ying XX, Zou Q, Xu YH, Wang EZ, Wang HY, Hu YH, et al. [The cytotoxicity of Her-2 pulsed DCIKS against breast cancer cells]. *Fen Zi Xi Bao Sheng Wu Xue Bao = Journal of Molecular Cell Biology / Zhongguo Xi Bao Sheng Wu Xue Xue Hui Zhu Ban*. 2007;40(4):193-8.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

2856. Yingling JM, McMillen WT, Yan L, Huang H, Sawyer JS, Graff J, et al. Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-beta receptor type I inhibitor. *Oncotarget*. 2018;9(6):6659-77.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2857. Yokoyama Y, Lew ED, Seeliger R, Walsh C, Barrera M, Tindall E, et al. Immuno-oncological efficacy of RXDX-106, a novel, selective and potent small molecule TAM (TYRO3, AXL, MER) inhibitor. *Cancer Research Conference: American Association for Cancer Research Annual Meeting*. 2017;77(13 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2858. Yonezawa A, Dutt S, Chester C, Kim J, Kohrt HE. Boosting cancer immunotherapy with anti-CD137 antibody therapy. *Clinical Cancer Research*. 2015;21(14):3113-20.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2859. Yoon MS, Pham CT, Phan MT, Shin DJ, Jang YY, Park MH, et al. Irradiation of breast cancer cells enhances CXCL16 ligand expression and induces the migration of natural killer cells expressing the CXCR6 receptor. *Cytotherapy*. 2016;18(12):1532-42.
배제사유 : 동물실험 및 전임상시험연구
2860. You F, Roberts LA, Kang SP, Nunes RA, Dias C, Iglehart JD, et al. Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells. *Journal of hematology & oncology*. 2008;1:2.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2861. Youness RA, Abdelmotaal A, Gad M. A Novel Immunological Role of Hydrogen Sulphide in Shaping Natural Killer Cells Cyotoxicity in Breast Cancer Patients. *Annals of Oncology*. 2019;30 (Supplement 11):xi39.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2862. Youness RA, Assal RA, Abdelmotaal A, Gad MZ. MiR-4317, a promising player tuning the anti-tumor armamentarium against breast cancer. *Annals of Oncology*. 2018;29 (Supplement 6):vi18-vi9.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2863. Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C, Blake SJ, et al. Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses. *Cancer Cell*. 2016;30(3):391-403.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2864. Young JS, Asaoka M, Katsuta E, Kawaguchi T, Qi Q, Liu S, et al. Young breast cancer patients demonstrate worse survival associated with aggressive oncogene expression but not with mutation load, tumor heterogeneity or pro-tumor immune cell infiltrations. *Cancer Research Conference*. 2018;79(4 Supplement 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2865. Yu M, Pan H, Che N, Li L, Wang C, Wang Y, et al. Microwave ablation of primary breast cancer inhibits metastatic progression in model mice via activation of natural killer cells. *Cellular & Molecular Immunology*. 2020;08:08.

배제사유 : 동물실험 및 전임상시험연구

2866. Yu RC, Guan CF, Zhang JH. [Immune function of cancer patients with spleen-deficiency syndrome]. Chung Hsi i Chieh Ho Tsa Chih Chinese Journal of Modern Developments in Traditional Medicine. 1990;10(9):535-7, 16.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

2867. Yu W, He X, Yang Z, Yang X, Xiao W, Liu R, et al. Sequentially responsive biomimetic nanoparticles with optimal size in combination with checkpoint blockade for cascade synergistic treatment of breast cancer and lung metastasis. Biomaterials. 2019;217:119309.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2868. Yu Y, Liu Y, Zong C, Yu Q, Yang X, Liang L, et al. Mesenchymal stem cells with Sirt1 overexpression suppress breast tumor growth via chemokine-dependent natural killer cells recruitment. Scientific Reports. 2016;6:35998.

배제사유 : 동물실험 및 전임상시험연구

2869. Yu YL, Wei CW, Chen YL, Chen MH, Yang GT. Immunotherapy of breast cancer by single delivery with rAAV2-mediated interleukin-15 expression. International Journal of Oncology. 2010;36(2):365-70.

배제사유 : 동물실험 및 전임상시험연구

2870. Yuan C, Wang Q. Comparative analysis of the effect of different radiotherapy regimes on lymphocyte and its subpopulations in breast cancer patients. Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies & of the National Cancer Institute of Mexico. 2018;20(9):1219-25.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2871. Yuan H, Hsiao YH, Zhang Y, Wang J, Yin C, Shen R, et al. Destructive impact of T-lymphocytes, NK and Mast cells on basal cell layers: implications for tumor invasion. BMC Cancer. 2013;13:258.

배제사유 : 동물실험 및 전임상시험연구

2872. Yuan Q, Sun N, Zheng J, Wang Y, Yan X, Mai W, et al. Prognostic and Immunological Role of FUN14 Domain Containing 1 in Pan-Cancer: Friend or Foe? Frontiers in Oncology. 2020;9 (1502).

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2873. Yue HH, Diehl GE, Winoto A. Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice [3]. Cell Death and Differentiation. 2005;12(1):94-7.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2874. Yule M, Wnuk-Lipinska K, Davidsen K, Blo M, Hodneland L, Engelsen A, et al. A phase II multi-center study of BGB324 in combination with pembrolizumab in patients with previously treated, locally advanced and unresectable or metastatic triple negative breast cancer (TNBC) or triple negative inflammatory breast cancer (TN-IBC). Cancer Research. Conference: San Antonio Breast Cancer Symposium, SABCS. 2017;78(4 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2875. Zaravinos A, Roufas K, Chasiotis D, Makris A, Efsthathiades C, Dimopoulos C. Prognostic impact of immune cytolytic activity and its association with checkpoint molecules and TIL/TAN load in human malignancies. *FEBS Open Bio.* 2018;8 (Supplement 1):301.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2876. Zaugg M, Lucchinetti E. Impact of anaesthesia regimen on middle and long-term cancer surgery outcome. *Regional Anesthesia and Pain Medicine.* 2014;1):e22-e3.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2877. Zavadova E, Vocka M, Spacek J, Konopasek B, Fucikova T, Petruzelka L. Cellular and humoral immunodeficiency in breast cancer patients resistant to hormone therapy. *Neoplasma.* 2014;61(1):90-8.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2878. Zdrrazilova-Dubska L, Valik D, Budinska E, Frgala T, Bacikova L, Demlova R. NKT-like cells are expanded in solid tumour patients. *Klinicka Onkologie.* 2012;25(SUPPL.2):2S21-2S5.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2879. Zerde I, Wallerius M, Sifakis EG, Wallmann T, Betts S, Bartish M, et al. STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer. *Cancers.* 2019;11(10):01.

배제사유 : 동물실험 및 전임상시험연구

2880. Zgodzinski W, Wallner G, Dabrowski A. Angiogenesis inhibitors. New anticancer strategy. *Polish Journal of Pharmacology.* 1999;51(6):455-62.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2881. Zhai L, Bell A, Ladomersky E, Lauing KL, Bollu L, Sosman JA, et al. Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies. *Frontiers in Immunology.* 2020;11 (1185).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2882. Zhai YF, Esselman WJ, Oakley CS, Chang CC, Welsch CW. Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells. *Cancer Immunology, Immunotherapy.* 1992;35(4):237-45.

배제사유 : 동물실험 및 전임상시험연구

2883. Zhan Y, Lew AM, Chopin M. The Pleiotropic Effects of the GM-CSF Rheostat on Myeloid Cell Differentiation and Function: More Than a Numbers Game. *Frontiers in Immunology.* 2019;10 (2679).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2884. Zhang A, Liu Z, Kan Y. Receptor dimerization - Rationale for the design of bivalent ligands. *Current Topics in Medicinal Chemistry.* 2007;7(4):343-5.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2885. Zhang B, Sun J, Yao X, Li J, Tu Y, Yao F, et al. Knockdown of B7H6 inhibits tumor progression in triple-negative breast cancer. *Oncology Letters*. 2018;16(1):91-6.
배제사유 : 동물실험 및 전임상시험연구
2886. Zhang C, Ben A, Reville J, Calabrese V, Villa NN, Bandyopadhyay M, et al. Immunotherapeutic impact of toll-like receptor agonists in breast cancer. *Anti-Cancer Agents in Medicinal Chemistry*. 2015;15(9):1134-40.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2887. Zhang C, Ren X. Herceptin enhances the antitumor effect of natural killer cells on breast cancer cells expressing human epidermal growth factor receptor-2. *European Journal of Immunology*. 2019;49 (Supplement 3):477.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2888. Zhang C, Zhang Q. Tumor microenvironment research in China. *Journal of Chemical and Pharmaceutical Research*. 2014;6(3):1428-33.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2889. Zhang F, Liu S. Mechanistic insights of adipocyte metabolism in regulating breast cancer progression. *Pharmacological Research*. 2020;155 (104741).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2890. Zhang H, Li N, Zhang J, Jin F, Shan M, Qin J, et al. The influence of miR-34a expression on stemness and cytotoxic susceptibility of breast cancer stem cells. *Cancer Biology & Therapy*. 2016;17(6):614-24.
배제사유 : 동물실험 및 전임상시험연구
2891. Zhang H, Zhang F, Zhu Z, Meadows G. Chronic alcohol consumption decreases the survival and compromises the antitumor immune response of mice bearing estrogen receptor positive E0771 breast cancer. *Journal of Immunology*. Conference: 101st Annual Meeting of the American Association of Immunologists, IMMUNOLOGY. 2014;192(1 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2892. Zhang HG, Kim H, Liu C, Yu S, Wang J, Grizzle WE, et al. Curcumin reverses breast tumor exosomes mediated immune suppression of NK cell tumor cytotoxicity. *Biochimica et Biophysica Acta*. 2007;1773(7):1116-23.
배제사유 : 동물실험 및 전임상시험연구
2893. Zhang J, Fang FQ, Zhang CX. Preliminary study of association between breast cancer and depression. [Chinese]. *Tumor*. 2011;31(5):457-9.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
2894. Zhang J, Guo S, Wang Z, Li Z, Qiao M, Shi Q. Orthotopic syngeneic tumor models for preclinical evaluation of cancer immunotherapy strategies. *Cancer Research*. Conference: 107th Annual Meeting of the American Association for Cancer Research, AACR. 2016;76(14 Supplement).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2895. Zhang L, Huang Y, Lindstrom AR, Lin TY, Lam KS, Li Y. Peptide-based materials for cancer immunotherapy. *Theranostics*. 2019;9(25):7807-25.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2896. Zhang LL, Wang XL, Ding Y, Yang HC, Liu YP. Relationship between infiltrating lymphocytes and cytokines of tumors and prognosis of invasive breast carcinoma of no specific type and carcinoma with medullary features patients. [Chinese]. *Chinese Journal of Cancer Prevention and Treatment*. 2018;25(9):634-41.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
2897. Zhang M, Guo R, Zhai Y, Fu XY, Yang D. Light stimulates IFNgamma-mediated intercellular adhesion molecule-1 upregulation of cancer cells. *Human Immunology*. 2003;64(4):416-26.
배제사유 : 동물실험 및 전임상시험연구
2898. Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. *Nature Immunology*. 2018;19(7):723-32.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2899. Zhang Q, Ou-Yang J, Zhou RF. Clinical and experimental features of natural killer cell leukemias in a chinese population: A single center experience of 10 years. *Blood*. Conference: 53rd Annual Meeting of the American Society of Hematology, ASH. 2011;118(21).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2900. Zhang Q, Xin H, Fen T. Function of microRNA-141 in human breast cancer through cytotoxic CD4+ T cells regulated by MAP4K4 expression. *Molecular Medicine Reports*. 2018;17(6):7893-901.
배제사유 : 동물실험 및 전임상시험연구
2901. Zhang SC, Hu ZQ, Long JH, Zhu GM, Wang Y, Jia Y, et al. Clinical implications of tumor-infiltrating immune cells in breast cancer. *Journal of Cancer*. 2019;10(24):6175-84.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2902. Zhang W, Yang H, Zhang Y, Lu Y, Zhou T, Li M, et al. A biotherapy based on PSCs-in-3D spheroid-ameliorated biologics depletes in vivo cancer-sustaining stem cells. *Oncotarget*. 2015;6(38):40762-74.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2903. Zhang WB. Basic research of biotherapy for osteosarcoma. [Chinese]. *Chinese Journal of Cancer Biotherapy*. 2008;15(2):101-4.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
2904. Zhang X, Fu X, Dong M, Yang Z, Wu S, Ma M, et al. Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: Super multidrug resistant cells? *Cancer Cell International*. 2018;18 (1) (150).
배제사유 : 동물실험 및 전임상시험연구

2905. Zhang X, Yang Y, Fan D, Xiong D. The development of bispecific antibodies and their applications in tumor immune escape. *Experimental Hematology and Oncology*. 2017;6(1) (12).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2906. Zhang Y, Manjunath M, Yan J, Baur BA, Zhang S, Roy S, et al. The Cancer-Associated Genetic Variant Rs3903072 Modulates Immune Cells in the Tumor Microenvironment. *Frontiers in Genetics*. 2019;10:754.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2907. Zhang Y, Morgan R, Podack ER, Rosenblatt J. B cell regulation of anti-tumor immune response. *Immunologic Research*. 2013;57(1-3):115-24.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2908. Zhang Y, Morgan R, Shin SU, Cho HM, Albayati A, Pimentel A, et al. Tumor educated B cells acquire immune suppressive function and promote tumor growth. *Cancer Research Conference: 105th Annual Meeting of the American Association for Cancer Research, AACR*. 2014;74(19 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2909. Zhang Y, Yu S, Han Y, Wang Y, Sun Y. Human leukocyte antigen-G expression and polymorphisms promote cancer development and guide cancer diagnosis/treatment (Review). *Oncology Letters*. 2018;15(1):699-709.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2910. Zhang YL, Lu R, Chang ZS, Zhang WQ, Wang QB, Ding SY, et al. Clostridium sporogenes delivers interleukin-12 to hypoxic tumours, producing antitumour activity without significant toxicity. *Letters in Applied Microbiology*. 2014;59(6):580-6.
배제사유 : 동물실험 및 전임상시험연구
2911. Zhang Z, Liu L, Cao S, Zhu Y, Mei Q. Gene delivery of TIPE2 inhibits breast cancer development and metastasis via CD8+ T and NK cell-mediated antitumor responses. *Molecular Immunology*. 2017;85:230-7.
배제사유 : 동물실험 및 전임상시험연구
2912. Zhang Z, Zhang Y, Xia S, Kong Q, Li S, Liu X, et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. *Nature*. 2020;579(7799):415-20.
배제사유 : 동물실험 및 전임상시험연구
2913. Zhang ZF, Shi BS, Wu HB, He JX, Weng XL, Dong L, et al. Immunomodulatory effect of lienal polypeptide on breast cancer patients undergoing chemotherapy. [Chinesel]. *Chinese Journal of Cancer Prevention and Treatment*. 2019;26(21):1627-31.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
2914. Zhao C, Fang Q, Tan K, Lu X. [Relationship among breast cancer and negative life event and cell immunity]. *Chung-Hua i Hsueh Tsa Chih* [Chinese Medical Journal]. 2002;82(18):1235-6.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구

2915. Zhao Q, Zhang W, Ning Z, Zhuang X, Lu H, Liang J, et al. A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity. PLoS ONE. 2014;9 (3) (e93103).
배제사유 : 동물실험 및 전임상시험연구
2916. Zhao S, Zhao H, Lv C, Gong J, Zhang J, Fang W, et al. Anticancer drug R&D landscape in China. Journal of Hematology and Oncology. 2020;13 (1) (51).
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2917. Zhao Y, Hu J, Li R, Song J, Kang Y, Liu S, et al. Enhanced NK cell adoptive antitumor effects against breast cancer in vitro via blockade of the transforming growth factor-beta signaling pathway. OncoTargets and therapy. 2015;8:1553-9.
배제사유 : 동물실험 및 전임상시험연구
2918. Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. Journal of Immunology. 2009;183(9):5563-74.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2919. Zheng G, Guo Z, Wen W, Jia L, Yang A. Cytokine-mediated crosstalk between HER2-positive breast cancer and NK cells promotes resistance to trastuzumab via HLA-G/KIR2DL4 signaling. European Journal of Immunology. 2019;49 (Supplement 3):1517.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2920. Zheng SC, Webster AP, Dong D, Feber A, Graham DG, Sullivan R, et al. A novel cell-type deconvolution algorithm reveals substantial contamination by immune cells in saliva, buccal and cervix. Epigenomics. 2018;10(7):925-40.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2921. Zheng Y, Fang YC, Li J. PD-L1 expression levels on tumor cells affect their immunosuppressive activity. Oncology Letters. 2019;18(5):5399-407.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2922. zhevago NA, Samoilova KA, Davydova NI, Bychkova NV, Glazanova TV, Chubukina Zh V, et al. [The efficacy of polychromatic visible and infrared radiation used for the postoperative immunological rehabilitation of patients with breast cancer]. Voprosy Kurortologii, Fizioterapii i Lechebnoi Fizicheskoi Kultury. 2012(4):23-32.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
2923. Zhevago NA, Zimin AA, Glazanova TV, Davydova NI, Bychkova NV, Chubukina ZV, et al. Polychromatic light (480-3400nm) similar to the terrestrial solar spectrum without its UV component in post-surgical immunorehabilitation of breast cancer patients. Journal of Photochemistry & Photobiology. B - Biology. 2017;166:44-51.
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2924. Zhong C, Lang Q, Yu J, Wu S, Xu F, Tian Y. Phenotypical and potential functional characteristics of different immune cells expressing CD28H/B7-H5 and their relationship with cancer prognosis. Clinical & Experimental Immunology.

2020;200(1):12-21.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2925. Zhou H, Luo Y, Lo JF, Kaplan CD, Mizutani M, Mizutani N, et al. DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor. *Proceedings of the National Academy of Sciences of the United States of America*. 2005;102(31):10846-51.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2926. Zhou J, Zhong Y, Hou Z, Zhang J, Li Y, Yan S. Generation and characterization of antitumor infiltrating lymphocytes from patients with breast cancer for adoptive cell transfer therapy. *Journal of Clinical Oncology*. 2017;35 (7 Supplement 1):145.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2927. Zhou Q, Gil-Krzewska A, Peruzzi G, Borrego F. Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy. *Clinical and Experimental Immunology*. 2013;173(1):131-9.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

2928. Zhou X, Liu J. A computational model to predict bone metastasis in breast cancer by integrating the dysregulated pathways. *BMC Cancer*. 2014;14 (1) (618).

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2929. Zhou Z, Li J, Ye Y. MICA-TM polymorphism (A5.1) as a potential predictive marker in response to NK immunotherapy for triple-negative breast cancer. *European Journal of Immunology*. 2019;49 (Supplement 3):1806-7.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2930. Zhou ZJ, Xie JL, Wei P, Zhou XG. [Pathologic subtyping of primary lymphoma of breast and prognostic analysis]. *Chung-Hua Ping Li Hsueh Tsa Chih - Chinese Journal of Pathology*. 2017;46(9):618-22.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

2931. Zhu L, Gangadaran P, Kalimuthu S, Oh JM, Baek SH, Jeong SY, et al. Novel alternatives to extracellular vesicle-based immunotherapy - exosome mimetics derived from natural killer cells. *Artificial Cells, Nanomedicine, & Biotechnology*. 2018;46(sup3):S166-S79.

배제사유 : 동물실험 및 전임상시험연구

2932. Zhu L, Kalimuthu S, Oh JM, Gangadaran P, Baek SH, Jeong SY, et al. Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by IL-15 priming. *Biomaterials*. 2019;190-191:38-50.

배제사유 : 동물실험 및 전임상시험연구

2933. Zhu LW. Count of T cell subsets in patients with breast cancer and its clinical significance. [Chinesel]. *Chinese Journal of Clinical Oncology*. 1994;21(3):209-13.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

2934. Zhu S, Lee DA, Li S. IL-12 and IL-27 sequential gene therapy via intramuscular

electroporation delivery for eliminating distal aggressive tumors. *Journal of Immunology*. 2010;184(5):2348-54.

배제사유 : 동물실험 및 전임상시험연구

2935. Zhu X, Moylan EJ, Xu Y, Yang Y, Porter DP, Fahey P. Chinese medicine for immunological functions in women with breast cancer or a history of breast cancer. *Cochrane Database of Systematic Reviews*. 2018;2018 (10) (CD013144).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2936. Zhuang SR, Chiu HF, Chen SL, Tsai JH, Lee MY, Lee HS, et al. Effects of a Chinese medical herbs complex on cellular immunity and toxicity-related conditions of breast cancer patients. *British Journal of Nutrition*. 2012;107(5):712-8.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2937. Zhuang Y, Xu W, Shen Y, Li J. Fcgamma receptor polymorphisms and clinical efficacy of rituximab in non-hodgkin lymphoma and chronic lymphocytic leukemia. *Clinical Lymphoma, Myeloma and Leukemia*. 2010;10(5):347-52.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2938. Zhus Y, Chen F, Kong L, Li T, Lu L, Yang J, et al. Magnetic Resonance Imaging of the Human Ferritin Heavy Chain Reporter Gene Carried by Dendrimer-Entrapped Gold Nanoparticles. *Journal of Biomedical Nanotechnology*. 2019;15(3):518-30.

배제사유 : 동물실험 및 전임상시험연구

2939. Zielinski CC, Muller C, Kubista E, Staffen A, Eibl MM. Effects of adjuvant chemotherapy on specific and non-specific immune mechanisms. *Acta Medica Austriaca*. 1990;17(1):11-4.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2940. Zielinski CC, Tichatschek E, Muller C, Kalinowski W, Sevelda P, Czerwenka K, et al. Association of increased lytic effector cell function with high estrogen receptor levels in tumor-bearing patients with breast cancer. *Cancer*. 1989;63(10):1985-9.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- γ)를 측정하지 않은 연구

2941. Zigler M, Shir A, Joubran S, Sagalov A, Klein S, Edinger N, et al. HER2-targeted polyinosine/polycytosine therapy inhibits tumor growth and modulates the tumor immune microenvironment. *Cancer Immunology Research*. 2016;4(8):688-97.

배제사유 : 동물실험 및 전임상시험연구

2942. Zimmer P, Baumann FT, Bloch W, Zopf EM, Schulz S, Latsch J, et al. Impact of a half marathon on cellular immune system, pro-inflammatory cytokine levels, and recovery behavior of breast cancer patients in the aftercare compared to healthy controls. *European Journal of Haematology*. 2016;96(2):152-9.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2943. Zitvogel L, Casares N, Pequignot MO, Chaput N, Albert ML, Kroemer G. Immune response against dying tumor cells. *Advances in Immunology*. 2004;84:131-79.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

2944. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. *Nature Reviews Immunology*. 2015;15(7):405-14.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2945. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. *Nature Reviews Clinical Oncology*. 2011;8(3):151-60.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2946. Zitvogel L, Kroemer G. Unchaining NK cell-mediated anticancer immunosurveillance. *Nature Immunology*. 2016;17(7):746-7.
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
2947. Zitvogel L, Rusakiewicz S, Routy B, Ayyoub M, Kroemer G. Immunological off-target effects of imatinib. *Nature Reviews Clinical Oncology*. 2016;13(7):431-46.
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
2948. Zitvogel L, Tahara H, Cai Q, Storkus WJ, Muller G, Wolf SF, et al. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. *Human Gene Therapy*. 1994;5(12):1493-506.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2949. Zlatnik E, Zakora GI, Starzhetskaia MV. [A novel method of drug-free immunocorrection by exposing cancer patients' blood to alternating magnetic field]. *Voprosy Onkologii*. 2004;50(1):50-4.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
2950. Zlatnik EY, Shatova YS, Novikova IA, Bakhtin AV. Local immunity of patients with various molecular subtypes of breast cancer. *Journal of Clinical Oncology. Conference*. 2015;33(15 SUPPL. 1).
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
2951. Zou DH, Yang HJ, Xie SN, Ling YT, Qian LJ, Yu Y, et al. Differences between the patients with breast cancer and with breast benign tumor in the correlation between the level of IL-2 and the proportion of lymphocyte subsets from peripheral blood. [Chinesel]. *Chinese Journal of Cancer Prevention and Treatment*. 2007;14(9):680-2.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
2952. Zou Q. Administration of ubenimex for patients with triple-negative breast cancer in chemotherapy. [Chinesel]. *Journal of Practical Oncology*. 2015;30(1):65-8.
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
2953. Zumwalde NA, Haag JD, Gould MN, Gumperz JE. Mucosal associated invariant T cells from human breast ducts mediate a Th17-skewed response to bacterially exposed breast carcinoma cells. *Breast Cancer Research*. 2018;20 (1) (111).
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
2954. Zumwalde NA, Haag JD, Sharma D, Mirrieles JA, Wilke LG, Gould MN, et al. Analysis of immune cells from human mammary ductal epithelial organoids reveals Vdelta2+ T cells that efficiently target breast carcinoma cells in the presence of bisphosphonate.

Cancer Prevention Research. 2016;9(4):305-16.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

2955. Zwirner N, Spallanzani R, Dalotto T, Rossi L, Avila D, Ziblat A, et al. Medroxyprogesterone acetate drives expansion of CD11b+Gr1high myeloid-derived suppressor cells which suppress NK cell effector functions in tumor-bearing mice (P2059). Journal of Immunology. Conference: 100th Annual Meeting of the American Association of Immunologists, IMMUNOLOGY. 2013;190(1 MeetingAbstracts).
- 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

2. 국내 DB

1. An GD, Kim KH, Lim HH, Kim MC, Lee SY. Comparison of Interferon-gamma Secretion by Stimulated NK Cells and T cells from Healthy Subjects. Laboratory Medicine Online. 2018;8(1):15.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
2. Byun JS, Jeong WI. Involvement of hepatic innate immunity in alcoholic liver disease. Immune Netw. 2010;10(6):181-7.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
3. Chung IB HH, Kim NO, Ha JS, Park HS, Park JY. The role of Interferon-gamma on the Expression of Class I Human Leukocyte Antigens in a Human First Trimester Trophoblast Cell Line. Korean J Obstet Gynecol 2003;Feb;46(2):378-386.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
4. GC J. Natural killer T cell and pathophysiology of asthma. Korean J Pediatr. 2010;2010 Feb;53(2):136-145.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
5. Guang Hua X, 김재화, Gao L, 유익동. 젖버섯아재비 자실체로부터 분리한 Azulene계 화합물이 Interferon- 생성에 미치는 영향. 대한화장품학회지. 2010;36(2):151-6.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
6. Hisamatsu T, Mikami Y, Matsuoka K, Kanai T, Hibi T. Immunological Abnormalities in the Pathogenesis of Inflammatory Bowel Disease. Intestinal Research. 2012;10(4):317.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
7. Jo DS HJ, Kim SY, Kim MS, Yi HK, Lee DY, Hwang PH. Changes in the expression of cytokines and apoptosis-related genes in children with infectious mononucleosis. Korean J Pediatr. 2009;Dec;52(12):1348-1357.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
8. Kim DH KM, Cho JH, Lim NK, Park JI, Jeong SH, Lee HW, et al. Aging Effects on Dendritic Cells after Total Body Irradiation in Mice. Korean J Hematol. 2007;Sep;42(3): 224-232.
배제사유 : 동물실험 및 전임상시험연구
9. Kim JY, Huh K, Lee KY, Yang JM, Kim TJ. Nickel induces secretion of IFN-gamma by

splenic natural killer cells. Exp Mol Med. 2009;41(4):288-95.

배제사유 : 유방암 환자를 대상으로 하지 않은 연구

10. Kim KJ PS, Lee YS. Immunologic Effect of Gamma Interferon on Human Melanoma Cell Line A - 375 - With Special Emphasis on Cytolytic Activity , Antiproliferative Activity and HLA Antigen Expression. Korean J Dermatol 1990;Apr;28(2):147-158.
배제사유 : 동물실험 및 전임상시험연구
11. Lee CB SW, Park JK, Haw CR. Effects of REtinoids on Keratinocytes HLA - DR and ICAM - 1 Expression Induced by Interferon - gamma. Korean J Dermatol 1995;Feb;33(1):33-43.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
12. Lee JS YC, Lyu CJ, Park SM, Cho HS, Kim KY. T Cell Function before, during and after Chemotherapy in Children with Acute Lymphoblastic Leukemia. Korean J Pediatr Hematol Oncol. 1997;Oct;4(2):350-362.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
13. Lee JT PS, Lee JH, Kim BK, Kim NK. Efficacy of in vitro treatment of chronic myelogenous leukemia cell line, K562 cells, using 4-hydroperoxycyclophosphamide, alpha-interferon and gamma-interferon. J Korean Med Sci 1996;Feb;11(1):26-32.
배제사유 : 동물실험 및 전임상시험연구
14. Lim YA, Kim SS, Cho SW, Cheong JY. Evaluation of the Effectiveness of NK Vue Gold Kit in Patients with Chronic Hepatitis B. Journal of Laboratory Medicine and Quality Assurance. 2016;38(3):151-8.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
15. Maeng SH LJ, Park CW, Cho YJ. The effect of Der p 2 antigen on the production of interferon gamma by CD3+T, CD56+NK and CD3+CD56+TNK cells from patients with mild persistent allergic asthma. J Asthma Allergy Clin Immunol 2003;Jun;23(2):341-348.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
16. Park AJ LM. Peripheral Th1 and Th2 Lymphocytes Values by Intracellular Cytokine Staining for Interferon-and Interleukin-4 in the Patients with Repeated Spontaneous Abortion. Korean J Lab Med. 2005;Apr;25(2):111-115.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
17. Park S, Mun YC, Seong C-M, Huh HJ, Huh J. Variable Natural Killer Cell Activity in Hematological Malignancies at Diagnosis. Laboratory Medicine Online. 2018;8(2):41.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
18. Uyangaa E, Choi JY, Ryu HW, Oh SR, Eo SK. Anti-herpes Activity of Vinegar-processed Daphne genkwa Flos Via Enhancement of Natural Killer Cell Activity. Immune Netw. 2015;15(2):91-9.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
19. 고창권, Matsuda M, 예상규, 민본홍, 이광호, Jong Gu Park. 배양 Monocytes에서 세포농도에 따른 Fc γ Receptors의 선택적 표현. 대한면역학회지. 1998;20(3):277-83.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구

20. 김광수, 박경순. XRP44X Enhances the Cytotoxic Activity of Natural Killer Cells by Activating the c-JUN N-Terminal Kinase Signaling Pathway. *발생과생식*. 2020;24(1):53-61.
배제사유 : 동물실험 및 전임상시험연구
21. 김광중, 박성희, 이유신. 인체 흑색종 세포주 A - 137 에 대한 감마 인터페론의 세포 살해능 , 증식 억제능 , HLA항원 표현에 관한 연구. *大韓皮膚科學會誌*. 1990;28(2):147-58.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
22. 김대원, 이의섭, 최윤표, 강승우, 정재준, 서보승. 게르마늄 수경재배 미나리 추출물 처리에 의한 In Vitro/In Vivo에서의 사이토카인 감소 및 면역 활성에 대한 효과. *한국식품영양과학회지*. 2020;49(1):101-10.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
23. 김영건, 노홍규, 박은신, 김호, 유순희, 박수정, et al. 갑상선 세포에서 전사보조활성인자인 CBP와 CIIA는 인터페론-감마 활성 부위에 대하여 서로 다른 조절 작용을 나타낸다. *Endocrinology and Metabolism(구 대한내분비학회지)*. 1999;14(3):493-504.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
24. 김용석, 김홍식. 진행 내장암환자에서 5-Fluorouracil 및 재조합 감마 인터페론(인터맥스(r)) 병용요법 의 제2상 임상시험. *계명의대논문집*. 1994;13(2):131-45.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
25. 김창욱, 신주엽, 윤승규, 혀원희, 남순우, 장우임, et al. 구연 : 라미부딘을 사용하고 있는 만성 B형 간 염에서 숙주의 HBV 특이 T세포 면역반응을 반영하는 ELISPOT Assay의 유용성. *Clinical and Molecular Hepatology(대한간학회지)*. 2003;9(3s):50.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
26. 맹선희, 이지수, 박창환, 조영주. 알레르기성 기관지천식환자의 말초 혈액 T세포, NK세포 TNK세포의 Der p 2 항원의 자극에 의한 interferon gamma의 생산. *천식및알레르기*. 2003;23(2):341-8.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
27. 박설희, 문영철, 성주명, 혀희진, 혀정원. Variable Natural Killer Cell Activity in Hematological Malignancies at Diagnosis. *Laboratory Medicine Online*. 2018;8(2):41-51.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
28. 변진석, 정원일. Involvement of Hepatic Innate Immunity in Alcoholic Liver Disease. *Immune Network*. 2010;10(6):181-7.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
29. 성혜란, 김지연, 박민경, 김일희, 이동욱, 한상배, et al. 결장암에 대한 활성 자연살해세포의 항암효능. *약학회지*. 2010;54(3):192-9.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
30. 안규대, 김경희, 임현호, 김민찬, 이상엽. 건강인에서 NK세포 자극 후와 T세포 자극 후 분비된 Interferon-gamma 농도의 비교. *Laboratory Medicine Online*. 2018;8(1):15-8.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
31. 유수연, 박원봉. 섬오가피 추출물의 항암관련 사이토카인 분비활성. *약학회지*. 2010;54(4):232-9.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구

32. 윤도희, 이은경, 김정원. The effect of histamine on the production of interferongamma and interleukin-12 in peripheral blood mononuclear cells from patients with atopic dermatitis. 천식및알레르기. 1999;19(3):459-67.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
33. 이춘봉, 심우영, 박재경, 허충림. 원저 : Retinoids각질형성세포에서 감마인터페론에 의한 HLA - DR , ICAM - 1 발현에 미치는 영향. 대한피부과학회지. 1995;33(1):33-43.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
34. 이해리, 전준호, 이기은. The Poly- γ -D-Glutamic Acid Capsule of *Bacillus licheniformis*, a Surrogate of *Bacillus anthracis* Capsule Induces Interferon-Gamma Production in NK Cells through Interactions with Macrophages. Journal of Microbiology and Biotechnology. 2017;27(5):1032-7.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
35. 임영애, 김순선, 조성원, 정재연. 만성B형간염 환자에서의 NK Vue Gold Kit 시약의 유효성 평가. 임상검사와정도관리. 2016;38(3):151-8.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
36. 전준호, 이해리, 이기은. 탄저균 poly- γ -d-glutamic acid 캡슐에 의한 자연살해세포의 인터페론 감마 생산 기전. 주간 건강과 질병. 2018;11(5):128-32.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
37. 정다운, 변정수, 구나연, 정문희, 김은희, 김형석, et al. 개 유선종양세포에 대한 자연살해세포 독성. 대한수의학회지. 2020;60(1):25-32.
배제사유 : 동물실험 및 전임상시험연구
38. 정원일. 실험적 항섬유화 치료법의 임상적용. Clinical and Molecular Hepatology(대한간학회지). 2011;17(1(S)):48-54.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
39. 정인배, 한혜경, 김나옥, 하정식, 박현숙, 박주영. 태반 영양모세포주의 class I 인체백혈구 항원 발현에 미치는 감마 인터페론의 역할. 대한산부인과학회지. 2003;46(2):378-86.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
40. 천은미, 김미선, 장윤혜, 박성숙, 조영주. 종종 기관지천식 환자의 말초단핵구에서 자연살해세포의 비율과 자연살해세포에서 interferon gamma의 생산. 천식및알레르기. 2000;20(3):535-44.
배제사유 : 유방암 환자를 대상으로 하지 않은 연구
41. 최영희, 이진희, 윤종현. S-689 콜라겐 유도 관절염 마우스 모델에서 편백나무추출오일의 치료 효과. 대한내과학회 추계학술대회. 2016;2016(1):394.
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)